<SEC-DOCUMENT>0000950170-24-093285.txt : 20240808
<SEC-HEADER>0000950170-24-093285.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808064628
ACCESSION NUMBER:		0000950170-24-093285
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvalent, Inc.
		CENTRAL INDEX KEY:			0001861560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40671
		FILM NUMBER:		241185912

	BUSINESS ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		508-446-2272

	MAIL ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nuvl-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-08T06:32:57.1626+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:nuvl="http://www.nuvalent.com/20240630" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_58fb946a-d3d5-4e31-9710-f5a6a16b59d3" name="dei:DocumentFiscalPeriodFocus" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de">Q2</ix:nonNumeric><ix:nonNumeric id="F_7e821d15-2e20-483b-a052-6ab928643366" name="dei:CurrentFiscalYearEndDate" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de">--12-31</ix:nonNumeric><ix:nonNumeric id="F_d4bee9f9-b1fa-48ec-9ef1-62d25451ea5c" name="dei:EntityCentralIndexKey" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de">0001861560</ix:nonNumeric><ix:nonNumeric id="F_1618a2c7-bd1b-47dd-ac0a-f82d55af4c7c" name="dei:AmendmentFlag" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_c8b76d45-ca24-479d-bfc0-33cd63ec8f6f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_5a4c6053-1bda-44a6-bb38-708e59ad7023" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_a657f8ec-8294-4130-9623-1489cad84d2f" name="us-gaap:PreferredStockValue" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_03e6a0da-df8a-46ea-9b2f-331e1a872a11" name="us-gaap:PreferredStockValue" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" unitRef="U_USD" xsi:nil="true"/><ix:nonNumeric id="F_eeee3d3c-e24c-41bc-bc07-f38b69f1afef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_8b8d5f06-27af-40b6-b289-326a2478818b" format="ixt-sec:durwordsen">three years</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nuvl-20240630.xsd"/></ix:references><ix:resources><xbrli:context id="C_8082afd8-a4a7-4bb4-9a00-4af3037f710e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81afe59a-ee6d-4907-9d22-6941e276a052"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84650898-1d7b-4a6d-9d23-20e46d3497a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_883bcdb9-2dfc-4e4d-8f72-50e4cd4d7ade"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88495ead-dcd3-431a-99e7-37e3f2e1e634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89bca620-1c60-420a-b2d6-3dff6795f400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b8d5f06-27af-40b6-b289-326a2478818b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d29fec8-02e5-44cb-889a-504ab81f9925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92daaa6c-720c-4d58-8355-66e550d7df66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_988aec88-7f73-46c4-ac21-a91b3287ea03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99559338-f498-4e29-bfdd-3b309f0eca12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a17bbbd-552a-4726-853e-2c935be60a16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9af9cb99-b002-4432-a278-828a6d780b37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d832d33-eda0-4982-a7a1-aa5692816a09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f503e5f-2ff7-4088-814e-386b1247b152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a06a450e-d5b5-4bc2-993a-a482facfadc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a09fdef8-930b-40df-ac06-fe78e76477a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4fd7116-d861-4be0-8726-91a1dd9e189f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8d3411e-0ed4-454f-b70f-25a209c05079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac50ef0f-861a-4b28-a19c-6dd7b8e6e453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae08e807-c123-4741-9dfa-0c6b0be22746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3935287-1f96-4f1d-9282-abc8a9aee1bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b405fb65-a7d6-40f5-8618-a2c821d37b18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b52acea3-f3de-4d64-9ead-cf62a5c5a4f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b64064b0-6d46-4f49-a54e-2ab50179487d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b727372e-2cfc-48db-824a-3abd0cf7dba1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8e8c5a4-91d7-4f1f-a636-6c63980a1c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba328089-ed54-41d2-ad71-894cccb07734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c11a9bc4-489e-4596-a690-f7a824830151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c71bc11f-7d4d-4e19-871d-ec730c358b89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8785a1c-3f0b-4321-ac33-780c77788865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c957d1b2-202c-4ada-b960-079ff36c0f99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9924db4-0921-4c31-8fa1-a6b333ccd48c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca48becd-bf94-4320-8c36-a47233fe5233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd5fd91a-db75-43c1-9258-0ae8a9ebe099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ceab70a5-e653-4ed2-a8bc-07d80f617df3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf25f6e9-997e-4fd3-8973-255b191f2346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf5818a4-e379-4f42-9868-d47198e49382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d471e413-6554-4db6-8acf-61536b52edf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6836ade-3210-4068-9569-ee8d4b8489da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd5d8f9a-c02d-4126-aac2-509d06b9f750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nuvl:DebtSecuritiesAvailableForSalesSecuritiesDueAxis">nuvl:DueFromOneToThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddea1eeb-c815-4ae5-84ce-bc1859802e66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfe98025-5701-4a70-a255-fc81b13f1c68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0b36d05-241e-4e01-9ba5-c205ade76ca0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e15c1c22-7704-4697-a74e-3af37fe7c701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4332e9d-ecab-43c2-822a-5e2730476c0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e62e5e75-78d6-4cd9-95e2-9ba468b61771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb05446e-36b7-480d-9b8b-648cbb9b5d4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb2dcb47-6bc3-4f5f-be73-df5f5439ce74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec26b0b0-5880-46be-8408-4d24973b61cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecc9c26f-8f32-4e51-b3cd-fa8909aa654c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f012d3bf-2d42-4757-97d5-7b4e06a3e34a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f030d09a-bfcb-4f49-badb-80572c40436d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2ca2358-9edb-42a6-8d65-b04cc7207234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3e3d576-37a0-46cc-af33-ff50831dba6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3ffb2d3-ee13-43a5-833d-7b195b6800b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4058c19-abfa-40e6-be1a-4383ef698fe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5a98332-a84d-4afb-92e2-c6864487eb2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5bf5cdb-82a5-406c-8a83-540c8950da4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6b5edb1-3582-4b9c-9677-0bc6546856c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc7521c0-d419-42f5-853e-f7e1a4596019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffe8f47d-8106-4757-8e21-7ecfce183967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01be8690-824b-416d-ad53-8ff91637a9af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01ff6aaf-04b9-4c59-ba37-c7595a4c3d72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03372593-ccd8-4694-bdcc-288af8b99337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_039ec984-4f30-4245-a719-3f78dc15fcec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03f2a1f5-5552-4bb3-8054-73c7ba425664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_056481b1-615a-4a0b-be83-d7a61b440963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05b26b2f-9751-4114-9b4d-1f27c7a082b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_073660e5-5cdc-4aa5-bdd8-945aa122a95e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08022210-395d-4e18-8e81-25fb26ecc016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c7272ae-5a35-4fd0-a989-3743ca61d47b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12550a26-38e1-43d4-ba71-fd211389e27b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12f49acb-8742-41d4-9923-a2216a6f6c00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1401fdb7-db69-4752-84b0-33a1bf08327e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b003891-9df8-4c3e-897c-1fb1aa2df080"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f7ddecb-f392-44f4-ad1e-e78403f10615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21251a65-514d-4821-8601-a38593377a16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26d88cb1-917a-47b7-bc4a-dda7edff6d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2772c92d-b1b2-4583-a232-57c12aa8bd76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bf2a1e3-cad2-4e60-8ad4-1deb2537ad3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2dee6185-6fe7-4fe7-9224-3070f221841e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e43a4a8-0858-4032-9cd8-7e0c716a772a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f79acac-e627-48d5-9564-fc705c1b6bf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_312fe5af-47eb-44f8-b640-5fa199c3922a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_314e26da-7245-417b-9c1d-86a1223c91d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36c20446-d6e8-4fbb-a272-98587f51dafb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38bd045b-6b7c-45d4-b4db-ce9530ca306e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39debf85-4fa8-4c07-b208-ccb5e963b79b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39f6ee0b-635b-48d3-989f-20a78ce49678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a3bd4d5-6d69-48ff-b7ae-649b9726debb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4087cba0-104d-4360-b9e5-71ace8a7d6ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4187e27a-41a0-40cd-9657-51ee99cb77a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_420d9d73-2ff1-4e4b-8061-261d7464f0ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42889623-0040-458a-920e-d65790deccca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43df5cb4-c8c5-4468-ad39-664e7ed58b84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4eea3c58-e991-4fc6-8757-166b21081709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f95f078-a582-42d7-8906-772ef768b12a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51dedf03-534d-456b-bc8d-dbddd1b00ea3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_528c05d8-ffba-4060-b718-ab6ab294db2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_587b9996-792c-406a-9097-ea9d86361e65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_589e1185-37d3-427a-b335-fd22cdf25399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5af88fcb-7693-4986-8b59-4188cdbae19f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b59d05e-c3b1-45c8-9ceb-30f281d1b071"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61343ea4-cef1-4e5a-bac8-86e012cbec65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6340f08b-92f6-445a-beaa-8a9f14410270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64aecf04-4116-445d-a4a6-95702c1e60de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ae41927-1c72-4a1d-ac10-40808ca06555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7397308e-56a8-4bd6-af70-4190269950ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7579b5b9-3b9e-41bc-94ba-1f9cf6e0adf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7660fae2-d3c3-4c79-8e9e-2e0a0f620221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76d6bf22-8e23-4100-ac8e-909ff6f3b8b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7af8fcae-e898-443a-a9f6-0e043da02452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nuvl:DebtSecuritiesAvailableForSalesSecuritiesDueAxis">nuvl:DueWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b51e495-8c14-4e56-ae9d-be367b379e30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bdeab21-6994-454d-9909-26915b05e48b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c716e1a-4265-4608-b04f-9b2f56f2081f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fed8a7e-5f09-4c6a-ad30-c11b950611c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>nuvl:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, DC 20549</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cdf292c-c2cb-42cb-87e5-32a992a51040" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c3a6c3e2-63bd-4c1a-98f4-66360f23f7b3" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11daf5f1-42c5-4052-bbe6-adf2f2361fff" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90b18be9-29f9-4d9f-ace4-002f9c9698a4" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a29d074f-f714-49e3-acf8-587bc85f0a3c" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from _____________ to _____________</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be51ae37-013d-467b-90eb-ee84f31aac28" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-40671</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img240556275_0.jpg" alt="img240556275_0.jpg" style="width:134px;height:40px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5da89b9-5c19-43e0-892e-3b2a684796d2" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">NUVALENT, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:8.65pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1dfb917f-42ee-4ea3-81b9-e13be1efd3e2" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3f4125af-eded-4fc2-b239-cda35c0ab535" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-5112298</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2e1add9e-ed8a-46b6-a394-09358f0b4540" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">One Broadway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_5897d42d-9b0c-4e0e-8ba7-0b80fa81254a" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">14</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> Floor</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bac6abac-30e3-4f9d-ad8f-9cc82695ffa4" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_8227cf35-9d97-4a97-9714-2b8dcd0a5654" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7dc4d630-b17a-4cb6-a7f6-54d3b1b6fecf" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02142</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40086cad-f478-4a4e-88ad-745ecdbeb9c1" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25b91616-0119-4b47-ab53-8aea6f877c60" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">357-7000</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.75pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40.008%;"/>
    <td style="width:1%;"/>
    <td style="width:18.004%;"/>
    <td style="width:1%;"/>
    <td style="width:39.988%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.006in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_52a15e38-22b5-4c86-a701-345c21161c97" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.006in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4ae82631-ae5b-41c8-8bad-1368c62466fa" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NUVL</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.006in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_934e4eae-5309-4825-a697-f1b4946f782a" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bba6315-79a7-45f3-bf9f-232444f35818" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7b932c8-f5f1-4b64-bfe2-360d3003d64f" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1.1%;"/>
    <td style="width:54.64%;"/>
    <td style="width:1.06%;"/>
    <td style="width:20.1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.1%;"/>
   </tr>
   <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d3bce95a-b7a7-4ddb-a393-635a37250ded" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_6a9c6509-d078-4c9a-a9bb-a0af53f25666" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_d6b25ead-7691-4780-a9ad-7d25b5925403" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> No </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4a65fad6-03e0-4c6a-bb20-1819a33c099a" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of July 31, 2024, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0e2cc6e-dbbc-405e-a880-3193f3e011fe" contextRef="C_7660fae2-d3c3-4c79-8e9e-2e0a0f620221" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,362,349</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock, $0.0001 par value per share, outstanding and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6249cb2-b606-4313-9e25-b42942a67d41" contextRef="C_7b51e495-8c14-4e56-ae9d-be367b379e30" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class B common stock, $0.0001 par value per share outstanding.</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report on Form 10-Q (Quarterly Report) of Nuvalent, Inc. contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Quarterly Report include, among other things, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, timing, progress, results, and costs of our zidesamtinib (NVL-520), NVL-655, NVL-330 and discovery programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, and when the results of the studies or trials will become available;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, scope and likelihood of regulatory filings and approvals, including timing of Investigational New Drug applications (INDs) and final U.S. Food and Drug Administration (FDA) approval of our current product candidates or any future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, scope or likelihood of foreign regulatory filings and approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one indication to other indications;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates of the number of patients that we will enroll and our ability to initiate, recruit, and enroll patients in and conduct and successfully complete our clinical trials at the pace that we project;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to scale-up our manufacturing and processing approaches to appropriately address our anticipated commercial needs, which will require significant resources;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain and further develop the specific shipping, storage, handling and administration of zidesamtinib, NVL-655 and NVL-330 at clinical sites;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to take advantage of accelerated regulatory pathways for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to commercialize our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the implementation of our business model, and strategic plans for our business, product candidates, and technology;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the period over which we estimate our existing cash, cash equivalents and marketable securities will be sufficient to fund our future operating expenses and capital expenditure requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future agreements with third parties in connection with the development and commercialization of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance of our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments in the United States (the U.S.) and foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to produce our product candidates with advantages in turnaround times or manufacturing cost;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitive position and the success of competing therapies that are or may become available;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our need for and ability to attract and retain key scientific, management and other personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of laws and regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments relating to our competitors and our industry;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of public health emergencies, natural disasters or geopolitical events, including civil or political unrest or military conflicts, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials; and </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other risks and uncertainties, including those listed under the section titled &#8220;Risk Factors.&#8221;</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;future,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;aim&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this Quarterly Report. If one or more of these risks or uncertainties were to occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report and the documents that we reference in this Quarterly Report and have filed with the Securities and Exchange Commission (SEC) completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements in this Quarterly Report represent our views as of the date of this Quarterly Report. We do not undertake any obligation to publicly update any forward-looking statement except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. All of the market data used in this Quarterly Report involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except where the context otherwise requires or where otherwise indicated, the terms &#8220;Nuvalent,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; &#8220;the company,&#8221; and &#8220;our business&#8221; in this Quarterly Report refer to Nuvalent, Inc. and its consolidated subsidiary.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY OF RISK FACTORS</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the section titled &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report and our other filings with the SEC before making investment decisions regarding our common stock.</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a limited operating history, have not completed any later-stage clinical trials, have no products approved for commercial sale and have not generated any revenue, which may make it difficult for investors to evaluate our current business and likelihood of success and viability;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the foreseeable future;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future prospects are substantially dependent on zidesamtinib (NVL-520), NVL-655 and NVL-330. If we are unable to advance these product candidates through development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our preclinical studies and clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our discovery and development activities are focused on the development of targeted therapeutics for patients with cancer-associated genomic alterations, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs may never lead to approved or marketable products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, European Medicines Agency (EMA) or other comparable foreign regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to zidesamtinib, NVL-655 and NVL-330, our prospects depend in part upon discovering, developing and commercializing additional product candidates from our discovery programs, which may fail in development or suffer delays that adversely affect their commercial viability;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our approach to build a pipeline of product candidates with commercial value;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to submit INDs, clinical trial applications (CTAs) or comparable applications to commence clinical trials on the timelines we expect, and even if we are able to, the FDA, EMA or any comparable foreign regulatory authority may not permit us to proceed;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may cause significant adverse events, toxicities or other undesirable adverse events when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim, preliminary and topline data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays or difficulties in the enrollment or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never commercialized a product candidate as a company before and currently lack all of the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market opportunities for any product candidates we develop, if approved, may be limited to certain smaller patient subsets and may be smaller than we estimate them to be;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where appropriate, we plan to pursue approval from the FDA, EMA or comparable foreign regulatory authorities through the use of accelerated registration pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw accelerated approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are licensed for marketing and receive federal healthcare reimbursement, any relationships we may have with healthcare providers will be subject to applicable healthcare fraud and abuse laws and regulations, which could expose us to criminal and civil penalties and exclusion from participation in government healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on a limited number of employees who provide various administrative, research and development, and other services across our organization presents operational challenges that may adversely affect our business;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position would be adversely affected;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal stockholders own a significant percentage of our stock and can exert significant control over matters subject to stockholder approval. Two of our directors are affiliated with one of our principal stockholders; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iv</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nuvalent, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:8.42%;"/>
    <td style="width:85.62%;"/>
    <td style="width:1.04%;"/>
    <td style="width:4.92%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_ifinancial_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I&#8212;FINANCIAL INFORMATION</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements (Unaudited)</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#consolidated_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">1</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#balance_sheet_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">1</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#consolidated_statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">3</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">4</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_onsolidated_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Condensed Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#notes_to_onsolidated_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">5</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#managemen_discussion_and_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 2.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#managemen_discussion_and_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#managemen_discussion_and_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">10</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#quantitative_and_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 3.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#quantitative_and_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#quantitative_and_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">19</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 4.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">20</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_ii_other_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II&#8212;OTHER INFORMATION</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">21</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1A</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">21</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 5.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#item_5_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">79</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 6.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">80</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signature"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08333333333333333in;text-align:right;"><a href="#signature"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">81</span></a></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">v</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ifinancial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I&#8212;FINANCIA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">L INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements (Unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NUVALENT, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BALANCE SHEETS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.98%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:17%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:17.02%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc565cf9-2b77-40f4-bc94-295fc17cd23f" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,700</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c5e8c2a-57ba-46c0-b0c0-4b97c4e848bf" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">335,387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18c2b36c-edda-4e19-a186-d076ba5ef2d2" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">580,294</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d84d4a57-0c84-4300-b577-fda3e601b3f0" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92ea86a2-14e9-462b-980d-654d7284de15" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b18d07f-e4dd-424d-8fe7-62abd91c5f84" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,583</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8c7e1df-1586-4d7c-b012-2154aafe427f" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">666,258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e793e49-7cda-41f2-bf2b-e51468577ea8" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">726,488</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52558552-755c-4545-9ec4-508340aebdfc" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,972</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9c95474-a283-4334-9c36-c97d5c9bf298" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,896</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_713b254f-0be9-4c10-b5c2-fa23b71fc581" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">675,230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e319662-e6a5-4b50-96a2-0369386203ec" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732,384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f0b67cf-01dc-481a-8910-da3937af307d" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69b0c469-3cf7-48f9-8c12-837967260187" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,274</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4cdf029-1b5e-4dc6-99e1-63e8515df640" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,789</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6cd5d0e-f4be-4028-bd8c-6ccc84d86011" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,549</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32320162-0c39-4c73-b43b-564c394dab15" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0129d1f4-bab5-413b-907e-1b2b6cb1d64e" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7059f1e3-ca7a-4b60-a781-6e83ad362284" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6477cbfc-281b-493c-a42e-3aa7cfba78e6" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_c8b76d45-ca24-479d-bfc0-33cd63ec8f6f;"><span style="-sec-ix-hidden:F_5a4c6053-1bda-44a6-bb38-708e59ad7023;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 8)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcf083ee-e04f-421c-8866-2c7d0e1c7d8a" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_63b0851e-ed67-4e3f-81ae-43c93ab59c8e" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c50fc542-b697-439d-9c59-b5503b2e5ead" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_00b940c5-e4bd-4d71-9b44-7b623e93b89f" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized;<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f602377-f4f1-43bb-bd0e-44137a9eb861" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d27a5750-5d13-4c8e-83f7-57303444915e" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9f896590-55f1-4130-8b08-795b72a41ee0" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4ba5efa7-44cb-4529-84fb-095f60959a7d" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued or outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_a657f8ec-8294-4130-9623-1489cad84d2f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_03e6a0da-df8a-46ea-9b2f-331e1a872a11;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67e501ac-da44-47ea-bdfb-4a29dfdd5780" contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a7fe9d3f-2fc1-41ba-b80a-b38a9b4ff409" contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c816708-f7f2-4d1d-80b5-89281b5f43f8" contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c8d973bb-7fd4-4243-9e2e-bfe16b85e085" contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">140,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized;<br/>&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e05c9c0-7234-48c5-a7e3-e3ecff3a9228" contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3bd3dbe1-2bd8-425f-931b-35c092c187d2" contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">59,284,728</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abfeeb17-82f2-41ce-995f-d81f5873f067" contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_adac4a6b-1c3f-45bc-a43f-c1ac15345eb6" contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,629,896</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at <br/>&#160;&#160;&#160;June 30, 2024 and December 31, 2023, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_960b1f9b-8c35-43dd-a9ec-3d1c4978536f" contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_692d9df4-31d0-4b89-8f39-671f639a773c" contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class B common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2920a23e-aadc-4def-8de3-5f65c38490e4" contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_28274551-4469-473c-a2cc-87c133ee969a" contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96fa5b9a-4255-49a9-828a-df29862f5bd6" contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ce989341-87b6-4670-a47a-af185ebe5efc" contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_493780d7-e590-4eb5-998a-72e7c7da3f97" contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f5eb8ee6-230e-4664-a3ef-19789b580f4c" contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a8f22227-c662-4523-bb4e-b2ffdcac16a5" contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_eb955bf0-0b46-45b9-aff7-9ee0c39b78be" contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at June 30, 2024 and <br/>&#160;&#160;&#160;December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecdfb124-a2f7-4307-a852-8bcf4a259ac4" contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdf338d4-6b5d-4dc7-bbd0-e0e8b6c6a0d3" contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78d085ef-f943-45cb-a269-65f3f6991b57" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,026,546</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_463917f9-860a-4fd5-b2dd-62b94ed5f444" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986,819</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fba43ce-3f47-4eb8-8878-63b403b54251" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,571</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0115430-d8c8-42ab-99d0-decf46ba7d52" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e250c4b-6da7-455c-b45a-0191d7e7d982" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387,944</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bcd52bb-1298-49bd-9a54-def865474cac" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">286,296</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2b4092b-b0d0-4631-95b7-5240bbcb9012" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">637,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed1e4f8e-3cf8-4074-ad1e-f20224225208" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">700,561</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0e314af-4865-4a2c-9b5b-54666d06106a" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">675,230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac68c8ff-c56b-4aa2-abaa-3d65cb1717b7" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">732,384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NUVALENT, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.231%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.258%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.258%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.258%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.998%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="text-indent:5pt;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f876768f-a168-4c2b-9ad2-fb494286eb95" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e112934-ca0b-4a6a-8638-d10488c22197" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,922</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41c59717-3aaf-4a29-816b-4b8ba3ad81fc" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,800</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb73608c-ff0f-4714-8950-7b2c594ec64d" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,047</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca8e8a7d-7ec8-432d-b6c3-cfcbb9c2391c" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,984</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d173d60-4713-4e86-a8ef-ea2c0ae33022" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f2d7ab8-e0ab-4811-93e4-d5f78f34aaf1" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6deab832-980f-4a70-a1f8-e35fad61668e" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7660161d-3865-4108-8ac5-d5e63d75fa82" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81b2bd26-29a3-44c8-a103-733890605557" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e89a7742-aa58-4fc3-85a8-2ad70d948c6b" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,738</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70953af2-4824-4df4-af8f-6109540f7112" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a17bbd8f-84cd-463b-81fa-dfb8248567b2" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3189760-bf6a-43b7-b339-2786dafe75f1" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0bb061b-6873-4be5-9b04-e2e82051962c" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,738</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13019e78-ca24-4d76-a018-ef696e5135fd" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">64,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense)</span></p></td>
    <td style="text-indent:5pt;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income and other income (expense), net</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9818e7c-d054-47dc-9c48-2367267db7f6" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="nuvl:InterestAndOtherIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3c8ca2e-1e12-4c0b-91ff-2f2cab0f505f" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="nuvl:InterestAndOtherIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,972</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8655f50b-dd5a-429d-a52f-18f6e2ca2e2e" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="nuvl:InterestAndOtherIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d45edfa8-0138-44dc-b813-2603eb8d9787" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="nuvl:InterestAndOtherIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0443fb05-c8ed-49af-acba-ea1747507a8b" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0b30960-d061-416e-a735-366ca5ac3bb1" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,972</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdbc338b-49b9-4dae-861d-c04fe253da84" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3ea4eda-fb4b-44df-b907-d8879c709290" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af263d7e-c60a-40df-bb29-e343909888be" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56,996</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b1d7840-6a90-4d7a-acf8-403ca1431ebb" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,090</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74d9cfe6-d808-478f-a7d9-62b037ae91b5" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd42bdd4-a305-44ca-8801-3d03acd04d15" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bce75cb-feec-4073-845c-e75c700e12ab" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0128d02b-2a24-43b7-8d6d-3fe8fa304293" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">553</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42f9bf64-a2e7-48ef-945d-c1b4254fc249" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff6936f7-084e-4b52-b0ad-a58fc2bb6f79" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,090</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73ca6360-1811-464d-8a6f-000bff7e9047" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa0da7a-e1b8-43e3-a92b-66f342e942e6" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to Class A and Class B common stockholders, basic and diluted</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84dd5a17-0ceb-4450-911d-845b844f48fa" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6a63ba15-666d-4843-9461-267a5adc2238" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.88</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38e2d560-6de3-4047-be5f-d00140fd3663" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_36d47359-8eb6-473b-8b8b-cb1e24e89e8a" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.51</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_660a7cb2-4c97-4442-afdb-de5d8f789127" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_587bda6f-65a9-4335-bdf5-a34b99bf14b1" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.58</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dba5232c-f382-4131-b8c9-ba1513cfef3b" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4a53bfa6-1a0d-4979-b6b9-d0e43c0169bb" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.96</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares of Class A and Class B common stock outstanding, basic and diluted</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57b72863-ac75-42c0-9f11-5f988d24bf68" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f368eead-a5f0-4093-936f-1459d3d87a67" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">64,605,308</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e61580bb-9e04-4885-9802-96fb64073c8c" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2f930796-cb91-450d-a161-8c06a702ac94" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">56,866,991</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_213e320e-0e23-4bcf-a3fe-57587adfeaf8" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_88cb88df-7486-4ff3-90ff-87864953e05d" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">64,377,948</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7f4a722-5e39-4fa5-8008-c46a652d5973" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_780e7397-8ef7-4261-b34c-832a5aafeec8" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">56,785,883</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="text-indent:15pt;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b744b7a-65b5-41f5-870f-69cf88270ded" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e40d2376-bd77-46eb-b256-541512531061" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,090</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4b66385-61b9-4715-92e8-bd6527cdbd24" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07792f0b-ddfa-4245-91dc-784edae70bbd" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="text-indent:15pt;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized losses on marketable securities</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47b2db93-2659-463b-9b51-27a776f1efc1" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_255a53d2-af2f-48e2-a1aa-3a138005e321" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81c04652-49da-4f3a-beb1-63f66a90b7d0" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,602</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2734a4a9-db98-4c44-a9ea-b5ddc9c98a48" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,043</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5df27f6-2217-4f13-944f-41728e803cf0" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,419</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff6ea92c-7c05-4bda-957a-f68b5d910b6a" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30,325</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_094dd18e-4099-466e-b23e-13b96fc68918" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5330ed6-73b1-45a1-8e00-014abf02228b" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,325</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NUVALENT, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.02%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.68%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Class A</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Class B</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b9d76fb-48e9-4c1b-9406-bbb4ac7dcd7b" contextRef="C_5af88fcb-7693-4986-8b59-4188cdbae19f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,629,896</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_438e0bce-10d8-48d0-b91c-e2a65df7b30a" contextRef="C_5af88fcb-7693-4986-8b59-4188cdbae19f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dabe91cd-f00a-495a-aa0a-e90f22b30396" contextRef="C_528c05d8-ffba-4060-b718-ab6ab294db2f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba46e279-cfd3-4019-b11c-4e172c0f2f50" contextRef="C_528c05d8-ffba-4060-b718-ab6ab294db2f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_680349a8-5671-4553-92a6-6e24d48df2ad" contextRef="C_6ae41927-1c72-4a1d-ac10-40808ca06555" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986,819</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c3755b2-df12-4209-91e0-01b8a2e3bd9b" contextRef="C_4087cba0-104d-4360-b9e5-71ace8a7d6ee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51b9a544-2684-4335-95fa-3836718eb7c9" contextRef="C_c11a9bc4-489e-4596-a690-f7a824830151" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">286,296</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d120311-5154-45ff-b31b-e45e578afd74" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">700,561</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c697424b-6db2-4c35-b09c-6c1ededa653c" contextRef="C_ba328089-ed54-41d2-ad71-894cccb07734" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">425,737</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aed87d07-3254-49d3-bfaf-316814bb7cc9" contextRef="C_21251a65-514d-4821-8601-a38593377a16" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,452</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f357cd5d-18a8-43c1-97ac-2e60ef7c9c4e" contextRef="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,452</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized losses on marketable securities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8370037c-f9c6-43c3-9707-8590f62cb517" contextRef="C_e62e5e75-78d6-4cd9-95e2-9ba468b61771" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20b95031-24ca-403a-989f-12007fb80455" contextRef="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91798bbd-9a54-4226-a146-ad74a6fecef8" contextRef="C_21251a65-514d-4821-8601-a38593377a16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40d90ffa-657d-4844-bbee-eef9707b80a7" contextRef="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d0eb5ad-a6f6-4075-b957-5d7cdcab1876" contextRef="C_314e26da-7245-417b-9c1d-86a1223c91d5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,482</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08b77ba9-aac2-485f-bf93-4e813db173ba" contextRef="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,482</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances at March 31, 2024</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a08bb06b-8994-4470-94dc-dfa9a088405c" contextRef="C_5b59d05e-c3b1-45c8-9ceb-30f281d1b071" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,055,633</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49b11910-1e29-48f5-bb36-3dfc803a8705" contextRef="C_5b59d05e-c3b1-45c8-9ceb-30f281d1b071" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6411c369-ace0-4880-a909-5139beedbbf2" contextRef="C_f5bf5cdb-82a5-406c-8a83-540c8950da4f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fed76f71-c0da-4a1d-b424-4ef92503cffb" contextRef="C_f5bf5cdb-82a5-406c-8a83-540c8950da4f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95aa8e28-45ba-46fb-93f4-20ec63e5511f" contextRef="C_01be8690-824b-416d-ad53-8ff91637a9af" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,007,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1673f6d9-5a37-471b-8725-5c6927fadb8e" contextRef="C_f3ffb2d3-ee13-43a5-833d-7b195b6800b9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_837b039d-eb39-4535-aa1e-093065cb64a7" contextRef="C_b8e8c5a4-91d7-4f1f-a636-6c63980a1c7b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">330,778</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b242126-9a7e-4912-8985-0dc488c6a3de" contextRef="C_056481b1-615a-4a0b-be83-d7a61b440963" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">675,039</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b44c6b9a-5aa9-4fef-947d-50987603cd40" contextRef="C_2dee6185-6fe7-4fe7-9224-3070f221841e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">223,858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7355db5f-8d0b-40f5-bbc2-317d1fb74f10" contextRef="C_6340f08b-92f6-445a-beaa-8a9f14410270" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,001</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_086d5708-9672-41a0-ae6d-5ba7db713edd" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,001</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c22dbf6d-31d6-4c68-8e06-bc62373a0393" contextRef="C_2dee6185-6fe7-4fe7-9224-3070f221841e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,237</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9975b75b-003a-4561-9758-d538b634b22c" contextRef="C_6340f08b-92f6-445a-beaa-8a9f14410270" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0c7994c-9eec-4f4c-a13b-aa39b71b5624" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized losses on marketable securities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5799d41a-0bf8-4109-86f0-6daf167a8945" contextRef="C_9a17bbbd-552a-4726-853e-2c935be60a16" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8c5bdf9-e948-4541-973a-83a565fd380e" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_133f08d3-2671-4784-a920-c9209de9efc3" contextRef="C_6340f08b-92f6-445a-beaa-8a9f14410270" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,125</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8edc59f2-a536-4f23-9abe-8d7fc0bdeb74" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,125</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bedf583-4637-4197-8b4c-90acd5620b1a" contextRef="C_c957d1b2-202c-4ada-b960-079ff36c0f99" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_027a85d6-d6be-41e6-8228-d7b72b8d2f06" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances at June 30, 2024</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa329878-b897-4582-a438-033e5cf1216d" contextRef="C_2f79acac-e627-48d5-9564-fc705c1b6bf5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,284,728</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55f24ab0-4d7b-44ed-9b8e-d4733f699217" contextRef="C_2f79acac-e627-48d5-9564-fc705c1b6bf5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fd1976f-5914-48c4-8d07-e06f6b40f57e" contextRef="C_84650898-1d7b-4a6d-9d23-20e46d3497a3" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f0864f9-0413-41c3-a1c2-b28821a01c05" contextRef="C_84650898-1d7b-4a6d-9d23-20e46d3497a3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4e19094-004e-4f71-8f8e-f34697503568" contextRef="C_81afe59a-ee6d-4907-9d22-6941e276a052" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,026,546</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2029dbf4-0fa3-4aed-be6c-60ec09c9acec" contextRef="C_7579b5b9-3b9e-41bc-94ba-1f9cf6e0adf5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,571</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2fe8e05-338f-4a2a-9533-096c06477997" contextRef="C_ecc9c26f-8f32-4e51-b3cd-fa8909aa654c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">387,944</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d5ac3a9-565b-4060-b3c2-a44482059a14" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">637,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.2199999999999998%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.78%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Class A</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Class B</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe1ec0d1-1b78-4b96-8783-4da69c80d0b9" contextRef="C_88495ead-dcd3-431a-99e7-37e3f2e1e634" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,233,701</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74ce2fa8-3cb9-4590-b445-3923a5627a18" contextRef="C_88495ead-dcd3-431a-99e7-37e3f2e1e634" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd4b00b6-b543-434a-a947-053bce47efc0" contextRef="C_420d9d73-2ff1-4e4b-8061-261d7464f0ac" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d87b84ae-745f-42a0-8a28-759d016d1105" contextRef="C_420d9d73-2ff1-4e4b-8061-261d7464f0ac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3748d225-b1f3-4b92-a512-751cac1ac2ba" contextRef="C_a4fd7116-d861-4be0-8726-91a1dd9e189f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">623,543</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c23f521-7790-431b-a7c8-5d69b502ecfa" contextRef="C_9af9cb99-b002-4432-a278-828a6d780b37" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1594b370-3425-4215-bfbe-8ee95282606f" contextRef="C_988aec88-7f73-46c4-ac21-a91b3287ea03" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,077</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f9bbf0f-bb7c-464f-9eb6-212d33d47129" contextRef="C_4187e27a-41a0-40cd-9657-51ee99cb77a5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">462,978</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81915108-4469-4d15-bc71-2bf8ac530166" contextRef="C_03f2a1f5-5552-4bb3-8054-73c7ba425664" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">82,989</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b66bef7-3f39-469e-8189-2014f90caa6e" contextRef="C_76d6bf22-8e23-4100-ac8e-909ff6f3b8b0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">619</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39d2798b-cde9-4e19-9bfc-b6b474eff6ae" contextRef="C_039ec984-4f30-4245-a719-3f78dc15fcec" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">619</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gains on marketable securities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b773e99a-cf26-498e-9e30-488f37ff2a71" contextRef="C_cf5818a4-e379-4f42-9868-d47198e49382" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f9a36bc-f7ce-41f1-b00c-7fb1e9a4e5bb" contextRef="C_039ec984-4f30-4245-a719-3f78dc15fcec" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_845328ce-7247-4c9f-9461-d809f117f334" contextRef="C_76d6bf22-8e23-4100-ac8e-909ff6f3b8b0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,371</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b4ae049-96c9-493f-b2fa-b692ccc266b4" contextRef="C_039ec984-4f30-4245-a719-3f78dc15fcec" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,371</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64f93b3e-a616-4668-9bfd-b2fc234c8404" contextRef="C_dfe98025-5701-4a70-a255-fc81b13f1c68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5893b0bd-909d-4826-84a2-9699d9cc6565" contextRef="C_039ec984-4f30-4245-a719-3f78dc15fcec" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances at March 31, 2023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fac325ed-e8f5-4b4d-8878-455f2a42b08a" contextRef="C_eb2dcb47-6bc3-4f5f-be73-df5f5439ce74" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,316,690</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbede22a-106e-4ff2-98d3-cdd08dd8b188" contextRef="C_eb2dcb47-6bc3-4f5f-be73-df5f5439ce74" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_039982db-950a-40df-9be9-bcd3ca572c6c" contextRef="C_92daaa6c-720c-4d58-8355-66e550d7df66" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09368350-fae7-4cf5-9e66-2d5f1eb4cd7a" contextRef="C_92daaa6c-720c-4d58-8355-66e550d7df66" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b381368-578c-4aba-8992-2ce89505b82b" contextRef="C_03372593-ccd8-4694-bdcc-288af8b99337" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">629,533</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9581a92-b80c-4267-9985-3539827498ab" contextRef="C_d6836ade-3210-4068-9569-ee8d4b8489da" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">302</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6102081e-9bcb-4632-aaee-3d6484b782ba" contextRef="C_89bca620-1c60-420a-b2d6-3dff6795f400" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">185,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeaa0c38-b334-4af6-86dd-ea722f8b39f2" contextRef="C_38bd045b-6b7c-45d4-b4db-ce9530ca306e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">443,968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf439f77-6f6c-4f9b-823f-35a052e600f1" contextRef="C_1401fdb7-db69-4752-84b0-33a1bf08327e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">202,210</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11ba6487-5221-4ed8-bc5e-f6a0b844b8ae" contextRef="C_f012d3bf-2d42-4757-97d5-7b4e06a3e34a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b348634-e942-4026-9677-05bed080dc39" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_921da313-d58b-4793-aa74-5749e08cf15f" contextRef="C_1401fdb7-db69-4752-84b0-33a1bf08327e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,575</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e425508-d891-4ec5-8152-cad6ae36b70e" contextRef="C_f012d3bf-2d42-4757-97d5-7b4e06a3e34a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b072f96-045d-41bb-86aa-8640a58d34f8" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized losses on marketable securities</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ba8b1b2-2af5-400b-84c6-22c8e82ee5a9" contextRef="C_2e43a4a8-0858-4032-9cd8-7e0c716a772a" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_321db90e-df50-4bbf-9d27-2e2e8e83172e" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42cdf691-2eb7-4974-8a19-91c8a2452ebc" contextRef="C_f012d3bf-2d42-4757-97d5-7b4e06a3e34a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9abd964a-cd3a-40bb-8a60-8e59d310c245" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43aa1b8c-8611-4932-8625-a6bca10ece6a" contextRef="C_fc7521c0-d419-42f5-853e-f7e1a4596019" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,090</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aaccab83-0348-412b-be7d-527dcb2a39c0" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,090</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances at June 30, 2023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82739b6a-ee4a-475c-9956-15749f8cfccc" contextRef="C_a8d3411e-0ed4-454f-b70f-25a209c05079" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,525,475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d2ab028-a647-4da5-9e36-c8626f76733e" contextRef="C_a8d3411e-0ed4-454f-b70f-25a209c05079" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10ba5d56-6421-458e-af79-2771e7ff278d" contextRef="C_883bcdb9-2dfc-4e4d-8f72-50e4cd4d7ade" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,435,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c24dd821-7539-4a45-8a33-be84dbf4b761" contextRef="C_883bcdb9-2dfc-4e4d-8f72-50e4cd4d7ade" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_601c1405-3fa7-470f-9c4d-9ba4f60ac3f8" contextRef="C_1f7ddecb-f392-44f4-ad1e-e78403f10615" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">637,043</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3b60d60-5f33-4d1c-be5d-e16b9c5f087e" contextRef="C_39f6ee0b-635b-48d3-989f-20a78ce49678" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,537</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6236ef17-ba33-47ff-bfdc-33f2996bd001" contextRef="C_cd5fd91a-db75-43c1-9258-0ae8a9ebe099" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">214,359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a073118-398f-4b13-a233-6ad29642a743" contextRef="C_ffe8f47d-8106-4757-8e21-7ecfce183967" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NUVALENT, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.98%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:17%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:17.02%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="text-indent:5pt;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff072c03-3d36-4528-a533-afc8afa1453c" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81099827-94d7-45fa-b59d-120fe4ddd8ef" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,282</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:5pt;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_826e3b11-d69d-4132-a955-c5b98b51234b" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,982</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b53503c-5cb3-4ffe-b431-593865a69519" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,219</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net accretion on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_163ad27c-da5d-4752-a798-dc00c21fa90f" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,815</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bbce9fe-70a5-4059-97ca-9e3a016ce3be" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:5pt;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf128fd7-47b5-4933-998d-014f7e6c4cb1" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,681</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4852226d-8eea-46e1-8252-0e0fc7b7b842" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8598f898-a66a-4fb4-8f5c-6c4a629de929" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,076</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba117d8b-964d-4335-a3ce-1d2709e3ae29" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">488</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6e3482c-8f22-489f-acb7-ee4e79c69ccd" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,871</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd5eaeff-afd1-4a88-8f48-45110c090eda" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,012</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_031f516d-a4c2-4e91-97ed-0f48c16c9e21" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,862</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0326a3d1-f37f-4ff9-b61e-2308f5581a05" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,302</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc34e24c-8998-483f-bef9-662120ab639a" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">77,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf4c19db-0edd-454a-bbda-63af5d427016" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,549</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be615a6b-fb6e-4bb0-ae0f-097b23eaef58" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">371,849</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f925127-d1a4-484c-9fc5-5e729be2304c" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269,559</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3788560f-64c0-449c-917f-51402e87e165" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e6e38a1-8dde-47d9-abd1-489137de5062" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,893</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0aec934-b3ee-472b-bf47-ccf76cfd8d4a" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">190,563</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_209762f2-8bd7-44fb-a441-f1105380e1ad" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,666</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f3f7672-000b-48d8-ab83-fd2d881bd0d1" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,745</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cf2514e-a3ba-4698-ae38-81c42e31bdb4" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments of insurance costs financed by a third-party</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22fd05d6-d656-4f5e-80ed-e2f796ce678a" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">622</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96953237-5232-40c6-a189-9f0d42444d63" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments of public offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a93b4952-10ba-4846-8703-999ae2f77e14" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de439d71-5a82-46a1-92f5-b2a217f3cf8d" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1a96656-3a1c-4f8e-9c57-f192fe1fed2b" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d090fe52-5ca0-42b7-acf7-0a0bd4b3735a" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31023f9c-bc3e-4079-9319-cdb639b88b39" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">257,687</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b76609d-6e3d-4d69-a0b5-bfcbe1cbb6b0" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">170,934</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faa9ae53-7094-4e4c-8ce7-e5dd75e174b4" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">335,387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0d0c330-3f99-4fa4-b987-74aebe41e544" contextRef="C_4187e27a-41a0-40cd-9657-51ee99cb77a5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241,806</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d77e729f-80b3-4186-8e3e-8cab0cd40a1a" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,700</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17c2fe33-f1a6-4584-b306-762cdae8626b" contextRef="C_ffe8f47d-8106-4757-8e21-7ecfce183967" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,872</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NUVALENT, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_onsolidated_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fd910f7-5dcc-42cf-96dd-4c9df48bc791" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nuvalent, Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company was founded in January 2017 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts, and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41fbd0ad-3f05-4dfb-818f-b39af9fa2e56" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment. All of the Company&#8217;s operations are in the United States.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks similar to those of other pre-commercial stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of which are larger and better capitalized, the need to obtain adequate additional financing to fund the development of its product candidates, the need to obtain and maintain adequate protection for the Company&#8217;s intellectual property, and the impact of public health emergencies, natural disasters and geopolitical events on the Company&#8217;s business. There can be no assurance that the Company&#8217;s research and development will be successful, that adequate protection for the Company&#8217;s intellectual property will be obtained and maintained, that any product candidates will receive required regulatory approval or that approved products, if any, will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred recurring losses since inception, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35e89615-26d3-41f0-b45e-b9b3dcea7fea" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">101.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95b15860-08f9-45bf-b9b1-288e2ed4fec0" contextRef="C_eb05446e-36b7-480d-9b8b-648cbb9b5d4a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">126.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023. As of June 30, 2024, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b89894e5-f057-4b72-ab0d-5db1f618632e" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">387.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will need to obtain additional funding through public or private equity offerings, debt financings or strategic alliances. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company may be required to delay, reduce or eliminate some or all of its research and development programs or the Company may be unable to continue operations. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00402dff-297a-4c55-863f-2d7fee41762d" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December 31, 2023, included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 (the &#8220;Annual Report&#8221;), on file with the SEC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The results for the period are not necessarily indicative of the results that may occur for future interim periods or the full fiscal year. Certain prior period amounts have been reclassified to conform with current period presentation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting policies the Company used in preparing these condensed consolidated financial statements are substantially consistent with those applied in the Company&#8217;s Annual Report.</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20e44edc-98ed-4e58-b84b-9f60eee4a7a5" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently issued accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in Accounting Standards Codification 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities, on an annual basis, to provide disclosure of specific categories in their tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9132130-3e84-47e9-bd97-f01ca89bf745" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_662e8e41-1fad-489e-be84-e9669500a007" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables provide the amortized cost and fair value of the Company&#8217;s available-for-sale securities by security type (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.629%;"/>
        <td style="width:1.013%;"/>
        <td style="width:1%;"/>
        <td style="width:10.16%;"/>
        <td style="width:1%;"/>
        <td style="width:1.013%;"/>
        <td style="width:1%;"/>
        <td style="width:10.16%;"/>
        <td style="width:1%;"/>
        <td style="width:1.013%;"/>
        <td style="width:1%;"/>
        <td style="width:10.16%;"/>
        <td style="width:1%;"/>
        <td style="width:1.013%;"/>
        <td style="width:1%;"/>
        <td style="width:9.834999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8be2acd1-54c0-4a4b-9388-488630a87d51" contextRef="C_b727372e-2cfc-48db-824a-3abd0cf7dba1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,591</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53e5fd4b-089d-4e95-9a6b-4f2bfb5156e7" contextRef="C_b727372e-2cfc-48db-824a-3abd0cf7dba1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20b0f1fb-15ac-4bc9-8acd-7c0872f28080" contextRef="C_b727372e-2cfc-48db-824a-3abd0cf7dba1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,445</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_008242b7-d9eb-40c9-8599-a99c6d38cae9" contextRef="C_f030d09a-bfcb-4f49-badb-80572c40436d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">321,594</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9957e3e5-1e32-4e78-b90a-50e7109ce2b0" contextRef="C_f030d09a-bfcb-4f49-badb-80572c40436d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6024b93-8a7c-48fe-ba14-36ee0bce3b7b" contextRef="C_f030d09a-bfcb-4f49-badb-80572c40436d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,235</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13ce140e-d20d-4c22-9b23-25dea24a0b61" contextRef="C_f030d09a-bfcb-4f49-badb-80572c40436d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,383</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64547350-8831-468f-886e-3e77d0bbf3e1" contextRef="C_08022210-395d-4e18-8e81-25fb26ecc016" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,967</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05b54129-6c7d-4df0-ac3e-0fd99551a4ef" contextRef="C_08022210-395d-4e18-8e81-25fb26ecc016" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05c80478-3b2d-4610-9bc0-a72ac5839f11" contextRef="C_08022210-395d-4e18-8e81-25fb26ecc016" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1aa5417-fb0c-4ff4-bd18-4b995af3d472" contextRef="C_08022210-395d-4e18-8e81-25fb26ecc016" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,763</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6c4efe0-0a9f-4f2d-9615-56cc030056b7" contextRef="C_42889623-0040-458a-920e-d65790deccca" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,713</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90280f27-5174-4966-8911-95edd5908291" contextRef="C_42889623-0040-458a-920e-d65790deccca" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0b94151-c03c-4b91-9ed1-69ca8f99369c" contextRef="C_42889623-0040-458a-920e-d65790deccca" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,703</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1b1f1fc-7ca6-4563-ac9e-dd59a6eebeef" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">581,865</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32cf77b3-946b-46a9-8c7c-683fea578b70" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d10d5341-0a76-4e39-95d8-a89843f8f60a" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,603</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7859cf9-7d25-4207-aa3d-5eadabd60347" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">580,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.120999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78ba332d-9104-4d61-bd27-a3ac639c5f71" contextRef="C_ae08e807-c123-4741-9dfa-0c6b0be22746" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,098</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_791a625d-235a-4651-b80c-0ab013a56dff" contextRef="C_ae08e807-c123-4741-9dfa-0c6b0be22746" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c68d7ccd-1592-49bf-a8a0-951b4cf8d4ac" contextRef="C_ae08e807-c123-4741-9dfa-0c6b0be22746" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4df83a36-43f2-4c09-9575-d916fe900c29" contextRef="C_ae08e807-c123-4741-9dfa-0c6b0be22746" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10b16c5d-038c-446e-8601-4ab6fb8d7937" contextRef="C_f5a98332-a84d-4afb-92e2-c6864487eb2f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,876</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70a686ee-1491-418e-847f-f61a7910b15f" contextRef="C_f5a98332-a84d-4afb-92e2-c6864487eb2f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">328</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b16258e7-5f4b-448c-bf41-d48139c03ee2" contextRef="C_f5a98332-a84d-4afb-92e2-c6864487eb2f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62a420f8-993f-4818-9054-4582d61dc9d0" contextRef="C_f5a98332-a84d-4afb-92e2-c6864487eb2f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,949</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ea79a6d-019e-43b3-850b-32e7520c710d" contextRef="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,044</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0b14bb6-ed5c-49e1-9e74-0562eb24ab9c" contextRef="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_384cb85f-3614-4cb2-a6a6-c61ce273d3b4" contextRef="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_849b1fb4-4b3d-45e0-8961-06dd28d216c4" contextRef="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,027</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb03b855-244b-4a38-80ab-54f595700e4c" contextRef="C_ec26b0b0-5880-46be-8408-4d24973b61cb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3277a3d3-afed-434f-8c3b-58dd5c52f9c1" contextRef="C_ec26b0b0-5880-46be-8408-4d24973b61cb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_421bae12-3d1b-450a-a3cb-b02b016e1a19" contextRef="C_ec26b0b0-5880-46be-8408-4d24973b61cb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28f2a6a2-7bba-4c7f-9c4d-d9f5dc6ec186" contextRef="C_ec26b0b0-5880-46be-8408-4d24973b61cb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,462</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fa72cba-1309-4fca-aa34-ace90481a41b" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384,487</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_deb9d29d-102b-4ca8-9b82-f5dbfcec1006" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3e25523-547d-4a95-9bd9-8684ee35a14e" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f230a04a-94df-42ac-b7c4-309131c9c689" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384,518</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1536dad2-b8c3-4022-8407-d92a65509de8" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the amortized cost and fair value of the Company&#8217;s available-for-sale securities by contractual maturity (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:17%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:17%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due within one year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef6b438c-c012-4c07-a7cc-c40bb14b4ecb" contextRef="C_7af8fcae-e898-443a-a9f6-0e043da02452" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">423,126</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1cda0f3-4031-4f67-9ff3-6dbccdb7e373" contextRef="C_7af8fcae-e898-443a-a9f6-0e043da02452" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">422,244</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due after one year through three years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_763c34cd-ea17-4c59-b503-6849e637cc68" contextRef="C_dd5d8f9a-c02d-4126-aac2-509d06b9f750" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,739</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49845b69-22d7-4142-9bf4-17da4121dc46" contextRef="C_dd5d8f9a-c02d-4126-aac2-509d06b9f750" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,050</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04abf05f-553c-4497-a7eb-f56ac7631f87" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">581,865</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5197f8f0-906f-4dac-9bb3-5a1fc572fae7" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">580,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s available-for-sale securities are classified as current assets as they are readily available to be converted to cash and for use in the Company&#8217;s current operations. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fa40e54-4e51-4de4-b32f-e1d699b77a23" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0b534aa6-1eee-4a3b-9a76-c29ff8895037" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e9711b40-2cc8-44fb-bcbc-cce89c13f864" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d4076341-0c86-46da-b1e1-2971ad445951" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit losses recorded during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024 and 2023. Interest income for the three months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a7bbe5f-c54b-4507-aa48-60aac3eb16c8" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0b85bb5-7ac3-437e-8f59-f4fe47af7229" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Interest income for the six months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8960557-e488-415d-844e-b4f44ef822e0" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d67d1296-8089-4993-a371-71595559e648" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10015dc9-d8b5-4861-b607-dfc544998b32" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0241df43-9683-4f55-a391-d962af54ac17" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for its assets, which are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d25b0f49-c9f5-47a1-be42-677635c55568" contextRef="C_d471e413-6554-4db6-8acf-61536b52edf5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,001</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3bb4a32-39fe-4070-9482-d533e059fec7" contextRef="C_f6b5edb1-3582-4b9c-9677-0bc6546856c2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,001</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9c54faf-9521-40de-85aa-4ca85048977d" contextRef="C_e0b36d05-241e-4e01-9ba5-c205ade76ca0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,445</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51a216ce-d4ed-4c96-9302-e918d73ba93a" contextRef="C_f2ca2358-9edb-42a6-8d65-b04cc7207234" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,445</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8516ffd-d846-4251-9bfa-eeb8c71b748c" contextRef="C_cf25f6e9-997e-4fd3-8973-255b191f2346" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,383</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a64abd59-e994-453a-813b-43b0b98d67a4" contextRef="C_e15c1c22-7704-4697-a74e-3af37fe7c701" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,383</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8eab3bec-dcdc-4b3a-930e-62612cf40fc4" contextRef="C_0c7272ae-5a35-4fd0-a989-3743ca61d47b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,763</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d294a17-4975-4f3e-8d07-e1a972b6e5d7" contextRef="C_8082afd8-a4a7-4bb4-9a00-4af3037f710e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,763</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a824828-f897-4007-8571-df5e6331a51a" contextRef="C_3a3bd4d5-6d69-48ff-b7ae-649b9726debb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,703</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81aab72b-6e27-4d3b-a5ef-a23a9082852d" contextRef="C_99559338-f498-4e29-bfdd-3b309f0eca12" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,703</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_550f7ca2-753e-4e0d-9d6f-efcd5e7a8a74" contextRef="C_ddea1eeb-c815-4ae5-84ce-bc1859802e66" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,001</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33d07e5f-5f71-4bce-80dc-25fd6eef6ff2" contextRef="C_7c716e1a-4265-4608-b04f-9b2f56f2081f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">580,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5525aff-e6b1-4ed0-b329-a40edf8b51af" contextRef="C_4eea3c58-e991-4fc6-8757-166b21081709" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">637,295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.417%;"/>
        <td style="width:1.009%;"/>
        <td style="width:1%;"/>
        <td style="width:10.046%;"/>
        <td style="width:1%;"/>
        <td style="width:1.009%;"/>
        <td style="width:1%;"/>
        <td style="width:10.107%;"/>
        <td style="width:1%;"/>
        <td style="width:1.009%;"/>
        <td style="width:1%;"/>
        <td style="width:10.107%;"/>
        <td style="width:1%;"/>
        <td style="width:1.009%;"/>
        <td style="width:1%;"/>
        <td style="width:10.288%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9c873b9-f715-4171-b4d1-48ff91087870" contextRef="C_01ff6aaf-04b9-4c59-ba37-c7595a4c3d72" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,055</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2186c33a-176d-4365-8b50-db49adea6d30" contextRef="C_a09fdef8-930b-40df-ac06-fe78e76477a8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,055</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b66113c0-18a4-471e-a0b4-eaa94d3cc1d9" contextRef="C_05b26b2f-9751-4114-9b4d-1f27c7a082b0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_720d6f7a-4406-42b4-9bf9-db8f902a1a44" contextRef="C_39debf85-4fa8-4c07-b208-ccb5e963b79b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42767ac3-1f6b-4878-9106-1a4caba17f6f" contextRef="C_1b003891-9df8-4c3e-897c-1fb1aa2df080" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,949</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1293a7e7-0e06-4c19-9266-e15fd81da85d" contextRef="C_b3935287-1f96-4f1d-9282-abc8a9aee1bf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,949</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e17998fd-af17-4b75-84f6-10f2677c9bd3" contextRef="C_312fe5af-47eb-44f8-b640-5fa199c3922a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,027</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_058ef4a0-8eb1-4afa-8b14-bd2fc68b4cac" contextRef="C_f3e3d576-37a0-46cc-af33-ff50831dba6c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,027</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3c0d709-faf3-42a6-897d-3284f7ae6a83" contextRef="C_7397308e-56a8-4bd6-af70-4190269950ff" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,462</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed43f038-12f3-4c0d-a62c-5a835173e1b5" contextRef="C_9f503e5f-2ff7-4088-814e-386b1247b152" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,462</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_404c9e7e-c72e-4eb1-b40a-47a3cd6bb6cd" contextRef="C_43df5cb4-c8c5-4468-ad39-664e7ed58b84" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,055</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed838b65-ad6b-49de-8a53-f2cc4476a820" contextRef="C_7bdeab21-6994-454d-9909-26915b05e48b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384,518</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e7d76c8-217f-4a14-a236-5619497480de" contextRef="C_e4332e9d-ecab-43c2-822a-5e2730476c0b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">711,573</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Commercial paper,</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">corporate bonds, government and agency securities and U.S. treasury bills were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the three and six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_213d9169-45c9-41ba-9df4-2f959d7b7254" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0a31aaa6-fc1c-4e08-b34f-e8a801ab8b92" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e5a5ca1f-a36c-42e4-9438-bf94d225e8c4" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f201afb4-99db-44dd-bdd8-702cf5c5c9ca" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers in or out of Level 3. The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd88d8fb-09fb-4559-a295-ba598fa8558d" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_997ebb5e-3a7f-4190-85c4-bbb74fefd098" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:17%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:17%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical and other research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c93b1a2d-d49d-4454-aaa9-d2a119ff65f5" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74d8eb99-5bc0-49e2-b342-65161d5c1c8a" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,769</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued manufacturing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e74a510-a144-4480-baff-9729afc25241" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="nuvl:AccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,548</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf1e2872-8a54-427b-b195-644257dd34ef" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="nuvl:AccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c39434a-9576-4e32-bf55-df0ccc9bac96" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,914</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9845437-270d-4872-b612-53f48975171c" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,326</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9aafb30-50e0-490f-8588-8fd34737beff" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,350</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c4a58ff-a3ba-4a4f-ab52-094f8011c553" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,624</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d8ed96d-1b15-4806-b381-4fc85aa194fc" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,789</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb3f73fb-a82c-4a8a-899b-dc64bf9daac9" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,549</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7e700f6-bf71-46fc-9fb8-9963c98c0c64" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6d3d4ea-aec1-4591-ade3-00bb46813855" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded stock-based compensation expense within its condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1%;"/>
        <td style="width:10.121%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0619e668-d00e-444a-ab86-a5b324de7813" contextRef="C_4f95f078-a582-42d7-8906-772ef768b12a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,322</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d2d6acd-b0af-48be-a647-dc1c74ee0e8c" contextRef="C_12550a26-38e1-43d4-ba71-fd211389e27b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,693</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79e858f4-3c2c-44f4-b58c-b223289591d3" contextRef="C_073660e5-5cdc-4aa5-bdd8-945aa122a95e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,985</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cb75b27-bea1-49e7-ac58-123221db8d4b" contextRef="C_587b9996-792c-406a-9097-ea9d86361e65" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb7c6e96-47bf-4885-ac0a-1d4756cc9749" contextRef="C_c71bc11f-7d4d-4e19-871d-ec730c358b89" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,803</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41a31ecc-03db-4d18-8e64-2de69be5b82e" contextRef="C_b405fb65-a7d6-40f5-8618-a2c821d37b18" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_884e1cad-5288-4752-8cbd-ec825a2cc9d2" contextRef="C_589e1185-37d3-427a-b335-fd22cdf25399" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b880bdd3-a453-44e3-a0db-90bb158d83ad" contextRef="C_b52acea3-f3de-4d64-9ead-cf62a5c5a4f2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,013</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79314ae3-88b5-4675-b452-df59904fa4f6" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2871b463-7582-42f3-ba37-d8b3cc157c90" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41c0f9eb-b431-4c91-9cbf-f32d9ecacc1c" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff005323-705a-42e3-8f68-76876042a698" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,219</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, total unrecognized compensation cost related to equity-based awards was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5adc72c-5ee6-4157-b40a-f6f8883d7776" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15bb8ac9-23e7-447b-ae1d-ada77db4a43f" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 equity incentive plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, the Company adopted the 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units (&#8220;RSUs&#8221;), unrestricted stock awards, cash-based awards and dividend equivalent rights. Stock awards granted under the 2021 Plan with service-based vesting conditions generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_eeee3d3c-e24c-41bc-bc07-f38b69f1afef;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">- or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5b8076c-d2af-4dba-be54-12444d03ae12" contextRef="C_c9924db4-0921-4c31-8fa1-a6b333ccd48c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> service periods, and stock options expire after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90a0dc5e-7031-4c4c-88cf-30e326ff63b7" contextRef="C_51dedf03-534d-456b-bc8d-dbddd1b00ea3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78681455-be4d-4146-9ac6-93c2ab6308d9" contextRef="C_61343ea4-cef1-4e5a-bac8-86e012cbec65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,068,809</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock remained available for future issuance under the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 employee stock purchase plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, the Company adopted the 2021 Employee Stock Purchase Plan, as amended and restated (the &#8220;ESPP&#8221;). The ESPP permits eligible employees to purchase shares of Class A common stock at a discount in accordance with the terms of the offering and consists of consecutive, overlapping 12-month offering periods, each consisting of two six-month purchase periods beginning in December and June of each year. During the three and six months ended June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_c24f72cc-5c2d-4a50-a4b7-da131e80253f" contextRef="C_26d88cb1-917a-47b7-bc4a-dda7edff6d61" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a00aff39-ee75-4240-bcbb-90991db47ec8" contextRef="C_a06a450e-d5b5-4bc2-993a-a482facfadc4" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,237</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were sold under the ESPP. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22e79810-7494-43b3-94c8-458d936fa2d0" contextRef="C_12f49acb-8742-41d4-9923-a2216a6f6c00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,873,832</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock remained available for issuance under the ESPP.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_688180a3-0258-4175-9a3a-1047d391dd71" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s option activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.98%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.84%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.18%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47cbe160-0e49-4526-97d3-36f5a29434a5" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,034,755</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_938a1f8f-9eae-45ca-96f1-d75a8d1d3997" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.66</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_021d1d4b-cfd6-408f-8ebd-743ee3d69721" contextRef="C_eb05446e-36b7-480d-9b8b-648cbb9b5d4a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.06</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9eeeaae-f61a-430f-8490-59d37921925a" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">449,403</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_596a1c13-1a35-41de-b2e0-fdcd34100e77" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,198,801</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27b9b825-b48f-484c-81f6-809420b0dde3" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">75.18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89afb13a-8f76-4a0c-83ae-145ab775e13c" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">649,595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45ed9db7-c272-4720-9382-79cb814c59e1" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.09</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cdc734b-8e07-4dc0-94c2-66ab5f197d27" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,717</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24213ff0-a754-435e-8565-d0fbef840d7f" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">34.87</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4165118c-b33f-4f47-98f3-430b31e60d9f" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,561,244</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d99f24f-3427-4d57-806a-de667ac5ba05" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">25.78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_af608ffa-173d-4033-b6fb-b7155ea55a8c" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.85</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f465f2ea-e58a-47d3-8d32-6b63edcf62d5" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">430,979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86db961a-5cdc-40cf-8da6-90ffbe541a0e" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,113,020</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b10d035-8d1a-4592-b699-306db617f190" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.42</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8726e2b2-2f63-456d-92c1-cabee4237502" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.18</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_782abb8d-54f5-4bbd-96e0-b7754f0202ca" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,837</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options exercised during the three months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b4273a6-7f69-418d-9695-88b00df751d4" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ba3fd67-7d53-403e-a31f-92059e8648ff" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8069dfb-1a9f-4ecb-a6de-c5706d5630de" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93996564-82f1-4c2a-9841-deaa62c6e76a" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock on the date of exercise.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant-date fair value of stock options granted during the three months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39ceb954-8250-48de-a264-1c0291077010" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">50.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8c78598-1644-490a-84a0-84b54ffd540e" contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">28.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The weighted average grant-date fair value of stock options granted during the six months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_890f62fb-fb41-41d0-9f7d-608f2744d6f4" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">51.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5b1dd56-d071-4656-8d88-90006c797721" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.68</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSUs</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af661204-0339-40d8-9fea-410adbaa7020" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:17.38%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:16.66%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Grant-Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4bfd5dd-eae7-438a-960c-ff26f42ade38" contextRef="C_9d832d33-eda0-4982-a7a1-aa5692816a09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">652,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d388a5c3-ed8f-4f77-b322-15842b074b29" contextRef="C_9d832d33-eda0-4982-a7a1-aa5692816a09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">73.93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd568673-e192-4b06-8c6e-c361ecfb7fe0" contextRef="C_9d832d33-eda0-4982-a7a1-aa5692816a09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fe9d4ba-ce0f-4c0a-909e-c0314455d74c" contextRef="C_9d832d33-eda0-4982-a7a1-aa5692816a09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">72.35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8459efa-94b8-4dd5-a50d-478b9bc73318" contextRef="C_ceab70a5-e653-4ed2-a8bc-07d80f617df3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">650,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0b53d9f-3fa5-42ce-9ee2-51a2a05eeefa" contextRef="C_ceab70a5-e653-4ed2-a8bc-07d80f617df3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">73.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01219a17-7b18-4df0-938e-33128c09403d" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has two classes of common stock outstanding: Class A common stock and Class B common stock. The rights of the holders of Class A and Class B common stock are substantially identical, except with respect to voting and conversion. Class B common stock is nonvoting, and each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company&#8217;s amended and restated certificate of incorporation. The Company allocates undistributed earnings attributable to common stock between the common stock classes on a one-to-one basis when computing net loss per share. As a result, basic and diluted net loss per share of Class A common stock and share of Class B common stock are equivalent.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12c3892f-e9a2-4ff3-9ebb-cc344205aecf" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.94%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:17%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:17.06%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_553a51f5-9d4c-477f-877b-8de1c5811a84" contextRef="C_2bf2a1e3-cad2-4e60-8ad4-1deb2537ad3d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,561,244</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d40271a7-65a8-4db4-8275-71d12664cdae" contextRef="C_ac50ef0f-861a-4b28-a19c-6dd7b8e6e453" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,514,372</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30f8d6c2-64fa-4cc9-949d-6eb90c991b49" contextRef="C_7fed8a7e-5f09-4c6a-ad30-c11b950611c2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">650,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0778c2b-924c-4b61-af81-a560b91422e0" contextRef="C_8d29fec8-02e5-44cb-889a-504ab81f9925" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f36f55f-3f57-4676-b804-fd7793a630a5" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,211,525</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad2cf8ca-974c-4c05-a81c-205619bbd01a" contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,514,372</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e1b9fbb-8d51-4c4d-a9eb-e728dcc0e58f" contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has revenue sharing agreements with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund, IV, L.P. (collectively, &#8220;Deerfield&#8221;), each an investor in the Company, and the Company&#8217;s scientific founder to pay each of Deerfield and the scientific founder a low single digit percentage rate of net sales of certain commercial products. The payment obligation expires on the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country for both Deerfield and the Company&#8217;s scientific founder. The Company accounts for the liability with Deerfield at fair value with changes recognized in the consolidated statements of operations and comprehensive loss. The Company accounts for the obligation to the scientific founder as a contingent liability. Given the inherent risks associated with obtaining regulatory approval and achieving commercialization, the Company ascribed no value to the revenue sharing agreement with Deerfield at inception or at June 30, 2024 or December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company currently does not have any net sales and, as a result, has not paid any amounts under these agreements and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_325049ae-5f6c-4b00-8677-b8775c46c740" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d74bc77d-7849-4e5d-b97e-60301ce5df39" contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t accrued any liability as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 under these agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="managemen_discussion_and_analysis"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Resul</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ts of Operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 27, 2024 (2023 Form 10-K). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Item 1A. Risk Factors&#8221; section of this Quarterly Report and our other filings with the SEC, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our team&#8217;s deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for clinically proven kinase targets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limitations faced by currently available kinase inhibitors can include (i) kinase resistance, or the emergence of new mutations in the kinase target that can enable resistance to existing therapies, (ii) kinase selectivity, or the potential for existing therapies to inhibit other structurally similar kinase targets and lead to off-target adverse events, and (iii) limited brain penetrance, or the ability for the therapy to treat disease that has spread or metastasized to the brain. By prioritizing target selectivity, we believe our drug candidates have the potential to overcome resistance, avoid dose-limiting off-target adverse events, address brain metastases, and drive more durable responses. This may result in the potential to drive deeper, more durable responses with minimal adverse events, and we believe these potential benefits may support opportunities for clinical utility earlier in the treatment paradigm.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Candidate Overview</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zidesamtinib (NVL-520)</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first lead product candidate, zidesamtinib (NVL-520), is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). Zidesamtinib is a novel ROS1-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of currently available ROS1 tyrosine kinase inhibitors (TKIs). Zidesamtinib has received FDA Breakthrough Therapy designation for the treatment of patients with ROS1-positive NSCLC who have previously been treated with two or more ROS1 TKIs, and orphan drug designation for ROS1-positive NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ARROS-1 clinical trial is a first-in-human Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating zidesamtinib as an oral monotherapy in patients with advanced ROS1-positive NSCLC and other solid tumors. Dosing was initiated in the Phase 1 portion of the ARROS-1 clinical trial in January 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the EORTC-NCI-AACR symposium in October 2022, we presented preliminary data from the Phase 1 dose-escalation portion of the ARROS-1 clinical trial based on an enrollment cut-off date of September 1, 2022, and a data cut-off date of September 13, 2022. That data demonstrated that zidesamtinib had been well-tolerated with no observed dose limiting toxicities, treatment-related serious adverse events, treatment-related dizziness, or adverse events leading to dose reduction or discontinuation. Favorable pharmacokinetics (PK) were also observed with low intra-cohort patient variability and increasing exposure with dose level. Objective responses (RECIST 1.1) were observed across all dose levels evaluated in a heavily pre-treated population, including in patients who received two or more prior TKIs and one or more prior lines of chemotherapy, and in patients previously treated with lorlatinib or repotrectinib. Responses were also observed in patients with ROS1 G2032R mutation and in patients with CNS metastases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we announced the initiation of the Phase 2 portion of the ARROS-1 clinical trial, following alignment with the FDA on a recommended Phase 2 dose (RP2D) of 100 mg once daily (QD). The Phase 2 portion of the ARROS-1 clinical trial is designed to evaluate the overall activity of zidesamtinib in patients with advanced ROS1-positive NSCLC and other solid tumors, examining several specific cohorts of patients based on the prior anti-cancer therapies that such patients have received. Phase 2 cohorts have been designed to support potential registration in kinase inhibitor na&#239;ve or previously treated ROS1-positive NSCLC patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to share an update on the status of the global Phase 2 portion of the ARROS-1 clinical trial in conjunction with an oral presentation of updated Phase 1 dose-escalation data, as well as new preclinical data further characterizing the intracranial activity of zidesamtinib, at the European Society for Medical Oncology (ESMO) Congress in September 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NVL-655</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our second lead product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first-generation (1G; crizotinib), second-generation (2G; ceritinib, alectinib, or brigatinib), and third-generation (3G; lorlatinib) ALK inhibitors. NVL-655 has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with two or more ALK TKIs, and orphan drug designation for ALK-positive NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ALKOVE-1 clinical trial is a first-in-human Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating NVL-655 as an oral monotherapy in patients with advanced ALK-positive NSCLC and other solid tumors. Dosing was initiated in the Phase 1 portion of the ALKOVE-1 clinical trial in June 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 13, 2023, we presented preliminary data from the Phase 1 dose-escalation portion of the ALKOVE-1 clinical trial at the AACR-NCI-EORTC symposium based on an enrollment and data cut-off date of August 8, 2023. In these data, 93 patients were enrolled, of which 91 patients had ALK-positive NSCLC. Patients were treated in six NVL-655 dose cohorts of 15 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg QD. These data demonstrated that NVL-655 had a favorable preliminary safety profile consistent with an ALK-selective, tropomyosin receptor kinase (TRK)-sparing design. The observed favorable preliminary safety profile allowed for achievement of NVL-655 exposure levels above target CNS efficacy thresholds for ALK, ALK single and compound G1202R mutations, and other recalcitrant ALK single mutations such as I1171N. Favorable PK and low intra-cohort patient PK variability were observed with dose-proportional exposure. Preliminary PK data suggested that dose levels of 50 mg QD or greater may provide increased coverage of single and compound ALK mutations in the CNS. Objective responses (RECIST 1.1) were observed in a heavily pre-treated population, including in patients who had likely exhausted all available treatment options (&#8805;3 prior ALK TKIs including a 2G ALK TKI and lorlatinib), in patients with ALK single or compound resistance mutations, and in patients with a history of CNS metastasis. Responses were also observed in lorlatinib-na&#239;ve patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the cut-off date for the preliminary data, 67% (34/51) of response-evaluable patients remained on treatment with NVL-655 with duration of treatment up to 12 months (median duration of treatment of 3.4 months). All patients with tumor response continued on treatment without disease progression.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we announced the initiation of the Phase 2 portion of the ALKOVE-1 clinical trial, following alignment with the FDA on a RP2D of 150 mg QD. The Phase 2 portion of the ALKOVE-1 clinical trial is designed to evaluate the safety and activity of NVL-655 in several expansion cohorts of patients defined based on the number and type of prior anti-cancer therapies they have received. The Phase 2 cohorts are designed with registrational intent for TKI pre-treated patients with ALK-positive NSCLC and to enable preliminary evaluation for patients with ALK-positive NSCLC who are TKI na&#239;ve.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to share an update on the status of the global Phase 2 portion of the ALKOVE-1 clinical trial in conjunction with an oral presentation of updated Phase 1 dose-escalation data at the ESMO Congress in September 2024. We also plan to share more detail on our broader front-line clinical development strategy for ALK-positive NSCLC in 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NVL-330</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our third product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed with the aim to address the combined medical need of treating tumors driven by HER2 mutations occurring through deletions, insertions, or duplications (collectively, known as HER2 Exon 20 Insertions, or HER2ex20), treating brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type epidermal growth factor (EGFR). Preclinical data, including those recently presented at the AACR Annual Meeting on April 8, 2024, have shown that NVL-330 inhibited HER2ex20 in cell-based assays, was brain penetrant, and was selective for HER2ex20 over the structurally related wild-type EGFR.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently enrolling patients in the HEROEX-1 clinical trial, a Phase 1a/1b, multicenter, open-label, dose-escalation and expansion trial evaluating NVL-330 in pre-treated patients with advanced HER2-altered NSCLC, including those with HER2ex20 mutations. In July 2024, we announced that the first patient was dosed with NVL-330 in the HEROEX-1 trial. The HEROEX-1 trial will evaluate the overall safety and tolerability of NVL-330. Additional objectives include determination of the RP2D, characterization of the pharmacokinetic profile, and preliminary evaluation of anti-tumor activity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Discovery Programs</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have prioritized a number of additional small molecule research programs following an assessment of medical need. Research for these programs is ongoing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since commencing significant operations in 2018, we have focused substantially all of our efforts and financial resources on research and development activities for our programs, including zidesamtinib, NVL-655 and NVL-330, establishing and maintaining our intellectual property portfolio, organizing and staffing our company, business planning, raising capital, and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated revenue from product sales or any other source.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since our inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our product candidates. We reported net losses of $101.6 million for the six months ended June 30, 2024, and $126.2 million for the year ended December 31, 2023. As of June 30, 2024, we had an accumulated deficit of $387.9 million. We expect to incur significant expenses and operating losses at an increasing rate for the foreseeable future. We expect our expenses and capital requirements will increase substantially in connection with ongoing activities, particularly if and as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to advance zidesamtinib, NVL-655 and NVL-330 in clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance the development of our discovery programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our pipeline of product candidates through our product discovery and development efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and incur related additional commercial manufacturing costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">implement operational, financial and management systems; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attract, hire and retain additional clinical, scientific, management and administrative personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know how; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire or in-license other product candidates and technologies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operate as a public company.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization capabilities to support product sales, marketing and distribution. Further, we expect to continue to incur additional costs associated with operating as a public company.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by general economic conditions, both inside and outside the U.S., including disruptions to, and instability and volatility in, the credit and financial markets in the U.S. and worldwide, including heightened inflation, interest rate and currency rate fluctuations, and economic slowdown or recession as well as concerns related to public health emergencies, natural disasters or geopolitical events, including civil or political unrest or military conflicts. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to have to delay, reduce or eliminate our product development or future commercialization efforts. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development efforts.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2027. Our existing cash, cash equivalents and marketable securities will not be sufficient to fund all of our product candidates through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of our product candidates. See</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> &#8220;&#8212;Liquidity and Capital Resources.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Our Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating expenses are comprised of research and development expenses and general and administrative expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.657323613205966%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">personnel-related costs, including salaries, benefits and stock-based compensation expense, for employees engaged in research and development functions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.657323613205966%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred in connection with our research programs, including under agreements with third parties, such as consultants, contractors and contract research organizations (CROs); and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of developing and scaling our manufacturing process and manufacturing drug substance and drug product for use in our research and preclinical and clinical studies, including under agreements with third parties, such as consultants, contractors and contract manufacturing organizations (CMOs).</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We track our direct external research and development expenses on a program-by-program basis. These consist of costs that include fees, reimbursed materials, and other costs paid to consultants, contractors, CMOs, and CROs in connection with our preclinical, clinical and manufacturing activities. Costs incurred prior to nominating a development candidate are included in discovery programs. We do not allocate employee costs, costs associated with our discovery efforts, and facilities expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and, as such, are not separately classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that our research and development expenses will increase substantially as we continue to advance zidesamtinib, NVL-655, and NVL-330 in clinical development, and expand our discovery, research and preclinical activities in the near term and in the future. Although we are currently enrolling patients in the Phase 2 portions of our ARROS-1 and ALKOVE-1 clinical trials and in our HEROEX-1 Phase 1 clinical trial, at this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any product candidates we may develop. A change in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">outcome of any number of variables with respect to product candidates we may develop could significantly change the costs and timing associated with the development of that product candidate. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and progress of development activities relating to zidesamtinib, NVL-655, NVL-330 and any future product candidates from our discovery programs, including any additional costs that may result from delays in enrollment or other factors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain our current research and development programs and to establish new ones;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful patient enrollment in, and the initiation and completion of, clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of trials required for regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the countries in which the trials are conducted;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the length of time required to enroll eligible subjects and initiate clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of subjects that participate in the trials and per subject trial costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential additional safety monitoring requested by regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration of subject participation in the trials and follow-up;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the receipt of approvals from applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, receipt and terms of any marketing approvals and post-marketing approval commitments from applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we establish collaborations, strategic partnerships or other strategic arrangements with third parties, if any, and the performance of any such third party;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing commercial manufacturing capabilities or making arrangements with CMOs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any changes in the outcome of any of these factors could significantly impact the costs, timing and viability associated with the development of our product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, investor and public relations and accounting and audit services. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount and continue to incur increased accounting, audit, legal, regulatory compliance, and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest income and other income (expense), net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income and other income (expense), net consists of interest income and other income (expense) unrelated to our core operations.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the three months ended June 30, 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the three months ended June 30, 2024 and 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.14%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,166</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,922</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,244</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,984</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,140</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,844</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,150</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,062</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,088</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(65,150</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(34,062</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(31,088</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income and other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,154</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,972</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,182</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,154</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,972</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,182</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(56,996</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(29,090</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(27,906</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(57,166</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(29,090</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28,076</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses for the three months ended June 30, 2024 and 2023 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.14%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct research and development expenses by program:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Zidesamtinib</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,886</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,165</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,721</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NVL-655</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,196</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,007</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,189</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NVL-330</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,316</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,578</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discovery programs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,450</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,773</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(323</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,201</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,209</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,992</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,695</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,243</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,166</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,922</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,244</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $49.2 million for the three months ended June 30, 2024, compared to $25.9 million for the three months ended June 30, 2023. The increase in direct research and development expenses related to zidesamtinib of $8.7 million was primarily due to increased manufacturing costs and costs related to the Phase 2 portion of the ARROS-1 clinical trial. The increase in direct research and development expenses related to NVL-655 of $9.2 million was primarily due to increased manufacturing costs and costs related to the Phase 2 portion of the ALKOVE-1 clinical trial, partially offset by a decrease in preclinical development costs. The decrease in direct research and development expenses related to NVL-330 of $2.6 million was primarily due to decreased preclinical development and manufacturing costs, partially offset by increased clinical trial costs as we prepared to initiate the HEROEX-1 Phase 1 clinical trial. The increase in personnel-related expenses of $7.0 million was primarily due to an increase of $4.6 million in stock-based compensation expense and an increase in headcount. For the three months ended June 30, 2024 and 2023, stock-based compensation expense was $7.3 million and $2.7 million, respectively.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our general and administrative expenses for the three months ended June 30, 2024 and 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.14%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,865</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,157</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,708</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional and consultant fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,652</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,262</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,390</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance and other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,467</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,721</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">746</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,984</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,140</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,844</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses for the three months ended June 30, 2024, were $16.0 million compared to $8.1 million for the three months ended June 30, 2023. The increase in personnel-related expenses of $5.7 million was primarily due to an increase of $4.6 million in stock-based compensation expense and an increase in headcount. For the three months ended June 30, 2024 and 2023, stock-based compensation expense was $7.8 million and $3.2 million, respectively.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest income and other income (expense), net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income and other income (expense), net for the three months ended June 30, 2024 and 2023, consisted primarily of interest income of $8.1 million and $5.1 million, respectively. The increase in interest income was primarily due to an increase in cash, cash equivalents and marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the six months ended June 30, 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the six months ended June 30, 2024 and 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.14%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,800</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,047</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,753</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,938</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,225</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,713</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117,738</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,272</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,466</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(117,738</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(64,272</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(53,466</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income and other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,643</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,990</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,653</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,643</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,990</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,653</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(101,095</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(54,282</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(46,813</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">553</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">553</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(101,648</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(54,282</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(47,366</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses for the six months ended June 30, 2024 and 2023 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.620000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.14%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct research and development expenses by program:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Zidesamtinib</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,252</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,908</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,344</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NVL-655</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,927</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,289</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,638</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NVL-330</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,710</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,942</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,232</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discovery programs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,550</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,861</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(311</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,367</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,899</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,468</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,994</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,148</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,846</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,800</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,047</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,753</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $87.8 million for the six months ended June 30, 2024, compared to $48.0 million for the six months ended June 30, 2023. The increase in direct research and development expenses related to zidesamtinib of $13.3 million was primarily due to increased manufacturing costs and costs related to the Phase 2 portion of the ARROS-1 clinical trial, partially offset by a decrease in preclinical development costs. The increase in direct research and development expenses related to NVL-655 of $14.6 million was primarily due to increased manufacturing costs and costs related to the Phase 2 portion of the ALKOVE-1 clinical trial, partially offset by a decrease in preclinical development costs. The decrease in direct research and development expenses related to NVL-330 of $3.2 million was primarily due to decreased manufacturing and preclinical development costs, partially offset by increased clinical trial costs as we prepared to initiate the HEROEX-1 Phase 1 clinical trial. The increase in personnel-related expenses of $13.5 million was primarily due to an increase of $8.8 million in stock-based compensation expense and an increase in headcount. For the six months ended June 30, 2024 and 2023, stock-based compensation expense was $14.0 million and $5.2 million, respectively.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our general and administrative expenses for the six months ended June 30, 2024 and 2023 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.668%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.258%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.258%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.818000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,027</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,030</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,997</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional and consultant fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,677</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,545</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,132</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance and other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,234</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,650</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">584</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,938</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,225</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,713</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses for the six months ended June 30, 2024, were $29.9 million compared to $16.2 million for the six months ended June 30, 2023. The increase in personnel-related expenses of $11.0 million was primarily due to an increase of $9.0 million in stock-based compensation expense and an increase in headcount. For the six months ended June 30, 2024 and 2023, stock-based compensation expense was $15.0 million and $6.0 million, respectively.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest income and other income (expense), net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income and other income (expense), net for the six months ended June 30, 2024 and 2023, consisted primarily of interest income of $16.6 million and $10.1 million, respectively. The increase in interest income was primarily due to an increase in cash, cash equivalents and marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have incurred significant operating losses. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from product sales for several years, if at all. Through June 30, 2024, we have funded our operations primarily with proceeds from the sales of convertible preferred stock, the issuance of convertible notes (which converted to convertible preferred stock in 2018), debt financing from stockholders (which was settled with convertible preferred stock in February 2021) and proceeds from the sale of common stock in our public offerings. As of June 30, 2024, we had cash, cash equivalents and marketable securities of $658.0 million and accounts payable and accrued expenses of $38.2 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 10, 2022, we entered into a Sales Agreement (the Sales Agreement) with Cowen and Company, LLC (Cowen) under which we may issue and sell shares of our Class A common stock, from time to time, having an aggregate offering price of up to $150.0 million through Cowen as our Sales Agent (the ATM Facility). We will pay Cowen a commission of up to 3% of the gross proceeds of any shares of Class A common stock sold pursuant to the Sales Agreement. On October 31, 2022, we entered into an Amendment No. 1 to the Sales Agreement with Cowen (the Sales Agreement Amendment). The Sales Agreement Amendment was effective immediately and reduced the maximum aggregate offering price of the Class A common stock that we may sell under the ATM Facility to $135.0 million. As of June 30, 2024, we have not sold any shares of our Class A common stock pursuant to the Sales Agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:17%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:17%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(77,247</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(46,549</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(190,563</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(125,666</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,123</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,281</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(257,687</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(170,934</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating activities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024, operating activities used $77.2 million of cash, resulting from our net loss of $101.6 million adjusted for non-cash items, including stock-based compensation expense of $29.0 million and net accretion on marketable securities of $6.8 million, and a net increase in our operating assets and liabilities of $2.2 million. The increase in our net loss was primarily due to increased manufacturing and clinical trial costs to support the development of our product candidates and increased</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">personnel-related expenses due to the growth of our company, partially offset by increased interest income due to an increase in cash, cash equivalents and marketable securities. The net increase in our operating assets and liabilities was due to an increase in accounts payable and accrued expenses of $7.0 million, partially offset by increases in other assets of $3.1 million and prepaid expenses and other current assets of $1.7 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2023, operating activities used $46.5 million of cash, resulting from our net loss of $54.3 million adjusted for non-cash items, including stock-based compensation expense of $11.2 million and net accretion on marketable securities of $5.4 million, and a net increase in our operating assets and liabilities of $1.9 million. The net increase in our operating assets and liabilities was due to an increase in accounts payable and accrued expenses of $2.3 million, partially offset by an increase in other assets of $0.5 million.</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in accounts payable, accrued expenses, prepaid expenses and other current assets and other assets were generally due to growth in our business, the advancement of our research and development programs and the timing of vendor invoicing and payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing activities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024, net cash used in investing activities was $190.6 million, due to purchases of marketable securities of $371.8 million, partially offset by proceeds from maturities of marketable securities of $181.3 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2023, net cash used in investing activities was $125.7 million, due to purchases of marketable securities of $269.6 million, partially offset by proceeds from maturities of marketable securities of $143.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024, net cash provided by financing activities was $10.1 million, due to proceeds from the issuance of common stock of $10.7 million, partially offset by payments of insurance costs financed by a third-party of $0.6 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2023, net cash provided by financing activities was $1.3 million, due to proceeds from the issuance of common stock of $2.3 million, partially offset by payments of insurance costs financed by a third-party of $0.9 million and payments of public offering costs of $0.1 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical and clinical activities and clinical trials for our product candidates in development and any product candidates we may discover and develop in the future. The timing and amount of our operating expenditures will depend largely on:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our discovery programs and product candidates, including the advancement of zidesamtinib, NVL-655 and NVL-330 throughout clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical development plans we establish for our product candidates, including zidesamtinib, NVL-655 and NVL-330;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and characteristics of product candidates that we discover and develop through our product discovery and research efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms of any collaboration agreements we may choose to pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable foreign regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of completion of commercial-scale outsourced manufacturing activities; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6611981160773293%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we had cash, cash equivalents and marketable securities of $658.0 million. We expect that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2027. Our existing cash, cash equivalents and marketable securities will not be sufficient to fund all of our product candidates through</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory approval, and we will need to raise additional capital to complete the development and commercialization of our product candidates. Our estimate as to how long we expect our existing cash, cash equivalents and marketable securities to fund our operations is based on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including those listed above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contractual Obligations and Other Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024, there were no material changes to our contractual obligations and commitments from those described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Contractual Obligations and Other Commitments&#8221; included in our 2023 Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not entered into any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no material changes to our critical accounting policies and estimates from those disclosed in our consolidated financial statements and the related notes and other financial information included in our 2023 Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is set forth in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="quantitative_and_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities related to our cash, cash equivalents and marketable securities. As of June 30, 2024 we had $77.7 million in cash and cash equivalents and $580.3 million in marketable securities classified as available-for-sale securities. We invest our excess cash in money market funds, commercial paper, corporate bonds, government and agency securities and U.S. treasury bills. We mitigate credit risk by maintaining a diversified portfolio, placing our cash with high credit quality financial institutions and limiting the amount of investment exposure as to maturity and investment type according to our investment policy. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income is sensitive to changes in the general level of interest rates; however, due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. A 10% change in market interest rates would not be expected to have a material impact on our financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Controls and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;" id="part_ii_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II - OTHER INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Legal Proceedings.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we were not party to any material legal proceedings.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk Factors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In evaluating the Company and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report and in other documents that we file with the SEC. Our business faces significant risks and uncertainties. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties were to actually occur, our business, prospects, financial condition or results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing the Company. New risk factors can emerge from time to time, and it is not possible to predict the impact that any one factor or combination of factors may have on our business, prospects, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our financial position and need for additional capital</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a limited operating history, have not completed any later-stage clinical trials, have no products approved for commercial sale and have not generated any revenue, which may make it difficult for investors to evaluate our current business and likelihood of success and viability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a biopharmaceutical company with a limited operating history upon which investors can evaluate our business and prospects. We were incorporated in January 2017 and commenced significant operations in 2018, have never completed a Phase 2 or Phase 3 clinical trial, have no products approved for commercial sale and have never generated any revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have devoted substantially all of our resources to research and development activities, including with respect to zidesamtinib (NVL-520), our ROS1-selective inhibitor, NVL-655, our ALK-selective inhibitor, NVL-330, our HER2-selective inhibitor, and our discovery programs, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet demonstrated our ability to successfully complete Phase 2 or Phase 3 clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for investors to evaluate our likelihood of success and viability than it could be if we had a longer operating history.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by biopharmaceutical companies at our stage of development in rapidly evolving fields. We also expect that, as we advance our product candidates, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We have not yet demonstrated an ability to successfully overcome such risks and difficulties, or to make such a transition. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant net losses in each reporting period since our inception, have not generated any revenue to date and have financed our operations principally through private placements and public offerings of securities. Our net losses were $101.6 million for the six months ended June 30, 2024, and $126.2 million for the year ended December 31, 2023. As of June 30, 2024, we had an accumulated deficit of $387.9 million. We have not yet completed any Phase 2 or Phase 3 clinical trials. As a result, we expect that it will be several years, if ever, before we generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses in order to discover, develop and market additional potential products.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur significant and increasing expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the pace of our development activities and the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve our objectives relating to the discovery, development and commercialization of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on our team&#8217;s expertise in chemistry, structure-based drug design, oncology drug development, business development and our patient-driven approach to develop our product candidates. Our business depends significantly on the success of our approach and the development and commercialization of the product candidates that we discover with this approach. We have no products approved for commercial sale and do not anticipate generating any revenue from product sales for the next several years, if ever. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful and timely completion of preclinical and clinical development of zidesamtinib, NVL-655, NVL-330 and any future product candidates from our discovery programs, and any other future programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining current and establishing new relationships with CROs and clinical sites for the clinical development of zidesamtinib, NVL-655, NVL-330 and any future product candidates from our current or future discovery programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing an efficient and scalable manufacturing process for our product candidates, including the production of finished products that are appropriately packaged for sale if our product candidates obtain marketing approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining current and establishing new commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining an acceptable safety profile following any marketing approval of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercial acceptance of our product candidates by patients, the medical community and third-party payors, including the willingness of physicians to use our product candidates, if approved, in lieu of (or in conjunction with) other approved therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfying any required post-marketing approval commitments to applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, assessing and developing new product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the U.S. and internationally;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">defending against third-party interference or infringement claims, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining coverage and adequate reimbursement by third-party payors for our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any competing therapies and technological and market developments; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attracting, hiring and retaining qualified personnel.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs, future commercialization efforts, product development or other operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have used substantial amounts of cash to fund our operations, and our expenses will increase substantially in the foreseeable future in connection with our ongoing activities, particularly as we continue the research and development of, initiate additional clinical trials of, and seek marketing approval for, our product candidates. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Even if one or more of our product candidates or any future product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA, the EMA or other regulatory authorities to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our clinical trials, including our planned and anticipated clinical trials, are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of our product candidates or any future product candidates that we develop. We have initiated Phase 1/2 clinical trials for our parallel lead programs, zidesamtinib and NVL-655, and a Phase 1 clinical trial for our third product candidate, NVL-330. We are not permitted to market or promote any product candidate before we receive marketing approval from the FDA, EMA or any comparable foreign regulatory authorities. We also continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of the date of this Quarterly Report will be sufficient to fund our operating expenses and capital expenditure requirements into 2027. Advancing the development of zidesamtinib, NVL-655, NVL-330 and our discovery programs will require a significant amount of capital. Our existing cash, cash equivalents and marketable securities will not be sufficient to fund all of our product candidates through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of our product candidates. Our estimate as to how long we expect our existing cash, cash equivalents and marketable securities to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be required to obtain further funding through public or private equity financings, debt financings, collaborative agreements, licensing arrangements or other sources of financing, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Our ability to raise additional funds may be adversely impacted by general economic conditions, both inside and outside the U.S., including disruptions to, and instability and volatility in, the credit and financial markets in the U.S. and worldwide, including heightened inflation, interest rate and currency rate fluctuations, and economic slowdown or recession as well as concerns related to public health emergencies, natural disasters or geopolitical events, including civil or political unrest or military conflicts. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. To the extent that we raise additional capital through the sale of equity or convertible debt securities, each investor&#8217;s ownership interests will be diluted, and the terms may include liquidation or other preferences that adversely affect each investor&#8217;s rights as a stockholder. Debt financing may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research or drug development programs, clinical trials or future commercialization efforts.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to the discovery, development and commercialization of our product candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future prospects are substantially dependent on zidesamtinib, NVL-655 and NVL-330. If we are unable to advance these product candidates through development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have initiated Phase 1/2 clinical trials of zidesamtinib and NVL-655 and a Phase 1 clinical trial of NVL-330. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful clinical development and eventual commercialization of one or more product candidates. We are not permitted to market or promote any product candidate before we receive marketing approval from the FDA, EMA or any comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our product candidates will depend on several factors, including the following:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful and timely completion of preclinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission of INDs in the U.S. and CTAs and/or comparable applications outside the U.S. for regulatory authority review and agreement to proceed with our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful initiation and completion of clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful and timely patient selection and enrollment in and completion of clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining and establishing relationships with CROs and clinical sites for the clinical development of our product candidates both in the U.S. and internationally;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining and growing an organization of scientific, medical and other professionals who can develop and commercialize our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the frequency and severity of adverse events in clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining positive data that support demonstration of efficacy, safety and tolerability profiles and durability of effect for our product candidates that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timely receipt of marketing approvals from applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timely identification, development and approval of companion diagnostic tests, if required;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development and, if approved, commercialization of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the U.S. and internationally;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the protection of our rights in our intellectual property portfolio;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing sales, marketing and distribution capabilities and the successful launch of commercial sales of our product candidates if and when approved for marketing, whether alone or in collaboration with others;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining an acceptable safety profile following any marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercial acceptance by patients, the medical community and third-party payors, including the willingness of physicians to use our product candidates, if approved, in lieu of (or in conjunction with) other approved therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to compete with other therapies; and </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to address any potential delays resulting from factors related to public health emergencies, natural disasters or geopolitical events.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have complete control over many of these factors, including certain aspects of preclinical and clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates from our lead programs, which would materially harm our business. If we do not receive marketing approvals for such product candidates, we may not be able to continue our operations.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our preclinical studies and clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for the sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Preclinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and the ultimate outcome is uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, there is a high risk of failure, and we may never succeed in developing marketable products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent receipt of marketing approval or our ability to commercialize our product candidates, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of our product candidates in preclinical studies or clinical trials to demonstrate safety and efficacy;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative or inconclusive clinical trial results that may require us to conduct additional clinical trials or abandon certain research, discovery and/or drug development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients required for clinical trials being larger than anticipated, enrollment in these clinical trials being slower than anticipated, particularly if there are other trials enrolling the same or overlapping precisely targeted patient populations, or participants dropping out of these clinical trials at a higher rate than anticipated;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the suspension or termination of our clinical trials for various reasons, including non-compliance with regulatory requirements or a finding that our product candidates have undesirable adverse events or other unexpected characteristics or risks;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than anticipated;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates being insufficient or inadequate; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators revising the requirements for approving our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we are currently contemplating, if we are unable to successfully complete clinical trials of our product candidates or other testing in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may incur unplanned costs, be delayed in seeking and obtaining marketing approval, if we receive such approval at all, receive more limited or restrictive marketing approval, be subject to additional post-marketing testing requirements or have the drug removed from the market after obtaining marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our discovery and development activities are focused on the development of targeted therapeutics for patients with cancer-associated genomic alterations, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs may never lead to approved or marketable products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The discovery and development of targeted therapeutics for patients with cancer-associated genomic alterations is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are evolving. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our preclinical work and clinical trials to date, that the genomic alterations targeted by our programs are oncogenic drivers, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. The patient populations for our product candidates are limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted alterations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations, which may require the use of companion diagnostic tests. Furthermore, even if we are successful in identifying patients, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type and commercialize our product candidates and achieve profitability. We do not know if our approach of focusing on treating patients with cancer-associated genomic alterations will be successful, and if our approach is unsuccessful, our business will suffer.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any delays in the commencement or completion, or termination or suspension, of our current, planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before we can initiate clinical trials of any product candidate in any indication, we must submit the results of preclinical studies to the FDA, EMA or other comparable foreign regulatory authorities along with other information, including information about the product candidate&#8217;s chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission under which we must receive authorization to proceed with clinical development. The FDA, EMA or other comparable foreign regulatory authorities may require us to conduct additional preclinical studies for any product candidate before they allow us to initiate clinical trials under any IND, CTA or comparable application which may lead to additional delays and increase the costs of our preclinical development programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining marketing approval from the FDA of zidesamtinib, NVL-655 or NVL-330 or of any other future product candidate in any indication, we must conduct extensive clinical studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we expect to rely in part on preclinical, clinical and quality data generated by our CROs and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. We have initiated Phase 1/2 clinical trials of zidesamtinib and NVL-655 and a Phase 1 clinical trial of NVL-330. An IND submission must become effective prior to initiating any clinical trials in the U.S. for any of our future product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the independent institutional review board (IRB) or independent ethics committee (IEC) of the institutions in which such trials are being conducted, by a data safety monitoring board for such trial or by the FDA or foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse events, failure to demonstrate a benefit from using a pharmaceutical, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs/IECs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of the Food and Drug Omnibus Reform Act (FDORA), Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Similarly, the regulatory landscape related to clinical trials in the European Union (EU) recently evolved. The EU Clinical Trials Regulation (CTR), which was adopted in April 2014 and repealed the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate CTA to be submitted in each member state, to both the competent national health authority and an IEC, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our current or future scientific advisors or consultants who receive compensation from us may become investigators for our future clinical trials. Under certain circumstances, we may be required to report some of these relationships to the FDA. Although we expect any such relationships to be within the FDA&#8217;s guidelines, the FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates. If we experience delays in the completion of, or termination of, any clinical trial of any product candidate, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenue will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and generate revenue, which may harm our business, financial condition, results of operations and prospects significantly.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Preclinical and clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and there is a high risk of failure and we may never succeed in developing marketable products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of preclinical studies may not be predictive of the results of clinical trials of our product candidates, and the results of early clinical trials may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be safe or effective in subsequent clinical trials. Favorable results from certain animal studies may not accurately predict the results of other animal studies or of human trials, due to the inherent biologic differences in species, the differences between testing conditions in animal studies and human trials, and the particular goals, purposes, and designs of the relevant studies and trials. We have, for example, observed preclinical CNS activity of NVL-330 in studies with rats and mice. These studies may or may not be predictive of CNS penetrance and activity of NVL-330 in human trials. Similarly, certain of our hypotheses regarding the potential clinical and therapeutic benefits of our product candidates compared to other products or molecules in development are based on observations from the preclinical studies and early clinical trials that we have completed, and results from such preclinical studies and early clinical trials are not necessarily predictive of the results of later preclinical studies or clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved as products. The development of our product candidates and our stock price may also be impacted by inferences, whether correct or not, that are drawn between the success or failure of preclinical studies or clinical trials of our competitors or other companies in the biopharmaceutical industry, in addition to our own preclinical studies and clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause adverse events that are unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any preclinical studies or clinical trials that we conduct may not demonstrate the safety and efficacy necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not know whether any clinical trials we conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain approval to market any of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In addition to zidesamtinib, NVL-655 and NVL-330, our prospects depend in part upon discovering, developing and commercializing additional product candidates from our discovery programs, which may fail in development or suffer delays that adversely affect their commercial viability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize zidesamtinib, NVL-655, NVL-330 and future product candidates from our discovery programs. A research candidate can unexpectedly fail at any stage of development. The historical failure rate for research candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of other research candidates that we may develop will depend on many factors, including the following:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">generating sufficient data to support the initiation or continuation of preclinical studies and clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory permission to initiate clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contracting with the necessary parties to conduct clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful enrollment of patients in, and the completion of, clinical trials on a timely basis;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timely manufacture of sufficient quantities of a product candidate for use in clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse events in clinical trials; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any delays resulting from factors related to public health emergencies, natural disasters or geopolitical events.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we successfully advance any research candidates into preclinical and clinical development, their success will be subject to all of the preclinical, clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, there can be no assurance that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from any product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our approach to build a pipeline of product candidates with commercial value.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A key element of our strategy, which is unproven, is to use and expand our expertise in chemistry, structure-based drug design and patient-driven approach to build a pipeline of product candidates and progress these product candidates through clinical development. Although our research and development efforts to date have resulted in the discovery of and initiation of clinical development of zidesamtinib, NVL-655 and NVL-330, such product candidates and any other product candidates we may develop may not be safe or effective as cancer therapeutics, and we may not be able to develop any other product candidates. For example, the potential product candidates that we have identified or identify in the future may not generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be product candidates that will receive marketing approval from the FDA, EMA or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future, which would result in significant harm to our financial position and adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our product candidates, the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested or may impose other prescribing limitations or warnings that limit the product candidate&#8217;s commercial potential. Even if approved, we may be required to conduct additional studies to verify or confirm the clinical benefits of our products. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our product candidates will ever obtain regulatory approval. Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, are only moderately effective or have undesirable or unintended adverse events, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical data of the clinical trial may fail to meet the level of statistical significance required to obtain approval of our product candidates by the FDA, EMA or other comparable foreign regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that our product candidates&#8217; risk-benefit ratios for their proposed indications are acceptable;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable regulatory authorities may fail to approve companion diagnostic tests required for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not obtain or maintain adequate funding to complete the clinical trial in a manner that is satisfactory to the FDA, EMA or other comparable foreign regulatory authorities; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have only limited experience as a company in the conduct of clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have only limited experience as a company in the conduct of clinical trials. In part because of this lack of experience as a company and our limited infrastructure, we cannot be certain that our preclinical studies and clinical trials will begin or be completed on time, if at all. Large-scale clinical trials require significant financial and management resources and we expect to rely on third-party clinical investigators, CROs, and consultants in connection with any large-scale clinical trials we conduct. Relying on third-party clinical investigators, CROs and consultants may result in us encountering delays that are outside of our control. We also may be unable to identify and contract with sufficient investigators, CROs and consultants on a timely basis or at all. There can be no assurance that we will be able to negotiate and enter into any necessary services agreement with CROs on terms that are acceptable to us on a timely basis or at all.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to submit INDs, CTAs or comparable applications to commence clinical trials on the timelines we expect, and even if we are able to, the FDA, EMA or any comparable foreign regulatory authority may not permit us to proceed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development efforts to date have resulted in the initiation of clinical development of zidesamtinib, NVL-655 and NVL-330. We may not be able to submit INDs for any future product candidates we may identify on the timelines we expect, or such submissions may not take effect on the timeline that we anticipate, or at all. For example, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that it will not change its requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to submit INDs, CTAs or comparable applications on the timelines we expect or to obtain regulatory approvals for our planned clinical trials may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely basis, if at all.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause significant adverse events, toxicities or other undesirable adverse events when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are associated with undesirable adverse events or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable adverse events or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related adverse events could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly. There have been, and it is likely that there will be additional, adverse events associated with the use of our product candidates as is typically the case with oncology drugs. Results of our studies or trials could reveal a high and unacceptable severity and prevalence of these or other adverse events. In such an event, our trials could be suspended or terminated and the FDA, EMA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Drug-related adverse events could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our product candidates may be used in populations for which safety concerns may be particularly scrutinized by regulatory authorities. Our product candidates may be studied in combination with other therapies, which may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause adverse events that are unrelated to our product candidates but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. For example, it is expected that some of the patients to be enrolled in our current or future clinical trials may die or experience major clinical events either during the course of our clinical trials or after participating in such trials for non-treatment related reasons.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If significant adverse events are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, EMA, other comparable foreign regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse events. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause adverse events that prevented their further development. Even if the adverse events do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable adverse events may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates previously not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, preliminary and topline data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have publicly disclosed interim, preliminary or topline data from our preclinical studies and clinical trials and we expect to do so in the future. These interim updates are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, we may report responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, preliminary or topline results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim, preliminary and topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim, preliminary or topline data we previously published. As a result, interim, preliminary and topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim, preliminary and topline data from clinical trials are subject to the risk that one or more of the clinical outcomes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim, preliminary or topline data and final data could significantly harm our business and prospects. Further, additional disclosure of interim, preliminary or topline data by us or by our competitors in the future could result in volatility in the price of our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the information we choose to publicly disclose regarding a particular study or trial is typically selected from a more extensive amount of available information. Investors may not agree with what we determine is the material or otherwise appropriate information to include in our public disclosures, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, any of our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA, EMA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. We utilize genomic profiling of patients&#8217; tumors to identify suitable patients for recruitment into our clinical trials. For these clinical trials, we seek patients with specific genomic alterations that our product candidates are designed to precisely target. We cannot be certain (i) how many patients will have the requisite genomic alterations that qualify for inclusion in our clinical trials, (ii) that the number of patients enrolled in each program will suffice for regulatory approval or (iii) if regulatory approval is obtained, whether each specific ROS1, ALK or HER2 alteration will be included in the approved drug label. Additionally, we face competition, including from large pharmaceutical companies with significantly more resources than us, for enrollment of our precisely targeted patient populations, which may impact our ability to successfully recruit patients for our clinical trials. If our strategies for patient identification and enrollment prove unsuccessful, we may have difficulty enrolling or maintaining patients appropriate for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment may be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; programs. Patient enrollment for our current or future clinical trials may be affected by other factors, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">size and nature of the patient population;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">severity of the disease under investigation;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">availability and efficacy of approved drugs for the disease under investigation;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient eligibility criteria for the trial in question as defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have a biomarker-driven patient eligibility criteria;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceived risks and benefits of the product candidate under study;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved or other product candidates being investigated for the indications we are investigating;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinicians&#8217; willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient referral practices of physicians;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to monitor patients adequately during and after treatment;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have never commercialized a product candidate as a company before and currently lack all of the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never commercialized a product candidate as a company. We may license certain rights with respect to our product candidates to collaborators, and, if so, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights and marketing approval, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that may affect our ability to commercialize our product candidates, if approved, on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, developing adequate educational and marketing programs to increase public acceptance of our approved product candidates, ensuring regulatory compliance of our company, employees and third parties under applicable healthcare laws, and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our product candidates upon approval. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenue from them or be able to reach or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited resources and are currently focusing our efforts on the development of zidesamtinib, NVL-655 and NVL-330 in particular indications and advancing our discovery programs. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently focusing our resources and efforts on our lead product candidates, zidesamtinib and NVL-655, for advanced ROS1-positive NSCLC and other solid tumors and advanced ALK-positive NSCLC and other solid tumors, respectively, on our NVL-330 product candidate for advanced HER2-altered NSCLC, and on advancing our discovery programs. As a result, because we have limited resources, we may forgo or delay pursuit of opportunities for other indications or with other product candidates that may have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development activities for zidesamtinib, NVL-655, NVL-330 and our discovery programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target markets for zidesamtinib, NVL-655, NVL-330 or any future product candidates we identify through our discovery programs, we may enter into collaboration, licensing or other strategic arrangements with the effect of relinquishing valuable rights in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of product candidates are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our product candidates may need to compete with drugs physicians use off-label to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, there is intense competition in the field of oncology. We have competitors both in the U.S. and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit and retain qualified scientific and management personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to face competition from existing products and products in development for each of our lead programs and in particular, our competitors that are developing product candidates often have the advantage of significant financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For zidesamtinib, there are currently three ROS1-targeted kinase inhibitors approved by the FDA for use in TKI na&#239;ve ROS1-positive NSCLC: crizotinib, entrectinib and repotrectinib. Crizotinib has also received approval for treatment of ALK-positive NSCLC. Ceritinib and lorlatinib are considered as other therapies recommended for use in ROS1-positive NSCLC patients according to the National Comprehensive Cancer Network guidelines. Lorlatinib is a dual ALK/ROS1 inhibitor that has received marketing approval for the treatment of ALK-positive NSCLC, and has demonstrated CNS activity as reported in its prescribing information. Taletrectinib is a dual TRK/ROS1 inhibitor and is in development by Nuvation Bio, Inc. for patients with ROS1-positive NSCLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For NVL-655, there are five ALK inhibitors approved by the FDA for the treatment of ALK-positive NSCLC: crizotinib, lorlatinib, ceritinib, alectinib, and brigatinib. All five have line-agnostic approvals for the treatment of ALK-positive NSCLC patients, including for patients who are TKI na&#239;ve. Additionally, lorlatinib has demonstrated activity in patients that have progressed on crizotinib, alectinib, or ceritinib. The FDA has accepted for standard review Xcovery Holdings&#8217; New Drug Application for ensartinib for the treatment of adult patients with metastatic ALK-positive NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For NVL-330, there is currently one antibody-drug conjugate approved by the FDA for the treatment of HER2 mutant NSCLC: fam-trastuzumab deruxtecan-nxki. There are no kinase inhibitors approved for this patient population. Other kinase inhibitors in development for patients with HER2 mutant NSCLC include Shanghai Hengrui Pharmaceutical Co., Ltd.&#8217;s pyrotinib, Boehringer Ingelheim Pharmaceuticals, Inc.&#8217;s zongertinib (BI-1810631), and Enliven Therapeutics&#8217; ELVN-002.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology product candidates. These companies also have significantly greater research and marketing capabilities than we do and may also have product candidates that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA, EMA or other comparable foreign regulatory authorities or in discovering, developing and commercializing product candidates in our field before we do.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our potential commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe adverse events, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are less expensive than any products that we may develop. Physicians may be more willing to prescribe our competitors&#8217; products for various reasons, and may rely on guidelines related to treatment of patients issued by medical societies, industry groups or other organizations, which may not include, and may never include, our products. Our competitors also may obtain marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development and marketing more complicated. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, as well as sophisticated quality assurance and quality control procedures. Slight deviations anywhere in the manufacturing process, including filling, labelling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Contaminations can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our third-party manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example, we may introduce an alternative formulation of one or more of our product candidates during the course of our clinical trials. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and impair our ability to generate revenue.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of the product candidate as well as competitive products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which a product candidate is approved;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the use of product candidates in the labelling approved by regulatory authorities, such as boxed warnings or contraindications in labelling, or a Risk Evaluation and Mitigation Strategy (REMS), if any, which may not be required of alternative treatments and competitor products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">willingness of physicians to use our product candidates, if approved, in lieu of (or in conjunction with) other approved therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of an approved product candidate for use as a combination therapy;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and undergo required diagnostic screening to determine treatment eligibility and of physicians to prescribe these therapies and diagnostic tests;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of sales and marketing efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable publicity relating to our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval of other new therapies for the same indications.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market opportunities for any product candidates we develop, if approved, may be limited to certain smaller patient subsets and may be smaller than we estimate them to be.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When cancer is detected early (referred to as localized disease), conventional treatments, which include chemotherapy, hormone therapy, surgery and radiation therapy and/or selected targeted therapies, may be adequate to cure the patient in many cases. However, once cancer has spread to other areas (advanced or metastatic disease), cancer treatments may not be sufficient to provide a cure but often can significantly prolong life without curing the cancer. First-line therapies designate treatments that are initially administered to patients with advanced or metastatic disease, while second- and third-line therapies are administered to patients when the prior therapies lose their effectiveness. The FDA, EMA and other regulatory bodies often approve cancer therapies for a particular line of treatment. Typically, drug approvals are initially granted for use in later lines of treatment, but with additional evidence of significant efficacy from clinical trials, biopharmaceutical companies can successfully seek and gain approval for use in earlier lines of treatment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to initially seek approval of zidesamtinib, NVL-655, NVL-330 and any other future product candidates in most instances for previously treated patients with advanced or metastatic cancer where at least one prior therapy has limited clinical benefit or where tumors have developed resistance to such therapy. For those product candidates that prove to be sufficiently safe and effective, if any, we would potentially expect to seek approval ultimately as a first line TKI therapy. There is no guarantee that our product candidates, even if approved for previously treated patients would be approved for an earlier line of therapy, and prior to any such approvals we may have to conduct additional clinical trials that may be costly, time-consuming and subject to risk.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new data and studies may change the estimated incidence or prevalence of the cancers that we are targeting, especially if new therapies that are approved while we advance our product candidates affect the treatment paradigm and/or the size of the target population. The potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Consequently, even if our product candidates are approved, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type. Even if we obtain significant market share for our products, if approved, if the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients rely on insurance coverage by third-party payors (third-party payors include Medicare and Medicaid (government payors) and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.), to pay for products. The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the U.S. and internationally, on the extent to which the costs of such product candidates will be covered and reimbursed by third-party payors. No uniform policy exists for coverage and reimbursement in the U.S. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the U.S., for example, principal decisions about reimbursement for new products are typically made by the Center for Medicare &amp; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. Factors payors consider in determining reimbursement are based on whether the product is: (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. This process will require us to provide</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As federal and state governments implement additional health care cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that our products, if approved, will be covered by private or public payors, and if covered, whether the reimbursement will be adequate or competitive with other marketed products. Such other actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for our products if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development. For further discussion, see &#8220;&#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for our product candidates;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; and &#8220;&#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The prices of prescription pharmaceuticals in the U.S. and foreign jurisdictions are the subject of considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed for marketing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the U.S., the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the U.S. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business exposes us to significant product liability and other risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability and other claims or incidents, such as cyber incidents and breaches, could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA, EMA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">awards to trial participants or patients. We currently have product liability and other insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to advancing our product candidates into later stages of development or marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial, product liability, and other types of insurance (such as cyber insurance) is becoming increasingly expensive and difficult to obtain. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability or other claims or incidents, including data breach and incidents, that could have an adverse effect on our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to regulatory approval and other legal compliance matters</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are and will continue to be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labelling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the U.S. and in many foreign jurisdictions before a new drug can be approved for marketing. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA, EMA or any other regulatory authority. The time required to obtain approvals from the FDA, EMA and other regulatory authorities is unpredictable and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can, and often does, change during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in applicable FDA, EMA or other regulatory policy during the period of drug development, clinical trials and regulatory review.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective or have undesirable or unintended adverse events, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that our product candidates&#8217; risk-benefit ratios for their proposed indications are acceptable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from any particular product candidates we are developing and for which we are seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market, promote and advertise the drug or the labelling or other restrictions. In addition, the FDA has the authority to require a REMS plan as part of approving a NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may develop our current or future product candidates in combination with other therapies, which would expose us to additional risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may develop our current or future product candidates in combination with one or more currently approved cancer therapies or therapies in development. Even if any of our current or future product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also evaluate our current or future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA, EMA or other comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with any of our current or future product candidates, we may be unable to obtain approval of or successfully market any one or all of the current or future product candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our current or future product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our current or future product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have conducted and intend to continue conducting certain of our clinical trials globally. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have conducted and intend to continue conducting certain of our clinical trials globally. The acceptance by the FDA or other regulatory authorities of study data from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice (GCP) regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements, and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with:</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional foreign regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign exchange fluctuations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cultural differences in medical practice and clinical research;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diminished protection of intellectual property in some countries; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.0100502512562812%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interruptions or delays in our trials resulting from geopolitical events, including civil or political unrest or military conflicts.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the U.S., including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential product candidates will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom (U.K.) as a result of the withdrawal of the U.K. from the EU, commonly referred to as Brexit. The U.K. is no longer part of the European Single Market and EU Customs Union. As of January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland, and Wales under domestic law, whereas under the terms of the Northern Ireland Protocol, Northern Ireland is currently subject to EU rules. The U.K. and EU have, however, agreed to the Windsor Framework, which fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the U.K. Once implemented, the changes introduced by the Windsor Framework will make the MHRA responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may however have a significant impact on the pharmaceutical industry and our business in the long term.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the U.K. for our product candidates, which could significantly and materially harm our business. Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the applicable regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and ongoing surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements and regulatory inspection. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labelling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as ongoing compliance with current good manufacturing practices (cGMPs) and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA, EMA and other regulatory authorities for compliance with cGMP regulations and standards. The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the U.S. prior to being imported or offered for import into the U.S. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA, EMA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in or the rejection of product approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the products, manufacturers or manufacturing process;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning or untitled letters;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">civil and criminal penalties;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of regulatory approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizures, detentions or import bans;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">voluntary or mandatory product recalls and publicity requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">total or partial suspension of production;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of restrictions on operations, including costly new manufacturing requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">revisions to the labelling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a REMS, which may include distribution or use restrictions; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct additional post-market clinical trials to assess the safety of the product.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several significant administrative law cases were decided by the U.S. Supreme Court in 2024, most notably Loper Bright Enterprises v. Raimondo (Loper Bright), which overruled Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. (Chevron). Since 1984, Chevron had required that courts defer to reasonable agency interpretations of statutes that are silent or ambiguous on a particular topic. In Loper Bright, the Supreme Court held that the U.S. Administrative Procedure Act requires courts to exercise their independent judgment when deciding whether an agency has acted within its statutory authority, and that courts are not required to defer to an agency interpretation solely because a statute is ambiguous, unless the particular statute at issue mandates deference. These decisions may result in additional legal challenges to regulations and guidance issued by federal regulatory agencies, including the FDA and CMS, that we rely on. Any such challenges, if successful, could adversely impact our business and operations. In addition to potential changes to regulations and agency guidance as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays in and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA, EMA and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA, EMA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA, EMA and other regulatory authorities strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted in the U.S. for uses that are not approved by the FDA as reflected in the product&#8217;s approved labelling, or in other jurisdictions for uses that differ from the labelling or uses approved by the applicable regulatory authorities. While physicians may prescribe products for off-label uses, the FDA, EMA and other regulatory authorities actively enforce laws and regulations that prohibit the promotion of off-label uses by companies, including promotional communications made by companies&#8217; sales force with respect to off-label uses that are not consistent with the approved labelling, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific communications concerning their products in certain circumstances. For example, in October 2023, the FDA published draft guidance outlining the agency&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers. This draft guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths, weaknesses, validity and utility of the information about the unapproved use. In addition, under recent guidance from the FDA and the Pre-Approval Information Exchange Act, signed into law as part of the Consolidated Appropriations Act, companies may also promote information that is consistent with the prescribing information and proactively speak to formulary committee members of payors regarding data for an unapproved drug or unapproved uses of an approved drug. We may engage in these discussions and communicate with healthcare providers, payors and other constituencies in compliance with all applicable laws, regulatory guidance and industry best practices. We will need to carefully navigate the FDA&#8217;s various regulations, guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are required by the FDA, EMA or comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates or a group of therapeutic products, and we do not obtain or we face delays in obtaining clearance or approval of a diagnostic test, we may not be able to commercialize the product candidate and our ability to generate revenue may be materially impaired.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required by the FDA, EMA or a comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates, such companion diagnostic test would be used during our more advanced phase clinical trials as well as in connection with the commercialization of our product candidates. To be successful in developing and commercializing product candidates in combination with these companion diagnostics, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to ensuring the safe and effective use of a novel therapeutic product or new indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared. In certain circumstances (for example, when a therapeutic product is intended to treat a serious or life-threatening condition for which no satisfactory available therapy exists or when the labelling of an approved product needs to be revised to address a serious safety issue), however, the FDA may approve a therapeutic product without the prior or contemporaneous marketing authorization of a companion diagnostic. In this case, approval of a companion diagnostic may be a post-marketing requirement or commitment.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Co-development of companion diagnostics and therapeutic products is critical to the advancement of precision medicine. Whether initiated at the outset of development or at a later point, co-development should generally be conducted in a way that will facilitate obtaining contemporaneous marketing authorizations for the therapeutic product and the associated companion diagnostic. If a companion diagnostic is required to identify patients who are most likely to benefit from receiving the product, to be at increased risk for serious adverse events as a result of treatment with a particular therapeutic product, or to monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness, then the FDA has required marketing approval of all companion diagnostic tests essential for the safe and effective use of a therapeutic product for cancer therapies. Various foreign regulatory authorities also regulate in vitro companion diagnostics as medical devices and, under those regulatory frameworks, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any future diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization in those countries.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genomic alteration or mutation alteration that the companion diagnostic was developed to detect. If the FDA, EMA or a comparable regulatory authority requires clearance or approval of a companion diagnostic for any of our product candidates, whether before, concurrently with approval, or post-approval of the product candidate, we, and/or future collaborators, may encounter difficulties in developing and obtaining clearance or approval for these companion diagnostics. The process of obtaining or creating such diagnostic is time consuming and costly. The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval (PMA), simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of preclinical and clinical data and the submission and review by the FDA, can take several years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delay or failure by us or third-party collaborators to develop or obtain regulatory clearance or approval of a companion diagnostic could delay or prevent approval or continued marketing of our related product candidates. Further, in April 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance and future issuances from the FDA, EMA and other regulatory authorities may impact our development of a companion diagnostic for our product candidates and could result in delays in regulatory clearance or approval or a change in the determination for whether or not a companion diagnostic is still required for our product candidates. We may be required to conduct additional studies to support a broader claim or more narrowed claim for a subset population. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include any of our future approved product candidates covered indications, we may no longer need to continue our companion diagnostic development plans or we may need to alter those companion diagnostic development strategies, which could adversely impact our ability to generate revenue from the sale of our companion diagnostic test.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining clearance or approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory clearance or approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory clearance or approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of our product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which could adversely affect and/or delay the co-development or commercialization of our companion diagnostic and therapeutic product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Where appropriate, we plan to pursue approval from the FDA, EMA or comparable foreign regulatory authorities through the use of accelerated registration pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw accelerated approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where appropriate, we plan to pursue accelerated development strategies in areas of medical need. We may seek an accelerated approval pathway for one or more of our product candidates from the FDA, EMA or comparable foreign regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six months (until the study is completed), and use expedited procedures to withdraw accelerated approval of an NDA or BLA after the confirmatory trial fails to verify the product&#8217;s clinical benefit. Further, FDORA requires the FDA to publish on its website &#8220;the rationale for why a post-approval study is not appropriate or necessary&#8221; whenever it decides not to require such a study upon granting accelerated approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">More recently, in March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. While a randomized controlled trial is the preferred approach, the guidance states that there can be circumstances wherein a single-arm trial is appropriate in the development of a drug for accelerated approval. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. While this guidance is currently only in draft form and will not be legally binding even when finalized, we will need to consider the FDA&#8217;s guidance if we seek accelerated approval for any of our products in the future and work with the FDA on this approach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. A conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to seeking accelerated approval, we will seek feedback from the FDA, EMA or comparable foreign regulatory authorities and will otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA or comparable foreign regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accelerated approval or any other form of expedited development, review or approval, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA, EMA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review in the U.S., and PRIME (priority medicines) in the EU, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zidesamtinib has received FDA Breakthrough Therapy designation for the treatment of patients with ROS1-positive NSCLC who have previously been treated with two or more ROS1 TKIs, and NVL-655 has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with two or more ALK TKIs. We may seek certain designations for our other current or future product candidates or other designations for zidesamtinib and NVL-655 that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, early and frequent interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development. Sponsors may also have greater interactions with the FDA and the FDA may initiate review of sections of the NDA of a product candidate with Breakthrough Therapy designation before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of data submitted by the sponsor, that a product with Breakthrough Therapy designation may be effective.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also seek Fast Track designation for one or more of our product candidates. The FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. Like with Breakthrough Therapy designation, sponsors with Fast Track products may have greater FDA interactions and the FDA may initiate review of sections of a Fast Track product&#8217;s NDA before the application is complete if it determines, after its preliminary data evaluation, that the product may be effective.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate intended to treat a serious condition and, if approved, offers a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation shortens the goal for the FDA to review an application within six months, rather than the standard review period of ten months.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These designations require a sponsor to submit an application for review and approval by the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if our product candidates qualify for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, we may seek PRIME for some of our product candidates in the future. PRIME is a voluntary program launched by the EMA that is aimed at enhancing the scientific and regulatory support for the development and accelerated assessment of new product candidates that target an unmet medical need. PRIME is aimed to offer early and proactive support to sponsors to optimize the generation of robust data on the product&#8217;s benefits and risks and enable accelerated regulatory assessment of new marketing applications. To be eligible for PRIME, a product candidate must meet the eligibility criteria in respect to its potential to offer a major therapeutic advantage over existing treatments, or benefit patients who do not have any treatment options. The benefits of PRIME include the appointment of a Committee for Medicinal Products for Human Use rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. We may apply for PRIME and it may not be granted. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the U.S. and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of researching and developing the drug will be recovered from sales in the U.S. Our target indications may include diseases with large patient populations or may include orphan indications. Zidesamtinib has received orphan drug designation for ROS1-positive NSCLC. NVL-655 has received orphan drug designation for ALK-positive NSCLC. There can be no assurances that we will be able to obtain orphan designation for our other current product candidate or candidates we may discover and develop in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product candidate is entitled to orphan drug exclusivity. Orphan drug exclusivity in the U.S. provides that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances. The applicable exclusivity period is 10 years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain orphan drug designation for a product candidate, we may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the U.S. may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to ensure that we will be able to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval process or entitles the product candidate to Priority Review.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court&#8217;s order, the FDA will continue to apply its existing regulations tying orphan drug exclusivity to the uses or indications for which the orphan drug was approved. We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S. and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act (PPACA). Since enactment of the PPACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017 (the Tax Act), Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the PPACA brought by several states without specifically ruling on the constitutionality of the PPACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been adopted since the PPACA was enacted, including aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Under current legislation, the actual reductions in Medicare payments may vary up to 4%. The Consolidated Appropriations Act (CAA), which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the CAA delays the 4% Statutory Pay-As-You-Go Act of 2010 (PAYGO) sequester for two years, through the end of calendar year 2024. Triggered by the enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The CAA&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, with passage of the Inflation Reduction Act (IRA) in August 2022, Congress authorized Medicare beginning in 2026 to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year and it only applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition are categorically excluded from price negotiation. In addition, the new legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference. The IRA also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These laws and other healthcare reform measures may result in additional reductions in Medicare and other healthcare funding and otherwise affect the reimbursement we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used. We expect that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in coverage and payments from private payors. Accordingly, the implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The prices of prescription pharmaceuticals in the U.S. and foreign jurisdictions are the subject of considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed for marketing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The prices of prescription pharmaceuticals have been the subject of considerable discussion in the U.S. There have been several recent U.S. Congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products, and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, the CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program (SIP) to import certain prescription drugs from Canada into the U.S. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America (PhRMA) but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Nine states (Colorado, Florida, Maine, New Hampshire, New Mexico, North Dakota, Texas, Vermont and Wisconsin) have passed laws allowing for the importation of drugs from Canada. Certain of these states have submitted SIP proposals and are awaiting FDA approval. On January 5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The final rule would also eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but has been delayed by Congress to January 1, 2032.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, acting pursuant to an executive order signed by President Biden, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b) improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 16, 2022, the IRA was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 6, 2023, Merck &amp; Co., Inc. filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce, Bristol Myers Squibb Company, the PhRMA, Astellas, Novo Nordisk, Janssen Pharmaceuticals, Novartis, AstraZeneca and Boehringer Ingelheim, also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the U.S. state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription product and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. In addition, in some countries, including member states of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take a significant amount of time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices, and in certain instances render commercialization in certain markets infeasible or disadvantageous from a financial perspective. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our products to other available products in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third party payors or government authorities may lead to further pressure on the prices or reimbursement levels. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, the commercial launch of our products could be delayed, possibly for lengthy periods of time, we or our collaborators may not launch at all in a particular country, we may not be able to recoup our investment in one or more products, and there could be a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are or may become subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are multiple privacy and data security laws that may impact our business activities in the U.S. and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, for example, under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), HHS has issued regulations to protect the privacy and security of protected health information (PHI) used or disclosed by specific covered entities including certain healthcare providers, health plans and healthcare clearinghouses. We are not currently classified as a covered entity or business associate under HIPAA. Thus, we are not directly subject to HIPAA&#8217;s requirements or penalties. The healthcare providers, including certain research institutions from which we may obtain patient or subject health information, may be subject to privacy, security, and breach notification requirements under HIPAA. Additionally, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face criminal penalties if we knowingly receive individually identifiable health information from a HIPAA covered entity, business associate or subcontractor that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health and genetic information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement such programs. As such, in addition to risks and obligations related to HIPAA, we also may be subject to various state laws regulating the use or disclosure of this information or requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic information laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Individuals from whom we or our collaborators may obtain health information, as well as the healthcare providers who may share this information with us, may have statutory or contractual rights that limit the ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the collection and use of personal data, including data concerning health, in the EU is governed by the General Data Privacy Regulation (GDPR), which extends the geographical scope of EU data protection law to non-EU entities under certain conditions and imposes substantial obligations upon companies and new rights for individuals, as discussed below in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Processing of personal data is governed by restrictive laws and regulations in the jurisdictions in which we operate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Brexit may adversely impact our ability to obtain regulatory approvals for our product candidates in the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA, the SEC and other U.S. government agencies or the EMA or comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA, EMA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA and other regulators have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA, EMA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. In addition, disruptions may result from events similar to the COVID-19 pandemic. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the U.S. facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, if a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our product candidates are licensed for marketing and receive federal healthcare reimbursement, any relationships we may have with healthcare providers will be subject to applicable healthcare fraud and abuse laws and regulations, which could expose us to criminal and civil penalties and exclusion from participation in government healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we are able to obtain marketing approval. Any arrangements we have with healthcare providers, third-party payors and customers will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws and regulations may constrain the business or financial arrangements and relationships through which we conduct clinical research, market, sell and distribute any products for which we obtain marketing approval. These include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-Kickback Statute</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, in cash or in kind, to induce or reward or in return for, either the referral of an individual for or the purchase, lease or order of a good, facility, item or service for which payment may be made under a federal healthcare program such as Medicare and Medicaid. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">False Claims Laws. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, impose criminal and civil penalties, including through civil whistleblower or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> actions against individuals or entities for, among other things, knowingly presenting or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HIPAA. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA imposes criminal and civil liability for, among other things, executing a scheme or making materially false statements in connection with the delivery of or payment for health care benefits, items or services. Additionally, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations on covered entities and their business associates that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information. </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Transparency Requirements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or transfers of value made to physicians, other healthcare providers and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Analogous State and Foreign Laws. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors and are generally broad and are enforced by many different federal and state agencies as well as through private actions. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the EU Member States. Our failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that any business arrangements we have with third parties and our business generally will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Processing of personal data is governed by restrictive laws and regulations in the jurisdictions in which we operate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are or may become subject to many cybersecurity, privacy and data protection laws in the U.S. and around the world. In the U.S., we are subject to numerous federal and state laws governing the collection, processing, use, transmission, disclosure, and sale (collectively, Processing) of personal data (which may also be referred to as personal information, personally identifiable information, and/or non-public personal information).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission (FTC) and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section 5 of the Federal Trade Commission Act, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). The FTC is also in the process of developing rules related to commercial surveillance and data security that may impact our business. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that requires us to adhere to very specific privacy and data security practices, which may impact our business. We may also be required to pay fines as part of a settlement (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New laws also are being considered at the state level. For example, the California Consumer Privacy Act (CCPA) went into effect on January 1, 2020, and established a new privacy framework for covered businesses such as ours. The CCPA imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. Further, in November 2020, California voters passed the California Privacy Rights Act (CPRA), which significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. While certain of our business activities will not be subject to these laws, it remains unclear how various provisions of the CCPA and CPRA will be interpreted and enforced.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to California, at least eleven other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws during the 2024 legislative sessions that will go into effect in 2024 and beyond, including New Hampshire and New Jersey. Other states will be considering these laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, Washington state passed a health privacy law in 2023 that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data and additional states (including Vermont) are considering such legislation for 2024. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, outside of the U.S., we are subject to foreign rules and regulations. Many countries outside of the U.S. maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area (EEA), and the processing of personal data that takes place in the EEA, is subject to the GDPR, which became effective on May 25, 2018. This provision expanded the scope of data protection in the EU to foreign companies who process the personal data of EU residents, imposed a strict data protection compliance regime with stringent penalties for noncompliance and included new rights for data subjects such as the &#8220;portability&#8221; of personal data. In particular, under the GDPR, fines of up to &#8364;20 million, or up to 4% of the annual global revenue of the noncompliant company, whichever is greater, could be imposed for violations of certain of the GDPR&#8217;s requirements. If we were found to be in breach of the GDPR, the potential penalties we might face could have a material adverse impact on our business, financial condition, results of operations, and cash flows. Compliance with the GDPR requires time and expense and may require us to make changes to our business operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the GDPR applies uniformly across the EU, each EU Member State is permitted to issue nation-specific data protection legislation, which has created inconsistencies on a country-by-country basis. Brexit has created further uncertainty and could result in the application of new data privacy and protection laws and standards to our operations in the U.K., our handling of personal data of users located in the U.K., and transfers of personal data between the EU and the U.K. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 in the U.K. that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May 23, 2018, and is now effective in the U.K., it is still unclear whether and for how long transfer of data from the EEA to the U.K. will remain lawful under GDPR. The U.K. government has already determined that it considers all EU and EEA Member States to be adequate for the purposes of data protection, ensuring that data flows from the U.K. to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the U.K. as being &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to the U.K., although this decision may be re-evaluated in the future.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. On July 16, 2020, the European Court of Justice invalidated the EU-U.S. Privacy Shield Framework, a mechanism under which personal data could be transferred from the EEA to U.S. entities that had self-certified under the Privacy Shield Framework. The Court also called into question the Standard Contractual Clauses (SCCs), noting adequate safeguards must be met for SCCs to be valid. European regulatory guidance regarding these issues continues to evolve, and EU regulators across the EU Member States have taken different positions regarding continued data transfers to the U.S. In the future, SCCs and other data transfer mechanisms will face additional challenges.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The EU initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022 and the European Commission adopted the adequacy decision on July 10, 2023. The adequacy decision will permit U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the U.S. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business at the international level.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, while the Data Protection Act of 2018 in the U.K. that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May 23, 2018, and is now effective in the U.K., it is still unclear whether transfer of data from the EEA to the U.K. will remain lawful under the GDPR. The Agreement provides for a transitional period during which the U.K. will be treated like an EU member state in relation to processing and transfers of personal data for four months from January 1, 2021. This may be extended by two further months. After such period, the U.K. will be a &#8220;third country&#8221; under the GDPR unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the U.K. The U.K. has already determined that it considers all of the EU and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the U.K. to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the U.K. as being &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to the U.K., although this decision may be re-evaluated in the future. The U.K. and the U.S. also have agreed on a framework for personal data to be transferred between the U.K. and the U.S., called the U.K.-U.S. Data Bridge. The U.K.-U.S. Data Bridge may be challenged in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products. Such laws may have potentially conflicting requirements or burdensome obligations that would make compliance challenging or expensive. Such changes may also require us to modify our products and features, and may limit our ability to make use of the data that we collect, may require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to Process data (including personal data), or in some cases, impact our ability to operate in certain jurisdictions. Any actual or alleged failure to comply with U.S. or international laws and regulations relating to privacy, data protection, and data security could result in governmental investigations, proceedings and enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity, harm to our reputation, and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to Process the information or impose other obligations or restrictions in connection with our Processing of information, and we may otherwise face contractual restrictions applicable to our Processing of information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage or may have engaged in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA, EMA or comparable foreign regulatory authority regulations, provide accurate information to the FDA, EMA or comparable foreign regulatory authorities, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, research, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct and engage contractors that agree to undertake certain measures with respect to their employees, but it is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third-party intermediaries from offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international or domestic sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to, existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to employee matters, managing our growth and other risks related to our business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success is highly dependent on our ability to attract, hire and retain highly skilled executive officers and employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have a small team focused on research and development of small molecule kinase inhibitors. To succeed, we must recruit, hire, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. Personnel with the required skills and experience may be scarce or may not be available at all. In addition, competition for these skilled personnel is intense and recruiting and retaining skilled employees is difficult, particularly for a development-stage company such as ours. Even if we are successful in identifying, attracting, hiring and retaining qualified</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employees, recent market changes, including labor shortages, and rising inflation have increased employee-related costs substantially, which may negatively affect our operating results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel in these positions, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide higher compensation, more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we rely on our scientific founder and head scientific advisor, physician-scientist partners and other scientific and clinical advisors and consultants to assist us in formulating our research, development and clinical strategies. Most of these advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, these advisors and consultants typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. Furthermore, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. In particular, if we are unable to maintain consulting or employment relationships with our scientific founder and head scientific advisor, physician-scientist partners and other scientific and clinical advisors, or if they provide services to our competitors, our development and commercialization efforts will be impaired and our business will be significantly harmed. For example, if we are no longer able to access our network of physician-scientists, our ability to define and characterize patients&#8217; needs for future product candidate development may be negatively affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our reliance on a limited number of employees who provide various administrative, research and development, and other services across our organization presents operational challenges that may adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we had 115 full-time employees, upon which we rely for various administrative, research and development, and other services. The small size of our centralized team may limit our ability to devote adequate personnel, time, and resources to support our operations or research and development activities, and the management of financial, accounting, and reporting matters. If our team fails to provide adequate administrative, research and development, or other services across our organization, our business, financial condition, and results of operations could be harmed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we had 115 full-time employees, including 84 employees engaged in research and development activities. In order to successfully implement our development and commercialization plans and strategies, and as we continue to grow as a public company, we expect to need significant additional managerial, operational, sales, marketing, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, recruiting, integrating, maintaining, retaining and motivating our current and additional employees;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing our internal development efforts effectively, including the preclinical, clinical, FDA, EMA and other comparable foreign regulatory authorities&#8217; review process for zidesamtinib, NVL-655, NVL-330 and our discovery programs, while complying with any contractual obligations to contractors and other third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing increasing operational and managerial complexity; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future financial performance and our ability to successfully develop and, if approved, commercialize zidesamtinib, NVL-655, NVL-330 and any future product candidates developed from our discovery programs and other product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of research, clinical development and manufacturing. There</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third-party service providers is compromised for any reason, our preclinical studies and clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval for any of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize zidesamtinib, NVL-655, NVL-330 or any future product candidate from our discovery programs and any of our other product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer actual or suspected security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations, and potentially significant delays in our delivery to market.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures in an effort to protect systems that store our data, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems and external processing and storage systems (i.e., cloud), and those of our third-party CROs, other contractors (including sites performing our clinical trials) and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. The risk of a security breach or disruption through cyber-attacks has generally increased as the number, intensity and sophistication of attempted attacks from around the world have increased. For example, companies have experienced an increase in phishing and social engineering attacks from third parties. Also, a majority of our employees are working remotely. As a result, we may have increased cybersecurity and data security risks, due to increased use of home wi-fi networks and virtual private networks, as well as increased disbursement of physical machines. While we implement IT controls to reduce the risk of a cybersecurity or data security breach, there is no guarantee that these measures will be adequate to safeguard all systems.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any disruption or security breach were to result in a loss, destruction, unavailability, alteration or dissemination of, or damage to, our data (including confidential information and personal data) or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. There can be no assurance that our data protection efforts and our investment in information technology, or the efforts or investments of CROs, consultants or other third parties, will prevent significant breakdowns or breaches in systems or other cyber incidents that cause loss, destruction, unavailability, alteration or dissemination of, or damage to, our data that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data, as well as claims or investigations from regulators or other third parties. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, data (including trade secrets or other confidential information, intellectual property, proprietary business information, and personal data), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal data, including personal data regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to financial exposure related to investigation of the incident (including cost of forensic examinations), subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of data, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notifications, follow-up actions, claims and investigations related to a security incident could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security breach. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in a loss, destruction or alteration of, or damage to, our data (including personal data), or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or privacy and security laws from countries outside of the U.S.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in or, failure or security breach of our systems or third-party systems where information important to our business operations or commercial development is stored. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Many of our research, manufacturing and preclinical activities are conducted by third parties outside of the U.S., including without limitation in China and India. A significant disruption in the operations of those third parties, a war, a trade war or political unrest could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We contract many of our research, manufacturing and preclinical activities to third parties outside the U.S., including without limitation, in China and India. Any disruption in the operations of such third parties or in their ability to meet our needs, whether as a result of a natural disaster, war or other causes, could impair our ability to operate our business on a day-to-day basis and to continue development of our programs. Furthermore, since many of these third parties are located outside the U.S., we are exposed to the possibility of disruption and increased costs in the event of changes in the policies of the U.S. or foreign governments, war, political unrest or unstable economic conditions in any of the countries where we conduct such activities. For example, a war or trade war could lead to tariffs, embargoes, sanctions or other limitations on trade, including without limitation those placed on Russia as a result of its military conflict with Ukraine, that may affect our ability to source the chemical intermediates used in our product candidates. By way of further example, a natural disaster, war, civil or political unrest or similar circumstances could hinder our ability to maintain or initiate clinical studies at our preferred sites, causing trial initiation or implementation delays. Any of these matters could materially and adversely affect our development timelines, business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">More recently, geopolitical tensions between the U.S. and China have led to a growing focus of U.S. lawmakers on the role Chinese companies play with respect to the U.S. biopharmaceutical sector. Like many other life sciences companies, we contract with certain Chinese companies that could be impacted by recently proposed U.S. legislation called the BIOSECURE Act. The BIOSECURE Act is, among other things, aimed at discouraging federal contracting with certain Chinese biotechnology companies for biotechnology equipment or services. While the BIOSECURE Act has not yet become law, we use certain Chinese service providers that would likely be impacted by the proposed legislation, if enacted. As a result, we may be required or decide to reduce the amount of business we do with them or terminate one or more of these relationships altogether. We maintain other service providers for similar services, but if we are required to change or terminate our Chinese service providers for any reason, we would be required to verify that any new provider maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The complexity of the transition process may impact the timing and our ability to secure replacement providers. Delays associated with the diligence, verification and onboarding processes could negatively affect our ability to develop our product candidates in a timely manner or within budget, which could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations are vulnerable to interruption by flood, fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters are located in Cambridge, Massachusetts. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, fire, earthquake, power loss, telecommunications failure, terrorist activity, pandemics or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information and personal data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issues in the use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. Our vendors may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience. If any of our vendors experience an actual or perceived breach or privacy or security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential information and our reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently do not have and have never had a significant marketing or sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration and such arrangements may prove to be less profitable than commercializing the product on our own. If we are unable to enter into such arrangements when needed, on acceptable terms or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek regulatory approval of our product candidates outside of the U.S. and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing regulatory requirements and reimbursement regimes in foreign countries, such as the lack of pathways for accelerated drug approval, may result in foreign regulatory approvals taking longer and being more costly than obtaining approval in the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials or our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval policies or regulations of foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impact of pandemics or other public health emergencies, natural disasters and geopolitical events on our ability to produce our product candidates and conduct clinical trials in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with legal requirements applicable to privacy, data protection, information security and other matters;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes and government payors in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential liability under the FCPA or comparable foreign regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geopolitical events, including war and terrorism, trade policies, treaties and tariffs.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax law could adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, the U.S. Treasury Department and other applicable tax authorities. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our federal net operating loss (NOL) carryforwards may be unavailable to offset future taxable income because of restrictions under U.S. tax law. Under the Tax Act as amended by the Coronavirus Aid, Relief, and Economic Security Act, our federal NOLs may be carried forward indefinitely, but for taxable years beginning after December 31, 2020, the deductibility of federal NOL carryforwards generated in tax years beginning after December 31, 2017 is limited to 80% of our current year taxable income. As of December 31, 2023, we had available federal NOL carryforwards of approximately $123.7 million and available state NOL carryforwards of approximately $144.0 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change in the corporation&#8217;s ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points (by value) over a rolling three-year period), the corporation&#8217;s ability to use its pre-change NOL carryforwards and certain other pre-change tax attributes to offset its post-change taxable income may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in the ownership. There is also a risk that due to regulatory changes, such as suspensions on the use of NOL carryforwards, or other unforeseen reasons, our existing NOL carryforwards could expire or otherwise be unavailable to offset future income tax liabilities. Because our ability to utilize our NOL carryforwards and certain other tax attributes could be limited as described above, we may not be able to utilize a material portion of our NOL carryforwards and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our intellectual property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivation proceedings provoked by third parties or brought by us or declared by the U.S. Patent and Trademark Office (USPTO) may be necessary to determine the priority of inventions with respect to one or more of our patents or patent applications or those of our future licensors. An unfavorable outcome may require us to cease using the related technology or to attempt to license rights to it from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevailing party. Our business could be adversely affected if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our development programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain protection of the intellectual property rights we own (either solely and jointly with others), or may in the future license from third parties (in particular, worldwide patents relating to any proprietary technology and product candidates we develop). We seek to protect our proprietary position by filing patent applications in the U.S. and select other countries related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. We do not yet have issued patents for all of our most advanced product candidates in all markets in which we may commercialize them, but we continue to actively pursue patent protection for our technology and product candidates in certain jurisdictions around the world. However, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, or the methods of use or manufacture of those products. If we are unable to obtain and maintain meaningful patent protection in jurisdictions important to our business for our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, or other proprietary technologies our business, financial condition, results of operations and prospects could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain or defend all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances involving technology that we may license from third parties, we may not have the sole right to control the preparation, filing and prosecution of patent applications or to maintain, enforce and defend the in-licensed patents. Therefore, any in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent rights of pharmaceutical and biotechnology companies, like ours, generally are highly uncertain, involve complex legal and factual questions and have been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents, particularly those related to oncology, has emerged in the U.S. The relevant patent laws and their interpretation outside of the U.S. are also uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patent eligibility of certain inventions or discoveries relating to biotechnology. These decisions conclude, among other things, that abstract ideas, natural phenomena and laws of nature are not themselves patent eligible subject matter. Precisely what constitutes a law of nature or abstract idea is uncertain, and certain aspects of our technology could be considered ineligible for patenting under applicable law. In addition, the scope of patent protection outside the U.S. is uncertain, and laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. or vice versa. For example, European patent law precludes the patentability of methods of treatment of the human body. We cannot predict whether the patent applications we are currently pursuing will issue as patents that protect our technology and product candidates, in whole or in part, in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Changes in either the patent laws or interpretation of the patent laws in the U.S. or other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, affect the value or narrow the scope of our patent rights.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, third parties may have intellectual property rights relating to our product candidates of which we are unaware. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases are not published at all. Therefore, neither we nor our future licensors can know with certainty whether either we or our future licensors were the first to make the inventions claimed in the patent applications we own or any patents or patent applications we may own or in-license in the future, or that either we or any of our future licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and future in-licensed patent rights are uncertain. For example, currently unpublished patent applications may later publish and limit our ability to obtain valid and enforceable patents.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, any issued patents we do obtain or in-license may be challenged, invalidated, or circumvented. We or our future licensors may be subject to a third-party pre-issuance submission of prior art to the USPTO, or to a foreign patent office, or become involved in opposition, derivation, revocation, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by any patents we obtain and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Moreover, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents we may obtain. For these reasons and others, we may face competition with respect to our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and any future in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and any patents we do obtain may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Furthermore, our competitors may be able to circumvent any patents we obtain or in-license in the future by developing similar or alternative technologies or products in a non-infringing manner. For these reasons, even if we are successful in obtaining patents or in-licensing patents in the future, our patent portfolio may not provide us with sufficient rights to exclude others from using or commercializing technology and products similar or identical to any of our technology and product candidates for any period of time.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may not protect our competitive position for an adequate amount of time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issued patents can provide protection for varying periods of time, depending, for example, upon the type of patent, the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. However, patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. The term of a patent outside of the U.S. varies in accordance with the laws of the foreign jurisdiction. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are approved for use or commercialized.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension in the U.S. under the Hatch-Waxman Act and in foreign countries under similar legislation, which if granted could extend the term of our marketing exclusivity for any product candidates we may develop, our business may be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date of product approval. In addition, the patent term of only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-U.S. jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on any patents that issue covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted and, even if granted, the length of such extensions. We may not be granted patent term extension either in the U.S. or in any foreign country, even where we obtain a patent that is eligible for patent term extension, if, for example, an applicable government authority determines that we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we obtain such an extension, it may be for a shorter period than we had sought. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, for any patents we may in-license in the future, we may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if a patent we in-license in the future is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed or whether the requested extension is obtained from the USPTO.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain or in-license patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we or our future licensors submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes to patent laws in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of patent laws in the U.S. or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of our owned and any future in-licensed patent applications and the maintenance, enforcement or defense of any issued patents we may obtain or in-license.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. For example, the USPTO regularly revises its policies and procedures for patent examination. Future political changes may impose new difficulties in obtaining patent protection. This combination of events has increased uncertainty with respect to the validity and enforceability of patents once obtained. Similarly, foreign courts and patent offices have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain patent protection in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors and other third parties may infringe, misappropriate or otherwise violate patents or other intellectual property that we own or license. As a result, we or our future licensors may need to file infringement, misappropriation or other intellectual property claims, which can be expensive and time-consuming. Any claims we assert against others could provoke them to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property rights. Our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on in the extent to which we obtain and enforce patent claims that cover our technology, inventions, and improvements.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. In a patent infringement proceeding, the perceived infringers could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are common. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings in the European Patent Office. The outcomes of allegations of invalidity or unenforceability are unpredictable. With respect to validity, for example, even if we are successful in obtaining patents or in-licensing patents, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our future licensing partners were unaware during prosecution.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An adverse result in any such proceeding could put one or more of the patents that we may own or in-license in the future at risk of being invalidated or interpreted narrowly, and could put any of our present or future owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding, for example, on the basis that our owned or in-licensed patents do not cover that technology. Furthermore, if the breadth or strength of protection provided by our patent applications and any future patents is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products, diagnostic tests or services.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patent applications or any future patents. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be adversely affected if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our discovery programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during litigation. Any of the foregoing could allow third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are pursuing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates may be subject to claims that they infringe the patent rights of third parties. Our competitors and others may have significantly larger and more mature patent portfolios than we have. In addition, future litigation may be initiated by patent holding companies or other third parties who have no relevant product or service revenue and against whom our future patents, if any, may provide little or no deterrence or protection. Competitors may also assert that our product candidates infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources and management attention to defend. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Because patent applications can take many years to issue, pending patent applications may result in issued patents that our product candidates infringe. For example, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of our product candidates or technologies. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe the intellectual property rights of third parties. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property rights. Parties making claims against us may also obtain injunctive or other equitable relief. For example, if any third-party patents were held to cover the manufacturing process of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidates. In the event of a successful claim of infringement against us, we may also have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, indemnify customers, collaborators or other third parties, seek new regulatory approvals, and redesign our infringing products, which may not be possible or practical. If we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we may be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and could require us to make substantial licensing and royalty payments. Claims that we have misappropriated the confidential information, trade secrets or other intellectual property rights of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain licenses from third parties on commercially reasonable terms, our business could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from the third parties. The in-licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to sell, assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, such as substantial licensing or royalty payments, our business could be materially and adversely affected. If we are unable to obtain a necessary license, the third parties owning such intellectual property rights could seek an injunction prohibiting our sales or we may be unable to otherwise develop or commercialize the affected product candidates, which could materially harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations, and prospects significantly.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in any future intellectual property licenses with third parties that we may enter into, or otherwise experience disruptions to our business relationships with our future licensors, we could lose intellectual property rights that are important to our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future enter into licensing and funding arrangements with third parties that may impose, among other things, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with those obligations, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements, or our counterparties may require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects, or impede, delay or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, disputes may arise regarding intellectual property that is or becomes subject to a licensing agreement, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other matters of contract interpretation;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe the intellectual property rights of the licensor that are not subject to the licensing agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether our licensor or its licensor had the right to grant the license agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property rights without their authorization;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our involvement in the prosecution of licensed patents and our licensors&#8217; overall patent enforcement strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amounts of royalties, milestones or other payments due under the license agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublicensing of patent and other rights under collaborative development relationships;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, intellectual property license agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we may in-license. If other third parties have ownership rights to patents and/or patent applications we may in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our in-licensed patents in order to enforce such patents against third parties, and we may not receive such cooperation. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite our efforts, our future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could seek regulatory approval for and market products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may attempt to develop and commercialize competitive products in foreign countries where we do not have any patent protection and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S., and even where such protection is nominally available, adequate judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling our inventions in such countries or importing products made using our inventions into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we do obtain patent protection or future licenses but enforcement is not as strong as that in the U.S. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of any patents we do obtain or in-license or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent as the U.S. or at all, inventions that constitute new methods of treatment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any patents we obtain at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We work with third-party contractors located in China to develop certain of our intellectual property. On December 1, 2020, the Chinese government implemented a new Export Control Law which regulates the export of certain technologies outside of China. As currently implemented, we do not believe the Export Control Law applies to our product candidates, and we do not expect it to impact our business; however the Export Control Law could be amended in the future in a way that could adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries, including India, China and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we do obtain or in-license patents and we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition, results of operations, and prospects may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our future licensors may be subject to claims that current or former employees, collaborators, CROs, universities or other third parties have an interest in our owned or future in-licensed patents and patent applications, trade secrets or other intellectual property as an inventor, co-inventor, owner or co-owner. For example, we or our future licensors may have inventorship or ownership disputes that arise from conflicting obligations of employees, consultants, CROs or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of any future owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, we may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Additionally, if residents of other countries can claim inventorship of our patents and patent applications, we may be required to fulfill additional obligations. For example, some countries, including China, require a patent owner to provide remuneration to inventors who assign rights to inventions developed during course of their employment. Litigation may be necessary to defend against claims based on foreign inventors. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future develop, acquire, or license intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). If the U.S. government exercises its &#8220;march-in&#8221; rights in any future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we may license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the U.S. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of such third parties, or that they have wrongfully used or disclosed alleged trade secrets of their current or former employers, or that we have misappropriated their intellectual property, or that they own what we regard as our own intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees, physician-scientist partners, consultants and contractors are or were previously employed at or engaged by universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Many of them executed proprietary rights, non-disclosure and/or non-competition agreements in connection with such previous employment or engagement. Although we try to ensure that the individuals who work for us do not use the intellectual property rights, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or they have, inadvertently or otherwise, used, infringed, misappropriated or otherwise violated the intellectual property rights, or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties. We may also be subject to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. Any litigation or the threat of litigation may adversely affect our ability to hire employees or engage consultants and contractors. A loss of key personnel or their work product could hamper or prevent us from developing and commercializing products and product candidates, which could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees, physician-scientist partners, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in obtaining such an agreement from each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Additionally, assignment agreements and related agreements may be interpreted under the laws of a foreign country, which may be unpredictable. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail in prosecuting or defending any such claims, we may be required to pay monetary damages, and we may also lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position would be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, our unpublished patent applications or other confidential research, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, we expect that, over time, our trade secrets, know-how and proprietary information may be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel to and from academic and industry scientific positions. Consequently, without costly efforts to protect our proprietary technology, we may be unable to prevent others from exploiting that technology, which could affect our ability to expand in domestic and international markets. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. These security measures may be breached or otherwise accessed in an unauthorized manner, and we may not have adequate remedies for any breach.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition or cancellation proceedings. This can be time-consuming and expensive, particularly for a company of our size. In addition, in an infringement proceeding, a court may decide that a trademark of ours is not valid or is unenforceable, or may determine another trademark is not infringing our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trademarks or trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark or trade name infringement claims brought by owners of other registered trademarks or trade names that incorporate variations of our trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks and trade names may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current trademark applications and additional trademark applications we may file in the future may not proceed to registration and/or may be opposed by third parties. Even if such applications proceed to registration, third parties may challenge our use of such trademarks or seek to invalidate our registration in the future. Other companies in our industry may be using trademarks that are similar to ours and may in the future allege that the use of our trademarks in connection with our products infringes or otherwise violates their trademark rights. Trademark-granting authorities may decide to investigate our trademarks on their own initiative if they believe that there may be potential issues to be resolved. In addition, failure to maintain our trademark registrations, or to obtain new trademark registrations in the future, could limit our ability to protect and enforce our trademarks and impede our marketing efforts in the countries in which we operate. Over the long term, if we are unable to establish brand recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our dependence on third parties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs, and strategic partners (collectively, partners) to conduct and support our preclinical studies and our clinical trials under agreements with us and plan to continue to do so for our future preclinical studies and clinical trials. These third parties have had and will continue to have a significant role in the conduct of our preclinical studies and clinical trials and the subsequent collection and analysis of data. For example, our partners contribute highly enabling technologies and services that include: (i) numerous physician-scientists at leading CROs, (ii) support for our translational research efforts, (iii) crystallography to enable structure-based drug discovery, (iv) biochemical and cell-based assays to guide lead generation and optimization, and (v) patient-derived, cell and xenograft models to translate our findings to the clinical setting.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we have limited ability to control the amount or timing of resources that any such third party will devote to our preclinical studies or our clinical trials. The third parties we rely on for these services may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. Some of these third parties may terminate their engagements with us at any time. We also have to negotiate budgets and contracts with CROs, clinical trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. If we need to enter into alternative arrangements with, or replace or add any third parties, it would involve substantial cost and require extensive management time and focus, or involve a transition period, and may delay our drug development activities, as well as materially impact our ability to meet our desired clinical development timelines.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our heavy reliance on these third parties for such drug development activities reduces our control over these activities. As a result, we have less direct control over the conduct, timing and completion of preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP standards, regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are reliable and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EMA also requires us to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials substantially comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under current cGMP regulations and require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients, may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, or if these third parties need to be replaced, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of our product candidates for preclinical studies and clinical trials, and expect to continue to do so for additional preclinical studies, clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quality and quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">long-term supply agreements, and we enter into contracts for the production of our product candidates on an as-needed basis, which means that aside from any binding purchase orders we have from time to time, we are subject to the supplier&#8217;s plant availability, ability to manufacture on our behalf, and/or a change in the terms on which it is willing to continue supplying to us at any time. If we were to experience an unexpected loss of supply of any of our product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing preclinical studies or clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our schedule and specifications, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the breach by the third-party contractors of our agreements with them;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our specifications;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of third-party contractors to comply with applicable regulatory requirements, including cGMPs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of our contract manufacturing partners and are dependent on these contract manufacturing partners for general project management, in-person oversight and for compliance with cGMP regulations for manufacturing both active pharmaceutical ingredients (API) and finished drug products. To date, we have obtained API and drug product for our product candidates from a limited group of third party contract manufacturers, and we continue to develop our supply chain for each of our product candidates. As we advance our product candidates through development, we will continue to take steps to protect against any potential supply disruptions through the use of a safety stock strategy and by maintaining relationships and contracting with additional suppliers. However, we may be unsuccessful in maintaining or putting in place additional framework agreements or protecting against potential supply disruptions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the U.S. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or comparable regulatory authorities, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we will need to find alternative manufacturing facilities, and those new facilities would need to be inspected and approved by the FDA, EMA or a comparable regulatory authority prior to commencing manufacturing, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any third-party manufacturer with whom we contract fails to perform its obligations, we may be forced to enter into an agreement with a different third-party manufacturer, which we may not be able to do on reasonable terms, if at all. As a result, our clinical trial supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original third-party manufacturer and we may have difficulty,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change third-party manufacturers for any reason, we will be required to verify that the new third-party manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop product candidates or commercialize our anticipated products in a timely manner or within budget. Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidate that such third-party manufacturer owns independently. This would increase our reliance on such third-party manufacturer or require us to obtain a license from them in order to have another third-party manufacturer manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to commercially produce our products either at a third party&#8217;s facility or in any facility of ours, we will need to comply with the FDA&#8217;s cGMP regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our precision medicines as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our precision medicines for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, product candidates, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the issuance of our equity securities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products, product candidates and marketing approvals; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our third-party manufacturers use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the U.S. and local laws in other foreign jurisdictions governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state, federal or foreign authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration depends, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical studies or clinical trials, the likelihood of approval by the FDA, EMA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our discovery programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we enter into any collaboration arrangements with any third parties for the development and commercialization of our product candidates, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates would pose numerous risks to us, including the following:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a business combination or sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not provide us with timely and accurate information regarding development progress and activities under the collaboration or may limit our ability to share such information, which could adversely impact our ability to report progress to our investors and otherwise plan our own development of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products or product candidates that result from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to ownership of our common stock</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our Class A common stock may be volatile, and our investors could lose all or part of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our Class A common stock has been and is likely to continue to be highly volatile and subject to wide fluctuations in response to various factors, many of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Broad market and industry factors may negatively affect the market price of our Class A common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Quarterly Report, these factors include, without limitation:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and results of INDs, preclinical studies and clinical trials of our product candidates or those of our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or announcements by potential competitors of their product development efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory actions with respect to our products or product candidates or our competitors&#8217; products or product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in our growth rate relative to our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning our patent applications, issued patents, or other proprietary rights;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sector;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us, our insiders or our other stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expiration of market stand-off or lock-up agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of any public health emergencies, natural disasters, or geopolitical events, including civil or political unrest or military conflicts; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, political, industry and market conditions.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our Class A common stock may be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and cost of, and level of investment in, research and development activities relating to our programs, which will change from time to time;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enroll patients in clinical trials and the timing of enrollment;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of manufacturing our current product candidates and any future product candidates, which may vary depending on FDA, EMA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies or other assets;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and outcomes of preclinical studies and clinical trials for zidesamtinib, NVL-655, NVL-330 and any product candidates from our discovery programs, or competing product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competition from existing and potential future products that compete with zidesamtinib, NVL-655, NVL-330 or any of our discovery programs, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any delays in regulatory review or approval of zidesamtinib, NVL-655, NVL-330 or product candidates from any of our discovery programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of demand for any of our product candidates, if approved, which may fluctuate significantly and be difficult to predict;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with zidesamtinib, NVL-655, NVL-330 or any of our discovery programs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to commercialize zidesamtinib, NVL-655, NVL-330 or product candidates from any of our discovery programs, if approved, inside and outside of the U.S., either independently or working with third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain collaborations, licensing or other arrangements;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to adequately support future growth;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential unforeseen business disruptions that increase our costs or expenses;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the changing, volatile and instable global economic and political environment.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our Class A common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global credit and financial markets have experienced extreme instability, volatility and disruptions in the past several years due to a number of factors, including the COVID-19 pandemic, ongoing military conflicts, bank failures and other market-influencing developments, including severely diminished liquidity and credit availability, declines in consumer confidence, increases in interest rates, declines in economic growth, increases in unemployment rates, increases in inflation and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions, whether due to public health emergencies, military conflicts, bank failures or otherwise, will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to secure additional financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. Our stock price may decline due in part to the volatility of the stock market and the general economic downturn.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders own a significant percentage of our stock and can exert significant control over matters subject to stockholder approval. Two of our directors are affiliated with one of our principal stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our holders of 5% or more of our capital stock and their respective affiliates beneficially own in excess of 50% of our outstanding Class A common stock and Class B common stock and in excess of 50% of our Class A voting stock. Two of our directors, Joseph Pearlberg, M.D., Ph.D. and Cameron A. Wheeler, Ph.D., are affiliated with our largest stockholder, Deerfield. Our principal stockholders, acting together or on their own, could exert significant control over matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that investors may feel are in their best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with each investor&#8217;s interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The dual class structure of our common stock and the option of the holders of shares of our Class B common stock to convert into shares of our Class A common stock may limit our Class A common stockholders&#8217; ability to influence corporate matters.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Class A common stock has one vote per share, while our Class B common stock is non-voting. Nonetheless, each share of our Class B common stock may be converted at any time into one share of Class A common stock at the option of its holder, subject to the limitations provided for in our third amended and restated certificate of incorporation, as amended, that prohibit the conversion of our Class B common stock into shares of Class A common stock to the extent that, upon such conversion, such holder and any other persons with whom such holder&#8217;s beneficial ownership would be aggregated for purposes of Section 13(d) of the Exchange Act would beneficially own in excess of 4.9% or 9.9%, as applicable, based on the holder&#8217;s election of any class of our securities registered under the Exchange Act. Consequently, if holders of Class B common stock exercise their option to make this conversion, such exercise will have the effect of increasing the relative voting power of those prior holders of our Class B common stock (subject to the ownership limitation described in the previous sentence) and increasing the number of outstanding shares of our voting common stock, and correspondingly decreasing the relative voting power of the current holders of our Class A common stock, which may limit our Class A common stockholders&#8217; ability to influence corporate matters. Because our Class B common stock is generally non-voting, stockholders who own more than 10% of our common stock overall but 10% or less of our Class A common stock will not be required to report changes in their ownership from transactions in our common stock pursuant to Section 16(a) of the Exchange Act and would not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our 2021 Stock Option and Incentive Plan (2021 Plan), could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional capital will be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by such sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to our 2021 Plan, our management is authorized to grant stock options and restricted stock units, among other award types, to our employees, directors and consultants. If the number of shares reserved under our 2021 Plan is increased pursuant to the terms of our 2021 Plan, our stockholders may experience dilution, which could cause our stock price to fall.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. For example, in the fourth quarter of 2023, we issued and sold 6,160,714 shares of Class A common stock in a follow-on public offering. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through future strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have increased costs as a result of operating as a public company, and our management is devoting substantial time to related compliance initiatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses. We are and will continue to be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including those related to climate change and other environmental, social and governance focused disclosures, are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time consuming. We have had to hire additional accounting, finance, and other personnel in connection with our status as a public company, and our management and other personnel devote a substantial amount of time to these compliance initiatives and we cannot accurately predict or estimate the amount or timing of additional costs we may incur to respond to these requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as a public company we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, we are required to maintain effective disclosure and financial controls and to make a formal assessment of the effectiveness of our internal control over financial reporting. In addition, we are subject to Section 404(b) of the Sarbanes-Oxley Act, which requires us to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Compliance with Section 404 has been and will continue to be both costly and time-consuming for our management.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future discover material weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Accordingly, we cannot assure our stockholders that we will not in the future identify material weaknesses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we have a material weakness in our internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the stock exchange on which our Class A common stock is listed, the SEC or other regulatory authorities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These inherent limitations include the fact that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert management attention.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our Class A common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of their stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our third amended and restated certificate of incorporation, as amended, and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things, include:</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a prohibition on stockholder actions through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a requirement that special meetings of stockholders be called only by our board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.5%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.5%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the authority of our board of directors to issue preferred stock on terms determined by our board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, Section 203 of the General Corporation Law of the State of Delaware (the DGCL) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any provision of our third amended and restated certificate of incorporation, as amended, our amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our third amended and restated certificate of incorporation or our amended and restated bylaws or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act (the Federal Forum Provision). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the U.S. may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="item_5_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other Information.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director and Officer Trading Arrangements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02728285-7fd0-41a0-aace-8e51f42def34" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table describes for the quarterly period ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, each trading arrangement for the sale or purchase of Company securities </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56a44532-722d-4dad-9128-1e8db40ca93e" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7771458-a53c-4206-982b-a23bf7199352" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a Rule 10b5-1 trading arrangement) or (2) a &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:14.94%;"/>
      <td style="width:12.4%;"/>
      <td style="width:25%;"/>
      <td style="width:10%;"/>
      <td style="width:26.38%;"/>
      <td style="width:11.28%;"/>
     </tr>
     <tr style="height:8pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;">
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name (Title)</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Action Taken <br/>(Date of Action)</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nature of Trading <br/>Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Duration of Trading <br/>Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Number <br/>of Securities</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_ab979a02-7e09-427e-9926-69d8968db931" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James Porter </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(</span><span><ix:nonNumeric id="F_53a66eea-66c6-4f06-b771-5cea644466bf" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">)</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b64b0eb2-37a0-4444-befa-30791de1abb8" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adoption</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;min-width:fit-content;">(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_5aec9579-86bf-439e-9e6b-a89784f25973" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">April 2, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;min-width:fit-content;">)</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Until </span><span style="font-size:9pt;"><ix:nonNumeric id="F_eb53e007-807d-4106-a578-840e1121fac5" contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 20, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b48d7541-2db6-4ba7-b910-6e8b825bf319" contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">351,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits.</span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:44.38%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
    <td style="width:1%;"/>
    <td style="width:9.64%;"/>
    <td style="width:1%;"/>
    <td style="width:7.04%;"/>
    <td style="width:1%;"/>
    <td style="width:9.28%;"/>
    <td style="width:1%;"/>
    <td style="width:8.66%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed Herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017023028601/nuvl-ex3_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amended and Restated Certificate of Incorporation of the Registrant, as amended</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40671</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/16/2023</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861560/000095017023008284/nuvl-ex3_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-40671</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/16/2023</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvl-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvl-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvl-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvl-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.4%;"/>
    <td style="width:96.6%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">These certifications are furnished with this Quarterly Report and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of such Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signature"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:1%;"/>
    <td style="width:3%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NUVALENT, INC.</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: August 8, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James R. Porter</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James R. Porter</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President and Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:1%;"/>
    <td style="width:3%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: August 8, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alexandra Balcom</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Alexandra Balcom</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nuvl-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, James R. Porter, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Nuvalent, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3%;"></td>
    <td style="width:46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: August 8, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James R. Porter</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James R. Porter</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nuvl-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Alexandra Balcom, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Nuvalent, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3%;"></td>
    <td style="width:46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: August 8, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alexandra Balcom</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Alexandra Balcom</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>nuvl-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, James R. Porter, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Nuvalent, Inc. for the quarter ended June 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Nuvalent, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: August 8, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James R. Porter</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James R. Porter</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>nuvl-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Alexandra Balcom, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Nuvalent, Inc. for the quarter ended June 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Nuvalent, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: August 8, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Alexandra Balcom</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Alexandra Balcom</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img240556275_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img240556275_0.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(                  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
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MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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M ?_$ .\  0 " @,! 0$!           )"P@*!08'! (# 0$!  ,! 0$! 0$
M          8'" 4$ P(!"1   00" 0("! 4+#0P) P('  $" P0%!@<1"!()
M(1,4"B(5MW@Y,;46=K8W=Y<8.!I!([/3M)755M875U@9,B14U'66AXB8N,A)
M46%"4C-#):?74S388B9Q@70UJ.AI$0$  0(# P4'#PD&!0,$ @,  0(#$00%
M(3$&05%A$@=QL2)R$W0V@3)"4F*2LB-SD[,4%347D:'1@M)3@U06P:+",T/#
M\*/3)#1C1$7QXY0E5>)D92;_V@ , P$  A$#$0 _ -_@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                &+O)W>AVS<0\R\6]N^Z\L:W5YTYE
MV''ZYH?%.,G?F]UN3Y*&:S7RF9PV*9:FU;7EJUY)&W\FM2M/X%9"Z63HQ>GE
MM'U+-Y.[J%FU5.2LTS-5<[*=G)$SZZ>B,9CEP<O-:SIN4SEK3[]VF,]>JB*:
M(VU;>68CUL=-6$3R8RRB.8Z@    .GV=^U.EM3-+OYBM0V*:E5O5*5U5K,O0
MVY+$43*=F7PUY[*/K.ZQ([UB^A414Z]/;3I^;N93Z[;HFK+15,3,;<)C#?&^
M(V[]S@7N*-#R^MQP[F<Q1:U:JW37317X/7BJ:HB**I\&JK&F?!QZW-$NX'B=
M\
M
M
M
M
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M(FNU5X-VCQJ)VX<G6IZU$SCA5.#OISTH
M
M
M
M
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M@
M
M
M
M                                                        !!]Y
MBGGS]G/8;\=:)A,HSN,[A<?[53=Q-QMFZ/Q1JN5@ZL]GY1Y";#D\/ITD4S7,
MEHUH<IFHGHGK:44;TE2:</\  ^KZYU;]<?5\A/LZXG&J/<4;)J[L]6GFJG<A
M/$7'>CZ%UK%$_6-0C_3HF,*9]W7MBGN1%57/3&]HE=^GFL]XWF'YZ9W-W(+\
M/QG7NQ6]=X,X_6]KG$^!?5<YU*W8P2WK=S;<]7=(][<EFK&0N1.D>V!\$"MA
M9=NA\+Z1H%'_ &5O',X;;E6$USS[</!CHIB(Y\9VJ+U[BK6.(:_^]N89;'9:
MHQBW'-LQ\*>FJ9GFPC8C=)"C@  D\\E_Z4WLD_#5B_K1F"-\8>C.=^1GOPDW
M!GI1DOEH[TK5PS"U.    "-+NU^^G7^U3$?NS*EG<(?=4_+5=ZECWMT]-:/,
M;7P[K&(E*F@ !VW3]ZVK0\DF4U;,6<;.JM]H@:J2T;T;57I#?HRH^M:CZ.7I
MXF^)G7JQ6NZ*>/.9#*:A:\EFJ(JIY)Y8Z8G?']O*[N@<2ZWPQF_KNBYBNS<]
ME&^BN.:NB<::HYL8QC?3,3M9Y<:=TFL;-ZC%[JR#4\V[I&V_ZQRZY=?T3X7M
M,JNDQ#W+U^#8<Z)$3_QNJHT@&J<*9K*XW<CC>L<WLX]2/7>IM]SRM.<'=M6C
M:QU<EQ%%.1U&=G7QGR%<^-.VU/17,T_^IC.#*B.2.6-DL3V212,;)')&Y'QR
M1O1',>Q[55KV/:O5%3T*A%)B8G"=DPNRFJFNF*Z)B:)C&)C;$Q.Z8GEB7[/X
M_0
M
M
M
M                                                     ,%N]CS'
M^T3R_M338>XSE"AA\_?H2W]5XLUIL&Q\L[LQCI8V+K>EP6J]AE"6Q"Z'XRR$
MM#$13)X);<;E1%[>C</:KKUWR>GVIFW$X55SLHI[M7/T1C5S0X>M<1Z1H%KR
MFHW8IN3&--$;;E7<IYN3K3A3COF&B[YBOO#_ '<=Y*9SCKABQ?[6^ KSI*DF
M#TG.6/YU-RQR.D8K=VY(HMH7:-#(0N_7L5AFTJKHWN@LRWF?"6Z^'^ =*TCJ
MYC.89G/1RU1X%,^YHG&,8]M5C/+$4J.XB[0M6UCK9?)3.5R$[,*9\.J/=5QA
M,1/M:<(Y)FIKY$\5^    "3SR7_I3>R3\-6+^M&8(WQAZ,YWY&>_"3<&>E&2
M^6CO2M7#,+4X    (TN[7[Z=?[5,1^[,J6=PA]U3\M5WJ6/>W3TUH\QM?#NL
M8B4J:    ![!QOS=N_&TD5?'W/C3 ))XIM>RCY):2-<[K(M"7JL^,F=Z518E
M]6KEZO8_ZAQM3T/(ZG$U7*>IF/;T[_5Y*H[NWFF$^X1[1^(^$*J;.5N>7TO'
M;8N3,T=/4G?;GQ?!QVU4U)!.-N<](Y(;#4IV_B;87M^'KV5DCCM2/:U%>N-L
M)X:^4C3TJB1JDR-:KG1L0KO4]!SVF3-=<=?+>WIW?K1OI]79S3+4_"':5PWQ
M?%-C+U_5]6F-MBY,15,\ODZO6W(W^M\/",:J*8>S'%6$
M
M
M
M
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MA:G    !&EW:_?3K_:IB/W9E2SN$/NJ?EJN]2Q[VZ>FM'F-KX=UC$2E30
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MS%%VF/74[KE$\U=$^%3T3AU9WTS,;7<3Q)
M
M
M
M
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M4<M1G,A=MWLI7&--=%454SW)C&.B>:=D[7WGS>H
M
M
M
M
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MLS[6O#FBJJ63"*BHBHO5%]**GU%3_I0C"XM^V-P
M
M
M
M
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MC&JQ<PIN1SS3MPN4^ZHF<(PZT4S.#U8Y*;@
M
M
M
M
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MDXSVBYBW?L;,>K/A4S/)71.%5$]%41/+&QV8\KL@
M
M
M
M
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M$OJ/P^P
M
M
M
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M>Z45Q#QOK.O]:S-7D-/G_3HG?'NZM]?<V4^Y0SDO0X
M$GGDO_2F]DGX:L7]:,P1OC#T9SOR,]^$FX,]*,E\M'>E:N&86IP    1I=VO
MWTZ_VJ8C]V94L[A#[JGY:KO4L>]NGIK1YC:^'=8Q$I4T
M  #T;0>5MTXXM)+KN4?["^1'VL)>\=K#V_3\)9*BO;ZB5WZLL+HY?U/%T]!S
M-0TG(ZE1AF:/C.2J-E4>KR]R<8Z$MX7XWXBX1O=?2;\_5IG&JS7X5JKNTX^#
M/NJ)IJZ<-C/_ (T[C=+WQ:^-R3VZKLDJLB;CLC.U:%Z9WH1N,RBMBAD>]W1&
MQ3)%*YSD:Q'_ %2O=3X;SVGXW;7QN6CEIC;$>ZIW^K&,<^#4O!W:WP[Q/-&3
MS<QDM7JPCR=R8ZE<_P#IW-D3,\E-75JF9PIBK>R%(ZM4
M
M
M
M
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M7TF]'UF(QJLUX4W:.[3C/6B/;4353TXO1SFI<
M
M
M
M                                                    '6=RW33^
M.M6SF\<@;5KFCZ7K-"7*;'MNW9K':[K>!QL*M26_F,WE[-3&XVG&YZ(LDTC&
M]51.O54/I9LWLQ=ILV*:J[U4X133$S,SS1$;9?*]>LY>U5?S%=-%FF,9JJF(
MB(YYF=D-2WS%/>B=#T=<]Q;Y?6N4^2]JB=<QEWN#WW&W:W'6'G:V6M)8X\TJ
MQ[#F=WN02N\<&0R:T<6V6%'-JY*M(CBT^'^S2_>ZN9UZJ;=K?%JF?#GQZML4
M],1C5TTS"J.(NT^Q8ZV5X?IB[=W3=JB>I'B4[)JZ)JPIV;JHEIA<Z]P?-O<U
MR#E.5.?>3MNY6W_+]&6MBV[*2WYJ]5CG.AQF(I-2+&8#"U%<J04:,%:G B](
MXFIZ"X,ED,GIMB,KD;=%JQ')3&'JSRS//,S,SSJ:SVH9W4\Q.:S]VN[F)Y:I
MQ]2(W1'-$1$1R0\</6\8                     !)YY+_TIO9)^&K%_6C,
M$;XP]&<[\C/?A)N#/2C)?+1WI6KAF%J<    $:7=K]].O]JF(_=F5+.X0^ZI
M^6J[U+'O;IZ:T>8VOAW6,1*5-                      'TT[MS'6H+V/M
M6*-VK(V6M;J325[->5O]S)#/"YDD3T_Z45%/Q711<HFW<B*J)C;$QC$]V'VR
M^8S&4OTYG*UUV\Q1.--5,S353//$QA,3W&8/&G=?D\;[-B>1JS\Q1;X8F;%0
MCC9EJ[4^"UV0IM]77R+&IT\4D?JYNB*JI*]2&ZGPE:NXWM-GJ7/:3ZV>Y.^G
MN3C'<A?G!_;CG<IU,CQ;1.8RT81%^B(B[3\I1LIN1SU4]6O#&9BNJ6<>N[-@
M-LQL67UO+4LQCINB)8IRH_U;U:UZPV87(V>I98UR>**5K)&]?2U""9G*YC)W
M9LYFBJBY')/?B=TQTQC#2>DZSI>NY.G/Z1?MYC*5>RHG'"=^%4>NIJC';35$
M51RQ#G3X.D
M
M
M
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MIB*>7#%1NN<2ZOQ!=Z^H7)\E$XTVZ=ENGN4X[9]U5,U<F.# 4[K@@
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MO6Z;MFJFNU5$3%43$Q,3MB8F-DQ/),/ZG\?L
M
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M56ZXB.[,QA#ZV=5TO,7(LV,SEZ[M6ZFFY1,SR[(B9F7OAX7O
M
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MRS3ACRX['>3P)*
M
M                                   1[^;']&?WU?-AY=^Y+(G>X6](
M\EYS;^%"/\5^C6>\UN?!E4WFI&4@   EQ\B#Z6GLS^W7=ODBY"(KQOZ*YSQ*
M?I*$LX%]+,GX]7T=:TG,SM0@
M
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M:^V7XKX=S=^C+9?-VJ[]RJ*::8F<9F=T1LY4A9P$A
M
M           CW\V/Z,_OJ^;#R[]R61.]PMZ1Y+SFW\*$?XK]&L]YK<^#*IO-
M2,I   !+CY$'TM/9G]NN[?)%R$17C?T5SGB4_24)9P+Z69/QZOHZUI.9G:A
M
M                                     86>9+]'7W\?,L[IOD-WH['#
MOI!D?/+/TE+B\2>CN?\ ,K_T52HZ-5,F
M)//)?^E-[)/PU8OZT9@C?&'HSG?D9[\)-P9Z49+Y:.]*U<,PM3@    C2[M?
MOIU_M4Q'[LRI9W"'W5/RU7>I8][=/36CS&U\.ZQB)2IH
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MYMSDZ1K.3UNU=S&0GK9>UF+EGK<E55N8BJ:>>GK8Q$\L1C&R78CS.L
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M.9WS:Y\&7?X4])<CYU;^%"V1,MM7
M                                                          1[
M^;']&?WU?-AY=^Y+(G>X6](\EYS;^%"/\5^C6>\UN?!E4WFI&4@   EQ\B#Z
M6GLS^W7=ODBY"(KQOZ*YSQ*?I*$LX%]+,GX]7T=:TG,SM0@
M
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MSR5U43NQ<1VK?>EI_P"7<U^S1'VXL^]ZODZ>\\'8EZ"V_.;W?AD>1I;@
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MQ%]UV..#Q3Z.9WS:Y\&7?X4])<CYU;^%"V1,MM7
M
M         1[^;']&?WU?-AY=^Y+(G>X6](\EYS;^%"/\5^C6>\UN?!E4WFI&
M4@   EQ\B#Z6GLS^W7=ODBY"(KQOZ*YSQ*?I*$LX%]+,GX]7T=:TG,SM0@
M
M                                   ,+/,E^CK[^/F6=TWR&[T=CAWT
M@R/GEGZ2EQ>)/1W/^97_ **I4=&JF3                            $G
MGDO_ $IO9)^&K%_6C,$;XP]&<[\C/?A)N#/2C)?+1WI6KAF%J<    $:7=K]
M].O]JF(_=F5+.X0^ZI^6J[U+'O;IZ:T>8VOAW6,1*5-
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M@R[_  IZ2Y'SJW\*%LB9;:N
M                                                     CW\V/Z,
M_OJ^;#R[]R61.]PMZ1Y+SFW\*$?XK]&L]YK<^#*IO-2,I   !+CY$'TM/9G]
MNN[?)%R$17C?T5SGB4_24)9P+Z69/QZOHZUI.9G:A
M
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MX1REDLE).^U;[TM/_+N:_9HBK>+/O>KY.GO-E]B7H+;\YO=^&1Y&EN
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M\G;SV2KBO+7*<8F/SQ/-,3LF)VQ,3$O8#R/8                *6<V$QD
M2#^4[])AV*_.?XB^Z[''!XI]',[YM<^#+O\ "GI+D?.K?PH6R)EMJX
M
M                       "/?S8_HS^^KYL/+OW)9$[W"WI'DO.;?PH1_BO
MT:SWFMSX,JF\U(RD   $N/D0?2T]F?VZ[M\D7(1%>-_17.>)3])0EG OI9D_
M'J^CK6DYF=J$
M                       PW[B?,*[).TYMR/N#[G.)..LQ0:C[.GV=F@S_
M "&C%15]9#QKJ;,]O]J).G1718U[45415ZJB+U]/T#6=4PG(9:[<HGV6&%'O
MZL*?SN/J/$&B:3C]H9FS;KCV/6QK]Y3C7^9E5JVRXC<]8US<,!.^U@=KP.(V
M7"6I8)JLEG$9W'U\IC9Y*UAD=BN^:G:8Y8WM:]BKT<B*BH<N[;KLW:K-S971
M5,3W8G"74M7*+UJF];VVZZ8F.Y,8PYX_#Z                       #"S
MS)?HZ^_CYEG=-\AN]'8X=](,CYY9^DI<7B3T=S_F5_Z*I4=&JF3
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M]',[YM<^#+O\*>DN1\ZM_"A;(F6VK@
M                                                           (
M]_-C^C/[ZOFP\N_<ED3O<+>D>2\YM_"A'^*_1K/>:W/@RJ;S4C*0   2X^1!
M]+3V9_;KNWR1<A$5XW]%<YXE/TE"6<"^EF3\>KZ.M:3F9VH0
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MN ).^U;[TM/_ "[FOV:(JWBS[WJ^3I[S9?8EZ"V_.;W?AD>1I;@
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M.#Q3Z.9WS:Y\&7?X4])<CYU;^%"V1,MM7
M
M   1[^;']&?WU?-AY=^Y+(G>X6](\EYS;^%"/\5^C6>\UN?!E4WFI&4@   E
MQ\B#Z6GLS^W7=ODBY"(KQOZ*YSQ*?I*$LX%]+,GX]7T=:TG,SM0@
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MWH['#OI!D?/+/TE+B\2>CN?\RO\ T52HZ-5,F
M     )//)?\ I3>R3\-6+^M&8(WQAZ,YWY&>_"3<&>E&2^6CO2M7#,+4X
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MKL<<'BGT<SOFUSX,N_PIZ2Y'SJW\*%LB9;:N
M
M      CW\V/Z,_OJ^;#R[]R61.]PMZ1Y+SFW\*$?XK]&L]YK<^#*IO-2,I
M !+CY$'TM/9G]NN[?)%R$17C?T5SGB4_24)9P+Z69/QZOHZUI.9G:A
M                                                           &
ML-[V']'7PQ\]/CKY#>XPLGLN](+WF=?TEI67:MZ.V?/:/HKRO@+Y9_    !<
M7=MGYNO 7X%>+/N&P1DG4?O"_P#+5_"EL#3?N[+_ "-'P8>U'C>T
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M;U)YO!G;&-6B^!N,*-?RWU'.S$:O:IV_^I3&SKQ[J-D5QS^%&R<*=A @2P
M           *6<V$QD 2#^4[])AV*_.?XB^Z[''!XI]',[YM<^#+O\*>DN1\
MZM_"A;(F6VK@
M                                         (]_-C^C/[ZOFP\N_<ED
M3O<+>D>2\YM_"A'^*_1K/>:W/@RJ;S4C*0   2X^1!]+3V9_;KNWR1<A$5XW
M]%<YXE/TE"6<"^EF3\>KZ.M:3F9VH0
M                                  !K#>]A_1U\,?/3XZ^0WN,+)[+O
M2"]YG7]):5EVK>CMGSVCZ*\KX"^6?P    7%W;9^;KP%^!7BS[AL$9)U'[PO
M_+5_"EL#3?N[+_(T?!A[4>-[0                      !A9YDOT=??Q\R
MSNF^0W>CL<.^D&1\\L_24N+Q)Z.Y_P RO_15*CHU4R8
M           D\\E_Z4WLD_#5B_K1F"-\8>C.=^1GOPDW!GI1DOEH[TK5PS"U
M.    "-+NU^^G7^U3$?NS*EG<(?=4_+5=ZECWMT]-:/,;7P[K&(E*F@
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M3OTF'8K\Y_B+[KL<<'BGT<SOFUSX,N_PIZ2Y'SJW\*%LB9;:N
M
M                   CW\V/Z,_OJ^;#R[]R61.]PMZ1Y+SFW\*$?XK]&L]Y
MK<^#*IO-2,I   !+CY$'TM/9G]NN[?)%R$17C?T5SGB4_24)9P+Z69/QZOHZ
MUI.9G:A
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M,QR3$[)C\FS:R_J>F9O2,]<T_/4]7,6YPGFF.2J)Y8F-L3^7"<8>!'N>
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M]!_6?!__ /+:;_\ E6/VS^<_C3^D/1O\[<!_" ^RM3_EK_S=?Z#^L^#_ /\
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MFJJU733$=,S3$1ZK[6-<T3,W:;&6SF5N7ZIPBFF[;JJF>B(JF9]1E0<QU
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M^DVPZM'(R:6;[ ]STES7Y!ST?-ZM8VM<Q/5)&WQ-7RW>S7ANYZSZQ;\6N/\
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ML^]ZODZ>\V7V)>@MOSF]WX9'D:6X                  "L-]X=^F&[OO\
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MRF*J:HW3$[I_XVQRLT9G+7\GF*\KFJ9HS%NJ::J9WQ,;X_XV3OC8Z2?9\0
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M=R8Q_P#J_P ]M3T_,Z3J-_3,W&&9R]VJW5W:9F)F.>)PQB>6)B7%'V>$
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MX3,1BOOASBO2^)+..5GJ9RF,:K54QUHZ8]M3C[*.CK13,X)/B-).
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M]NG!/UCY0*8[5O\ R,EXEWOT+L[)/_'SWCVN]6W&"I%P@
M   PL\R7Z.OOX^99W3?(;O1V.'?2#(^>6?I*7%XD]'<_YE?^BJ5'1JIDP
M                        !)YY+_TIO9)^&K%_6C,$;XP]&<[\C/?A)N#/
M2C)?+1WI6KAF%J<    $:7=K]].O]JF(_=F5+.X0^ZI^6J[U+'O;IZ:T>8VO
MAW6,1*5-/:>-N"-XY'=#<KU?B/77JBNV#*Q21UYH^JHJXNK\"QE'^A>BL\,*
M.3HZ1J]#AZGK^1TW&BJ?*9GVE.^/&G=3ZNWFB5B<(=F7$G%TTYBU1]6TF?\
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MAL>>G210    $G?:M]Z6G_EW-?LT15O%GWO5\G3WFR^Q+T%M^<WN_#(\C2W
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M0!(/Y3OTF'8K\Y_B+[KL<<'BGT<SOFUSX,N_PIZ2Y'SJW\*%LB9;:N
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MW'KY]7&*.Y5,QN6'V<:%]J:U]?OTXY/*85=$W)]9'J837T33$3O6-QGQHH
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M92   "7'R(/I:>S/[==V^2+D(BO&_HKG/$I^DH2S@7TLR?CU?1UK2<S.U"
M      8?=[7?+V^]@7"^3YJ[@-J;BL<UTV/U#3\4M:YO/)&S-B22#5])P4MB
MN_)7W>-KK$[W14Z$"K-:FBB17'6T;1<_KN<C)Y"G&K?55/K:(]M5/)'-&^9V
M1$RY&M:YI^@9*<[J%>%.ZFF-M5=7M:8Y9YYW1&V9B%;[YEGFY]S?F3[C8CW?
M*R\>\#X?*ONZ%P!JN2LNU3$I ^5F/S>XWO5U)]_W9E9_1^0MQLKUWND2C5IQ
MRR,=H7AWA33>';,39CRF>F,*KM4>%//%,>QIZ(VS[*9P9RXDXMU/B2],7Y\G
MD(G&FU3/@QS35/LZNF=D>QB,451)T6   #N&E<>[]R5F&:[QSH^X;_L$C4='
M@M*UK-;5F)&N<C&N9C,%2OW7-<]41%1GI5>A\KV8L9:CRF8KHMV^>J8IC\LS
M$/K9R^8S-?D\O17<N<U-,U3^2(F68N)\K+S)<U39?H]B?=:RO(YS6?&/!G(6
M&L.\/1?&E+,8*A<]4Y%ZM?ZOP/3TM53D5<3<.T3U9SV5QZ+E$]Z9=BGA?B2N
M.M&1S>'3:KC\TQ$O)>4.ROO#X3IVLGR_VK]P_&F(I^/VC.[MPWR%KFOM:QKW
MOECV#*:_7PT\#6QN59(YW,^"OI]"]/5EM8TG.3%.4S67N5SR4W*)G\D3C^9Y
M,UHNL9*)JS>5S%JB.6JW7$?EF,/SL9#I.:   $D_EV^:?W1^6[O;<QQ'L;ME
MXLS62@M\A\$[;;LV./MSA1&0V;E*)$FGTS</96-2#,XYK+'BBB9:9;JL=5?'
M>(.&-,XAL=3-T]7-1'@7:?74_M4\],[-^&$[4CX>XIU3AR_U\I5ULK5/AVJO
M65=SVM7-5&W=CC&Q9!]@/F(=O'F+\/1<I<'9U]?,8CV&AR3Q?GY*\&]<9[':
MJMG^+<Y0B>K;V(N.23XORU;QT<@R)Z,<V:*Q!#GK7= U#A_-_5<[3X$XS17'
MK:XYXGDGGIG;'<F)G1N@<0Z?Q%D_K61J\.-E=$^NHGFF.6.:J-D]V)B,[CB.
MZ       TL_>_?\ EY_ZV?\ PSEP]D__ +_^!_O*8[7?_C_X_P#LM+,N%3(
M  6 GNL7=Q_.GVC\@]J>QY+U^T]LNY/S&H03+X9).)>5KF3SU2M KD62X_ \
MAU\YZY_B5(*^0IQ>%K49XJ)[3=*^JZK;U2W'Q69HPJ\>C"/ST=7NS$ROWLNU
M;ZUI%S2KD_&Y:O&GY.O&8_)7UNY$Q"1KS:/-NXE\LKBV)B1XKD+N5WO&V).)
M>'777MC2#UDM1V_\AOHRQW\+Q_B[<3V,:UT5O,VXG5*CF(RW;I1[A;A7-<29
MKEMZ=1/AW/\ #1CLFN?R4QMGDB9%Q9Q9E.&<KR7-2N1\7;Q_OUX;8HC\M4[(
MY9IK6^Y3N;YO[NN6]DYN[@-]R^_\@;-.OK;V1E]7C<)BV2RR4-:U7#0^'&ZU
MJ^)29S:M&I''!'XG/5'2/D>[1.G:;DM*RM.2R%N+=BGDC?,\LU3OFJ>69VLW
M:EJ>>U?-U9W4+DW,Q5RSNB.2*8W4TQR1&QX*>YX0        !^FN<QS7L<YC
MV.1S7-56N:YJ]6N:Y.BHY%3JBH!NP^0SY[6=VO.:?V0=[&Y?&F5R+,?K';[S
MOLEJU-FLWEW3MIXKBWD_,V7SID\ID(Y&0X3-6'1S3RQI4N23SS02K3?''!%%
MJBO6M&HPIC&J[:C=$<M=$<D1[*F.[&$1,+IX$XZN7:Z-$UJO&N<*;5V=\SR4
M5SRS/L:IW[IF9F);FI4*Y     02>\C?1+<Z_;KP?\KNHDW[//2JQXESZ.I!
M>T?T3O\ CVOI*5:$:+9L             W@/=$?O=]\?VZ<$_6/E ICM6_\
M(R7B7>_0NSLD_P#'SWCVN]6W&"I%P@                  PL\R7Z.OOX^9
M9W3?(;O1V.'?2#(^>6?I*7%XD]'<_P"97_HJE1T:J9,
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M     "3OM6^]+3_R[FOV:(JWBS[WJ^3I[S9?8EZ"V_.;W?AD>1I;@
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MFJ.B8PGHW<C5FCZKE]:TVUJ66_R[M..'+35&RJF>FF8F.G?NEDZ<UTP
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M=$;<:>C&(]:TAP#Q-.NZ9.6S=6.I9:(BJ9WUT[J:^F=F%73A,^N3\D%3T
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M':X7$'!.J\-Y*G/9ZYEZ[5=V+<1;JKF<9IJJQGK6Z8PPIGEQQPV(<R6H>
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M8     $G?:M]Z6G_ )=S7[-$5;Q9][U?)T]YLOL2]!;?G-[OPR/(TMP
M             %8'[PC=JW_. [P9Z<[+$,=K@ZD^2-55K;6-[:N&\=>@7JB?
M#K7JLD;O_P!3%-)\!1-/">4B=^%S\]ZY,?F9D[0*HJXOSDT[8QM1^2S;B?SH
M8R7H: 73!CULT    &DM[P1Y(ZX23;N_7L_TUSL-/+8S_<CPUJF*:B8-ZLL6
M\QS9IF*I(W_T:9[/6;+0KQ*ZK*]V48BP.O.K7)P'QGU^IH>K5^'NLW*IW\UN
MJ9Y?:3._UN_JXTKQ_P $]2:]>T>CP-]ZW3&[GN4Q')[>(W>NW=;#30+>4X
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MK[^/F6=TWR&[T=CAWT@R/GEGZ2EQ>)/1W/\ F5_Z*I4=&JF3
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M>>_]+3WF?;KI/R1<>FF."/17)^)5])6R]QUZ69SQZ?HZ$1Q*D3 +I@QZV:
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MO*?W#9T]FG?>%CY:CX4/%J7W=F/D:_@RIT36S'X    -^KW2[\S#N0^<]/\
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MX    +B[ML_-UX"_ KQ9]PV",DZC]X7_ ):OX4M@:;]W9?Y&CX,/:CQO:
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MDMJBHQ$:GZB=#(F:M18S-RS&ZBY53^29AL;*W9OY6W?G?7;IJ_+$2[Z?!]P
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M_)T3&S]:K#U*9CE6EV7:-3F]2N:O>C&UEJ<*/E*XG;^K3CZM43R-_ HM?8
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M,L[IOD-WH['#OI!D?/+/TE+B\2>CN?\ ,K_T52HZ-5,F
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M3N8U[8.,/ZBXAG3,G7UM)R$S13ANKN[KE?-,1,=2F=V%,U1.%3&\DRH@
M   "3OM6^]+3_P NYK]FB*MXL^]ZODZ>\V7V)>@MOSF]WX9'D:6X
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M7\&5.B:V8_    !OU>Z7?F8=R'SGI_DIX\*,[4_OC+^;?XZU\]D_W-F?.O\
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M,XU?K58SW,(G<U#P7H?V%H5NQ=C#.7?C+G/%541A3^K3A3/3$S&]+:15+
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M7M;H?LYS$WN&*+<_Z5VY1^?K_P"-G#M*R\6.*;ER/]6S;K_-U/\  U_2=H"
M  %J9Y*G.5KN"\L#M%W7)VW6\[K_ !PO$^=DE5765O<-9O*\7U+%V16IZZYD
M\+JM2X^3JYTBV?$Y5>KC,?&.2C(<2YNS3&%%5SKQ_$B*_P TU3'J-2\%YZ=0
MX8RE^J<;E-OJ3W;<S1M[L4Q/JI3",I0   &EG[W[_P O/_6S_P"&<N'LG_\
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M]2B=D=$U8S[F)7%P[V7V[?5S7$-77KW^1HGP?UZXVSTQ3A'NIAMT\=\;\?\
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MJ]2F<(GDJJB4Z[/]"^V=<IO7J<<EE<+E7--6/Q=/JU1UICEIIF.59?&<VDP
M           .!V;:=8TK!Y#9]RV/ ZEK6(@6SE=AV;+X_ X/&5D5$6QD,ME;
M%2A2@151/')(UO\ UG[MVKEZN+5FFJNY.Z(B9F>Y$;7SNW;5FB;MZJFBW&^:
MIB(CNS.R$.?<?[P/Y7_;HN1QS>=).<]IQWKVKJ_;SA).1FV9('K%X*V\OM83
MBN7QRM5$Z9]5\*>+IX5:JR[3^ ^)=0PJ\AY"U/LKL]3^[MK_ +J'ZCQ_PQIV
M-/E_+W8]C:CK_P![91_?0.=PWO:W)V53(XKM8[6]/TR!R2P4-RYOV;*;QE7Q
MR.<U+S=(TMVGXS$WXH5ZQLDS.4@;*B*]LK$6-TWR'99EJ<*M3S-=<\M-N(IC
MN=:KK3,?JTSW$%U#M8S->-&EY6BB.2J[5-4]WJT]6(G]:J.Z@K[A?.0\RKN9
M6]5Y#[L.2L-KMYLT,NG<5WJ_$&K/HS-1C\9?H<;U];L;!05/JMRDUYSO^TY2
M;9#A'AW3<)R^5MS<CV5<>4JQYXFO'"?%P0;4.,>)-3QC,9NY3;GV-$^3IPYI
MBC#&/&F49]FS9NV;%RY8GMV[<\MFU:LRR3V;-F>1TL]BQ/*Y\LT\TKU<][E5
MSG*JJO4D<1$1A&R(1F9F9QG;,OX']     6_/9'^9AVB?-@X"^2G4S)^M??&
M;\YN_#J:YT3[ERGFMKZ.ED^<UU     1[^;']&?WU?-AY=^Y+(G>X6](\EYS
M;^%"/\5^C6>\UN?!E4WFI&4@   EQ\B#Z6GLS^W7=ODBY"(KQOZ*YSQ*?I*$
MLX%]+,GX]7T=:TG,SM0@    J]//N[@+'<%YI'<G:CN.LZ]P_F<;V_ZM769M
MA,97XHI)AMNIMD9T8C9N4)L_:\"(BQ+95CNKFN<[2G V0C(<,Y>,,+EZ)NU=
M/7VT_P!SJQZC,7'FH3J'%&9F)QMV:HM4]'DXPJCW_7GU4.1+D/   "8+R,^X
M7MF[4^__ %#G[NHY!9QKH?'_ !UR8[7MC?IFZ[PY^\;3@/L)HXZ+&:%KFT9^
MD^UKFRY1WM255A:V-8GO;ZU.L3XUR&I:IH5>0TRWY2_<N48QUJ:?!IGK3.-4
MTQ.V*=F/3R)=P/J&F:5K]&?U2YY*Q;MUX3U:JO"JCJQ&%,53NFK;AT<K=P_2
M'?)Y_K??^P'=#_\ "937] \6_P I_P VS_U%V?B%PA_.?\J__P!,_2'?)Y_K
M??\ L!W0_P#PF/Z!XM_E/^;9_P"H?B%PA_.?\J__ -,_2'?)Y_K??^P'=#_\
M)C^@>+?Y3_FV?^H?B%PA_.?\J_\ ],_2'?)Y_K??^P'=#_\ "8_H'BW^4_YM
MG_J'XA<(?SG_ "K_ /TS](=\GG^M]_[ =T/_ ,)C^@>+?Y3_ )MG_J'XA<(?
MSG_*O_\ 3/TAWR>?ZWW_ + =T/\ \)C^@>+?Y3_FV?\ J'XA<(?SG_*O_P#3
M/TAWR>?ZWW_L!W0__"8_H'BW^4_YMG_J'XA<(?SG_*O_ /3/TAWR>?ZWW_L!
MW0__  F/Z!XM_E/^;9_ZA^(7"'\Y_P J_P#],_2'?)Y_K??^P'=#_P#"8_H'
MBW^4_P";9_ZA^(7"'\Y_RK__ $VG1[PEWE]MO?%WG\9<L=KG(_\ .?Q_KW;#
MIG'>8S_V'[[I7L>XXGE;FG9<AA_BKD35]2S5CV?"[;CYO:(JSZK_ &CP-D62
M.1K+;X"TC4=%T>YE=3M^2OU9FJN(ZU-7@S1;B)QHJJC?3.S''9NW*>[0=9TW
M7-9M9O2[GE<O3E::)GJU4^%%=R9C"NFF=U43CAAMW[T$A-D&   "P?\ =2=Y
MGS_E_<L:7;F?+)H'=%MS,<QTOC96P6T<=<99BO!'$^>1\/7.LR4J^%D<3EDZ
MIXG^L4H;M0L1;UVU>C=<RU./=IKKCO8- =E=^;F@7;,[[>:JP[E5%$]_'_C%
ML\E;+-   #2S][]_Y>?^MG_PSEP]D_\ [_\ @?[RF.UW_P"/_C_[+2S+A4R
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M/>9]NND_)%QZ:8X(]%<GXE7TE;+W'7I9G/'I^CH1'$J1, NF#'K9H
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MOC:.>8ICPZ>?;3C,1RU12K'#2#,X    -KOW5GO(_FW[CN3>S7:LIZK6.X7
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M,3[7J\S3W!&ASH>@V[=VG#.7OC+G/$U1LIGQ:<(F/;=;#>F$(DEX
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M6?<-@C).H_>%_P"6K^%+8&F_=V7^1H^##VH\;V@
M #"SS)?HZ^_CYEG=-\AN]'8X=](,CYY9^DI<7B3T=S_F5_Z*I4=&JF3
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M       'BO<G^;KS[^!7E/[ALZ>S3OO"Q\M1\*'BU+[NS'R-?P94Z)K9C\
M  &_5[I=^9AW(?.>G^2GCPHSM3^^,OYM_CK7SV3_ '-F?.O\%#:N*P6H
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M=??Q\RSNF^0W>CL<.^D&1\\L_24N+Q)Z.Y_S*_\ 15*CHU4R8
M       #./LI\N;NX[_]O76>W'B[(YS"T+L%/:^4-A6;7.)]&29T*O?L^[6:
MTU3VV*O.DZ8RA'?S-B!KGUZ<R-=TXNL\0:5H5KRFH78IKF/!HC;75W*>;DQG
M"F)WS#MZ+P[JVOWO):=:FJB)PJKG9;I\:KGY>K&-4QNB6\MY=GNZ7:3V@K@^
M1>>(J'=5SU1=6R$&0W#"Q1\0:3DXVK(U=.XWNONUL[?HSR? RF>==D]9!%9J
M5<=,BH4KQ!V@:KJW6R^1QRN1G9A3/QE4>ZKY(GVM.&^8F:H7AP]V=Z3I'5S.
M>PS6?C;C5'Q=,^YHVXS'MJL=T3$4RV'6M:QK6,:UC&-1K&-1&M:UJ=&M:U.B
M-:U$Z(B?4("L)#!YB'GG=F?8''G-+?GF\\=PN/BF@AX4XSRM&P[ Y5(U=#!R
MANR,OX/CV)'>'UM967LVQDC)&XY\3O6),- X*U?7>K>ZOD,A/^I7$[8]Q3LF
MON[*?=8H9Q#QQHV@=:S-7E]0C_3HF-D^[JVQ1W-M7N<&B9W_ 'F]]YGF'Y._
MC>5-Y=IG#?MZ6<)P)QQ+>P/'-.*M82;&S[+$MF7*<@9RHL;)/;,O-89#8\;Z
M<%-C_5)=NA<)Z1H%,596CKYO#;=KPFOIPY*8Z*8C9OF=ZC-?XNUGB&J:<U7U
M,GCLM48Q1T=;EKGIJF=NZ(W(NR2HP  )//)?^E-[)/PU8OZT9@C?&'HSG?D9
M[\)-P9Z49+Y:.]*U<,PM3@    C2[M?OIU_M4Q'[LRI9W"'W5/RU7>I8][=/
M36CS&U\.ZQB)2IH            #./M+XV15N<E96O\ W*SXK5VR-]'546++
M95B*G7JB*M6)R+T],Z*G]RI!.+]3];IEJ>:JO_#3_BG]5I+L+X0QFYQAGJ-W
M6M9;'\EV['T=,_*1,;I9JYG+X_ 8G(YO*V&U<;BJ=B]=L.]/JZ]:-TDGA:GP
MI)'(WHQB=7/<J-1%540A%FS<S%ZFQ9C&[75$1'3+1.H9_*Z7D;NHYZN*,I8M
MU5UU3R4TQC/=GDB(VS.$1ME#QO\ N60W[;<QM.1ZL?D+*^R5O%XFT<="GJJ%
M%G3HWI7K-:CG(B>.3Q/7TN4N73\E;T_)T96WNIC;//,[Y]6?R1LY&!.*.(,U
MQ1KN8UK-[*KM?@T\E%N-E%$>+3$8SRU8U;YETX]J/@         !)WVK?>EI
M_P"7<U^S1%6\6?>]7R=/>;+[$O06WYS>[\,CR-+<                  !5
ML>>_]+3WF?;KI/R1<>FF."/17)^)5])6R]QUZ69SQZ?HZ$1Q*D3 +I@QZV:
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MGV5P#-/RVOI%.P?YZ?:S\N6BG'XB]'\]YG>^CJ=GAOTBR'GMCZ6E;BF56M
M    *W;WF_Z4W;/P+<._6?(&ANS?T9H^6N=^&<NTSTIK^1M]Z6O@3Q7X   ;
M(GNLWTF&>^;#RG]UO&)7G:;Z.4^<T?!K6-V7>DM7FM?PJ%BH4 T.
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MUN>%?\R-Y_;1^*NG_P I>]]2?A+J/\W9][4?HC_<5_6YX5_S(WG]M'XJZ?\
MRE[WU)^$NH_S=GWM1^B/]Q7];GA7_,C>?VT?BKI_\I>]]2?A+J/\W9][4?HC
M_<5_6YX5_P R-Y_;1^*NG_RE[WU)^$NH_P W9][4?HC_ '%?UN>%?\R-Y_;1
M^*NG_P I>]]2?A+J/\W9][4?HC_<5_6YX5_S(WG]M'XJZ?\ RE[WU)^$NH_S
M=GWM386\F'RO=]\K[C+FG0]\Y1U'E&WRCO> VZA?U'#YG#UL76P^OR8:2I<C
MS+G2S3S2O\;7,^"C?0OI(%QAQ+8XES-F_8M5VHM433,53$XXSCR+!X-X8O\
M#&6O6+]VB[-VY%433$QAA&'*F@(>F8   :6?O?O_ "\_];/_ (9RX>R?_P!_
M_ _WE,=KO_Q_\?\ V6EF7"ID   .Z<;??$T'[=-6^OE$^.8_\>OQ*N]+[9;_
M ,BWX]/?A<R&0VQP        !6&^\._3#=WW^@#_ '7N$S27 /HEE/XOTUQF
M7M"]+\Y_"^@MH628(8   &U;[I=^>?W(?-@G^5;CLK#M3^Y\OYS_ (*UI]D_
MWUF?-?\ <H;]91B^@     -8;WL/Z.OACYZ?'7R&]QA9/9=Z07O,Z_I+2LNU
M;T=L^>T?17E? 7RS^    "XN[;/S=> OP*\6?<-@C).H_>%_Y:OX4M@:;]W9
M?Y&CX,/:CQO:                       ,+/,E^CK[^/F6=TWR&[T=CAWT
M@R/GEGZ2EQ>)/1W/^97_ **I4=&JF3                !Z_P &\ <U=R_(
M6)XIX#XSV[E;D',]7U-:T_%39*S#49+%#8RV6M?K>.P&!HOG9[3D+TU:C5:Y
M'32L;Z3R9W/Y/3LO.:SURBU8CEJG#U(Y9F>2(QF>2'KR.GYW4LQ&5R%JN[F)
MY*8Q]6>2(CEF<(CEEN5^7A[K?I^K?$/)_F%[1!O>=:R'(0=NG'.7NT]*QMA>
MKXJO(O(M"2EFMKG@9(WUU#"+CZ<=F+I[??K.<U]1:_VEWKO6RV@4]2C=Y6N/
M"GQ*)QBGNU8SA[&F5Q\/=E]FUU<SQ!5Y2YO\C1,Q3'CUQA-73%.$8^RJAMP:
M'H&B\6ZC@] XTTW5^/\ 1M8I,QVNZ?IF"QFM:U@Z$:N<VIBL)AZU/'48?&Y7
M*V.-OB<Y7+U554JJ_?OYF[5?S-=5R_5.,U53,S,],SME;-C+V,K9IR^6HIMV
M*8PBFF(BF(Z(C9#$GO6\QKM'[ -0^R;N.Y1Q^$S=^E/<U3B_74AV/EC>5A;-
MX&:QI5:S#;]BFL0+ N3OR4,-7G<UEBY"KF]>KHW#^JZ[=\GI]J:J(GPJYV44
M]VKGY<(QJF-T2Y.M<1:3H%GRNHW8IKF/!HC;<J\6GFY.M.%,3OF&C3YB?O%O
M=MW?IG>.N");_:KP+>2SCY\=IV:EDY>W;%R.2-R;CR1292M8.A>@C^'B\"VE
M'ZN>6M;M9&%44NKA_L_TK2>KF,]AFL]&W&J/BZ9]S1RS'MJL=T3$4RI#B+M$
MU;5^ME\ACE<A.S"F?C*H]U7&&$3[6G#?,3-4->-SG/<Y[W.>][E<YSE5SG.<
MO5SG.7JJN55ZJJD^5Z_(    D\\E_P"E-[)/PU8OZT9@C?&'HSG?D9[\)-P9
MZ49+Y:.]*U<,PM3@    C2[M?OIU_M4Q'[LRI9W"'W5/RU7>I8][=/36CS&U
M\.ZQB)2IH           ';]#T_(;YMF&U;&HK9<E91MBSX5<RC0B19KUZ1/0
MGAK5F.<B*J>-_A8GI<AXL_G;>GY2O-7=U,;(YYY(]6?R;W>X8T#-<3ZYE]%R
MFRN]7X56&,441MKKGQ:8F8CEG"F-LPF'PF&Q^NXC&X/%0)6QV*IP4:<*=%5L
M-=B,:KW=$\<K^GB>Y?2YZJJ^E2FK]ZYF;U5^].-VNJ9F>F?^-C?FG:?E-)R%
MG3<C3U,I8MQ11'-%,8;>>9WS/+,S,[V&'=GR5T;4XUQ5A.K_ %&4VA8U]*-1
M6S8G%2?J)XG(EJ1/J^B%>O17(3;A'3-LZG>CGIM]ZJK_  Q^LSUVZ<7X4V^#
M\C7MGJW,SA^6U:GZ2J.BWTPP8)XS4           "3OM6^]+3_R[FOV:(JWB
MS[WJ^3I[S9?8EZ"V_.;W?AD>1I;@                  *MCSW_ *6GO,^W
M72?DBX]-,<$>BN3\2KZ2ME[CKTLSGCT_1T(CB5(F 73!CULT
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M<@ S3\MKZ13L'^>GVL_+EHIQ^(O1_/>9WOHZG9X;](LAY[8^EI6XIE5K0
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M1LHI\6F-D=W;5/+,KWT?A_2="L^2TVS315AMKG;75XU4[9[FRF.2(9H''=D
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M]*.[5*)C5,M<Y)R\Q^2N?TKW[)JXG2<U1RQF(G\M$?H;895RU@
M          &EG[W[_P O/_6S_P"&<N'LG_\ ?_P/]Y3':[_\?_'_ -EI9EPJ
M9   #NG&WWQ-!^W35OKY1/CF/_'K\2KO2^V6_P#(M^/3WX7,AD-L<
M  5AOO#OTPW=]_H _P!U[A,TEP#Z)93^+]-<9E[0O2_.?POH+:%DF"&   !M
M6^Z7?GG]R'S8)_E6X[*P[4_N?+^<_P""M:?9/]]9GS7_ '*&_648OH     #
M6&][#^CKX8^>GQU\AO<863V7>D%[S.OZ2TK+M6]';/GM'T5Y7P%\L_@    N
M+NVS\W7@+\"O%GW#8(R3J/WA?^6K^%+8&F_=V7^1H^##VH\;V@
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M1'_&U@+4M0S>K9^]J>>JZ^;OW*JZYZ:IQV1R1&Z(W1$1$;(<6?9X@
M    2=]JWWI:?^7<U^S1%6\6?>]7R=/>;+[$O06WYS>[\,CR-+<
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M3NMHVE589Z8^,N1_IQ,>MI]W,;9GV,;O"G&FU> N":=2ZNM:M3CD8GXNW/\
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MR(9,[;.+_M;6*>&\G5CD,C5/E,-U5_#"?FHF:/&JKB=T,4"7*.
M   D[[5OO2T_\NYK]FB*MXL^]ZODZ>\V7V)>@MOSF]WX9'D:6X
M        "K8\]_Z6GO,^W72?DBX]-,<$>BN3\2KZ2ME[CKTLSGCT_1T(CB5(
MF 73!CULT               U7O/V\E"/N:P>>[S>U/5&)W%:SB_:^6>-M?H
MUH'<Y:SBX7.DV7#U8$A6URSKM"/PK&B/FS]")L#/%<@KQV;-X%XR^S:Z='U2
MK_\ 7U3X%<S_ )<SR3[B9][.W=,X5;Q[P5&IT5:SI5'_ .QICXRB(_S:8Y8_
M]2(]6N-F^(B= IS7,<YCVN8]CE:YKD5KFN:O1S7-7HJ.14Z*BEZJ$?D
M &:?EM?2*=@_ST^UGY<M%./Q%Z/Y[S.]]'4[/#?I%D//;'TM*W%,JM:
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M3ZO.RWQKD)T[B?-VL,+==SRE/-A<\/9W*IF/4YD5!)T6   ";7W>ON%B[?\
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MKOKK5R8B>>G?35^M3,3ZK6VC:E;UC2[&I6O6W;<3,<U6ZJG]6J)CU&3IS73
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M519R>2CUE55=<]VF*::?A5+B[)<I3-[.YZ?7TTV[<=RJ:JJO@TMW0IE=8
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M+2S+A4R   '=.-OOB:#]NFK?7RB?',?^/7XE7>E]LM_Y%OQZ>_"YD,AMC@
M      "L-]X=^F&[OO\ 0!_NO<)FDN ?1+*?Q?IKC,O:%Z7YS^%]!;0LDP0P
M   -JWW2[\\_N0^;!/\ *MQV5AVI_<^7\Y_P5K3[)_OK,^:_[E#?K*,7T
M  !K#>]A_1U\,?/3XZ^0WN,+)[+O2"]YG7]):5EVK>CMGSVCZ*\KX"^6?P
M  7%W;9^;KP%^!7BS[AL$9)U'[PO_+5_"EL#3?N[+_(T?!A[4>-[0
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MLHW^%CC0W'W!?V=75K>E4?\ Z^J<;E$?Z=4SZZF.2W,\GL)W>#,13JG%GJK
M   !FGY;7TBG8/\ /3[6?ERT4X_$7H_GO,[WT=3L\-^D60\]L?2TK<4RJUH
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MC*0   2X^1!]+3V9_;KNWR1<A$5XW]%<YXE/TE"6<"^EF3\>KZ.M:3F9VH0
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M9F%D=G7$U.D9Z=+SE6&GYFJ,)G=1<W1,\T51A35/),4SLB)6(Y0+0H
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M55KV/:J*BHJHJ*9*U*,-1OQ._P M7\*6P--F)T[+S&[R%'P8>VGB>T
M                 86>9+]'7W\?,L[IOD-WH['#OI!D?/+/TE+B\2>CN?\
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MNU_B_P#ISAR=/RE6&JY^*K=.$[:+>&%VOHG"8HIW3UJNM'K)1@%IL9
M         $G?:M]Z6G_EW-?LT15O%GWO5\G3WFR^Q+T%M^<WN_#(\C2W
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M.(Q\:*L=Z^^S+B"G.:=.B9BK_NLOC-&.^JU,\GB3.'13-.&Z6U"5DM(
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MV4[9V13$9MXQXMO\29SJ6L:-*M3/DZ=TU3NZ]?NIY(]C&R-LU3,+I,$,
M!;\]D?YF':)\V#@+Y*=3,GZU]\9OSF[\.IKG1/N7*>:VOHZ63YS74    !'O
MYL?T9_?5\V'EW[DLB=[A;TCR7G-OX4(_Q7Z-9[S6Y\&53>:D92   "7'R(/I
M:>S/[==V^2+D(BO&_HKG/$I^DH2S@7TLR?CU?1UK2<S.U"     !I@>\]>67
M;OI5\QOAO7_:)*E7"ZAW0X?%546PM.JRMA-%Y@DBAC\=AE*!M? YF17.=' W
M&RHSU4=N9EO]FW$<4X\/9RK9,S59F?RU6_5VU4]/6C?A"FNTWAF:L.(LG3MB
M(IOQ'-NIN>ILHJZ.K.Z)EI3%QJ7    !O&>1!Y[^-W+&Z9V3=[.YT\7NN+IX
M[5N!^>-IR,52CO%&I%%0PO&G)>:ORLAK[S7A8ROA\Q8>C<ZU&U;3OC/U4N2I
M?C?@BJS57K.C43-F9FJ[:IC;3.^:Z(CV/+53'K=\>#C%-W<"\=4WJ:-%UJN(
MOQ$4VKM4[*HW117,^RY*:I]=NGPL)JW#"I5O@       'XEECACDFFD9%#$Q
M\LLLKVQQQ1QM5SY)'N5&L8QJ*JJJHB(@B,=D;R9B(QG<U,?-O]X\TGA^OL_;
MUV!9S#<B\M^&QB-J[B*OL&=XTXYE5RPV:?''C;;QG)&X1-1W_J'23 4'*Q6.
MR$JRQ5K3X5[/;V;FG/Z[3-O*[Z;6V*Z_'Y:*>CUT^YC"9J?BWM&L9.*M/T"J
MFYF]U5W9-%'B<E=73ZV/=3C$:*^U;7M&];+GMSW78LYMVW[3E;V=V7:-FRM[
M.;#L&;R=A]O(Y?-9G)SV<AD\E?M2NDFGFD?)(]RJY552Z[5JU8MTV;---%JF
M(B*8B(B(C=$1&R(CF4;=NW;]VJ]?JJKO5S,U553,S,SOF9G;,SSRV0?=6./T
MVCS%=ZW*Q$U:O&?;-ON7JSJCG+'G-DW/CK4:<+499A\+IL+E\D[QN9,Q$C5O
MA1SF/97O:=?\EP_19C?<S-,>I%-=7?B%C]EF7\KQ%<O3NM9:J?5FJBF/S3*P
MX*#:#    !I9^]^_\O/_ %L_^&<N'LG_ /?_ ,#_ 'E,=KO_ ,?_ !_]EI9E
MPJ9   #NG&WWQ-!^W35OKY1/CF/_ !Z_$J[TOMEO_(M^/3WX7,AD-L<
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M3UL4LN!AKRT-@Y4NU)8NC75GX["O1[)H;]QB.A=9O#_9OG<YU<SK4SE\MO\
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M=%,1$\N,[5&:[Q7K/$-?_>W.KE<=EJC&FW'-C&.-4]-4S,<F$;$;1(D<
M              !)YY+_ -*;V2?AJQ?UHS!&^,/1G._(SWX2;@STHR7RT=Z5
MJX9A:G    !&EW:_?3K_ &J8C]V94L[A#[JGY:KO4L>]NGIK1YC:^'=8Q$I4
MT       Y[5]=R.V[#B-;Q,?K;^8NQ4X/0JLB1ZJZ>S+T]*5ZE=KY9%_[,;%
M7]0\^:S-O)Y>O,WIPMT4XS_9'=F=D=,NGHNDYO7=5L:1D8QS68N11'-&.^J?
M<TTQ-54\E,3*8G4M8QVFZWA]8Q3?#1P]..K&]41K[$O5TEJW,B>CU]RU(^5_
M3T>)Z]/04SG,U<SN9KS5[_,KJQ[G-'<B,(CN-_:%HV4X?TC+Z-D8PRV7MQ3$
M\M4[ZJIZ:ZIFJ>F98O\ =?R3\4X:MQ[BK'AR&>C9=SSXW?#K86.5?9Z;E:J*
MR3*6HNKDZ]?4Q*UR*V5"4\):9Y:].HW8^+M[*.FKEG]6/SST*7[<>+_J.GT<
M*9*O#-9J(KO3&^FS$^#1T3<JC&?<4S$QA7"/@L5E8                2=]
MJWWI:?\ EW-?LT15O%GWO5\G3WFR^Q+T%M^<WN_#(\C2W
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M8WT\N,853G'BS@S.\-WIO6NM=TFJ?!N8;:<?8W,-T\D5;*:N3"<:8A1)BA8
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MLUS[FJJCO]?^U[5^E^__ ///_P#RS_\ ]9SQ_A/_ /Y__(_^\]OXN_\ ^O\
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MBKJ5^)7/@S/137LCIK:')=ZB@   WZO=+OS,.Y#YST_R4\>%&=J?WQE_-O\
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M5RJJB.K1,S,1OPC'9&/1N:_MTU46Z::YZU<4Q$SNQF(VSAT[W,GX?L
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M=L>VJQGECJ[D^Y!4]      TL_>_?^7G_K9_\,Y</9/_ .__ ('^\ICM=_\
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M:>"OM+YP^2+;B'=H?HK?\>W])2FG9QZ66/$N_1U++XSFTH
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MY)9E[<N+_K.;M\)9*KXBQ,7+\Q.^Y,>!;V<E%,]:J-OA54[IH88DV9Z
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M/RY:*?CB+T?SWF=[Z.I^^&_2+(>>V/I:5N*95:T         $7'F$^4-V?\
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M56W]7I6CV9</7OM"YK&=MU44V:>I;BJ)B9KJCPIC&/8T[/U^AO.%*KP
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M3;W$_P! ?-/XK-Y_@(?:&G_O[/OZ?TGV;J/\O>]Y5^@_)M[B?Z ^:?Q6;S_
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MUZV)4]"KZQC7)UC*NXHU/Z[G?JUJ?^WLXQW:O93ZFZ.Y,QO;'['>$/Z?X?\
MM;.48:KGXBN<=]%G?;HZ)JQ\I5NWTTS&-#U?DW>J?'6F9?9K/JWV((O9L34D
M7I[?F+37MH5>B.8YT?C:LDOA7Q-@C>Y/J')TO(5ZEG:,K3CU9G&J>:F-\_V1
MTS$)QQEQ+E^$N'K^LWL)NTT]6U3/L[M6,44\FS'PJL-L44U3&Y#]D+]S*WKF
M3R$\EJ]D+4]VY9E7K)/9LRNFGE>O_>DD>JJ7);MT6K=-JW&%NF(B(YHC9# ^
M:S5_.YFYG,U5->9NUU5UU3OJJJG&9GNS+Y#]O@                 $I?;/
MB<GA^*L=7RN/N8VQ/E,K<BKWJ\M6=U6Q,Q8)_4S-9(V*9K?$Q51/$WHJ>A44
MJGB>]:O:M559JIJIBFF,8G&,8C;&,<S:O8[D<YD."+5K/6KEF[5>N5Q373--
M4TU3'5JPG"<)WQLVQMC9,/?R/+2
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M+/FGZ9G='XNR>0S]$T9BC.V.Y,>5IPJIGEIGDGU)PF)A:BF9&I
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MJ>[5AUI]6631S73
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M5LBKN3A5[G#:H/B+@36-!ZU^B/K&GQ_J41MICW=&V:>F8ZU/NL=B$0F:$@
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MB,)\K<B.K1/_ *5O;%'15/6KCDJB)P>]D?6>
M                         P?[L>P3@[NWWSMNY=W+&_$7,7:US;Q9S#QE
MR3AZD#LXE/CWD37=ZS''.=1SX$R^G;A'@WP^KD>K\9<E;<K^E)X;/:TO7<[I
M5C,92S/6RF:LUVZZ)W>'1-,5QS54X^K&R>28XFJZ#D=6OY;-WHZN<RM^BY17
M&_P*XJFB>>FK##HG;'+$YP'%=L
M
M
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M\DRH[6N'=6T"]Y+4;4TT3/@UQMMU>+5S]$X51RQ#!H[3B
M        "3SR7_I3>R3\-6+^M&8(WQAZ,YWY&>_"3<&>E&2^6CO2M7#,+4X
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MNJ:ZYF:YWS.V9[LKXLV;.6M4V,O13;L41A333$4TQ$;HB(PB(Z(?W/R^H
M
M
M
M
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M=4
M
M
M
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MO5YU;]M/%_V)H<:#DZL-2S],Q5A.VBQ&RN?XD_%QR33Y3;C$(V2S60@
M       />^-.WK=N05KY"S"[6=:E\$GQQDX'^T7(7(CD=B<:KHI[C7M<BME>
ML4"HJ^%[E3PD?U3B+(Z=C;IGRN:CV-,[(GW56Z.YMGH6?P=V4\1\5=3-WJ9R
M>CU83Y6Y3/6KC_TK>RJO'DJF::)C=5,Q@D!X]XBTGC:NU,#C4FRCH_!:SV1\
M%K+V/$G1[6S^!K*<#T^K% V-B]/A(Y>JK7FHZQGM3J_[BK"UR41LICU.6>F<
M9:FX5X#X<X0M8:79ZV=F,*KUS"J[5S^%A$44S[6B*8YXF=KTXY:9
M
M
M
M
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MDH8R#K'0I-Z*K>L4"(KU3HCY7.=]5RERZ=D;>G9.C*V_8QMGGJG?/Y=W1A#
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M:N/BJ)]Q;G&)F.2JOK3C&-,4;F1Q&EN
M
M
M
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M5NBUE:(PIHHIBFFF.:*8B(A]A^'H
M
M
M
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M@\.:+PUDXR6BY>BS:V=:8VUUS'+77.-54]V=FZ,(V.UGD=P
M
M
M
M
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M(YV4.V[B_P"U-6IX9R56.1R56-W"=E5^8PP_A4S-/C55Q,;(8E$O44
M ]IXVX(WCD=T-RO5^(]=>J*[8,K%)'7FCZJBKBZOP+&4?Z%Z*SPPHY.CI&KT
M.'J>OY'3<:*I\IF?:4[X\:=U/J[>:)6)PAV9<2<733F+5'U;29_U[L3%,Q_Z
M=.RJY._;&%&,837$I!..>$]'XVCCGQE'XRSJ,Z3;#E6QV,AXE:K7MHM\*08R
M%R.<G2%J/<U>CWOZ(I7FI:YG]3F:;M75R_M*=D>KRU3W=G-$-3\)=G7#?"%$
M7<G:\MJ>&V_<PJN=/4Y+<;9C"B(F8V5558/73CIX
M
M
M
M
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M33313%-,84Q&$1S0P?=NW+]VJ]>JFJ[75-54S.,S,SC,S/+,SMF7\C]/P
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M$:UJ)T1$^H169F9QG>N:FF*8BFF(BF(PB(Y'Z#^@
M
M
M
M
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M(Y9WS,[9G;,S+DCY/8
M
M
M
M
M   !XSSQV[\']S_'N3XJ[@>+]1Y7T'+=7SZ_MN,CNLJ6TBDABRV#R,;H,OK>
M>JQS.2#(8^Q5O5U<JQ2L5>I[,CJ&=TW,1FLA=KM7XY:9P]28W3'/$Q,3RP\>
M?T[(ZGEYRNH6J+N7GDJC'U8G?$\TQ,3')+3 \Q7W7CD+1%SW*7E];#:Y0U&/
MVO)W.WS>LG2J<E8.NCTGDK<?;G;=1P>^4JT3Y/54<DN/RK(8&LCGREJ5$+?X
M?[2\O?ZN6UZF+5W=Y6F)ZD^-3MFF>F,:=NZF(4UQ%V89BQULUP_5-VSOFU5,
M=>/$JV15'15A5LWU3+4PW#3=NX]VC.:1ONK[#I6Y:QD)\3L>I[9ALCKVR8'*
M5E\-C'9C"9:O4R6-NPJOPHIHV/3K]0M.S>M9BU3>L54UV:HQBJF8F)CGB8V3
M"I[UF]E[M5C,4U47J9PFFJ)B8GFF)VQ+K9]'S    !)YY+_TIO9)^&K%_6C,
M$;XP]&<[\C/?A)N#/2C)?+1WI6KAF%J<    $;7=75L7>7,=3J0R6+5O6\'5
MK5XFJZ6>Q8R&3BAAC:GI=)+(]&HGZJJ69PG531H]5=<X41=JF9YHB*<99"[;
MK-W,\=VLO8IFN_<R=FFFF-LS55<N1$1'/,SA#-OB70*_&^DXO7FI$_(N:N0S
MMJ-$Z6LQ;8Q;2H__ ,R&JQC*\3O1XHHFJJ(JJ0;5]0JU//5YG;Y+=1'-3&[\
MN^>F6C>!>%K7"'#EG2HPG-S'7O51[*[5$=;;RQ3$113/+33$X8S+HG<=R3]@
MFD2XW'S^KV+;&V,7CU8[I+3Q_@1N6R2>CJUT4$J0QJBM<DLS7MZ^!3W\-:9]
M?ST7;D8Y:SA5/3/L:?R[9Z(PY4:[6^+_ .F>')R>4JPU;/15;HPWT48?&W.C
M")BBF=DQ57%4>ME%T6JQ:  /]1%<J-:BJJJB(B)U557T(B(GI554_A$3,X1O
M9-\:=L>W;<M?)[3Z[4< _H]&68?_ %^]%]7^]L=*B>PL?T5/66?"Y.J.;%(U
M2+ZGQ1D\GC:RF%[,=$^!'=GE[E/Y87)P?V-:]KTT9S6NMD-+G;A5'Q]<>YMS
MZR)]M<PG=,450SWTGCK4./:'L.KXB"DZ1C66\A)_?&5R"M7Q>*[?D3U\K?&J
MN2-%;$Q5^ QJ>@K_ #VI9S4;GE,U7-4<D;J8[D;O5WSRS+3_  YPEH/"F6^K
M:+8IMS,1%5<^%<KP]O7.V=NV*=E,>QIB'=SPI(
M
M
M
M
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M9'<IJPJY(QWJ-XBX U?1.MF,M$YG3XV]:B/"ICW=&V>[53C3RSU=R!(G"!@
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M[J=]7YHZ&I^#^S#AOA**<S31]:U>,/CKD1,TS_Z5&VFWT3&-?)-<P]N.&L<
M
M
M
M
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MJ9JJF9JE>-NW1:HBW:IBFW3&$1$81$1NB(C9$1S/Z'\?L
M
M
M
M
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M8F8GG9H^2_\ 2F]DGX:L7]:,P<?C#T9SOR,]^'9X,]*,E\M'>E:N&86IP
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MZ(
M
M
M
M
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MG&>EWN&."N'N$;'D](L1&8F,*KU>%5VONUX;(V1X-$4T8[>KCM>B'-2P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
F                                               /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nuvl-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-08T06:32:58.0562+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.nuvalent.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nuvl="http://www.nuvalent.com/20240630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" id="ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>995455 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecurities" id="MarketableSecurities">
        <link:definition>995475 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>995495 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>995505 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995515 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995525 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995535 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995545 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesTables" id="MarketableSecuritiesTables">
        <link:definition>995555 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995565 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <link:definition>995575 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>995585 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995595 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" id="DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>995605 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer">
        <link:definition>995615 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995625 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail" id="MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail">
        <link:definition>995635 - Disclosure - Marketable Securities - Summary of Marketable securities by Security (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail" id="DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail">
        <link:definition>995645 - Disclosure - Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" id="DisclosureMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>995655 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" id="DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail">
        <link:definition>995665 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995675 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail" id="AccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>995685 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail" id="StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail">
        <link:definition>995695 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" id="StockBasedCompensationAdditionalInformationDetail">
        <link:definition>995705 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>995715 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail">
        <link:definition>995725 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>995735 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="nuvl-20240630.xsd#StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="nuvl-20240630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="nuvl-20240630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail" xlink:href="nuvl-20240630.xsd#MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="nuvl-20240630.xsd#AccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/CoverPage" xlink:href="nuvl-20240630.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="nuvl-20240630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="nuvl-20240630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer" xlink:href="nuvl-20240630.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="nuvl-20240630.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail" xlink:href="nuvl-20240630.xsd#DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" xlink:href="nuvl-20240630.xsd#DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="nuvl-20240630.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail" xlink:href="nuvl-20240630.xsd#StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="nuvl-20240630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:href="nuvl-20240630.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="nuvl-20240630.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="nuvl-20240630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="nuvl-20240630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusiness" xlink:href="nuvl-20240630.xsd#DisclosureNatureOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="nuvl-20240630.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecurities" xlink:href="nuvl-20240630.xsd#MarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurements" xlink:href="nuvl-20240630.xsd#FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpenses" xlink:href="nuvl-20240630.xsd#AccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensation" xlink:href="nuvl-20240630.xsd#StockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShare" xlink:href="nuvl-20240630.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingencies" xlink:href="nuvl-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nuvl-20240630.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="nuvl-20240630.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesTables" xlink:href="nuvl-20240630.xsd#MarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsTables" xlink:href="nuvl-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesTables" xlink:href="nuvl-20240630.xsd#AccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationTables" xlink:href="nuvl-20240630.xsd#StockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="nuvl-20240630.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="nuvl-20240630.xsd#DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:href="nuvl-20240630.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="nuvl-20240630.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_MarketValue" xlink:label="nuvl_MarketValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_UnvestedRestrictedCommonStockMember" xlink:label="nuvl_UnvestedRestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_MarketValueStockHeldByNonAffiliates" xlink:label="nuvl_MarketValueStockHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentSecuritiesMember" xlink:label="nuvl_GovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TrancheRightAxis" xlink:label="nuvl_TrancheRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DueFromOneToThreeYearsMember" xlink:label="nuvl_DueFromOneToThreeYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_InsurancePremiumFinancedByThirdParty" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_EmployeesAndDirectorsMember" xlink:label="nuvl_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_EquityAdjustmentPromissoryNoteInterest" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ClassAAndClassBCommonStockOutstandingMember" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_AccruedManufacturingExpenses" xlink:label="nuvl_AccruedManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_InterestAndOtherIncomeExpenseNet" xlink:label="nuvl_InterestAndOtherIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DueWithinOneYearMember" xlink:label="nuvl_DueWithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ServiceBasedMember" xlink:label="nuvl_ServiceBasedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_JamesPorterMember" xlink:label="nuvl_JamesPorterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_SeriesAConvertiblePreferredStockMember" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ClassAAndClassBCommonStockMember" xlink:label="nuvl_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_MarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_MarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gains (losses) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities credit loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_UnvestedRestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted common stock [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_UnvestedRestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_UnvestedRestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, inputs, level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_MarketValueStockHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market value stock held by non affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_MarketValueStockHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Value Stock Held By Non Affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_MarketValueStockHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The market value of the Company's stock held by non-affiliates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash outflow to repay a third-party for insurance premiums paid by the third-party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Insurance Costs Financed By Third Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of insurance costs financed by a third-party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value transfers in or out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional authorized shares reserved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contractual Maturities of Available-for-sale Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Class A and Class B common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Securities Available For Sales Securities Due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sales Securities Due [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash financing information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche Right [Axis].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value | $ / shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to purchase common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding as of March 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of stock options , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock awards granted, expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueFromOneToThreeYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due From One To Three Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueFromOneToThreeYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due From One To Three Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueFromOneToThreeYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due after one year through three years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award annual increase amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value | $ / shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of insurance premiums financed by a third party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Premium Financed By Third Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance premium financed by a third-party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable securities by Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based payment weighted average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently issued accounting pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of public offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of promissory note from related stockholder party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of Notes Receivable from Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EmployeesAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EmployeesAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees and Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) to stockholders' equity for the interest on a promissory note from a related party stockholder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Adjustment Promissory Note Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on promissory note from related stockholder party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service-based vesting options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one stock option and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Stock Option And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Option and Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement of preferred stock tranche rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Temporary Equity, Carrying Amount, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock tranche rights upon settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of new shares of temporary equity issued during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A And Class B Common Stock Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A And Class B Common Stock Outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of note payable and accrued interest to Series A convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized compensation cost related to common stock options and unvested restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of stock-based compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued clinical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical and other research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses and other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical and Other Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities, tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche Right [Domain].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_TrancheRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InterestAndOtherIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of interest income and income (expense) related to nonoperating activities classified as other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InterestAndOtherIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income Expense Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_InterestAndOtherIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income and other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Class A and Class B common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueWithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due within one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueWithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due Within One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DueWithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due within one year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon initial public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period shares new shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock awards granted, vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of note payable and accrued interest to Series A convertible preferred stock , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Securities Available For Sales Securities Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sales Securities Due [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of Class A and Class B common stock outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ServiceBasedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service Based.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ServiceBasedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Based [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock in follow-on public offering after underwriting discounts and commission and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, inputs, level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_JamesPorterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">James Porter [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_JamesPorterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">James Porter [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_JamesPorterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">James porter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate grant date fair value of share options (or share units) granted during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregate Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of restricted stock, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of stock option activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Class A and Class B common stockholders, basic and diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock upon initial public offering, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government and agency securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government And Agency Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government and agency securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of purchase price of each shares purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A and Class B Common Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A and Class B Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Outstanding as of June 30, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Outstanding December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables from Stockholder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory note from stockholder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Assets Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of Class A and Class B common stock outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock (as converted to common stock) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. treasury bills [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award annual increase percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net accretion on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance , Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for credit risk and significant suppliers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk And Of Significant Suppliers [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of credit risk and of significant suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities credit loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_MarketValue" xlink:to="nuvl_MarketValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_UnvestedRestrictedCommonStockMember" xlink:to="nuvl_UnvestedRestrictedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_MarketValueStockHeldByNonAffiliates" xlink:to="nuvl_MarketValueStockHeldByNonAffiliates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:to="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_GovernmentSecuritiesMember" xlink:to="nuvl_GovernmentSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DueFromOneToThreeYearsMember" xlink:to="nuvl_DueFromOneToThreeYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_InsurancePremiumFinancedByThirdParty" xlink:to="nuvl_InsurancePremiumFinancedByThirdParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EmployeesAndDirectorsMember" xlink:to="nuvl_EmployeesAndDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_EquityAdjustmentPromissoryNoteInterest" xlink:to="nuvl_EquityAdjustmentPromissoryNoteInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" xlink:to="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ClassAAndClassBCommonStockOutstandingMember" xlink:to="nuvl_ClassAAndClassBCommonStockOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_AccruedManufacturingExpenses" xlink:to="nuvl_AccruedManufacturingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" xlink:to="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_TrancheRightDomain" xlink:to="nuvl_TrancheRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_InterestAndOtherIncomeExpenseNet" xlink:to="nuvl_InterestAndOtherIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DueWithinOneYearMember" xlink:to="nuvl_DueWithinOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ServiceBasedMember" xlink:to="nuvl_ServiceBasedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_JamesPorterMember" xlink:to="nuvl_JamesPorterMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_SeriesAConvertiblePreferredStockMember" xlink:to="nuvl_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_SeriesBConvertiblePreferredStockMember" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_GovernmentAndAgencySecuritiesMember" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ClassAAndClassBCommonStockMember" xlink:to="nuvl_ClassAAndClassBCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" xlink:to="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_InterestAndOtherIncomeExpenseNet" xlink:label="nuvl_InterestAndOtherIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nuvl_InterestAndOtherIncomeExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_SeriesAConvertiblePreferredStockMember" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_EquityAdjustmentPromissoryNoteInterest" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_24"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_26"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesAConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_EquityAdjustmentPromissoryNoteInterest" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_InsurancePremiumFinancedByThirdParty" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_InsurancePremiumFinancedByThirdParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_JamesPorterMember" xlink:label="nuvl_JamesPorterMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_JamesPorterMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" xlink:label="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_UnvestedRestrictedCommonStockMember" xlink:label="nuvl_UnvestedRestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nuvl_UnvestedRestrictedCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_MarketValue" xlink:label="nuvl_MarketValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_MarketValueStockHeldByNonAffiliates" xlink:label="nuvl_MarketValueStockHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="nuvl_MarketValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="nuvl_MarketValueStockHeldByNonAffiliates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentSecuritiesMember" xlink:label="nuvl_GovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvl_GovernmentSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DueWithinOneYearMember" xlink:label="nuvl_DueWithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DueFromOneToThreeYearsMember" xlink:label="nuvl_DueFromOneToThreeYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DueWithinOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DueFromOneToThreeYearsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentSecuritiesMember" xlink:label="nuvl_GovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nuvl_GovernmentSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TrancheRightAxis" xlink:label="nuvl_TrancheRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="nuvl_TrancheRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_AccruedManufacturingExpenses" xlink:label="nuvl_AccruedManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nuvl_AccruedManufacturingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ClassAAndClassBCommonStockOutstandingMember" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ClassAAndClassBCommonStockMember" xlink:label="nuvl_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_EmployeesAndDirectorsMember" xlink:label="nuvl_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ServiceBasedMember" xlink:label="nuvl_ServiceBasedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvl_ClassAAndClassBCommonStockOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_ClassAAndClassBCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_EmployeesAndDirectorsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvl_ServiceBasedMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/CoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_SeriesAConvertiblePreferredStockMember" xlink:label="nuvl_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_SeriesBConvertiblePreferredStockMember" xlink:label="nuvl_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_EquityAdjustmentPromissoryNoteInterest" xlink:label="nuvl_EquityAdjustmentPromissoryNoteInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_EquityAdjustmentPromissoryNoteInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_InsurancePremiumFinancedByThirdParty" xlink:label="nuvl_InsurancePremiumFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="nuvl_InsurancePremiumFinancedByThirdParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_JamesPorterMember" xlink:label="nuvl_JamesPorterMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="nuvl_JamesPorterMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_UnvestedRestrictedCommonStockMember" xlink:label="nuvl_UnvestedRestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nuvl_UnvestedRestrictedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_MarketValue" xlink:label="nuvl_MarketValue"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_MarketValueStockHeldByNonAffiliates" xlink:label="nuvl_MarketValueStockHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="nuvl_MarketValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="nuvl_MarketValueStockHeldByNonAffiliates" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentSecuritiesMember" xlink:label="nuvl_GovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nuvl_GovernmentSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:label="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DueWithinOneYearMember" xlink:label="nuvl_DueWithinOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_DueFromOneToThreeYearsMember" xlink:label="nuvl_DueFromOneToThreeYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DueWithinOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" xlink:to="nuvl_DueFromOneToThreeYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentAndAgencySecuritiesMember" xlink:label="nuvl_GovernmentAndAgencySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_GovernmentSecuritiesMember" xlink:label="nuvl_GovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nuvl_GovernmentAndAgencySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nuvl_GovernmentSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TrancheRightAxis" xlink:label="nuvl_TrancheRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TrancheRightDomain" xlink:label="nuvl_TrancheRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nuvl_TrancheRightAxis" xlink:to="nuvl_TrancheRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="nuvl_TrancheRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" xlink:label="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ClassAAndClassBCommonStockOutstandingMember" xlink:label="nuvl_ClassAAndClassBCommonStockOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ServiceBasedMember" xlink:label="nuvl_ServiceBasedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ClassAAndClassBCommonStockMember" xlink:label="nuvl_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_EmployeesAndDirectorsMember" xlink:label="nuvl_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:label="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nuvl_ClassAAndClassBCommonStockOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nuvl_ServiceBasedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nuvl_ClassAAndClassBCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nuvl_EmployeesAndDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="nuvl_InterestAndOtherIncomeExpenseNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_InterestAndOtherIncomeExpenseNet" xlink:label="nuvl_InterestAndOtherIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" xlink:label="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="nuvl_AccruedManufacturingExpenses" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" xlink:label="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="nuvl-20240630.xsd#nuvl_AccruedManufacturingExpenses" xlink:label="nuvl_AccruedManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_GovernmentSecuritiesMember" name="GovernmentSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty" name="RepaymentsOfInsuranceCostsFinancedByThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_TrancheRightAxis" name="TrancheRightAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_TrancheRightDomain" name="TrancheRightDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_InterestAndOtherIncomeExpenseNet" name="InterestAndOtherIncomeExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_MarketValue" name="MarketValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_MarketValueStockHeldByNonAffiliates" name="MarketValueStockHeldByNonAffiliates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_DueFromOneToThreeYearsMember" name="DueFromOneToThreeYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_AccruedManufacturingExpenses" name="AccruedManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_ClassAAndClassBCommonStockOutstandingMember" name="ClassAAndClassBCommonStockOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember" name="TwoThousandTwentyOneStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis" name="DebtSecuritiesAvailableForSalesSecuritiesDueAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" name="ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_GovernmentAndAgencySecuritiesMember" name="GovernmentAndAgencySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_EquityAdjustmentPromissoryNoteInterest" name="EquityAdjustmentPromissoryNoteInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="nuvl_ClassAAndClassBCommonStockMember" name="ClassAAndClassBCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_InsurancePremiumFinancedByThirdParty" name="InsurancePremiumFinancedByThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain" name="DebtSecuritiesAvailableForSalesSecuritiesDueDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_ServiceBasedMember" name="ServiceBasedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_UnvestedRestrictedCommonStockMember" name="UnvestedRestrictedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_DueWithinOneYearMember" name="DueWithinOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses" name="AccruedClinicalAndOtherResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="nuvl_JamesPorterMember" name="JamesPorterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309690896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NUVALENT, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001861560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5112298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">357-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NUVL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,362,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011313425024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,700<span></span>
</td>
<td class="nump">$ 335,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">580,294<span></span>
</td>
<td class="nump">384,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,264<span></span>
</td>
<td class="nump">6,583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">666,258<span></span>
</td>
<td class="nump">726,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">8,972<span></span>
</td>
<td class="nump">5,896<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">675,230<span></span>
</td>
<td class="nump">732,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,403<span></span>
</td>
<td class="nump">9,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">30,789<span></span>
</td>
<td class="nump">22,549<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">38,192<span></span>
</td>
<td class="nump">31,823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">38,192<span></span>
</td>
<td class="nump">31,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,026,546<span></span>
</td>
<td class="nump">986,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(1,571)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(387,944)<span></span>
</td>
<td class="num">(286,296)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">637,038<span></span>
</td>
<td class="nump">700,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">675,230<span></span>
</td>
<td class="nump">732,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011304375376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">140,000,000<span></span>
</td>
<td class="nump">140,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">59,284,728<span></span>
</td>
<td class="nump">58,629,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">59,284,728<span></span>
</td>
<td class="nump">58,629,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,435,254<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,435,254<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309268288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 49,166<span></span>
</td>
<td class="nump">$ 25,922<span></span>
</td>
<td class="nump">$ 87,800<span></span>
</td>
<td class="nump">$ 48,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,984<span></span>
</td>
<td class="nump">8,140<span></span>
</td>
<td class="nump">29,938<span></span>
</td>
<td class="nump">16,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">65,150<span></span>
</td>
<td class="nump">34,062<span></span>
</td>
<td class="nump">117,738<span></span>
</td>
<td class="nump">64,272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(65,150)<span></span>
</td>
<td class="num">(34,062)<span></span>
</td>
<td class="num">(117,738)<span></span>
</td>
<td class="num">(64,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_InterestAndOtherIncomeExpenseNet', window );">Interest income and other income (expense), net</a></td>
<td class="nump">8,154<span></span>
</td>
<td class="nump">4,972<span></span>
</td>
<td class="nump">16,643<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">8,154<span></span>
</td>
<td class="nump">4,972<span></span>
</td>
<td class="nump">16,643<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(56,996)<span></span>
</td>
<td class="num">(29,090)<span></span>
</td>
<td class="num">(101,095)<span></span>
</td>
<td class="num">(54,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (57,166)<span></span>
</td>
<td class="num">$ (29,090)<span></span>
</td>
<td class="num">$ (101,648)<span></span>
</td>
<td class="num">$ (54,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to Class A and Class B common stockholders, basic</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to Class A and Class B common stockholders, diluted</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Class A and Class B common stock outstanding, basic</a></td>
<td class="nump">64,605,308<span></span>
</td>
<td class="nump">56,866,991<span></span>
</td>
<td class="nump">64,377,948<span></span>
</td>
<td class="nump">56,785,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Class A and Class B common stock outstanding, diluted</a></td>
<td class="nump">64,605,308<span></span>
</td>
<td class="nump">56,866,991<span></span>
</td>
<td class="nump">64,377,948<span></span>
</td>
<td class="nump">56,785,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (57,166)<span></span>
</td>
<td class="num">$ (29,090)<span></span>
</td>
<td class="num">$ (101,648)<span></span>
</td>
<td class="num">$ (54,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on marketable securities</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(1,235)<span></span>
</td>
<td class="num">(1,602)<span></span>
</td>
<td class="num">(1,043)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (57,419)<span></span>
</td>
<td class="num">$ (30,325)<span></span>
</td>
<td class="num">$ (103,250)<span></span>
</td>
<td class="num">$ (55,325)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_InterestAndOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income and income (expense) related to nonoperating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_InterestAndOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011304752880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Common stock [Member] </div>
<div>Common Class A [Member]</div>
</th>
<th class="th">
<div>Common stock [Member] </div>
<div>Common Class B [Member]</div>
</th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,233,701<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 462,978<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 623,543<span></span>
</td>
<td class="num">$ (494)<span></span>
</td>
<td class="num">$ (160,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options , Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,192)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,316,690<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2023</a></td>
<td class="nump">443,968<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">629,533<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="num">(185,269)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,233,701<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">462,978<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">623,543<span></span>
</td>
<td class="num">(494)<span></span>
</td>
<td class="num">(160,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,525,475<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2023</a></td>
<td class="nump">421,153<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">637,043<span></span>
</td>
<td class="num">(1,537)<span></span>
</td>
<td class="num">(214,359)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,233,701<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">462,978<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">623,543<span></span>
</td>
<td class="num">(494)<span></span>
</td>
<td class="num">(160,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(126,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,629,896<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">700,561<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">986,819<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(286,296)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,316,690<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2023</a></td>
<td class="nump">443,968<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">629,533<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="num">(185,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options , Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="num">(1,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,090)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,525,475<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2023</a></td>
<td class="nump">421,153<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">637,043<span></span>
</td>
<td class="num">(1,537)<span></span>
</td>
<td class="num">(214,359)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,629,896<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="nump">700,561<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">986,819<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(286,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options , Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">6,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="num">(1,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,482)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,055,633<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2024</a></td>
<td class="nump">675,039<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,007,128<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(330,778)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,629,896<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 700,561<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">986,819<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(286,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options , Shares</a></td>
<td class="nump">649,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,284,728<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2024</a></td>
<td class="nump">637,038<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,026,546<span></span>
</td>
<td class="num">(1,571)<span></span>
</td>
<td class="num">(387,944)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance , Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,055,633<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2024</a></td>
<td class="nump">675,039<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,007,128<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(330,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options , Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">4,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">15,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(57,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,166)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance , Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,284,728<span></span>
</td>
<td class="nump">5,435,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 637,038<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,026,546<span></span>
</td>
<td class="num">$ (1,571)<span></span>
</td>
<td class="num">$ (387,944)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011418120144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (101,648)<span></span>
</td>
<td class="num">$ (54,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">28,982<span></span>
</td>
<td class="nump">11,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Net accretion on marketable securities</a></td>
<td class="num">(6,815)<span></span>
</td>
<td class="num">(5,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,681)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(3,076)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,871)<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">8,862<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(77,247)<span></span>
</td>
<td class="num">(46,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(371,849)<span></span>
</td>
<td class="num">(269,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">181,286<span></span>
</td>
<td class="nump">143,893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(190,563)<span></span>
</td>
<td class="num">(125,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">10,745<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty', window );">Payments of insurance costs financed by a third-party</a></td>
<td class="num">(622)<span></span>
</td>
<td class="num">(910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of public offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,123<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(257,687)<span></span>
</td>
<td class="num">(170,934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">335,387<span></span>
</td>
<td class="nump">241,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 77,700<span></span>
</td>
<td class="nump">$ 70,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay a third-party for insurance premiums paid by the third-party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011310786368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (57,166)<span></span>
</td>
<td class="num">$ (44,482)<span></span>
</td>
<td class="num">$ (29,090)<span></span>
</td>
<td class="num">$ (25,192)<span></span>
</td>
<td class="num">$ (101,648)<span></span>
</td>
<td class="num">$ (54,282)<span></span>
</td>
<td class="num">$ (126,200)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011313339200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table describes for the quarterly period ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, each trading arrangement for the sale or purchase of Company securities </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a Rule 10b5-1 trading arrangement) or (2) a &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:14.94%;"></td>
      <td style="width:12.4%;"></td>
      <td style="width:25%;"></td>
      <td style="width:10%;"></td>
      <td style="width:26.38%;"></td>
      <td style="width:11.28%;"></td>
     </tr>
     <tr style="height:8pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;">
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name (Title)</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Action Taken <br/>(Date of Action)</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nature of Trading <br/>Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Duration of Trading <br/>Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Number <br/>of Securities</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">James Porter </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(</span><span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">)</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;min-width:fit-content;">(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">April 2, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;min-width:fit-content;">)</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rule 10b5-1 trading arrangement</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Until </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 20, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">, or such earlier date upon which all transactions are completed or expire without execution</span></p></td>
      <td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Up to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">351,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares of Class A common stock</span></p></td>
     </tr>
    </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">James Porter <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">April 2, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">October 20, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">351,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011310061008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nuvalent, Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company was founded in January 2017 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts, and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment. All of the Company&#8217;s operations are in the United States.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks similar to those of other pre-commercial stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of which are larger and better capitalized, the need to obtain adequate additional financing to fund the development of its product candidates, the need to obtain and maintain adequate protection for the Company&#8217;s intellectual property, and the impact of public health emergencies, natural disasters and geopolitical events on the Company&#8217;s business. There can be no assurance that the Company&#8217;s research and development will be successful, that adequate protection for the Company&#8217;s intellectual property will be obtained and maintained, that any product candidates will receive required regulatory approval or that approved products, if any, will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred recurring losses since inception, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">101.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023. As of June 30, 2024, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">387.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will need to obtain additional funding through public or private equity offerings, debt financings or strategic alliances. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company may be required to delay, reduce or eliminate some or all of its research and development programs or the Company may be unable to continue operations. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309071568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Basis of Presentation and Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and under the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December 31, 2023, included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 (the &#8220;Annual Report&#8221;), on file with the SEC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The results for the period are not necessarily indicative of the results that may occur for future interim periods or the full fiscal year. Certain prior period amounts have been reclassified to conform with current period presentation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting policies the Company used in preparing these condensed consolidated financial statements are substantially consistent with those applied in the Company&#8217;s Annual Report.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently issued accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in Accounting Standards Codification 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities, on an annual basis, to provide disclosure of specific categories in their tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011310053760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables provide the amortized cost and fair value of the Company&#8217;s available-for-sale securities by security type (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.629%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.834999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,445</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">321,594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,967</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">581,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">580,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.120999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">384,487</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">384,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the amortized cost and fair value of the Company&#8217;s available-for-sale securities by contractual maturity (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due within one year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423,126</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due after one year through three years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,050</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">581,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">580,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s available-for-sale securities are classified as current assets as they are readily available to be converted to cash and for use in the Company&#8217;s current operations. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit losses recorded during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024 and 2023. Interest income for the three months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Interest income for the six months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011407115728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for its assets, which are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,445</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,445</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">580,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">637,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.417%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.046%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.107%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.107%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.288%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">384,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711,573</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Commercial paper,</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">corporate bonds, government and agency securities and U.S. treasury bills were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the three and six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transfers in or out of Level 3. The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011407098624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical and other research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued manufacturing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,548</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,914</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,326</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,789</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,549</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011408926224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded stock-based compensation expense within its condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,322</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,693</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,803</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,219</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, total unrecognized compensation cost related to equity-based awards was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 equity incentive plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, the Company adopted the 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units (&#8220;RSUs&#8221;), unrestricted stock awards, cash-based awards and dividend equivalent rights. Stock awards granted under the 2021 Plan with service-based vesting conditions generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_eeee3d3c-e24c-41bc-bc07-f38b69f1afef;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">- or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> service periods, and stock options expire after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,068,809</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock remained available for future issuance under the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 employee stock purchase plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, the Company adopted the 2021 Employee Stock Purchase Plan, as amended and restated (the &#8220;ESPP&#8221;). The ESPP permits eligible employees to purchase shares of Class A common stock at a discount in accordance with the terms of the offering and consists of consecutive, overlapping 12-month offering periods, each consisting of two six-month purchase periods beginning in December and June of each year. During the three and six months ended June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">5,237</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were sold under the ESPP. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,873,832</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock remained available for issuance under the ESPP.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s option activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,034,755</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.66</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.06</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">449,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,198,801</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">649,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,717</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,561,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.85</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,113,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.18</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">256,837</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options exercised during the three months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock on the date of exercise.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant-date fair value of stock options granted during the three months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The weighted average grant-date fair value of stock options granted during the six months ended June 30, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">51.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.68</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSUs</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.66%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Grant-Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">652,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011311407328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has two classes of common stock outstanding: Class A common stock and Class B common stock. The rights of the holders of Class A and Class B common stock are substantially identical, except with respect to voting and conversion. Class B common stock is nonvoting, and each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company&#8217;s amended and restated certificate of incorporation. The Company allocates undistributed earnings attributable to common stock between the common stock classes on a one-to-one basis when computing net loss per share. As a result, basic and diluted net loss per share of Class A common stock and share of Class B common stock are equivalent.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.06%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,561,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,514,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,211,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,514,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309117792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has revenue sharing agreements with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund, IV, L.P. (collectively, &#8220;Deerfield&#8221;), each an investor in the Company, and the Company&#8217;s scientific founder to pay each of Deerfield and the scientific founder a low single digit percentage rate of net sales of certain commercial products. The payment obligation expires on the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country for both Deerfield and the Company&#8217;s scientific founder. The Company accounts for the liability with Deerfield at fair value with changes recognized in the consolidated statements of operations and comprehensive loss. The Company accounts for the obligation to the scientific founder as a contingent liability. Given the inherent risks associated with obtaining regulatory approval and achieving commercialization, the Company ascribed no value to the revenue sharing agreement with Deerfield at inception or at June 30, 2024 or December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company currently does not have any net sales and, as a result, has not paid any amounts under these agreements and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t accrued any liability as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 under these agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011407150080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently issued accounting pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in Accounting Standards Codification 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities, on an annual basis, to provide disclosure of specific categories in their tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309090032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.06%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,561,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,514,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,211,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,514,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011407067856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Marketable securities by Security</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables provide the amortized cost and fair value of the Company&#8217;s available-for-sale securities by security type (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.629%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.834999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,445</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">321,594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,967</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">581,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">580,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.120999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">384,487</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">384,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Contractual Maturities of Available-for-sale Debt Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the amortized cost and fair value of the Company&#8217;s available-for-sale securities by contractual maturity (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due within one year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423,126</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due after one year through three years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">158,050</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">581,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">580,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011415504400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Assets Measured on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for its assets, which are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,445</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,445</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">580,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">637,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.417%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.046%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.107%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.107%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.288%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasury bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">327,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">384,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711,573</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309063696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical and other research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued manufacturing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,548</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued employee compensation and benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,914</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,326</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,789</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,549</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309067664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock-based compensation expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded stock-based compensation expense within its condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.475%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.121%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,322</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,693</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,985</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,803</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,219</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s option activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,034,755</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.66</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.06</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">449,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,198,801</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">649,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled or forfeited</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,717</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,561,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.85</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,113,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.18</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">256,837</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s RSU activity since </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.66%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Grant-Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">652,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of June 30, 2024</span></p></td>
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309844080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.06%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,561,244</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,514,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,211,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,514,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011313619088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 57,166<span></span>
</td>
<td class="nump">$ 44,482<span></span>
</td>
<td class="nump">$ 29,090<span></span>
</td>
<td class="nump">$ 25,192<span></span>
</td>
<td class="nump">$ 101,648<span></span>
</td>
<td class="nump">$ 54,282<span></span>
</td>
<td class="nump">$ 126,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 387,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 387,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011313574656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">9,211,525<span></span>
</td>
<td class="nump">8,514,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">8,561,244<span></span>
</td>
<td class="nump">8,514,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011307776144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable securities by Security (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 581,865<span></span>
</td>
<td class="nump">$ 384,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,603)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">580,294<span></span>
</td>
<td class="nump">384,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">105,591<span></span>
</td>
<td class="nump">67,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">105,445<span></span>
</td>
<td class="nump">67,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">321,594<span></span>
</td>
<td class="nump">193,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,235)<span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">320,383<span></span>
</td>
<td class="nump">193,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nuvl_GovernmentAndAgencySecuritiesMember', window );">Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">124,967<span></span>
</td>
<td class="nump">89,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">124,763<span></span>
</td>
<td class="nump">89,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,713<span></span>
</td>
<td class="nump">34,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 29,703<span></span>
</td>
<td class="nump">$ 34,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nuvl_GovernmentAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nuvl_GovernmentAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011313493904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 581,865<span></span>
</td>
<td class="nump">$ 384,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">580,294<span></span>
</td>
<td class="nump">$ 384,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueWithinOneYearMember', window );">Due within one year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">423,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">422,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueFromOneToThreeYearsMember', window );">Due after one year through three years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">158,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 158,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueFromOneToThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis=nuvl_DueFromOneToThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011415584784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease', window );">Marketable securities credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011304643840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 580,294<span></span>
</td>
<td class="nump">$ 384,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">637,295<span></span>
</td>
<td class="nump">711,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">57,001<span></span>
</td>
<td class="nump">327,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">105,445<span></span>
</td>
<td class="nump">67,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">320,383<span></span>
</td>
<td class="nump">193,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">124,763<span></span>
</td>
<td class="nump">89,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | U.S. treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">29,703<span></span>
</td>
<td class="nump">34,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">57,001<span></span>
</td>
<td class="nump">327,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">57,001<span></span>
</td>
<td class="nump">327,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">580,294<span></span>
</td>
<td class="nump">384,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">105,445<span></span>
</td>
<td class="nump">67,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">320,383<span></span>
</td>
<td class="nump">193,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">124,763<span></span>
</td>
<td class="nump">89,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | U.S. treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 29,703<span></span>
</td>
<td class="nump">$ 34,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nuvl_GovernmentAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nuvl_GovernmentAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011313576096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Fair value transfers in or out of Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011308847648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses', window );">Accrued clinical and other research and development</a></td>
<td class="nump">$ 13,977<span></span>
</td>
<td class="nump">$ 6,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nuvl_AccruedManufacturingExpenses', window );">Accrued manufacturing</a></td>
<td class="nump">10,548<span></span>
</td>
<td class="nump">6,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">4,914<span></span>
</td>
<td class="nump">7,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total Accrued expenses</a></td>
<td class="nump">$ 30,789<span></span>
</td>
<td class="nump">$ 22,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses and other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nuvl_AccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nuvl_AccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nuvl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309321232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 15,125<span></span>
</td>
<td class="nump">$ 5,848<span></span>
</td>
<td class="nump">$ 28,982<span></span>
</td>
<td class="nump">$ 11,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">7,322<span></span>
</td>
<td class="nump">2,693<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">5,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 7,803<span></span>
</td>
<td class="nump">$ 3,155<span></span>
</td>
<td class="nump">$ 14,997<span></span>
</td>
<td class="nump">$ 6,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011307802928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based payment weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.35<span></span>
</td>
<td class="nump">$ 28.89<span></span>
</td>
<td class="nump">$ 51.79<span></span>
</td>
<td class="nump">$ 20.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember', window );">2021 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards granted, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember', window );">2021 Stock Option and Incentive Plan [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,068,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,068,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,873,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,873,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2021 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock awards granted, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2021 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock awards granted, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309306320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Number of Shares | shares</a></td>
<td class="nump">8,034,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">1,198,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised | shares</a></td>
<td class="num">(649,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled or forfeited | shares</a></td>
<td class="num">(22,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Number of Shares | shares</a></td>
<td class="nump">8,561,244<span></span>
</td>
<td class="nump">8,034,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable | shares</a></td>
<td class="nump">4,113,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 17.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">75.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">16.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled or forfeited | $ / shares</a></td>
<td class="nump">34.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">25.78<span></span>
</td>
<td class="nump">$ 17.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 13.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Term</a></td>
<td class="text">7 years 10 months 6 days<span></span>
</td>
<td class="text">8 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Term, Exercisable</a></td>
<td class="text">7 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance | $</a></td>
<td class="nump">$ 430,979<span></span>
</td>
<td class="nump">$ 449,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 256,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011418135232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, granted | shares</a></td>
<td class="nump">652,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of March 31, 2024 | shares</a></td>
<td class="nump">650,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 73.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">72.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding as of June 30, 2024 | $ / shares</a></td>
<td class="nump">$ 73.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011408846928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">9,211,525<span></span>
</td>
<td class="nump">8,514,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">8,561,244<span></span>
</td>
<td class="nump">8,514,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">650,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140011309078144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&86I,0;P_D9 [;[KF+O7^JY]]B]02P,$%     @ S#4(67Q8,79$ P  R T
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MD(9HD,<C#0(LO F-:!C:589*-5#5$E2U%%5-8JF9WC< A#R:@.SW)OBJA(I
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MXL\:[L2>A3MY4:4_R\X]RX5!G(K8'FC&J+DFJ&HIJIK$4C.;3(.JV$\[^L4
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MV,QVH/WVLYV0 3(,K;PA?KC?_\[V&5]O1=D+3P$$>BURPOM6*L2B:]L\3J'
M_)(N@,B9&64%%K++YC9?,,")AHK<]APGM N<$2OJZ;$IBWJT%'E&8,H0+XL"
ML[<;R.FJ;[G6>N AFZ="#=A1;X'G\ CB:3%ELF<W*DE6 .$9)8C!K&]=N]U)
MH.RUP<\,5GRCC=1*GBE]49V[I&\Y*B#((19* <O/$FXASY60#.-WK6DU+A6X
MV5ZKC_3:Y5J>,8=;FO_*$I'VK8Z%$ICA,A</=#6!>CTMI1?3G.M?M*IL6RT+
MQ247M*AA&4&1D>J+7^M]V #<?8!7 ]XN$.P!_!KPCP6"&@B.!5HUT#IV#6$-
MA,=Z:-= >Q<(]P"=&NCHTZV.0Y_E  L<]1A=(::LI9IJZ(30M#S"C*C4?11,
MSF:2$]$4OZ$E1U-@^AJ0&- @XW%.><D 7:"GQP$Z/_N$SE!&T(^4EAR3A/=L
M(7TK!3NN_=Q4?KP]?GQT3XE(.1J2!!(#/SK,A__B)X=YUSL@8,M-:W;.6^_<
MC7=0\6M)+I'O?$:>XP6&@&X/X_>82=S=BP^.]^X;\.'QWDWXZ'UK'[\O^,EA
M? #QON"W3M)O[H"O]?S_N0.F5*_D K.<>FRZ?(%CZ%OR->' EF!%'S^XH?/%
ME":G%!N<4FQX2K'1*<7&IQ2;G$AL*_6")O6"0^K1=UF<W)&8%H#.OU'./YG2
MK9((M80J19;11:OMAF'/7FXFDL$L"(*.MVTV,)AY5\Z5LVTV-)FUW*L=M9'!
MS'7<,.ALVXU-:PB\W> F)CDOE'588U=ML[WQXA7 YKKZX2BF)1'5Q6]&FP+K
M6M<5.^,W;G?H&L9';G=<U4]_Y:MJ3OYUSC/"40XSZ<JY;,M2@%454M41=*'?
MVV<JY.NMFZDL*H$I SD_HU2L.\I!4Z9&?P!02P,$%     @ S#4(67:+2&9V
M!   M0P  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R=5VU/XS@0_KZ_
M8M255JT$Y*44"K25"LOIV!,L@G+WV4TFC85C9VVGI?_^QDD)917,Z;ZTL3WS
MS#.>ETPF&Z6?38YHX:40TDQ[N;7E>1"8),>"F2-5HJ233.F"65KJ56!*C2RM
ME0H1Q&%X$A2,R]YL4N_=Z]E$559PB?<:3%443&\O4:C-M!?U7C<>^"JW;B.8
M34JVPD>T3^6]IE70HJ2\0&FXDJ QF_;FT?EE%#N%6N)OCANS]PS.E:52SVYQ
MDTY[H6.$ A/K(!C]K?$*A7!(Q./7#K37VG2*^\^OZ'_4SI,S2V;P2HE_>&KS
M:6_<@Q0S5@G[H#9_XLZAD<-+E##U+VP:V>%9#Y+*6%7LE(E!P67SSUYV%[&G
M, X_4(AW"O5%!(VAFN5W9MELHM4&M),F-/=0NUIK$SDN750>K:933GIV=D/W
MFZ*&A68IERN8:\WD"NG>K9D$EBPXN2#9H5TV:/$':$.X5=+F!JYEBNE[_8"8
MM?3B5WJ7L1?P1R6/8!@>0!S&QV!RIM%X8(>MU\,:=O@!;)>W![#<PHU,^9JG
M%1-=SC>@Q]V@KG[.3<D2G/:H0 SJ-?9FW[Y&)^&%A_)Q2_G8ASZ[918U9P(6
MJ L#*NL*61=I/^PB1\B4H.)T4)8M!5)2FT3S)1HZT6!)XE?%-)D76RB)A$H!
M77R!HH-OT3D 9$D.=D>+O=%J<0PC>'HN*YWD5$O.C2M5E$QNP6!2:6XYF66I
M*BWA.RWREDOF5A0>56E(N::*5IK$)(ED&4^0%C9G%K@!Y&1(0S\: (.$LE%3
MX1\ E\;JJND$!+LA2Q8EE()).K.-/U810\M-MJW9,L)VA4]MPQ4ZM2)TB"EW
M*'4('BKR)PJ7H\.HGPR@S_9WNFYBX(SW8\?MV]=Q'(<74LG#3Y1JR>B"X(WC
M01%,B3/<6"S@.!P[RXX+KBK!:@<?#_\:G'^Y8P5"?\&MP ',&]<7[)F\7FQ+
M_""#X([92K\[_5[I!G9?8[72N**PP%U5+%%_^4'&#-PKER;0AZN<8P;7+Q33
M^OI^-F$"(N)BZ]#Z,"\U%Q#OTF?PV=W!H\N>)VE)Z2=E )DES5I[1,FGW+N&
M\@^9%IR.4L>N*LG2)N>TSX1PJ-*PI(D?]1(*9U$*W.4:OI246]2 ;4[O+UK6
M[ G@J72I,1Q%!V$8[KI0G;J"&0-SAU*0&#7KY-E3ZJ.VU$?>FG2!ZZIDKU9W
M^WD7%@^UDY;:B;]=N&SJXN97^R =/(1.6T*G7N3]G-E/XWG30KJH^@&I2Z"'
MU[CE-?;'\+>R_H_<_* 9$\9'[JPE=^;%:6N01H;.:'ZBOE^W'CI1^#:$A/_[
MMA;M&Z!S'O$#?W9CT=Z<%'F1KEUS8-Y;^P3A]Y[EHQ6_T8K]L6@;\7S-N'#O
M[TYJ#<JH1G&3^GI&[8RZV218[]L/]B;) O6JGI<--;A*VF:H;'?;F7S>3*)O
MXLU ?\OTBMZZ(# CU?#HE(SK9D9N%E:5]5RZ5):FW/HQI^\*U$Z SC.E[.O"
M&6B_5&;_ E!+ P04    " #,-0A960#I^Q@'   P$0  &    'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;*58VV[<-A#]%6)3!"VPV9L=)TUL [&3H F0-$B:
M]J'H R6-5JPI4B$IKS=?WS.D+KOVV@C0%Z\NG.&9F3.'(Y]NK+OR%5$0-[4V
M_FQ2A="\F,]]7E$M_<PV9/"FM*Z6 ;=N/?>-(UE$HUK/5XO%R;R6RDS.3^.S
M3^[\U+9!*T.?G/!M74NWO2!M-V>3Y:1_\%FMJ\ /YN>GC5S3%PI?FT\.=_/!
M2Z%J,EY9(QR59Y-7RQ<7Q[P^+OA3T<;O7 N.)+/VBF_>%6>3!0,B37E@#Q(_
MUW1)6K,CP/C6^9P,6[+A[G7O_6V,';%DTM.EU7^I(E1GD^<345 I6QT^V\UO
MU,7SE/WE5OOX5VRZM8N)R%L?;-T9 T&M3/J5-UT>?L1@U1FL(NZT443Y6@9Y
M?NKL1CA>#6]\$4.-U@"G#!?E2W!XJV 7SC_*T#H2MA07K<<[[T_G 7[Y[3SO
M?%PD'ZM[?)R(#]:$RHLWIJ!BWWX./ .H50_J8O6@P_>MF8FCQ52L%JOC!_P=
M#4$>17]']_C[W:VE4=\E\V J+JWQ5JM")EJ80GQRY,F$] "I>*N,-+F26GS!
M0P('@Q=_O\I\<&#1/X<RE  <'P; G?7"-S*GLTG#>[EKFIP_?K0\6;Q\(+SC
M(;SCA[S_8 T?]'$8X7(F[OH6']MKJ9&2J7AG\IGX.50D'C]ZOEHM7E[:NI%F
M&^^6+W\1R@LI<NRE<JF?^( V%YFR32714#FU@9^+/%F)TH+P5 @4(8? !&76
M F!RA2;>BB#=F@)>8S\G&T4>!DXT6!?KLU&A$CGJ1FXF_@"F#HS82%[9,C>%
M,N*]-"WD!]Q:/A.2 ;XF+3<24>;6-=9%&NR[0!P5%.\;# .YY.=2UIE3Q9JF
MXH/T7N85P(?@IY%2M30(U@L%9%F?.>QF#9+9D$O1>5HSN6;BE=:<XS#NR3E<
M/GOI^]4@K6",V)E7?36*<Q'YZ>^ ]6WV+V1/!"N<\E=XH&JEI>,'H;(^%M1R
M(CG!3U" FEPD?*I1J@BGN-ON;M&4*:!.;CO%5:[;@L,I"&=%02@!U_"*MKQ*
M7:NBE1IY84>&N((62Z]Q(#1BW!HEOE8RTP1(MFASSB3CH*!B7Y;.UAWF =Z4
M\[SE8#:5RJN8(,T\<;$(&>K!R\&6(+7Z3L4^")L%'%M"%H3*!L)%$?=">&62
M  2%=27($PT[U%PSWI2+VX%EYA6L*>0/[Q$YH<S^AC .W?'$7#Y4?IC@R,(B
MY)#7@PUAFSC&RQ56YQ%,TV9:Y<Q3C4: :"$-B(#Q&&YBF!?*2X^,^&B^)MM
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M\-6 F?#%(]PX7?NO#$OMG*[\98%CMS D@/?TNZ.](0?=9Z?SOP%02P,$%
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MUJ@;NH?Z)-!-U13;X[!BEH23; PY&9-+,G62<<8'7X<W0[!T5YI.;V$NJ\H
MFX3CF!_HD;^(+)PTXH,32/,XS+.4R'+6<P^SB'OV:1Z%;)(,WF.!]9S"Y;'/
M%/]/F<K&833):< R[R=)O!,GSJ/O,A1/>)B/,R+EHTQ=@IQLDDS^/4'Y)(P(
M/G6F8V?I!&S\:'IX$B;9!,:^:JX*;LXH,3RG43XFBDD\\8QYGGO*;B6-\\>V
M].ZMH=28_W%3%W3UN4NDH_32.]%O\)?N[2M'Y*A4[XG(1MJ2S!59;%&X:B6,
MA[&O5,)8R)+$ZXFEI5H>U&RI5;<JW1][$14NS<,QG_A_E$8/=MAN0_G$_5C0
M0B,4E3!&+B7%( P]55K['6 ,6N,DE,JM5W2]@JRV]Y!@%<S1I8TVCB5[FA?"
ME'T]E(;.(/CT?<]K[X>Z$MJ>]*Z;H>-/;C;NTQ"2QH6T4-$1(*8:"Z7I28(%
M<7?;HL1=?IPS(^^@[A\N= \7/*B25W$'; B?&LHT4J5D4Z@:/<M[J!= P(92
M<@+Y,*97O*I\0T)+5(1[24AL38N^3ZFV3SM](>N=RS@;9O_P&4=/.GWLZ1H=
MM1=TC:Q\$T6E4%UC^T[C(#WT:1=]>W*OWC=Y]!BM9&.@PB691L-Q&H#N&Z=^
M8E7KFY6YLM3Z^&%)^P>U4Z#UI5)V/W$.#MWK[&]02P,$%     @ S#4(65J-
MPO1<!   5@L  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK599C]LV
M$'[WKQ@H1= "JG7[V+4-[)'T0!=89)/TH>@#+8TM(I*H):GU^M]W2,DG;"<+
M]$7BD)QOYIOAD#-9"?E-Y8@:7LNB4E,GU[J^\CR5YE@RU1<U5K2R$+)DFD2Y
M]%0MD656J2R\T/<'7LEXY<PF=NY1SB:BT06O\%&":LJ2R?4M%F(U=0)G,_&)
M+W-M)KS9I&9+?$+]I7Z4)'E;E(R76"DN*I"XF#HWP=5M;/;;#5\YKM3>& R3
MN1#?C/!'-G5\XQ 6F&J#P.CW@G=8% :(W'CN,)VM2:.X/]Z@?[3<B<N<*;P3
MQ=\\T_G4&3F0X8(UA?XD5K]CQR<Q>*DHE/W"JMT;Q0ZDC=*B[)3)@Y)7[9^]
M=G'84QCY9Q3"3B&T?K>&K)?W3+/91(H52+.;T,S 4K7:Y!RO3%*>M*153GIZ
M]I%Q"5]9T2 \(%.-1(JX5A-/$[C9XJ4=T&T+%)X!&L"#J'2NX$.587:H[Y%3
M6\_"C6>WX47 /YNJ#Y'O0NB'\06\:,LTLGC1]YG><Y46PI!5\,_-7&E)A^/?
M4YQ;R/@TI"F8*U6S%*<.581"^8+.[/V[8.!?7W XWCH<7T)_2VHN \5].(,%
MGW.$A2BH-'FU!,WF!87$<JDT:%J\$V7-JO7[=Z,P&%XK6!B@%PN4<Y1,IOF:
M$"1P0F-*H58NK'*>YL D0MD:RX#I?553CE32:2.EL4MEQ17\S"LR*1K%JDS]
M<M4[YS-!T=G [=GH_84O6$  [3_L_A%\%IH5O3NF<L#GAI-IHW_5HX.*:RHB
M^8TNO45#UN G2(:N[P<TL%3#ZX-1N]A[L"HF2*",\UQS)#R*48DRY:R FM4H
MMXJ!G[AQG!S+I"!K(9E&F MC?;,>A;X;C:)CN?>;>$%9&?9 L0&Z+*MTO>?"
MSD 8N\-!="SWOO2?^J"EC>(:YKPH=CKAV!WZT9'8VPM(,O+=<!P?!&00#6DN
MN92C>TRQG%,THL#F*?I_\A2%Y%>2G$E4M_KF3 U(;>0?B6?S%(PC=QR/C^4?
MS]-H[/KA\$B\F*4H=N-!>"3V]L,1C6(W"48'X1@&@9L,(S@1R152>=IJS&"^
MWJ]U^\IEID:?&Z%IU.G5DJ?$P19[1AQY2F'<D=N4O<3-_<%@D_%R=S;H?=.Y
MK70\>9GTX3A)+J2'>7!A^;U F]E3X;S NE'F*NHH=USYIFWH8M"R5[SD!9,_
MQ#U\&_?[QEZ(9H/.):(EHO@KE.WCBN9Q/;S^[!937^ :/>)G25:"N+-*+5!:
M'N0W]60@%INRZ]O+/V52KHU)ZXHRZZ>N?9:FHC&%7;.UK2H;]C25)I#X2BVB
M,E&O:RE>>6DR12A$<,=20494M;#P*A=2_ZI1EE Q3='I["J$@C-*E8UJ_]0C
MZNWU.G1,EK:C4V#=:]N>[>RV:;QI>Z7=]K;CI$MBR2L%!2Y(U>\/$P=DV\6U
M@A:U[9SF0E,?9H<Y-;XHS09:7P@Z+)U@#&Q;Z=E_4$L#!!0    ( ,PU"%EW
M\]57K0(  .4%   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;(U4VX[3
M,!!]WZ^PP@J!%#777FDK=2\($"NM=@4\(![<9-)8ZTNPG>WNWS-VVE!0M_"2
MV.,YQ^=D,C/?*OU@:@!+G@279A'4UC:S*#)%#8*:@6I XDFEM* 6MWH3F48#
M+3U(\"B-XU$D*)/!<NYCMWHY5ZWE3,*M)J85@NKG"^!JNPB28!^X8YO:ND"T
MG#=T _=@OS2W&G=1SU(R =(P)8F&:A&LDME%[O)]PE<&6W.P)L[)6JD'M_E8
M+H+8"0(.A74,%%^/< F<.R*4\7/'&?17.N#A>L_^WGM'+VMJX%+Q;ZRT]2*8
M!*2$BK;<WJGM!]CY&3J^0G'CGV3;Y>9Q0(K66"5V8%0@F.S>]&GW'0X DY<
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M:[JKHF4#>K\RQC<;#M#>?J=_ E!+ P04    " #,-0A90[,N"38#  "_!@
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M&ZJU1G)E8S;E44M<+=%.S^^Y? +-%Q601\@[6>H2%#G[;"3J?.II]&$TO7S
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M'QPUQWKTI.,7]^APL>)>J_^Q2_.#V.L^]MV+F_76$#FHO3LDLBUU@>8"+7;
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MW GTK]M=%O>*V&WQ:XTA%U/W@ \*'"U66M MIYS0:(>DF0DHM)2DQ_K\-H;
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M[CF^Y]B.[V0KY)TJ #2Z9Y2KJ5=H79[[ODH+8%B=BA*XF<F%9%B;KES[JI2
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M(F;'$ ^\#CJO@Z->+Y@"G4&%",MY!7W.!H]BGON>^1WX>XP;].&RQS@_CGN
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M\(RPS$!>GU,J7DZR%V;+%Z3'_P-02P,$%     @ S#4(68L&QRF\ @  $P@
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MK+]@$\^QY4L%4^X7UHUNX$%:*2V*!FP\*"BOG^2AR<,6P/!T \(&$#X%Q,\
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M1)B;N?F@Q7QQN;G3%HT?\^Y_V'LMED[5:YV<-SC!>THH"L@ZP?^*;AL<=MN
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M5 X0[U>$\..-G* Z 9S^#U!+ P04    " #,-0A9JIO(W@H#  !N"   &0
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M@]X)'4]5=;=J8N3&=92E--2?W#"C#P)45H#>KZ0T=Q/KH/G$B'\#4$L#!!0
M   ( ,PU"%GX03T#(P,  &H,   9    >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;,U776_3,!3]*U:0$$AC^>CW:"NMW1!#&U2K!@\3#VYRVUB+XV [[?CW
M7#MIUI2L8E(E]M+:CN_Q.<?7SLUP(^2#B@$T>>1)JD9.K'5VYKHJC(%3=2HR
M2/')4DA.-7;ERE69!!K9()ZX@>=U74Y9ZHR'=FPFQT.1ZX2E,)-$Y9Q3^7L"
MB=B,'-_9#MRR5:S-@#L>9G0%<]!WV4QBSZU0(L8A54RD1,)RY)S[9U/?,P%V
MQG<&&[73)D;*0H@'T[F*1HYG&$$"H380%/_6,(4D,4C(XU<)ZE1KFL#=]A;]
MDQ6/8A94P50D/UBDXY'3=T@$2YHG^E9L/D,IJ&/P0I$H^TLVY5S/(6&NM.!E
M,#+@+"W^Z6-IQ$X XC0'!&5 L!_0?B:@50:TK-""F95U034=#Z78$&EF(YII
M6&]L-*IAJ=G&N9;XE&&<'G_%3+D62I$92#*/J03R@<PQ6:(\ 2*6Y#S5+&))
M;MPF<PASR30#12X?PR2/(")+*3B9"I[EFMJ=P:!+*E.6KG91WUV IBQ1[Q%?
MF1$U=#4*,#3<L"0[*<@&SY#MDAN1ZA@73W'E>KR+PBOUP5;])#@(^"5/3TG+
M.R&!%[0;^$S_/;QU@$ZKVHR6Q6L]@W<LK^^O$9A<:>#J9Y/+!8MV,PMS<9RI
MC(8P<O!F4"#7X(S?OO&[WL<FBXX$5C.L71G6/H1>-TP]&08UP\*Z8; U+$/#
M;"J>$,I%GNHFKPH"'4O W(GK\2#P_4[0&;KK71O^GM?O^.U6+ZCFU11V*H6=
M@PJ_98:V(EJ0+)=AC#>6T<-1"MX-X0.YOP&^ -FXSP>A7[K/1P*KN="M7.B^
MBH/1/:9A1P*K&=:K#.O][X/1:TCXKA^TVWL'HVG>@8/1KQ3V#RJ\G=\UOD$.
M1KUT"X\$5A,XJ 0.7D7.#XYIV)' :H;YWE,MX_WOK"\9[*9SM^,%?7\OZQOF
M>7L)[^Y4;1SDRA:S"NGATD4)4XU6!?.Y+1/WQB>FD+;5X!-,487?4+EB^/9(
M8(F0WFD/^<BBL"TZ6F2V-EP(C96F;<;X,0#23,#G2R'TMF,6J#XOQG\ 4$L#
M!!0    ( ,PU"%D_?#J/[0$   X$   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;(U4;6O;,!#^*T+L0PM;Y#AI.XIM2!W&.AB$AFZ?%?MBB^K%D\YQ
M^^\GR4[(H"G[8MU)]SQWSYWD;##VQ;4 2%Z5U"ZG+6)WSYBK6E#<S4P'VI_L
MC54<O6L;YCH+O(X@)5F:)+=,<:%ID<6]C2TRTZ,4&C:6N%XI;M\>0)HAIW-Z
MW'@238MA@Q59QQO8 CYW&^L]=F*IA0+MA-'$PCZGJ_E]F8;X&/!+P.#.;!*4
M[(QY"<YCG=,D% 02*@P,W"\'*$'*0.3+^#-QTE/* #RWC^S?HG:O9<<=E$;^
M%C6V.?U*20U[WDM\,L-WF/3<!+[*2!>_9!AC[Y:45+U#HR:PKT )/:[\=>K#
M&6!^"9!.@/1_ 8L)L(A"Q\JBK#5'7F36#,2&:,\6C-B;B/9JA Y3W*+UI\+C
ML"B-4@+]6- 1KFM2&HU"-Z K 8Y\(:NZ%J'?7))'/5Z:T/VK-2 7\MI'/&_7
MY.K3=<;0EQ-(636E?AA3IQ=2_^CUC"R2SR1-TN4[\/)C^!HJ#Y]'^.)?./--
M.'4B/74BC7S+"WRKJK(]U$0*OA-2X-M[BD:*VT@1'LBA2#)V."_ZHXBQ+G8V
MK?!2?G+;".V(A+W')+.[&TKL>/M&!TT7![@SZ*]#-%O_8,&& '^^-P:/3K@3
MIU] \1=02P,$%     @ S#4(6;@2 P@; P  ,!(   T   !X;"]S='EL97,N
M>&ULW5A1;]HP$/XKD3M-K30U0-J4K("T(56:M$V5VH>]588X8,FQ,\=TT%\_
MGQT"I3[$^K"5!='8]_F^^WQWJ2,&M5D)=C=GS$3+4LAZ2.;&5!_CN)[.64GK
M<U4Q:9%"Z9(:.]6SN*XTHWD-3J6(>YU.&I>42S(:R$5Y4YHZFJJ%-$-RT9HB
M?_N2#TDWO2"1IQNKG W)P^G[GPMEKM]%_G[RX>2D\W!VO6L_=< 9B8.DEP>0
MGG?LA3([%*-/#Z/?1XY17QU$O8?9$<=-[D>#0LE-"1+B#38R+5GT2,60C*G@
M$\W!JZ E%RMO[H%AJH32D;&UMU*Z8*F?/-SU,VB+AJ?D4FD7VT?P?R?-\AU@
M/0.!7(A68(]XPVA046.8EC=VXA8[XPLH:L;WJ\HJG&FZZO8NR<;!W6R0B=(Y
MTVV8+EF;1@/!"I"C^6P.=Z.J&$!C5&D'.:<S):G3L/9H!I9VRH2X@V?F1_&,
M>UELU;0#%97MT IJAI[&3X!_F\US;].^CC>J^*,RGQ=V.]+-H5?8K68%7[KY
MLF@%8.Q=G)U6E5A]$GPF2^8W?W# T8"N_:*YTOS)1H-6F5H#TR1Z9-KPZ;;E
MEZ;5/5N:=3LM"UQS[P@U_]T\SYADFHIMT;;WWW*67ZTXN?I7DMU_E5W!08W-
M0?C615X>@\CT&$0>04\FV9O4&#='X];Y^^ST;:T1O.4,R7=XGQ*;H-%DP87A
MLIG->9XS^>(0MO2&3NSK\#-^NSYG!5T(<]^"0[(9?V,Y7Y19N^H6$M&LVHR_
MPO:Z:?N*96-QF;,ER\?-5,\F;AC9@8W:7."PB]RX*XQ@/AX+(X!A<3 %F(_W
MPN+\3_OIH_OQ&*:M'T3ZJ$\?]?%>(63L/EB<L$]FK_!.LRQ)TA3+Z'@<5##&
M\I:F\ VS8=K  XL#D?XLUWBU\0[9WP=83?=U"+93O!.QG>*Y!B2<-_#(LG"U
ML3C@@54!ZQV('XX#/17V21*H*J8->X)Q),LP!'HQW*-IBF0GA4^X/MA3DB19
M%D8 "RM($@R!IQ%', 6@ 4.2Q)V#.^=1O#ZGXLUO1*/?4$L#!!0    ( ,PU
M"%F7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] A
MB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:
MU;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]
MVR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::
M1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$
M%     @ S#4(619W[12! P  /QD   \   !X;"]W;W)K8F]O:RYX;6S%F5UO
MVC 40/^*E:?M@84DE+55J42!;D@M10OJZV22"U@X-K(=^O'KYR2@F1:N]N+Q
ME-AQG)-+?(]M;EZD6L^E7)/7@@O="U;&;*[#4&<K**C^)C<@[)6%5 4UMJB6
MH=XHH+E> 9B"AW&[W0T+RD1P>[/O:ZI"MR -9(9)82NKBF<&+_KO]:I(MDRS
M.>/,O/6"^IQ#0 HF6,'>(>\%[8#HE7SY*15[E\)0GF9*<MX+HN;",RC#LD_5
M:04YHW-=UQ@Z_T4M2"_HMFV'"Z:TJ5O4_5/+N 7;N"F51MXS;D -J8$?2I8;
M)I95-_8M0N<UZCCLCTT0K]6_A%$N%BR#H<S* H1IXJB 5X!"K]A&!T30 GK!
M0&Y!D2E=0O52]BGCO'E!8\F<<*EK9B^H<5XS>N1YF@Q'DW0T)/8L?7H8#_LS
M6[CK/_0G@Q%Q(&,$,CXCY._8@4P0R.0LD.G,'AY'$P>R@T!VS@AY$,D+!/+B
MG)") ]E%(+M^(:?TC6PUF8*J;Q<9D"'3&9>Z5.[8_HX@?O>+.!::Y3;;S!3-
M;;XC?:6H6$)UEW8(+Q'"2[^$$VILM(A<D+M2,P':Y;I"N*[\<MU1S72%-56@
M;=.Z!:$B)VE9%-1-W6TL=[?]8CY2M08K0@XDA:Q4S#!P(QBA8O%LEGO*%'FF
MO 3R"+0:%1\_O A32N39*?TL4R7D9/1J.]&'8<,L$GG62&IDMF[9#]"R#611
MP=6-7#Y,()%G@TQLOP]2UYF/I"MZD.PBS!J1;VW(HF"F_LCJH3JP<TN;]D!D
M'T8%9HW(LS;0S'(@X @S1^19'3BFJ^ (TT?DV1]'$R#Y,JMJ]%>7$I-)Y-DF
M)S+AGM.=8V,VB3W;Y&-&/!;'&#-*[-DHIU+C#M3%1!<KGLWR.4,>C20FF=BS
M9#[/NTB+]/.<52TI=S$QU\2>78-GH8Z+B8DG]BR>XUFHU<P5U9N+B:DG]JP>
M%/- /3&FGMBS>DYA[CY/%Q-33^Q9/:>2NHVG[3UW,3'WQ&=RSRZ>[M8)YI[D
M?[MG%\:2UUG*Q<0,E)S+0,TH<C$Q R6>#81@5K^ZBXENF)UIJ5-'\W!;#[-0
MXME".*8[%TXP"R6>+71DVN$.(A<3LU#BV4+H*HVT7$S,0DEMH7"_89_#PDYC
M\HE]A+;U&>795)'JT&PT="ZJ%<"BY'Q@ZY[$@Z3Y?O]__]_%[1]02P,$%
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MKO'\=U(=^F_=>/RP?&Y.V!EPMG -O?\%4$L#!!0    ( ,PU"%FJ9Q1AF $
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ S#4(69E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #,-0A93/%B15@&  "B)   &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ S#4(6?&S#K9-!0
M=Q<  !@              ("!FPX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( ,PU"%E\6#%V1 ,  ,@-   8              " @1X4
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #,-0A9:4Q[
ME^L%  !S'   &               @(&8%P  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ S#4(698(+(EY"P  AVL  !@
M ("!N1T  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,PU
M"%F3[7H!@ 4   L6   8              " @6@I  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " #,-0A9[P#&T]\"  "R"@  &
M        @($>+P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ S#4(67:+2&9V!   M0P  !@              ("!,S(  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,PU"%E9 .G[& <  # 1   8
M              " @=\V  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " #,-0A93466?:H&  ""$@  &0              @($M/@  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,PU"%G.N"WB?P0
M ,D*   9              " @0Y%  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ S#4(65J-PO1<!   5@L  !D              ("!
MQ$D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #,-0A9
M=_/55ZT"  #E!0  &0              @(%73@  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,PU"%D][Y;)BP<  ,T3   9
M      " @3M1  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ S#4(643^JRP>!   C@D  !D              ("!_5@  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #,-0A9HHRVY.,%   %#@
M&0              @(%270  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( ,PU"%DONWLW4P0   D+   9              " @6QC  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ S#4(64.S+@DV
M P  OP8  !D              ("!]F<  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " #,-0A9U!+U0/D#  "J"0  &0
M@(%C:P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,PU
M"%EK&,,PCP,  ,0(   9              " @9-O  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ S#4(6<#B8J:[ @  Y@4  !D
M         ("!67,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " #,-0A9:.?Y:I $   A"P  &0              @(%+=@  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,PU"%F)<$>)%@,  (P&
M   9              " @1)[  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ S#4(6;2Q2;:8 P  >0\  !D              ("!7WX
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #,-0A994'^
MV_("  "5"0  &0              @($N@@  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( ,PU"%E2B-.[U 0  (L9   9
M  " @5>%  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MS#4(66W)8=DQ P   PT  !D              ("!8HH  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " #,-0A9TGAA?; "  #!"   &0
M            @('*C0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( ,PU"%FA0GXBT04  "PM   9              " @;&0  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ S#4(68L&QRF\ @
M$P@  !D              ("!N98  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " #,-0A9G;<6"]H"  #<!P  &0              @(&L
MF0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,PU"%D+
M;Y1[J0,  -X0   9              " @;V<  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ S#4(6;Q4S"!Y!0  _B(  !D
M     ("!G:   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M" #,-0A960;S*)4$   -%   &0              @(%-I@  >&PO=V]R:W-H
M965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,PU"%FJF\C>"@,  &X(   9
M              " @1FK  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L!
M A0#%     @ S#4(6?A!/0,C P  :@P  !D              ("!6JX  'AL
M+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #,-0A9/WPZC^T!
M   .!   &0              @(&TL0  >&PO=V]R:W-H965T<R]S:&5E=#,W
M+GAM;%!+ 0(4 Q0    ( ,PU"%FX$@,(&P,  # 2   -              "
M =BS  !X;"]S='EL97,N>&UL4$L! A0#%     @ S#4(69>*NQS     $P(
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9>&UL4$L%!@     M "T ,@P  #*_      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>122</ContextCount>
  <ElementCount>165</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecurities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Marketable Securities - Summary of Marketable securities by Security (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail</Role>
      <ShortName>Marketable Securities - Summary of Marketable securities by Security (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail</Role>
      <ShortName>Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nuvl-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="nuvl-20240630.htm">nuvl-20240630.htm</File>
    <File>nuvl-20240630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img240556275_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="414">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nuvl-20240630.htm": {
   "nsprefix": "nuvl",
   "nsuri": "http://www.nuvalent.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "nuvl-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "nuvl-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 161,
   "keyCustom": 4,
   "axisStandard": 11,
   "axisCustom": 1,
   "memberStandard": 19,
   "memberCustom": 5,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 5
   },
   "contextCount": 122,
   "entityCount": 1,
   "segmentCount": 29,
   "elementCount": 419,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 414,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://xbrl.sec.gov/ecd/2024": 9
   },
   "report": {
    "R1": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_88495ead-dcd3-431a-99e7-37e3f2e1e634",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_03f2a1f5-5552-4bb3-8054-73c7ba425664",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusiness",
     "longName": "995455 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecurities",
     "longName": "995475 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpenses",
     "longName": "995495 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensation",
     "longName": "995505 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995515 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995525 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995535 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995545 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesTables",
     "longName": "995555 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995565 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesTables",
     "longName": "995575 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationTables",
     "longName": "995585 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995595 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
     "longName": "995605 - Disclosure - Nature of Business - Additional Information (Detail)",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer",
     "longName": "995615 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail",
     "longName": "995635 - Disclosure - Marketable Securities - Summary of Marketable securities by Security (Detail)",
     "shortName": "Marketable Securities - Summary of Marketable securities by Security (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
     "longName": "995645 - Disclosure - Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)",
     "shortName": "Marketable Securities - Summary of Contractual Maturities of Available-for-sale Debt Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7af8fcae-e898-443a-a9f6-0e043da02452",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail",
     "longName": "995655 - Disclosure - Marketable Securities - Additional Information (Detail)",
     "shortName": "Marketable Securities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
     "longName": "995665 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4eea3c58-e991-4fc6-8757-166b21081709",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
     "longName": "995675 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail",
     "longName": "995685 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail",
     "longName": "995695 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ca48becd-bf94-4320-8c36-a47233fe5233",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
     "longName": "995705 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
     "longName": "995715 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_b64064b0-6d46-4f49-a54e-2ab50179487d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
     "longName": "995725 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_9d832d33-eda0-4982-a7a1-aa5692816a09",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9d832d33-eda0-4982-a7a1-aa5692816a09",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "995735 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_64aecf04-4116-445d-a4a6-95702c1e60de",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7fed8a7e-5f09-4c6a-ad30-c11b950611c2",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c8785a1c-3f0b-4321-ac33-780c77788865",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13 [Member]",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40",
      "r43",
      "r776"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r605"
     ]
    },
    "nuvl_AccruedClinicalAndOtherResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "AccruedClinicalAndOtherResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued clinical",
        "terseLabel": "Accrued clinical and other research and development",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses and other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical and Other Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total Accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued Liabilities, Current, Total",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_AccruedManufacturingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "AccruedManufacturingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "terseLabel": "Accrued manufacturing",
        "label": "Accrued Manufacturing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r54",
      "r107",
      "r457",
      "r480",
      "r484"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r14",
      "r346",
      "r349",
      "r408",
      "r475",
      "r476",
      "r717",
      "r718",
      "r719",
      "r722",
      "r723",
      "r724",
      "r725"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r722",
      "r723",
      "r724",
      "r725",
      "r777",
      "r804"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r130",
      "r131",
      "r132",
      "r133",
      "r144",
      "r167",
      "r168",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r225",
      "r226",
      "r229",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r389",
      "r390",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r442",
      "r443",
      "r444",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r270"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r679"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r640",
      "r650",
      "r682"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r675",
      "r683",
      "r687",
      "r695"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r305"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Net accretion on marketable securities",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r251",
      "r790"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r79",
      "r103",
      "r124",
      "r159",
      "r163",
      "r165",
      "r166",
      "r202",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r334",
      "r338",
      "r391",
      "r452",
      "r528",
      "r577",
      "r578",
      "r605",
      "r618",
      "r746",
      "r747",
      "r791"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r108",
      "r124",
      "r202",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r334",
      "r338",
      "r391",
      "r605",
      "r746",
      "r747",
      "r791"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r594"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r221",
      "r451"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r221",
      "r365",
      "r446",
      "r594",
      "r597",
      "r733",
      "r781",
      "r782",
      "r783"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r101",
      "r572"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r61",
      "r123"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r61"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r97",
      "r129",
      "r167",
      "r204",
      "r205",
      "r206",
      "r212",
      "r213",
      "r225",
      "r229",
      "r312",
      "r316",
      "r317",
      "r325",
      "r326",
      "r328",
      "r341",
      "r342",
      "r353",
      "r354",
      "r389",
      "r390",
      "r399",
      "r403",
      "r404",
      "r442",
      "r443",
      "r473",
      "r474"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r97",
      "r167",
      "r204",
      "r205",
      "r206",
      "r212",
      "r213",
      "r214",
      "r225",
      "r229",
      "r312",
      "r316",
      "r317",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r340",
      "r341",
      "r342",
      "r343",
      "r353",
      "r354",
      "r355",
      "r358",
      "r389",
      "r390",
      "r399",
      "r403",
      "r404",
      "r442",
      "r443",
      "r473",
      "r474",
      "r707"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, immaterial effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r143",
      "r209"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ClassAAndClassBCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "ClassAAndClassBCommonStockMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A and Class B Common Stock.",
        "label": "Class A and Class B Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ClassAAndClassBCommonStockOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "ClassAAndClassBCommonStockOutstandingMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A And Class B Common Stock Outstanding [Member]",
        "documentation": "Class A And Class B Common Stock Outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r104",
      "r105",
      "r106",
      "r124",
      "r148",
      "r149",
      "r151",
      "r153",
      "r161",
      "r162",
      "r202",
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r391",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r516",
      "r537",
      "r555",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r705",
      "r720",
      "r726"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r239",
      "r612",
      "r613",
      "r614",
      "r615"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r73",
      "r453",
      "r515"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r231",
      "r232",
      "r568",
      "r741",
      "r743"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r722",
      "r723",
      "r725",
      "r777",
      "r803",
      "r804"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value | $ / shares",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r516"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r48",
      "r516",
      "r534",
      "r804",
      "r805"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r455",
      "r605"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r111",
      "r113",
      "r117",
      "r448",
      "r465",
      "r466"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "ConcentrationOfCreditRiskAndOfSignificantSuppliersPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk and significant suppliers.",
        "label": "Concentration Of Credit Risk And Of Significant Suppliers [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk and of significant suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r612",
      "r613",
      "r614",
      "r615"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of note payable and accrued interest to Series A convertible preferred stock",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Conversion of note payable and accrued interest to Series A convertible preferred stock , Shares",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease), Total",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease)",
        "terseLabel": "Marketable securities credit loss",
        "documentation": "Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "DebtSecuritiesAvailableForSalesSecuritiesDueAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Available For Sales Securities Due.",
        "label": "Debt Securities Available For Sales Securities Due [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_DebtSecuritiesAvailableForSalesSecuritiesDueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "DebtSecuritiesAvailableForSalesSecuritiesDueDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Available For Sales Securities Due",
        "label": "Debt Securities Available For Sales Securities Due [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r272",
      "r300",
      "r301",
      "r303",
      "r589"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_DueFromOneToThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "DueFromOneToThreeYearsMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due From One To Three Years [Member]",
        "label": "Due From One To Three Years [Member]",
        "terseLabel": "Due after one year through three years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_DueWithinOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "DueWithinOneYearMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due within one year.",
        "label": "Due Within One Year [Member]",
        "terseLabel": "Due within one year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to Class A and Class B common stockholders, basic and diluted",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to Class A and Class B common stockholders, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r146",
      "r148",
      "r151",
      "r152",
      "r153",
      "r158",
      "r323",
      "r332",
      "r362",
      "r363",
      "r449",
      "r467",
      "r574"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to Class A and Class B common stockholders, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r148",
      "r151",
      "r152",
      "r153",
      "r158",
      "r323",
      "r332",
      "r362",
      "r363",
      "r449",
      "r467",
      "r574"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net income (loss) per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r155"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r154",
      "r156",
      "r157"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost related to common stock options and unvested restricted stock",
        "terseLabel": "Unrecognized compensation cost related to common stock options",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share based payment weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Options to purchase common stock [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and directors.",
        "label": "Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "nuvl_EquityAdjustmentPromissoryNoteInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "EquityAdjustmentPromissoryNoteInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to stockholders' equity for the interest on a promissory note from a related party stockholder.",
        "label": "Equity Adjustment Promissory Note Interest",
        "terseLabel": "Interest on promissory note from related stockholder party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r94",
      "r114",
      "r115",
      "r116",
      "r125",
      "r126",
      "r127",
      "r131",
      "r138",
      "r140",
      "r142",
      "r160",
      "r208",
      "r215",
      "r226",
      "r259",
      "r310",
      "r311",
      "r319",
      "r320",
      "r321",
      "r324",
      "r331",
      "r332",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r361",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r401",
      "r408",
      "r463",
      "r475",
      "r476",
      "r477",
      "r494",
      "r555"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r637",
      "r647",
      "r679"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r634",
      "r644",
      "r676"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r379",
      "r594"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r379",
      "r594"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r779",
      "r780",
      "r786"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assets Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r595"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r595"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r378",
      "r379",
      "r381",
      "r412",
      "r413",
      "r414",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r594",
      "r597"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r594",
      "r782",
      "r788"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r445",
      "r594",
      "r598"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair value, inputs, level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r261",
      "r266",
      "r366",
      "r379",
      "r412",
      "r585",
      "r586",
      "r587",
      "r594"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair value, inputs, level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r261",
      "r266",
      "r366",
      "r367",
      "r379",
      "r413",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r594"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r594",
      "r782",
      "r788"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "terseLabel": "Fair value transfers in or out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r787"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r378",
      "r379",
      "r381",
      "r412",
      "r413",
      "r414",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r594",
      "r597"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r788"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r252",
      "r257",
      "r352",
      "r386",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r464",
      "r580",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r606",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r735",
      "r736",
      "r737",
      "r738",
      "r778",
      "r781",
      "r782",
      "r783",
      "r785",
      "r788"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r683"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r683"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r683"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r683"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r683"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Loss on extinguishment of debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r27",
      "r28"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r539"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "nuvl_GovernmentAndAgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "GovernmentAndAgencySecuritiesMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and agency securities.",
        "label": "Government And Agency Securities [Member]",
        "terseLabel": "Government and agency securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_GovernmentSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "GovernmentSecuritiesMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities.",
        "label": "Government Securities [Member]",
        "terseLabel": "Government securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r75",
      "r78",
      "r450",
      "r460",
      "r576",
      "r577",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r230",
      "r371",
      "r375",
      "r380",
      "r470",
      "r472",
      "r540",
      "r571",
      "r596",
      "r802"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r230",
      "r371",
      "r375",
      "r380",
      "r470",
      "r472",
      "r540",
      "r571",
      "r596",
      "r802"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r88",
      "r141",
      "r142",
      "r159",
      "r164",
      "r166",
      "r308",
      "r309",
      "r315",
      "r468",
      "r591"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r675",
      "r683",
      "r687",
      "r695"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r699"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r699"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r699"
     ]
    },
    "nuvl_InsurancePremiumFinancedByThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "InsurancePremiumFinancedByThirdParty",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of insurance premiums financed by a third party.",
        "label": "Insurance Premium Financed By Third Party",
        "terseLabel": "Insurance premium financed by a third-party"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_InterestAndOtherIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "InterestAndOtherIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income and income (expense) related to nonoperating activities classified as other.",
        "label": "Interest And Other Income Expense Net",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Income (Expense), Net, Total",
        "label": "Interest Income (Expense), Operating",
        "terseLabel": "Interest income",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r729"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Contractual Maturities of Available-for-sale Debt Securities",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r91",
      "r170",
      "r171",
      "r387",
      "r388",
      "r800"
     ]
    },
    "nuvl_JamesPorterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "JamesPorterMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "James Porter [Member]",
        "label": "James Porter [Member]",
        "documentation": "James porter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r124",
      "r202",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r335",
      "r338",
      "r339",
      "r391",
      "r514",
      "r575",
      "r618",
      "r746",
      "r791",
      "r792"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r74",
      "r459",
      "r605",
      "r721",
      "r739",
      "r789"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r100",
      "r124",
      "r202",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r335",
      "r338",
      "r339",
      "r391",
      "r605",
      "r746",
      "r791",
      "r792"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r238",
      "r306",
      "r485",
      "r581",
      "r744",
      "r745"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Accrued liability",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r706"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r238",
      "r306",
      "r485",
      "r581",
      "r744",
      "r745"
     ]
    },
    "nuvl_MarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "MarketValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Value",
        "documentation": "Market value."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_MarketValueStockHeldByNonAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "MarketValueStockHeldByNonAffiliates",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market value stock held by non affiliates",
        "label": "Market Value Stock Held By Non Affiliates",
        "documentation": "The market value of the Company's stock held by non-affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Gain (Loss)",
        "verboseLabel": "Marketable securities credit loss",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfContractualMaturitiesOfAvailableforsaleDebtSecuritiesDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Marketable securities by Security",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "verboseLabel": "Unrealized gains (losses) on marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r267",
      "r306",
      "r369",
      "r440",
      "r469",
      "r471",
      "r485",
      "r506",
      "r507",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r569",
      "r570",
      "r579",
      "r584",
      "r588",
      "r597",
      "r598",
      "r602",
      "r603",
      "r607",
      "r748",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r597"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r597"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r267",
      "r306",
      "r369",
      "r440",
      "r469",
      "r471",
      "r485",
      "r506",
      "r507",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r569",
      "r570",
      "r579",
      "r584",
      "r588",
      "r597",
      "r598",
      "r602",
      "r607",
      "r748",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r89"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r63",
      "r76",
      "r98",
      "r110",
      "r112",
      "r116",
      "r124",
      "r130",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r150",
      "r202",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r323",
      "r332",
      "r363",
      "r391",
      "r462",
      "r536",
      "r553",
      "r554",
      "r616",
      "r746"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r136",
      "r144",
      "r158",
      "r167",
      "r168",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r225",
      "r226",
      "r229",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r389",
      "r390",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r442",
      "r443",
      "r444",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r136",
      "r144",
      "r158",
      "r167",
      "r168",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r225",
      "r226",
      "r229",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r389",
      "r390",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r442",
      "r443",
      "r444",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r641",
      "r651",
      "r675",
      "r683"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r728"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r576",
      "r727",
      "r729",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses on marketable securities",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r71"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities, tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r109"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r639",
      "r649",
      "r681"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r642",
      "r652",
      "r684"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r642",
      "r652",
      "r684"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of public offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value | $ / shares",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r253"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r516"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r253"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r516",
      "r534",
      "r804",
      "r805"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r454",
      "r605"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock in follow-on public offering after underwriting discounts and commission and offering costs",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r734"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r110",
      "r112",
      "r121",
      "r124",
      "r130",
      "r138",
      "r141",
      "r142",
      "r202",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r323",
      "r332",
      "r333",
      "r336",
      "r337",
      "r363",
      "r391",
      "r450",
      "r461",
      "r493",
      "r536",
      "r553",
      "r554",
      "r592",
      "r593",
      "r617",
      "r719",
      "r746"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r260",
      "r267",
      "r295",
      "r296",
      "r297",
      "r306",
      "r369",
      "r415",
      "r424",
      "r440",
      "r469",
      "r471",
      "r485",
      "r506",
      "r507",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r569",
      "r570",
      "r579",
      "r584",
      "r588",
      "r597",
      "r598",
      "r602",
      "r603",
      "r607",
      "r610",
      "r742",
      "r748",
      "r782",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r260",
      "r267",
      "r295",
      "r296",
      "r297",
      "r306",
      "r369",
      "r415",
      "r424",
      "r440",
      "r469",
      "r471",
      "r485",
      "r506",
      "r507",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r569",
      "r570",
      "r579",
      "r584",
      "r588",
      "r597",
      "r598",
      "r602",
      "r603",
      "r607",
      "r610",
      "r742",
      "r748",
      "r782",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesFromStockholderMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables from Stockholder [Member]",
        "terseLabel": "Promissory note from stockholder [Member]",
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r634",
      "r644",
      "r676"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock (as converted to common stock) [Member]",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentOfNotesReceivableFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentOfNotesReceivableFromRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of promissory note from related stockholder party",
        "label": "Repayment of Notes Receivable from Related Parties",
        "documentation": "The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "nuvl_RepaymentsOfInsuranceCostsFinancedByThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "RepaymentsOfInsuranceCostsFinancedByThirdParty",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay a third-party for insurance premiums paid by the third-party.",
        "label": "Repayments Of Insurance Costs Financed By Third Party",
        "negatedLabel": "Payments of insurance costs financed by a third-party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r571",
      "r577",
      "r799"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expenses [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r635",
      "r645",
      "r677"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r636",
      "r646",
      "r678"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r643",
      "r653",
      "r685"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "verboseLabel": "RSUs",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r68",
      "r458",
      "r479",
      "r484",
      "r492",
      "r517",
      "r605"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r125",
      "r126",
      "r127",
      "r131",
      "r138",
      "r140",
      "r142",
      "r208",
      "r215",
      "r226",
      "r310",
      "r311",
      "r319",
      "r320",
      "r321",
      "r324",
      "r331",
      "r332",
      "r344",
      "r347",
      "r348",
      "r351",
      "r361",
      "r399",
      "r401",
      "r475",
      "r477",
      "r494",
      "r804"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Summary of stock-based compensation expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r69"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "nuvl_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B convertible preferred stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ServiceBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "ServiceBasedMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Based.",
        "label": "Service Based [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseAmount",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Amount",
        "terseLabel": "Share based compensation arrangement by share based payment award annual increase amount"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage",
        "terseLabel": "Share based compensation arrangement by share based payment award annual increase percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock awards granted, vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Outstanding as of December 31, 2023",
        "periodEndLabel": "Outstanding as of March 31, 2024",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding as of June 30, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding December 31, 2023",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional authorized shares reserved",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Cancelled or forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "nuvl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate grant date fair value of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregate Grant Date Fair Value",
        "terseLabel": "Aggregate fair value of restricted stock, vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Service-based vesting options granted",
        "verboseLabel": "Number of Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding Balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Beginning Balance, Number of Shares",
        "periodEndLabel": "Ending Balance, Number of Shares",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Beginning Balance, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Shares, Vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Cancelled or forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock awards granted, expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Term, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Term, Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of purchase price of each shares purchased",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance , Shares",
        "periodStartLabel": "Beginning Balance , Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r604"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage",
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r104",
      "r105",
      "r106",
      "r124",
      "r148",
      "r149",
      "r151",
      "r153",
      "r161",
      "r162",
      "r202",
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r391",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r516",
      "r537",
      "r555",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r705",
      "r720",
      "r726"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r48",
      "r51",
      "r52",
      "r94",
      "r114",
      "r115",
      "r116",
      "r125",
      "r126",
      "r127",
      "r131",
      "r138",
      "r140",
      "r142",
      "r160",
      "r208",
      "r215",
      "r226",
      "r259",
      "r310",
      "r311",
      "r319",
      "r320",
      "r321",
      "r324",
      "r331",
      "r332",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r361",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r401",
      "r408",
      "r463",
      "r475",
      "r476",
      "r477",
      "r494",
      "r555"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r160",
      "r401",
      "r441",
      "r487",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r535",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r611"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r160",
      "r169",
      "r401",
      "r441",
      "r487",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r535",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r611"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r638",
      "r648",
      "r680"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock to common stock upon initial public offering, Shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r30",
      "r48",
      "r51",
      "r68",
      "r250"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares issued",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r48",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock upon initial public offering, net of issuance costs",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued during period shares new shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r48",
      "r68",
      "r488",
      "r555",
      "r564"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Issuance of common stock upon exercise of stock options , Shares",
        "negatedLabel": "Number of Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r48",
      "r68",
      "r281"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock to common stock upon initial public offering",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r48",
      "r51",
      "r52",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r48",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum aggregate offering price",
        "terseLabel": "Issuance of common stock upon initial public offering, net of issuance costs, Shares",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r48",
      "r68",
      "r494",
      "r555",
      "r564",
      "r617"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r48",
      "r51",
      "r52",
      "r68"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r65",
      "r518",
      "r534",
      "r556",
      "r557",
      "r605",
      "r618",
      "r721",
      "r739",
      "r789",
      "r804"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash financing information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r304",
      "r456"
     ]
    },
    "us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityIssuePeriodIncreaseOrDecrease",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Settlement of preferred stock tranche rights",
        "totalLabel": "Temporary Equity, Carrying Amount, Period Increase (Decrease), Total",
        "label": "Temporary Equity, Carrying Amount, Period Increase (Decrease)",
        "terseLabel": "Reclassification of preferred stock tranche rights upon settlement",
        "documentation": "Change in the value of each type or class of stock classified as temporary equity during the period. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r29"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending Balance , Shares",
        "periodStartLabel": "Beginning Balance , Shares",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "nuvl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of convertible preferred stock, Shares",
        "documentation": "The number of new shares of temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of convertible preferred stock",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_TrancheRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "TrancheRightAxis",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Right [Axis].",
        "label": "Tranche Right [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_TrancheRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "TrancheRightDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Right [Domain].",
        "label": "Tranche Right [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r252",
      "r257",
      "r352",
      "r386",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r464",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r606",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r735",
      "r736",
      "r737",
      "r738",
      "r778",
      "r781",
      "r782",
      "r783",
      "r785",
      "r788"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "nuvl_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employee stock purchase plan.",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nuvl_TwoThousandTwentyOneStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "TwoThousandTwentyOneStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one stock option and incentive plan.",
        "label": "Two Thousand Twenty One Stock Option And Incentive Plan [Member]",
        "terseLabel": "2021 Stock Option and Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r130",
      "r131",
      "r132",
      "r133",
      "r144",
      "r167",
      "r168",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r225",
      "r226",
      "r229",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r389",
      "r390",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r442",
      "r443",
      "r444",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
      "http://www.nuvalent.com/20240630/taxonomy/role/MarketableSecuritiesSummaryOfMarketableSecuritiesBySecurityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury bills [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r585",
      "r587",
      "r594",
      "r801"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "nuvl_UnvestedRestrictedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.nuvalent.com/20240630",
     "localname": "UnvestedRestrictedCommonStockMember",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPer"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted common stock [Member].",
        "label": "Unvested Restricted Common Stock [Member]",
        "terseLabel": "Unvested restricted common stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r82",
      "r83",
      "r84",
      "r85"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares of Class A and Class B common stock outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r153"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.nuvalent.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares of Class A and Class B common stock outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r153"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0000950170-24-093285-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-093285-xbrl.zip
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M[>ZI4I.FCT7:#[K3D7BWIUCANEV3P4F,Q0)V.UR3[0Z8M?".T[HA"V0%+'8
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M-6\8E:K[UQ1=#$>9&NH!W>%TIE;6K?EP/E-/>.R><(6I.T2G% :+#8D$_&'
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M(!1Q-M56"< MKD@8I.+I3N3@4JR0&>!"9K=J*\<EFYGA[4F@HIJMO-,-Z!F
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MRY>S_I#+G8"SYU)- S&\ 4BJBP?LT;BY"*'A6MR5H:M6BRP:KBEH!4(^N@E
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M=@P5O0$@@4AGRD9"JQB+3UICC!#$HS9YG(=M7-J5 !W.JBM=92-BQ&4KBO6
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M3.&J*U]BU4R%],8+<:CDLV: A!PI276VH#7S.L$1N>^V.#OI[8\WE_^M-P"
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M,/-%0#LOJ3.L%L4'&MD\O*1#!?<'8L/X651@-R.PX%ZV%&0TM/ER5_9P)25
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M[J'W[[-\.CB/^GE;;N]YZ>X 9I[F/='_IB>F%E;B,YOCD']:D+>$5C4#;)U
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M#;I3AFW"RWQ+W-*BQ?5F)XLP#,V85X\P:G!)90B0,OM,!5"-8OM.C%3CH@U
M8>EB>#7R17C74;VF4XF,257">(E)7W:(Z(NM4I/W"ZX6^M:B?PDSD!_PK":D
M)>&AA>-D[$:L9<LJNL&PVE+$=,TK(MF;[*/RE'F;E2S3@:I_/%G7))M3N+.=
M8@\2#6H3?=PF(IE\2T.K"(YS#^KL++87]?.1LNM4Y_T57R5;#(!2Z$CG6FOC
M1DE:0_(CM*2DY.W$Q'%>7I$B[1M;[[([';J=VD>:'3I-Q42O+LB^D_?,?:+
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MN:2&28?:/>)QM5Q$QO!WF7IJ@GLG//70XHP/Y7P?7OC$@%[US/O*/MOH,JU
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M>JUTOK+KV9#I"<]$.$S%J3GI<<)$8X?3?52IZ'.S"L5Y$;E6E12KK:(HFL
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MRW=JA_.% O#[A!H:A?%I8,9,89D\Z3'0D[/KWP;QP5P?ZW:(.E(9)D_EG6C
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M&)ZB]%4W>+V96%SU7GO'+ZI9O9U2W_1HD8WIJSCA-HR/L^C^Y7^WPO_>UL4
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ML)PS@8!GHS,Z-!K"RPH1@Q"48;_+ELIBMG26U1W2C3Y6)#8?+N8]FWXOU '
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M5IYSV<6M['D&6(EAN-:<2M:MG%:@R'7 =00.<P8PYE_J:-F3W[ T9 0SJSW
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M'*"0'DD.>UD3GRB_8.9'7RD,RF[I1US8#O'9\;CP:(AUH*7?K\R(X'1<7MI
MQE72(D9RK=-='TY?A3YHG%-:89CKJ_5SU48W(22=MV!5Q;,97GIS@6N7=L\
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M92HH'6NV<$^2:"8*EA?/$[*=YR(JFWM@EF-1J<Z1P]7-*3";G=1K 3S\'<U
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M2[L6 N[IXKI=!3:9LP6$AS3#A0B'YN@V1P'G^#.B:?=BGI?=I@6IU6]S+?O
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M3OEABQBBOMSZG69:S 36WOUQ)D!C+M$U ^=E/5R%T".6([QLXX>).-/XX>)
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MO(C?"D;^.=KBD+C.9#9*Y;E?]YE--N6,(V_:\&@\'MD:*S[GK?;7#>PR0X0
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M53EI\8KDE9P P81JZ;KF?[RJJ[&*P8W1YP%0'(,TZ(O+"GDU9ADX>./%9Y3
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MK4+V(Z1<_EU//I5C*_N=126) [V"R84XEZG9F6[3'[+%)5,F"5@)4--03UU
MSL$I@ /^(--MM&G(UT^D*3X<+#<%6%PO7&NPXVZB+V00?;<97W*".,7^B"SX
MAP8X#[%UFPB]SKV?OEN+'2X9\W-D\86/+YDXW,=?=<Z,2[+5Q)U_(6)G=E41
MQY1Z;#D9]SBAGKVXG\-H#;_?O3:ON](+V@YVVDTX6UJV>^ONMK)U>EE$]M>A
M]C7U1]NG@!94<T/\V>2KS&I4*I#B&KLO"P[V,&B6P"PS8Q2:6+(9&NU.XG\&
MX8]J>%]F>@A>JR^%\*6:XD)_GBEFF@XK7<E?=0G&AFX#-::M;!)IS1J9%<R2
M?K-Z+.S(8#G&(.@[P;[P<7)'J)_:+*2FKKQ_E?6@'"F]]><NFKJ5FI+F/(D:
MW1Q3C]EH^'$?\9T56-N,(^:7/]N]M+U_^.8+C[C18=,IH,ML+?^CW%1M^2E
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MR9OQXDIM7WMY]Z<9&BZ?H][>&#55P6$8*KJ>\@]E^4%IL0](P6),&[703Z<
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MF;VPSP%DVS2U*S$[)B4]01["XKOC+:.,'WO.<P6+2XP$LXY*Z2.S[W9-JW9
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ME-7H:,63G;8 <1[G31!K<11[<CXD:"_EEVKNXW#]$/%;.H0Y%!!KR' > UG
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MPK]&:80E3_-KE>>U'+C&=8W=+MSOFPD]7RF1\MU9J+F*#?VTWJ=)NI[]W2E
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M7[AUAT7+_!^N5)Q[S,F 96\DC)7@G#-Z!S,L@"_I@KDMR6[#REF^I=;Y8NC
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MM(9:1.1&>KA\ 64N\/6P4T!7W[';*6 FIR98Y!0P=0KX]GA!9NP,GO$?A>]
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M\!0/:AE&1444PEIRB!@WIV5TK%SKE^9A=EYV[KMF=@WA0#_L?A:=%%;2BL#
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M!MC[U4<W.L3X&T'PE4$=.N=<RE[].__RYUN2C/<_AHI2F"=<Y7F0!XNHZ5.
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M,06T9(]J_&:SWG+(0)-1N+2T&@CD%1<W'Q>I.%83RK'R9@C8XC%Q<6-\?+=
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MQQ#OA"J3^K=M5G,/T.AVF7J^2B="D*(M4=$6[T[A2P2!6ENW05ZO/JW?R)O
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MO@2O\$LH3M]5.;T&(:@+-$]GR!.AL&FRS4)&X/12!F+KHO>R<R6"%#KS)JN
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M/&FGKUQ<;ZMM!;-:M2H1^#T-#_AZ*VTPP/JFU;8F8S0\DAJZ;B-JKG+[.^Q
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M6AG;V[EU3G%K\60PX*]M=Y82/JL24/]E>HX/IZ>CXEHT^>/57?+EP^-.&#,
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M'2IQIUI!Q&5(W2*T44%IV79W_X'Y89YYGGWZ^@_.#^_W^9SSG/-^QTC:RX(
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M)YK 1Q;M/[34(^8[VK'64A'F5%F/GI3.('N&-#[3ZC@\+IU??@_O5QTO;FM
M+46Z;ONP3!9:]3KB]']'T/D7%,SP*JK]L<G6'I.V&G 5(J^&F#JAZ_N%#C4\
M!OUJH>*:S]"Y],&D-P'Q:*:F2GG'S=H!<UKA/V0)0&,;D_%N5\GK%*Q=,'M
MG*3^H9#MT28R>=,?(JF(/[@VFBIRAT]P+$0R8XZ1!=<RRT 0# X=6N/=B^VR
M42N;7IZ-2%"C/Z_2]"H@^J4Z+N64F;Q,J7S !XVEM=R4<BAQD+AQ+F(DMP^E
MZM%%?;= F8*,DVJ=](9C;]MIZJJ;8[;?/T:HOM11?!SSX=%"2^J"@ 1ISG1
MC<3,WC#E]>T9O(NW1LQ@"6+NR]O/>4>#*H+>I4"1NTK0JK82#C5U,N5;7?=T
MB%U&1)!!A/?Z9']2]3VDYF(R_;>=]K5"T[+"&7QI_[PDW"<CX1;DI<HM%$Z0
M%CJE I?E73S]#3!#W6M U0C 8M/^>T]K ,WNT%8NQVH,+5 ^ F>'E#(X=$91
MK+C!F6,PP0G\3SZ"!AQ.I'PJ[AY82-)_]&>+XX_ER\H(!K6L9<F;!XD=?N1
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M*IO]M$%!L5;.5MB&,NH(2V?H_WS7^LQG/O.9SWSF,Y_YG1S>%?T;4$L#!!0
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MC=!Y9E-.C ) D.;2$NU-3!@S-F/.")_Y;MBM(#]X69Z>%A,<>WTXMLB<P$H
M:@IWA6R-R 57B2',Q[ JC":P*HR17,0FSW,A1,:?1=-QT7SAT^=/1Z] EM3%
MP;@ 83RII@Z8>_70N4I-%G-&$FV!-G!]M&:"Y+%P7"H+2\6^8^@Z WF?ZIC
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M?.RN-J1KO].9:/4L#R@8;PNUL[%:W=P!'JS)8,1V;VEKA2Q:5D$Z%9/@ABE
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M$) Q%41;84AFC!&I%0#)K\2"WA&1;U5 4KK'TVT(R"'[8,@3OF.N@KG]\>X
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MH4:\T<Y%^B)]#Y*^E!-JDS807!=*UPH<H0925E8E2;G,O930V$6089A1]7O
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MT4739$"#C:I\S*.+JHS1 =3;0>GM[2Z%]EP8Q04D6]T#PA18I340Z5,DAL3
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MB@[Y^H0=@8)K7Z1S':&19N;.>;9G8C3VC??7B5K%MD& 1@.4>#[]R^H&2(
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MO&B_:BF7A7N1=JUP?YI>7N:-%?AN@9#5'26K.2G/3/O>:H5G&$?@K5Q' "!
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M9H(TM]C=PM)E]@/^IPTM-I/.K+( UM=V,(T/I;W8:UL/\K,0P"IJ\_ 7DM4
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M4?MG+,=#7/+;103A&@Q&7^KAYZKE@ZJ97L)HX;%--8&O[3QD",O2='5$4N[
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MX@&84M[A803Q)!4R"?Z4P7D?G(I,L6W W)9W&CFE/5KJ*K_*/BY%I!;L8YM
MY&_-XVIR :3Z?)'_C=U'I:Y4.05:3H&^N+^@9)YQ'U"T1(&U+0QR H,:TMQ$
MR<#PEBO9!B&(H).Q8*'3@#A8L\A:3U'.3<#2F:0$/A!KFPC=4ZP4EBH6>4'1
M@J);0U%N-!=.&D1I !0EG"+C$D=$!0OX2(+G*R=L-H&BVVZT!>B)!2[H60+B
M!Y2L4VSYDLE>,MD?4TF86Y>P2$@(YA'G)H?1HT-)2.O!ZB=)J_LJR6NEA24>
ML80=XHP29#UC2&GLE5)::RD.Q+ 7FO1@-"6CO9CV!50+J.ZJ0@DQ*NF$D<$R
M(1ZL!SO?,02@F;Q0--FX%5#=LITO-.Y1L]/J@T</IL\X'G3BAV.>=[#%CF/E
M;\\;5;:IX*MQS.UWFR9.FOS)Y"+>M!>"%Q1@.'>/K":CRL4L89G)X'[XV]OF
MHCMS,QI7TR96[1&9U7'-WS.ZBF.;^;OI5S!^>,V7_&/=B>YG4&CSS;N3Y3CF
M;MU1$,":R)%C-*%(@C3&*67IR@:AMUR[Z,&+3(9GK,&YNK5$EBO*6(H"?M['
MFGL&VSWD>9\//MFASW]_&,=03_*A[U^ O4?AIZ'/#3[ Y.O^746C.PSZZ6\_
M+($0 I;(0)1=W"8.'[1BG6#<6HE(C#&W/7#(6"61IR8EK8W ; 5PL8]&)+!W
M8SZ4R8FVR*80$4[!&D:ML(H?%1&B480XCA'U/F_[)H><=QYY'[7QA"4M5]H-
MO>1$X$$3(7 ,7@LG"'L-$Y+!(D<B012(8P-,T(B5PNTD8.V-C8A*8> >:Y#F
M)B %OV$.7QCM#Y0(P]$:;?R"#U8Q;3>*H?(M=:H!D =N&$>?U7^H A V'Z.\
M6 ^XNQE<MWF<5493?ZTNX?.+IHK#/+ZE,T#M)? +ZU<_92,V-A-0+GYT&5M=
MDR?1/>H)CZB^@&+[7X>F9)A5SD61D!>\+;.MD 4=@B2V8*1&1Z1?V?Y[B9*9
MD^^GEGK??[V*PR;^+4X>-&#ED@$K'NM<UB>'Q/MP]2#3.*_]P2TY>"%:.">0
MLOE\.5,1Z03PF'B*7-FD*%TI<? 2E;KE)1<'N>0]0+KF*L)PKN/@YF'8>"+N
M'"9H>&TD%B)S@P9[A(!MH3F/R/$$_R1-:<2;J5"P50XBLO]P&FY!C7OFEU2!
M4".1QAI,*6,8LDP1I @87D*8*/F*HGB)^;7M-<?' !M+,8=U(87_IZK:HB.M
M(_V_WUS9SQ$-1P#(LT>_6:Y),HA?4:C'L9UN+L,PO1R^"W5S-; W;_.W[0!G
M>Y2X+^KANW].FTF=;N8/;*]" %5/#- \,YZQP=->KUL0N43Z-GIS2_"+V]W<
MEM[=%FV;GOC6#K[8FV96M6&1]"MTA5E=B/FW:T(XM@*#$IC\=Y.1_^_\GJ=$
MPMOGA&QBMW&-MU-0*>-!/8RWBUP/\Y_(Y>(M&XG[M,&84:H^=!_=)6%:^/]"
M;#R*US+4BT\COVZR:P*!<Y[8LBCL=9;W6'GA%8_-Z*'*1AB#K> -"AK,3ZXE
M04[FRD8)O ]0*=HQN@F[(1_F;,]R?JP;#P[H%,!UEZ6+-I$AL7)R=0,KS/O5
MW3G7ZJ]M;]YXN2B]!S#(I120C1;6 L.:A,09,E*#XY-R\VUF" I&4IL$MYZL
MQ!)?Q7[OVX#VC,[AY^&O.:R4PQ_M1OBK.%(>[W;!O5I:304O:')<?EW,?J&,
MUD4=QW;L+VY:)ZIN=PHR?7L5C-9?M/L%ES-:5W:R5($+C.H<@NJH7[E,_H<J
M:>W!"-QB$2]C]E'#BZL^5^*Q*E=]_.I*6F#-TU<_I(SC ,:QHPI"JRCXVOHZ
M1U.KX3PF>%OCA/!7%SDYG:(F2\9>5HX[+'5VY%Q5@*D TX$57SIV7/I+O(Z#
MBA38*4)1A&)9*&@1BB(412B6A8(5H2A"483B-H@ZFMA!$8FMG<(]^Y+Y'W)"
M??SWM+ZV@QPP>+MIZ#FJ [A/1I[#./.TKRK)YS+EPM$GO;QG..7"T2>]O&<X
MY<+1)[V\)S?EG94);>=4#T/.Z 6_;[U;\(C_LIB-(N:)1;-GXOOY, ?HW?QU
M-(PW%;SO7W%2):!G*2!ZC 5Y2S'J39[NH,+AW+C6FR005Y8@%SE%4BG)A!="
MK*D"RA6)G# D13ZD'IQ$VOJ$9&Y@Z@2-(:W4M<B1A??#D/_Y_BZ^L"9?=U.%
M+50/XX</?!PK[^^TJ.-AL'Q!N()P3UU\30D]^M4O,EYDO,AXD?$36_0BXT7&
M7^.I..8<MXPB9E)$'"N,#-<4!<%8Q (^]"N'N!*X(S$X@IB *[DS'AGP;!!V
M7@HNM9!^I6U.\50.I+9>V;]_?H2KC6UU)\AN*UF53?P23B]3/NDI%R8O4S[Y
M*1<F+U,^^2D7)C^C*9?=_UWF-H\N+^/8UW907=FK."Y[_V<353C70%H)EA_K
MHA?1/H=5WGQ]7N,%3S8A(RA!'(>(M+ 6<6^UP%P;I<+]&'G$CLF !:*<1,0C
M)L@X*Y"G6-@0E?1V[]THL>AQON667X7E"["55=X[L!6;Y5@7O8CV.:SR%CKK
M64JDCRCP&,!2,1(9ABF*ANB@F+.&V95]?>HM94(C$X-#G%J)=) ".<R]5Q0K
MRE:Z4A2;Y6CW]4NDZYF1KO%5+@@?*S<JAUS.2<S.5;,4H_%8%[V(]CFL\N:3
M0;4@,J6 @N82#$"1@U;)HAB=]HHXQ7.#H7O=ZQ(524:#C%$1\108TD8Q1(5P
MQ) $-J/<L]'(*.XQS8K1>/PL7X#M'%:YV"QGN.A%M,]AE3=NLUC)K0O"H&AR
M]US!+-*$.<29P\[H()5=:>8=B?#$4XJ4RJV(I%'(*AX1LXFI%)57F!2;Y8!8
MOJ1T[3#0]>,()CC,K2W:UJGV<QSZFX63+R7R=39R=ZZJIEB1Q[KH1;3/894W
M;D7J:!UST:/@@T?<@15I&(Y(4DFH3QPGOV)%8J^HHC8B89G(D2^,K-$&,<69
MMY($KMR^MTLI[RE9K,@38/D";.>PRL5F.<-%+Z)]#JN\^12O0 VW1"%N5+8_
M6$0Z8(4BL491)Z,(*Z5;--;4IJ!SUVVXT3F.C,48<9L89BHI@E?Z;Q>;Y>@B
M7R7%ZT5R]O?^IWXU&;>]76\J5P\&)=CU:E%[:0.I Q3&%R[ZXQ0X>@VU#>/S
MY8VU3H=U#H,Q"H3LFP_. $+6&[G*:LHUU2AI P8K!OM6"T502")*QH@59.4<
M [/,!1X$DD$:Q'5*R"D;D>3&@64L0W3[#LQ1TU-XRS9NP<^"GP4_SP8_BPE6
M(*1 2(&0S>^-$FN=H@[)2,$$"\PA*V)"EC)K,-AF@JZ4OS!&",,8F&W<:,0C
M-<BE$!!S#)N$H[=DI41T,<$.6VYVEH3WDM#CX0<7JQ)*W*PXT3[-\A1&TUR9
M>X]J:#\-"9Y"C!/52$+@I+RE2 G6%E<*R 294$P^B*BLMFHE6R>$:$F,#GE-
M!.(V"J2YC\AYHH71F$:Y>DZM:>*Q-RGX)IL<GQ(J1GS!SX*?K\1/Q@)6420D
MDB*(.X!!C8-'5*0@8TPR)7H?/Y571$9B$:<2\%-BG>O")&0<34(FBC5).\=/
MC7O4\ *@!4 +@!8 /<ZH:D&4@B@%4<X'41ZH,2P$%3:!#RL=F&0Q8.08-<AR
M'$/23A";[IMD/$;+O-#YZ#/<D[Q$6@F%B)2.$C#(%#:[-LDD4V"2;;E WXD!
MZ&)@%7[/(? G#9U0^'O;X;U[K__FZYXZ^_E<9SWU5I-'[70RFJ]R'D\]_)R'
MGR]' WLSFD[@%5]C>->]SI@^_OW\>A#-@;UJXMLF7ME<KV].AE:0NT>_61?'
MOJZ;VM6#>G+S=OZ,AP+4[5NYZG.B?O_NS9^^<1'I8VP>N^:Q[W$?<_G:AVQF
M( 0_.N,S&PC5^ED/>60;17]S%V6=A*[?6EF5]:>W!%J/G'I#P'FGMG=@B)WN
M!&][6A'^2%.KE^[=;Y<>3S"AVO=]Z>3"C0;A07)E>Z9J#9KJKVWV?LSE*YK*
M3JJ/T<=+%\<5([V*8LI>SC4OW\T]&LXJX%3 ::<-]TX?F_X2K^.@(@5VBE 4
MH5@6"EJ$H@A%$8IEH2@&:A&*(A2WU/IM-+&#(A);*Q'P=*?M24[:\>7E?K#-
M117_/:VO[2 '#=YN&GJ.*B6W=$HO4RX<?2[+>X93+AQ]TLM[AE,^)XX^@;F>
M\/Q*F?X=^BU_'0WC307O^U><5&E:6E)N(+%L[Y[KKC(M#T--;CZ+TGBMF#,H
MJ7S(CRB"' ^DK0%D"-9**[Q2QIND)*U-"'.XD7MAD+-,(:^$$99[%M3*4?4<
M,W@_#/F?[^\B!]O+JF14]; H;8]/@.<+Q!6(*P6]BXP7&3^9Y2XR7F2\R'B1
M\6>Y*I1HZ1FSB"@9$&=2(.T$1L%Q8T.T,K 55\5BDT),.O<F<HCCD)#U6*(4
ME8Y*<J6L+J[*(4%<V9M_78RKC6YUI\1NZ[^5#?JR^5.F?-)3+DQ>IGSR4RY,
M7J9\\E,N3'Y&4R[[_[O,6QY=7L:QK^V@NK)7<5QV_\\FJG"ND;02+3_612^B
M?0ZKO/$@N9.2$.8Q(MIRQ!6)R&+'4;36\,"\)\&LY/,(1Z6C"1DE".*$<&0<
M#X@DJKRR6%.']]QZ0JH>UKB$R(^?XPNNG<,J%Y/E#!>]B/8YK/+F&Y92'&12
M%G&.)>+49?,C&12<3@932RQ?Z4W"3(@N:8%XLAIQCQ5R%&ODO1/12.:4V7?#
MTF*R;&Q7O\2YGAGG&E^-<AW7RHW*(9=S$K-S52S%9CS612^B?0ZKO'&;D5,E
ME?4,D20=XEII9 A8CV K>NLL44FN%/\G#F.F#4$FI&PSLHBT41X>X8BU-"0P
MU_9L,Q+#>H:;8C0>/\L78#N'52XVRQDN>A'M<UCEC=LLA!IF550(QQSG\L0@
M0Z5$D8@4- E6BY6N\(X9)JA68*08N">1 /=HBJSSVAH;(W&K/22+S7)L@:Z2
MT/4B.?MQ!!,<YL85E1V&RGZ.0W^S<.ZE1+[.1N[.5=44*_)8%[V(]CFL\L:M
MR$B4,3H%9!-1B#LED.9)(H(3E4IYXP);V2TE-$5A$^(J.L1YTLA)CI%(EACC
MF:'4[MF*U*:'J2I&Y/%S?,&U<UCE8K*<X:(7T3Z'5=ZXR8*%CHE;C'3,G;IM
MLD@[PI$+-'FI'??6WS=9$HLL""414W CE]Z#P<,82DE@S4AP5OIBLAP.QY<$
MKQW&O?[>_]2O)N.V;^M-Y>K!H(2Z7BUJ+VT,=8#"^,)%?YP"1Z^@MF%[OKQA
MUNFPSF$P1H&0??/!&4#( ^<NF<=!80,#3 QQ:F5.+@N(4<V3LE%:O1*64\PH
MAG5$0N9##"Y(L'$56+O$8"J-$3CM>W.7\1Z7=+LV;L'/@I\%/\\&/XL)5B"D
M0$B!D,WOC ;.0- U(C2;8&"/(2NI1P),+T$4B\2)^R:820*S*!*B*2G$L=9(
M$QX1T](1RI4C8J6533'!#EMN=I:"]Y+0X^$'%ZL22MRL.-$^S?(41M-<E7N/
M:F@_W0B>0HP3U4@<<V^BBL@K&A'/NU^.8XNXLLP'Z9ST*QG?G(4DO./(:R\0
MYU(C&YA!4G)X4A#::;ZBD9HF'GV'@F_RR?%IH6+%%P M /IJDUXS[:0 ",S'
M?$V(2%O!4*+><ZZDU72EY8MR(5I'"9+&<,0%#\@8;!"5A@B'1>1ZM33,M@%4
M\YX@N@!H = "H 5 CS.L6A"E($I!E/-!E/4FF8PJ*.DUHD0EQ"WAR%(FD9#$
M<*.XQB'>-\DB9XQ&$U#T%LPXYBG2E%HD(E4,@QWG\<Y-,D5(3RA63+(71E;A
M]QP#__.<@'^;7L9Q[>'O4%\_:4*$PM^[C7G>&\PW7_X A?XZ&L:;ZK)MLU>E
MZ3 TU9<XCM5UYM)0N9MJ<A&K#Z-+&-E-Y6P#'X+P_'LZFL!OL_NN@%+P-F!0
MD"IX;N:<A7/+O0I&[R^J<821-^WQYNHO\3H.*E)=MEF?L3WT_*6>7-3#]H4)
M!*4;0W51Q[$=^XN;?G6_XT5OOK(OI]NCB_986'GW2^:7ZR'VJL^/G!MO/UV3
M9/NME9XV]?#S?)EGZPMKDU'E.L[6O5OQIH;1V_&3UIL^;[T_P@-A%/F"R<4X
MQG8B3?VUN@1B7#15' 88W7]-A[%BN%=13'E["?S"]K<^O3Q@(&Q+W77#>,8[
MMM!UE@5#I$%<>/A!G,WUPSBBR0@3E%-4K%2G]99K%WU +N40!*,8:0\ZTG)%
M&4M1P,_[^NY6T_WU;L'_+ZSWWX<CU\3Q=0;;GX97TTGS:X2W^7I0VSS,7S,7
MY57_SC9U\Y?: J?6DYO?QG;8I#AN_A8G+]*8"-@S:\V\_P4L^>#9#LN(M5:B
MY(E'/&*-'.,)16TU)M9I9^A*OP$?C4A&H<A=SG;3%MD4(L(I6,.H%5:MA+B/
ME#Q16.$M2<@R">2AD2/#F6X9(U JHO8KW".YC3YAGCLQ2,2Y", X0&$C%*:>
M1-E:6"=!GD2!1U(N^&Q"/I@<0&1"T"A/- D/$N?M2AF_@+4W-B(J!0BDM 9I
M#K:E@M\PAR^,7CD9=/#D&8[6&*(O^&!?$ Z*<D:2K/1 R8VFDVJ49EJ,]:O?
M0"5Y.Q[?9/W4ZJTF?[^@0=L AGH'RM?[T70(RO+*WK2-C%L=[?TX:]WX]2H.
MFZRBKZ[&HZ] WDG6=1&TX9U*;*H >G$R:A_?7(S&$P3^UR4PQ006?_;>)E:#
MV8*""NXOV;SK3%JP>_\3_GV!3KKE_MD#YRG#0>N@DT/8P \N@)LM-0(Y*XQ.
M5@NA5W8'7X(-[V?T_*4CY_MA>-\1\R]WT[]SKWZ#EWTW&/E_O:DB</(5/&@"
M%S_-1]F72?^E2^UPHT'8!#>+?C4C4?7]C-]>(UH;'MU2@L9&.=(8%9T3$3&;
M?7MBP&X1GB/GG.(IIH"-W@1'?O(7,4P'\>>TRHF_91Y]%1/*9_&@G)__V[=C
M^?X^PL%7H'2R.S$#RC0:#$9?,H#^H?4"1M,&H+'YX]L]XOX"+\X# [/N\ZM'
M+>UT,IJ'1/)08"89 O+E:&!O0&7 T[_&\*Y[$\&XCW\_OP'F,[!737S;Q"N;
MG;GY.K9AK^[9;]:E?5W73=VI[;?S9SR4S]6^5L([W_SI&Q>0UWZOMOV"S0[@
MD7PZ_<UTNG5\]YP<N^?DE.GC2RD[U>D]N8GQL[*5YR/?(G'N0O6OU?0/46\I
M^O)R'GE*RNXAD&ZG@G.*$RZB]"#U/D8?+UT<5XSTEF*819P.J63'4S96+^L0
M!G'_.\C/HN_<9/>#>MANX>1(Q2@'LZL<Q\]!^?:CD*,@HZL<=2K)]4=8$F<_
M208GFD#@#7/$TH!"CMIR+CBRUAH4J"7$I"1%6CFFY;72PA*/6,(Y@8 29#UC
M2&GLE5)::RGF08;A]'KP=B:9'V:"^7X8?LYB^>M,*N'OCW<R.8_Q;*H@.NL9
M5>I"G0#O%Z@K4/<:J%,\Z.B,0<)YC+B)-&^.4B0%D20(3[Q>V=[*A7EEWA>5
M@>>.#]P@*WA$U#J!B3)<JW P4"=[2I;.#Z\QI[=T[/2HS6EXZS0!+[7)+,5@
M/AL)*LIC*;,F*FX%P<@2SL%.UA@YFQ(RBAJ;/!64DTW9R7]=E+A-F\.X)_B6
MCSX5%B_F<%GE P4RGTBD6M%\=!. C"J''#$"2<ZI4"$P'E=ZM;[4"MXFD,F>
M9KC@6(D=;]38C9=7@]%-C"  EYE=V[S#-FKLXC#"/:6T\_F(55$<2ZGWGAG.
MN,VY9* $(J/()2%02-A[;P!?C'R-!3Q/1_M^)H*_QH&=+"6C?9B.QS#"#2D0
MWC.$%P5R_)Q>\.P<5GD+.U^:"\X4H@H'Q+-)["2A2+#$M5&"*++2!^4YAO"N
M\4SU&)4%STKT=Z,&<9L_46S>4@BW%,)]L9ZQ-CF&D< Q;SOBA+3(E6U38%PQ
MY6):";B\Q&YN]QE73W!L5LF0'A-;CKJ<5/7;HS:Y"FCNFP_.%C2IYU;HE$]J
M.XNXY?";$Q1APY/&A'@A5AJXO,0XWQ%H2KKE2,-)@>9!A;/W5#)\!]A;K/12
M5:U455M;52WH&(P,B#@B$-=8(L<T 9WBP2RW!)302FCH)2;[JN*9YPLN?+2I
MHK>XI_26LP-/K,#:41OOK^DY\>RF$P55"ZH^7C[<L:18<LAJZL&FUQ9I8QP*
M'JSV9(*UWFS"IM\EJE+:$[R@ZI;*5CY8^><@#-,-%.Q8H=3&RQI%%17&"0R8
MI," D<DCDYQ&QDCFC?88A&\3163N2A;]G#XLY,[,=KT^C)I)\^G"CN-WN0;G
M+_8FGW]H=EG>:(.E939<0DCVJT\3( )J:5,MDN\L"ATY&5C@T2)@.^!18<!T
M#I$AC)WC4A.FQ<H9Q-<5.IKOR7Z*X^O:QSO&7*3]^P%P9OO;SRD7HOL\A$F&
M7V#@HXZ?S[$NTF\+15;'0)1Q+F':M-S;5===2IR;54^:ETJM)VT=I9 _"VU%
MI1RBRO@ CX!_6DS(]95&5W'</J$K_IJ?.8X7<%NNW@HP Q\WLP),S4/EE[90
M \F8?91 XJK/E7BL2% ?O[H0$>X3^NJ'E'$<P#B.IDC4,8833W9^M[5M9*EM
MLZ+V<OWNOX[:NMW?+]7M+E5NBAP5.7JB''VJOQ8IVG:MJ*+>"RQ]"Y8>+%TW
MRU0]/UAZ8?''Q^EUJ@CT.%%.<<)%@KXE02^I]U@DJ*B<LQ68HG**RBD25%3.
M@;B-I4S$H_3]]8$ZPK=M0DH.[A&>,2U5-C=9*$T2$Z74*& <$>?<(NNT1%8X
M1GF(2I.5DQL\&9&PTG"1IHC3H) V6"*E:$Q*:D>H7<GRZG;G8UB_>3^K-K3!
ML]6TG*U^#= _E=TWI4T/\D1; ;?C!C<::) VMY+%-J'<5A99R14*GGC%8\11
MKQP,(%0(;*E$3$>". L<.:L(2H$2PK2)5*VV6]\EN-&>-%ONO'ZRX'90[%[0
MK:#;JPJDFZB%3APQGQ/T.?SFA/;(4<JH-L*0L&*Z8<6DQ%$@X4-.ZK>BZQEL
M>#XH1:DU8K4%ZB[1+?=_T*+ 6['=CF^1"[IM$-V8=THXJI"+EN3V#PI9+S0B
M &Z4!*<#=_?136CEC#'@B9J,B%A:9+!1*%H3M&22Q#6'.G>);J)'<2GZ]9KP
M9BGZ=4??'^,PCF>-TVR J^IFDO/PKV,)<):J-J6JS:M+@3GE901UPI7+X0,M
M0 5ABTC@2DCOC>(K)V"](LX3DI */" >B4%:D8"B5PQ[)K339L^Q48VW'#XX
MJ>HVQ08OV%FP\]G8R8EE)'J/, L.\4 TTE%R1$.4QD7A-(TKU0,X%LE)0%D5
M '1Q$DA+N-%2K\'D9\H1O5?L9#TBMAR;.&OL/"B/MH#GOOG@;,%3:S <O0U(
M4*W!^A04:>^R$:FI #3T)M#5V(>)A(")RE1@N5&018XQD?>MJ ^)"F;V:W@2
MWC-FRYU]SQH]B^59P+. YW\[K;$+@(&6"P!"'N$W##:HP<X1H8-F-JQ8GH+"
M&RU#B84(UBH8JB8"_OHDJ15>6)[H7L%3]C I7OL!YLZVHZ]SC93)6Z#8>@9^
M/-B\6.5$S(O'S!Z+[Q>".<!0]+-+$)9 <ZF[6.HNKD_K8(1;T%I:.X&X5 (Y
M#AY 2,(8S!/HHM7&;38GM^5$MV1XKF:+P6%@$E2@HHRE*.#G?HU_T2-TIZ&3
MHR^\N-$MS$T9^P4X"W >*G!2K8CCDB'5'4M(##G+% K:,>^)4-[@E7PX'XU(
M.44D5ZWE1%MD$[@ . 5K&-C^5O$]9XSH;?=_/W/<+!9G <[S!DY./$XF.K S
M&4'<&X*,=PDE1H.)W@)XKAR3>$E!U]T>D] ]H[=\".S,D;,$G N6%BQ=QE*0
M>"P8!2,4"PM&:/;CD]1(2:TDYM1*HU>.G 6LO;$142D,>/S6(,U-@'LL./SP
MA<G'U/;IO9,>):5MPJO;)AR$@7GOW=]\W9.G#IP1O_K!-,2NV+P?V 8XZ\I^
MCF@X H=J=O.;Y5KT@_@5A7H<6W[*Y;6GE\-WH6ZN!O;F;?ZV'<(L:(_[HAZ^
M^^>TF=3I9O[ ]BH4A^&)K/',+@0;K)'R.I*K)4;KVFW<-MVX)?W"[[>,>'&[
M^=&N1K>C81/,Y*T=?+$W3:Y$O;@J*R2'"5^(I0V/99:SU<4X0\SO)B/_W_DE
M3V'#]CDAEZ1O >OM= CB/ZB'\7;]ZV'^$[E<LG\CM?#;LO*C5'WH/KI+CK?P
M_X78N'RVO'8P(KJ&7=:W<3G=;@COVVX%\QJV5:[IU:LFHXD=@)X<W_:,6&Z*
MX$?-I!IW?5'@XBK^>UI/;F;M$^P7.PY-]<4VU:T1M3BO9PQZ\QOAP@:OJ$<B
M1G#1B%#@X&&+DDQ::Q:44JL;"2]HB_>D[AQ_&PVO8P,D?-]2[+=,],7O<X>.
MOXTF_U^<W/7N>-!ZD4O6BWAT[P'W'S9>=L^%%5P]@"'T*GB#OZCJICVNXV?\
MY6*UP(HCL)8J6W4%MC+#P=^ L-55V]<DL_,KV>[-^B8O1#BGK3>(LJC OU<.
MV4C R0]6J>"XY6RE#?I+8@);8YZN\<L/H_'LHWP=6>(4U$3_-DS'-]&.]P)'
MM'^GU>\C\=Z8,U.CZ2\JCD/6!R]LFM1=FE_UM@9>JOVWJM:1&>17]3!;@/EX
M'=@GPV,AT>OXX:<AZ,O!3=:5!'3E0CLA&T97+63!9RV5VJ98U<]7K0K*9Q)_
MNJ77+T"OZ@_YRO_XG:84OVMOR)^V?Y-W?^Q7O\V?TUY\-1Y=UR'FMD'C]A6?
MQW8XR7AWMPIM'Z-JU+ZPZ54@/^C?4R!8JN=-CNZ^[/ZT5T ;7W>*O0T(P%=C
M@!80NLGM39U27_-%5D=-]8?9''[]]/=F/OQ>:T \\!QOFXME>Z&M1U?G"<(O
MF;NN0:_!]+HAS?J+S2]N9P[WMA;R';E;,N5.35738>?L%1DIZ^'GMG-3W35E
M^MP=%(5ES%]V.N7U:F/QSHREJ/Z*+NH <WK[PW]'^(\%YE&DW(-"<!XYCQ5*
M3#MI$K$IIOUP]"3W!KD5WJ5_=C\85(TVL13K-'@03F,E/0HT%S\*SB(7!4>$
M<LX#9J#.5Y+(O3$4KN0(&YIW AA!.EFP :5CC'D?^&HDZH%N;&/@VL]MB[#O
M;E8Z";9ZO/WQCXY;.VV]7C_G[+LF#O?"+&DT':.L$@]/4<^D?F8) LQD4%E"
MO6Q6UN-8M<[^EKC,8(N#%Q$IW.X=@;!K[1-B.#(J4Y+,J96C"B3$D#!#@N4S
MLD(ZP 8=4' A!.(PCG8E6ZEE(?<XE[G[7/9]ID%[<<=C!\=B\$]G=!T<B_6K
MSF'>WPCNN>J'YF$K+37A0@"P9D8F''P=Z^$'\]0ZR; .*P?$)6&<1<N1CPD$
M)@J 9>LUTC)B0KV+?M7#?C'$ @^Y./XYM=\V[Z]M/<A!,/"*?LQ&Q9*#W;37
M+'K6/_WMAT</DV.I>QH?E'O=3:0-].4H=/4^QW,N1\,9.([CI:V'K2L](T=K
M8Z;I9 I863?-U(*%N<[:*E[1LE<T<]UG=+V:COT%,&!QCM8Y1_,XQ\RT_V5.
MK,Q7O=P>%02^[;"5M7CV)-IPXZ++]/VG7WY9]I;R)UG]7V:O) (MZLS,\V5I
M<C#I=E$>$0H[J2QX)(T?3<$-J<%_\[E9;"L)K8^1!P)6Q&7[B/S'*"503^!G
M=!U?ATW==,U@\^_13[.'UFM=C0%X7?E"0A&\$)YU>^NMZ1*MOY@_)'^1W_%E
M5#7@472WW#%7=TOE(C#$,%\+@_T8?<Q UXZEU1GP@/:96;'VJX_3]G7M'-K.
M@*VI5'^MVH<#[99ZFVU&V3Q#O2PSZX/52"A/BGJ/A*>@;*S R'*G4+"$D:@Q
M%:L1.2H#6&..($.4S65,%%A:W*(0K (3+,D@R8JRR0SQ$\!@#!W=.KNI4R&W
MX;I\T9R),P\WK]8EZV=M,;8I,8-B5 )QRC',P.737,80\%14]"O[Z19+RP6.
M"%P@N,=YBHQA%LBE:;(^V>!7DCKW-6O1HVS=H=B#4Z=?(FC'!C3*@F;, %2,
MQ$>,1$JC,II@I'A[-L,Q9#@8?%R =<ADLC2LI"43FCA8D@YIQ2D8EH$#!U.&
M+*"_M#))C_'1&(FDIQ7K:?9P,M[1&(EKK,-6!H[%W-FZ8?AI,?ZP2)7%K(]7
M!QVDUD1CRQ H/1 D IK!6 !X@KD*#/1"4&03FU.?_$4,TT&<R<:*<+6S[0+>
MS7M@Z>MZ<M-F&?P&[_TNYRV\J6+C[57.FQA/X]-25([4&,X6:1H-!J,OK:W5
MRDPSO831PF.;1>LX6[%$O6MF?%+9&>G ),NRM3]4N+4C&6FU"7N[P,+S9*[9
MS%;/[=KI9#1/8\MC S+D_*%\.1K8F]%T J_[&L.[>9]XW,>_G]\ $P0[N8EO
MFWAEQV#\SY>YW1+HGOUFW8GFZ[JI73T \KV=/^.!H\K=:[GL&_W:%O>/?8^W
M_8+#'T!?\_V/@3QOI5]7DO5D.A5O^QS\P4QT]]WO3F>N97['/;_"JV5^QS*_
M)_/J(73 W&3/T/\[2WM\^>H? D4*NQ=H/L.U?,2;T.?A3!2&*<)_KFMYZO,K
MO%KF=RSS.UL?XGUW8JJX$(7;3W.N)SR_XD(4AMFY\!]AK<RSG-XIZN6SM=)*
MI+=,^)SY_]<VX; >?B[\<-83/EL!>/_Y\SA^MI/BJ!?GY\ LYJ.:WU$!2%$7
M9<(GS-XEC%W8O[#_1M@_U^S,Q\:F=E XXJPG?+8B\!-(0#UL:E_XH7A(Q4,J
M /)< .D.>A?T..L)GRWW?_\UCGW=% _JO"=\MOS_6QQ?%E8XZPF?+>__PPZF
M!?B+VU3<IAV QW(G+]S/C;R:T: .ZWJ_G02\C%+5%<]Z.8-\@VBWS<\.@6Q%
M!Q<QVI88_3*N_2NT=!&A(D+G+D)_J&?%Y/]8Y*C(49&CU\C1Y&(T;>PP%%G:
MI'?Y0!$Y#Z1(_EF>Y#-:E._!_7I%$;F?IY-F HS75E=O:]2N%*9\"D>V ZR'
M 1[Z%OAN_1@>I]=LWFV)2S$O-CI[++Y?=?-8G-DUCUW?G7I_#+39V3VRX&L!
MXOB[L7/E701R(1RY05Q0B8P*##&9A*6&,V[%_4+!3G(LN<-(!BX13W"C%3PB
M:IW 1!FN5=A8[>U9\> %B>\V:5]==%OW,.,])<26NK87N=BA7)PA^BU#P4-S
M_5\GN=P;AT'#M"5))V2BC0"#WB(C$T%!":L#"<R8E29M>X;!^7G06=KS?/.^
M#1$M]X6&7V/XE/OE-#^G]VV9>/LQ5\(>-^W+;KM&XT4$I8\U+5!]*0MV'K\P
MG2%VGM$JK^\/@2D!5.,.^10 NS @GXXN(,59[DHKC:(K_2&BPX)S&<$V= IQ
MC0,R3CLDN?;.&2<"MQMK2ODHWMT>!U[(>\\)''2#'<P?8A/=Q_*17I1%,@Y>
M,LX8_XKMN$';,9H8HP6S,4EB$6<8L)0;C(0)3!E*#!7VP&S'VX,2;=K/LK7X
MZ>.M/<@6[4'$'C$(.3<]CEDQ"5\1Y)WG$#TCR'M*0<Q7R&;;B>UIU7%.B6)G
MJ+S.T$39N,X21EKB"4/$,I';)T;D:,0H!1\8)QA'M1+O>%%_N%?JK%:JFY]F
MG>E_'(^:US<4)3UB<DMN4C35\4O&&>)?,=XWV7M6.>,T%<AQG1#7W"--DD0:
M&TZQPR%$MA,@;)Z%A/L._BK1)[K@Y_$+U XRILZ>)H4.A0Y%1@IO'$I:X"G%
M/UYA$,Z-IA(S.GV?Z0R1Z162\8<7-IA_GNNEC4V.,(MT4N!&60RN%[,1$2ZL
M4TI$POQ&7*_)R/_KIZ:9QO!Q.JZ'GSL7JCN/V'XY<[%N >&1$!-^Q#F2W/2$
M.;V\PJ<%'IYT%N#HI.D,,;/$F3:99RUB,,$IY*FBB"N*D6&:(F6\TX1[8>)*
MPLU>XDQS$#R84!.1?6Q.#DO/T" I;G1QHPL=BHSLFR:%#B4Y:<>AI@]VZ.-@
M$$,U&F=K)\6ZY"KMW(=Z_)#^J1N"SRI3<)SNUVYB5\0'KQAW2$>L$ \>W#GN
M*9+2.I&(48$>1/[4#QW63,=W_MRK\Z<H[2FBMNN1/:4JQ,&&1$H$K$3 CGZY
M-Y]IQ2EA(+C(*@$8R$1$6DB! DXN)LUQ4.D@(F!K,'/?,3#&^WK+B'OJIL]A
M2%7Q[XM_7^A09&3?-"ET*%787FWGK59A^Z_I,%8,MQ78> EO[3.\1?LT.\UA
M-'6#>*8!KO4T. PDVWR& 9&"$.V18RSE(^4*&9U8/I#N6.LJF17_RFNEA24>
ML80=7$D)LIXQI#3V2BFMM13'4,E-2-*CG.\R)G6/M_89E2IV0 E&E6#4\\ R
M&),H3XAQFN/W0B&-I05,D5)9+YS%*V4O]PR6^XY!4=%7Y<C?"0C3&6+G&:WR
M^GIO-DFL4[*(*!80QP!;3B:'G")"1"N$U9O)M3_)>F^JKT6I]W;LDG'&^%=L
MQPW:CHE+D6BT* IM$<_5TG5@%$DG60P^21H.S7;<3KTWAGM&E=3\UX237Y!2
M>;+AY)E'8W,\I823SU%-G:$QLOE3M3(XDPN1"A\\6/H^@7;*5CM.R47!B<7Q
M$+33@K1O* S,>X2P'J:X:*3CEXLS1+]BI&\0!I4C.& F /QR469A*'+2&,0P
MX*,D*A&##PP&]QW@):S/:<'.XQ>F,\3.,UKE]0%>K:B,U%%$DV2 =S(@0SU!
MWKH8.65*8'H( =Z'\>ZA "_928 W5[,L =[CEHPSQK]B.V[2=M34.J<#$CP)
MQ)T#+)41HUR4BB=P,*E?:>CQ8MMQ,UBZ'. E&XKP4B%[FI6#)ZL17O@]DWV-
MM@CU]9,F1"C\_?0YR7D8\E6AUWO#^>;K'Z#1;Q>QLI\_C^-G<#^J>LYWU75F
MO!RT;7)%M6K4L6@5YS75JM#67JLF</_D8AQC=0G/O( KA@&^70KU5G88VB;.
MU1?;5+>HM3C99\QD\R$VQZEB8"BI) T83SKC@P%74SN,0U*"!+Z"#Y9K%WU
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M(' H8@T"O"B2F4__/N4T@&"11$DL)[.;V!()G/+T\GL*Q,NI4DE,=1-0F7)
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M(^\_77UY>_3KVX]'EY=OKT!$3? &*DR4>Y_",L/P)9X+&;%FR@C\"441E1Z
M^ ],U$J=?I-TUKL-,[T$/90\2Q).R5?E$9BY7B3K9#^+:<FA58ZL]EDR!+R6
M)9\>\,?1ND6+'S\="2!/CEE&+&C_K,O%B,73+>@<N.]$Y$9*I2"DAIC]%FR4
M>]HH+[-O<4@&JF\$I!;Z!0Y% 8W0%/[SGXSB/_^4P5.LIZQ]GE0QOXS?G@M4
MRK+V$N-[5(56R>%+'\!Y8-M<AE0P6BB \4$C_/;3*]@@1F"2PMH3;1(+EV/4
M9$ ]8[2_)?]BT8@I[L*$=XJ1&&),$!+46\)/X*-!]=_Q/M'T*>1PXR&\O'K_
M]N/G+UZOTY/+T"L(PAQGSZ#2-T\IE-!AI@^\L0AN8@IUB".E1J;9M$IDE:L=
MQK;$#V@BK?)LA4,.'6D<%D"I:/P*K4RNT1X#]4C1YLM#,"^P-%Q-N0%_X\J0
MO.!AN0!_AS+T\(,.9KZ4XS1_(7/2DW3CW_O=0?]*N_YSZZ!/@M5AF12[%?_9
M31'[,;5$#^=_;K&X*LTJ4GB<QR'M94E&%J#]]02F;P7T:;NF*AN_A'8<#4+#
MVO>)G->F7D#\]/+JM_Z[5]0BT.UZDVOX> A.?(#<]/*?[UYQ?<R=UH36AK:J
M,:@D>94+UC#."LP<R. (/JHF;S=A'^#LOF#"5?$%1783#Y-55'S/0JRH&:M:
M[5"$@UB<AD])[\**9:%^H)(?_5VR9948Z>BC4J^A7Y,"L<]$A3),I",7US%I
M(2I83N?,=B\-_NLO_<'%FQL21BVBI>U\U"JWB-U=\=(C''*OZZJ77/729JN7
M=E/I_IL:UF1A@AQ7F'K5E)T!EO"J<I6UV'62#4$ WU''M=2F*'=7NDE:J_/+
MHX6N$;HA5!J"+@;^%_,XF,M4KV0/J\I)T86P)]">X$'\*?,L;)V'>9!24>T"
MS>JK$;'O*RQ[AL5^SL)8R(S(+R*B5WU*\9JN0?F___S+IU?()M<4!HL;QLSQ
M;GC*3QPDQK#GZ<G)3AS-AD).A<!ZK(5A87DB:\:!@S288G<IV&G);#(=P]N5
M)?3R\N>?7C5C>^KQ'.&BN.F1ROV5'GSCJ6.^X&5M*K3+\3J,A4NK\&7O[V^\
M$/@^(X9^Y<NSKWVFCY\1F(YDGD^D8TGQ@V%.3:G\96[&C?/Z]P?P?>.?OL(S
MM&+'YL ?)5Z,$Z$Q*:QM?I-[19+ ^UP43283>Y'#;3OWN*'U@LGSK]L-F;>I
M6/+//WWZU_MG"R8K0KMS'+F%2C891EYT*BFW.M>"R,_O;>TOA9KXM(SJ#C8>
MHUYPU=*.PH Y1<XIAFZ%SA<$L:GDHBT^?5E=@]?JG?,NJ,6,ZR#8,+P86)2.
M(4%^IHA\_#*<;SCV+GIV0**-!SK>;[6'*/D(=%O$WS2W45#("I'T3KS)-2R,
M_W/2I?]PJ C^*_^..^MS^.B?[RAB)!??$EPW^@/C]2,3D[9NJPA&:)>"-8'%
MTE3E#0I61[;@6&N:'>/FV32;S)";22E-4<LKN^'+%=@-0( Y&Q\HXSFJI:.J
M:ZTBP#B;-%H84D$H):;VI*/>,DH=#+,;77F%\5>!#7%!B.UW0*8X*KU0FL8G
MQ20!0A3D!.)$>'_O 5F8Z*Y27"3.8+-!$L;:W%$/,%5@W A9>!][O;/>KW86
MX+>?N,IJ47@??F]'^.MQ>1W7/\(F2N8;8 UU D!MUDG"DX@:BNH:K"A-"G9
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MX!@A&!%Y9-&'!9BI"9'<$' ZCN9_2= ,<<G%\8Y@'<%NFF"Q#X 123@0B&B
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MG7>?.R+?2T6Y9^>TH5.Y*PB@3]78($5%9,D>$#1QX[TDK4XM<&=BZUZWTUO
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M;&IP2< O"&?V"O&GOW<^=]!J#X#"9QZ8O0FO!K-:U_BP$)RRF"\:NR0F6 8
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M4%^Q.A$IZRJN.#0!6;O^:V@'@@E.5CU2Y9+I1%3=(A:=)5SX5E1#<*R*!7M
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MN3&7X*^['ZJ^TZK2"U1E0 L%DT]UN%DW:YH2.:4I5P/BJ7J$*&@NB:\;./-
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M\#Z\N^3BB/>_7!I)LZ .'J&+N>-XGO[R5F*8P]'."J%/69:"4G&G.D/8&ZT
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MX=[W,)GS.';5<E 6B'*K'&98.%N Z')OB0Q88^VY*)'E3VU*?<@347HN(-L
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ML7JO18'C#%,K5D>EO$@0%!7+PGJ9H6\?EZWL Z".5(PP;(_6"0<" V^*0"'
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MAWUIP52O29&\_ZOPO;)2#K]_K28I4NE</>XDZP;^/WOOVB.WD66+_I6$+^9
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MMHM^4TY*DR=.4X0.C!@PXOW;,PI'=7!=NBO'%Y;&WN2&0D5L7ET&T6KX0@>
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MQ*FQL%7Q\<:?VJ$XO/=?8GS*VLMD#_?'#^Y.Y+G4M%Q#%X_>KT%YW/F:-1'
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M_!E=_5<O7S\N5D]^_"M<[(=GK[XVCZPP6H["M.>O /+0M$RG#/U+]QO%:7*
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M&3LF<BYP=@WS[A*' )M3[>Y1S';"&&*K,::!$JLPTI#;V=9(U#:\G="D$)F
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M+:;$H(EI9>_S\#S=MYMKQ']DE=O-O#\J=Z$4;0P2\>:\K\;]JN4)+(7'A'8
MB<=G0AW*&E6@A^IVZGK,Q4@;Z8V><1LA4]LXB\'N ^8G)U9&VP:1*A@<V2,S
M#^26X* @;V ?#TY4;__.>R)0C@!,1V[V07KID?/!48A8UG9V("$W.=LG;B>9
M#%(GSNY3N^I&#>?+J$;^7E&/;W"'2\Y"O*P(,JHD>'M7*-8!)YDN<&S.?HD-
MVB=3(-WFIMI,;"PREF-2X_DKAJNA$(^]Y$3>"\S-GSUA*$S& F?'CC*8"5%
MBPX]4]O,VO5]UGEZ$:6Z:#50A""T4'VDO!&2"/].FH'UVX)9F?B!R ? Q1">
MS7_5YU24F5C?Z$\3Z-[6+:4&32('(^]Y[Z,'P@%>0:^IY1EY2NU)/P<1X8-W
M@/Y0=,W5<%T0: C^=!@[H4;"*'5SO%QEGE7NNX>T1%)O83XF?6G1"MIQ.\<?
M96A_ME(X=OXD=E$ZU;>':VAKXPDJ]X7JYYV.ZLI?X75T;6V4L'WZ6(/3 )=<
MZ?C1\9;JJ5(.LH_#H-*H?D]18D$Q+/U/;T!ORRO\GZ"_6')ZZ,.+@^8_Z6WA
MF*#45&+L-+Q%&)L@+45Y=YV#M</-V!_:JO:_<KGZY1HF(%F\E,+IK9-&XLRS
M\+FT=D&GRWB*V6J6B'+?,LC1AG;G6$W;_>\YUQ9XUN> 9WVSP+,6>-8B6?TM
MGXT)?W1OJ5&(?!+C-_;>&/_Y)*5KUQ7D=3=59S1Y\=@H]XQ<9L$]KK91QH?(
MZ7#<<H 718X%_:#YE(73@RX?:/'*H4PM 4"R$$<./HY? 2KQ*NTT5Z;W;GL4
MT=EPHW$^3N.+$[XDFN+D)&@B%WN)N\0\^@:B&ZA)($8-JM5U[:YDV'&'5[ '
M=M7LR'GCT8GE8YA)@Z%QKI9@Q*MZVW+>FF7:CB3RW/9]16.+YH[N37'R^5V)
M29Q5TSHZ2P05PMVY-&.7#(:5HLAA*]^L:7D-[Q*V3A$).Q?90LSTHC*W?"L9
M"P@-0C0D1FM&#,LFE#D9^]Y\G*CQ5=?>#M>+MG'.T)YR/ O%1N>SE&V?G6]*
MXENRGCVC"I*0NE1 #?.%R#3U?4E)G_2Y9%_@0=K[FN]EJW9,IOZ;W6 %3$Q1
M4KL7J1BIE)=D]"H/9C8K][OXK"K[Y"V+0>"D=WC=U"R0N7R $%".<EMBMEW*
M=D>.J ,(!/_#Z>#VI#==#B#'BKKG?CWIPTPS X<55V,1"MH/[-A4N8KW/%%"
MN7<EI/2:=%60_*%;Q%.,AY5N7&2Z./H4!F#G:S7,9DW'+C1&%%>1ZIZ^-I&&
MOT+7T6$=6&FQC*R<L/*(Y&EQ5@L"@7;]*Q5(>7C2^F*Z,KI,&O^?I^+RGA >
M%RM7CA%,%!2A:R757W6<J0F">QTW2O2#,')^[T#CP0^,LWM1V&'H<B<7+:)2
M"_\"?&[=5=NKG"(2 Z@ZIZC[Y*U-?D&)EI(9)C2L@N\RR C/OO3R),OC!Y!4
M(9P6S[[T8FG!>SFDDE;MS("JV4%:>.5FD:'7*O?@I<+(:F%JJH;ZZE >A>R$
MA^JE5,7]07CEU*.(X .V?<RCS/?EL)/.VLP.8O1[#K]D^FE(085=Q@][A39.
M/O\=$OYVZZY@Q,([@>EOME&;X 0Y&Y.((_49\M.88?%%WW>AJ$\IZE5R$VO7
MY<X-1V+BJ=TJA9UG*.NI'.PX)0^1C<(<%K66Q=38U"  AY1-_9O$Q1))Y777
M3"<HAV)8[&NQ+[(O]4UYJH\<ZW 5IA46.UKLZ*MO?0KJ3S:I'#>V"9_'KA*K
M*S>%(P!5'O$62ASK]AVDLV4'R-R>R+&\0RRM]2)F0#O.4,E>O8+L_1FQQPEC
MTXM*-+!7KXE_[;AZ\.K9B]</"P9YI>A VP=&6''NZ)82#^.T%I>[;)7$Y1H%
MU6:["I*^L9[J3$:&P,0E:%PL[.2AWO;4_E'<=**\NQC08D G-2)3.3]P.P+6
MTBI//(F'\.>TD&/;RU=PD8;ZC.%L7XQN,;JOOK6"RI%N+7BK^1Y)4I^'R*]R
M(USA <U9X7!WLV$!@N'ZH8B.2\RIC"2+'2YVF'=^%B.<YSP' Q4MGC6#7=BR
MCHM=+78%*7)-T9:.^C$&&_N<R.@!_7/A8UR,9C$:<D;)P8@E81J#G_*#T*CD
M,:%/!BN3008M7VPK)>OI-YUS#8]S;AUHVOHG-KF#MX"KBMTA]N72\SG,@!+&
M(?YM\U. XE\.VL6V0QN-0#)BW3E!)@8?+E:S6,U7WX[-KKQI:9*&5-C *='A
M2@XLGR<L"O.+!9D WT+',!V,3\R@\KN/*/#G)-U_SSAV Z"9D4T([9MQ")H]
MC.DRF"#E/S<(G?4Q@@1=MSU*'\W"N@)F**=^ATCE#I7] I(^F4 OAURWG&>3
M(THL1%7JD*[A= <$X"8SH[N,RGV.4;D_+*-RRZC<)V8R_[TB;=]<YV7@>$XM
MJ^$3R%.28BI//HO8'B"F65&Z9VHQR4!![<HI=QU^2SXB5#0P [=GY;8]S=#=
M%X@M#9X3)7758X:-F'QD95L]\+[%=0(&[%>@$TB"W]Y10''H8<$U(Q[*">TZ
M@2<(D^?&+VW+54<X2[L]H.SU#_W870D[75=NJZA*"7_]5YB7=S7=G=*5:UBD
M%J$G.IC$R), 8@M(>P0"?Z!#=[GZH;T%!B70C@3J?5H%X,OM_1+34"(7Y 'Q
MOWJ@ZI$P'! (;<U:T"4,WL*@,\RQ;QD]Z"XA/"%2?9B+C)D1_4=Q$*:N=B04
MT_H/;\S,"/[JY>K[JO/)05TUMLA!% VX(.&NE"6L@BU(,E%<XG/"(Q QM)Y^
M<GS7->@NP<C%1="$3F\&([+9'P)3),!@U5HV=IAF94JI*"E7CF/BJK*:.XK3
M6;?;2O4*V'WH:XIBZM(JV^)]VQZU_ZWC@5@O"N+B,+R?T4)>=64C!!C,&U\C
ML241A]F+%OC:>8%UL,V!73!"W+(_*:X7@\7)7,JZ:N?4B\BFK P:*63!_.*$
M?XOO&1Q E;WK>S,H^XM#;2,:E);7&VF+S8HFQ\*CF*:@9<ZK>()K F $<((2
MU]:.*7=@T@YXTY ?=7O>QF0+)TH4O]=KOTT'G&NRF^N(SD[.4+6HM=]=NPH)
MT>@"K-,;*_U!%E+1O<(*(0:.+TLS<]Y/]?.TH!&OIWI&6.!RYT206%@+%?'F
M>)I744J@NZH**O&[,8+0V/[:@7NDG0T\[7JO;X2'NVE75V.)VY<U^N;ZNHX'
M4R)>[)/O2FG"[#?*>)MQ"9T.1%)YJ8B*%0R(0(;J=#C%) F65F?=[(!L.O,9
ME H1@P.>+"-P[^.E7WD]8:SPWNQV'@3[54D&=B1-!R>246=T[<&?=$#XK^HW
MM-EZ(:2CX 3AG0;HCB4;#$7M98+JFUP$W'&@+AQ4_63F? H!4GQ/ <:'6XPV
M-%49M'5R0M>0YG"A&+C5$7D0K]SU0IB+6TOIG?4/AGJ0JAU;^M429X8=]:R5
MT#O ;XR,7>W?KT],4:/2AX4W[FCF1\-HEM]!/F\-XMB<6@BY<F#)M)[&_V#;
M067#NZBQ@]4KL+R&I$BD[#=NA5&#IF%Q.>7Y8&)F(\<S;?FREL/:VH(0EB8&
M8<G#=CDET:AF15'5K1,O/UOH"@.WX>T"I].VNMI+\(P&B,.D<:/.$/B_L8:#
M,>$6ILJIH#UMZ.UB/KET?-*D9RP"RX%PZ>]/V"7.LD;D#NE]7(\G1'"_9]3]
MBG3_1MH:?)O40R1JT_/N"+_I312VQL"VM1^1N>U6$DLZEX A-%)$%9UXE!QW
M@YF#3BPX[GA>M[=T:U4TJ<@G2S@#0[LS3$?@LYK!"'Q.5- $)X2G^VHX'ES/
M-*8L!:%SW2$(G"*3@N0810!ZL4",ZI^8B5YM.,M/VU^C?$Q"39A"IW:I4TN-
ME]XZ)O:A_(KTN%+M/; 8/;6*)8TZR8)/AW0X4;/5]F6$>D9_V1#?&FUB$U[8
M?ID%9T9XSAC&>0 ][&J3L+,#7ZYYA1_X?K[(^LW/XL^$H]KG#TRBJ,N8Q;ZN
M'F3^)L6:%SC.S!Q7]!_5=O7 8&3I"P\3RI#HUR7YE.F8O]2C6SWMVI[_Y^MK
MX.TH5C^,(%I;K)Y"G<([]V%S^;"@RL"1 VOAM'Z3 N!([0.Y.SX#$)C:/ GZ
M*1[]\:9W S_"']4[P(5 KBY2Y 4VC2[5]@T5B]R[ 'KKGOT=.FQ(#\/YA6>.
M'*,EX!"VED)=BSV7J]<(7&CO:I?A*2'19H8=QHZA0R0+<CT5%43.TW#FX2M^
M7_ZNJ4(H,P$$L@!CF9N!7[-1NVWL&K;YMWJY^@F<3(4D)8?6N[ CR6DR;=6\
MF[&/\GR7_F-/74315<<I+CA=56B];4A_0\(?;"[&;4'S[J+"S#F\'^%D#>;6
M2T&1(QX]J!-!FCU0#MN[N/:'P\HU1""+)&P^T"!)=&57I_C-O\\2J8[)V<;E
M3&]N>,>VI]HYBI H?R"N.:JE/9U?>F37P1XF4PKMF2*H$*X69$?WME+DFP:Q
M%/PLV3V^V!,F0%I8@WVKW=00WNN=GWC1'_4D]R5#UT*-#2/'AAL_ K5A48;4
M&YQZURVF8O5Q@J3N,7875U!0K"M44-X.?2YX $I=G]/UY-'7$%3&5]^U!.%0
M_DC,":6:3$R_K.GV%'O9^ T]@O^/_[D_AT/XM>MN( !:/7B*PZ"PX:Z0IA)"
M6NNXOG/P^*H*QV>9?W@\<,V%?OCA]4._)U^\Q@?9.BS%4]^CV9*?]B<#N^W2
M/LM=;AD;R_HH6M2ZH5[;Y,BC*OVN11_D[T=EV<("^Q"O[%A3:?9]@A^S1Q3S
ML$0-G\P-F)^CK$MQJ]*LT=_DAL%DQVY;QZ=#WU/S":J(N);\C+ABJFPTN6B6
M,"'2#"KXP.0OQ??*Y-"P26@Q,P4^JOU=KKXG[ABY,5'$);D^NB@%U:E;U+*0
MF(F]Z:K_S]6#ZB&.&Y!-2/6)C '$8SE8@N+ZG_V'_:>AZ%N$BB_5;HA3IS9\
M2/AIN#CL4V](XB2QML'$Y!(BP6=O'N+37NB%$6JW>N#_WK!,'<FDH7X3<*;)
M.<7#UW!.( 69+"R^/B$9&WMC' LK]N\;ZO/'!>JS0'T^,=3GBPS#3*D^HA8%
M21*@YA2'//8IYR5E%27F?&EXUD.T@MVZ@@JO36L$(5AP\.[T7@*2$C2+4=A(
MR#VA/-)Q%$W,5TBUC4U!:;K>FU#:QQ,[YST!TSQ U]B9RD</*5C-)WZH?TJ1
MH^QXBA\)M"LJENQ=V9/21:BER-\P,<+*.)>G#QBML*8)YI.8*?F(1\$RW;0'
MFY:%T^@3 +L<74+9""'X6N'!DL1./EM$P<N,#8F)M;':%O4%\,NJ>A<2!J1H
M9=@0MQ+]?9U>;?BK"8JHO7 8H\7?MK?-+<AVPQ(2R7F3ZH1*;FZNIR\K$56;
M0(9/!=1I>3Y^#? O#&0.2DHQERGJ<IU:-TDU?"C2CH>X)D37SZOX$M1@1[T\
MI-(?^Q[[++WSN1, _Q_]&0/[K_^\^OPAVOE%\Z<D^DT$R(0*J=U5U1O::V6:
MQ4*(R$,=-8AGN ["U*@X</*MV8F3?UZPBJ_D,<7A_XM?SQLI-#%GN?%:\9[K
M)W5/T4?\=>RJ?BO,4R5#$:7_@>5JRK@P8-*7S]F/>^<V(_W7)E2+:>^:^AC?
M8Z@/Y3MI" ]P0$" @K[< 912TC]1J8[-X;Z<N\]I2_LU1_1-AEJV$QHO0G?Z
M Q!/R=!.D;(!8I71I?H;U#[QEN1$1CA5$'@! V-B)1@W=4%R00"D_,_^S]V5
MV 83VH9S3?$25*(/MUN99\I?NL"B&943+%LNY?6!</VF<D:5JA^F,YC);:5"
MXYU*8AF@A:T6(CMW'RLHWW'N)95!5$;#HD#ZZN"7L?H;K@C5?2U+9.BRFHB^
M 5Y5L7K;^(.>$6M$)M\%KC>4/3-:L*@>_?UW3R[B^YL"6D/K^G+UB[3'&3C/
MT+'0/&(/UUZ(XJ;"8A"2H/RQ)UYF_O7%"K4_M0V$8#7J;IS 67!(*.[294M#
M%*39'\4'S464)UZXAGY:UT^'$P38D];O":4PWR HJ(J*Y((R:Y;][7N3@T2H
M&/9OD!0D$_E:;3OQVB1Y) \'9A\T7>_8WH0K#S^?1-11^_FUW]VPF8)D38B]
M3GN2@A+2C8KJS/X*9S4ERGMR\)PN#,@V:&( !PG+_F87D<\+;%$&59]LP$A]
MS*J1Q"?2ZBX"9(J\7(Z-AI2P,K<1B_%,DP\;8?4G(M<H [PW6^7E./1\YG,G
MBBP[U4)21"@:%K8!:/X4S\& O,%>#KKZD(5R^NA$V=+"$Q29IO@:2O1N'<%"
M&70:(H&5VWL3[RL\XR:E D+3HP )',7/QJX]> ?YM/265YJ?Q3BFJQ!52K>#
M>P,N536LY34.44(L,8=DP6,/^S%=%X&DS/77G\N<D-Q 8<[26@32Y.884/GL
M;\4D/I' JXN 3S?^O"(I3[/>_KL .*WZ?8^8)G!BT)@LX^)+?^QA4%\:D[V+
M;I*?W.^O=A!I5(P1H_=LY=IA-&0 V?,H&T&!.!*W"VTNQH;TV6[ZFWF?HN]#
MD"2 ! 0LF+GSO)BIHMI3L14^QY&IOM=X\>)4P&&Z=&&N2X]YQ3/BPO*F*=+W
M2"TLM!Y^#_)J QK&0D!M:O@R,6E"6H2XWM_4KGK'YQ&$@/R;%@&%\T(^_$+N
M7@JSR';H,LSS/T3G@^:CR>X.DH1!IFL*I..,4TB4R>D3B,1"G%6"'5.($_[;
MW]EFTV('%P\N 33 7LSYN#OJ4&HS0<8>M0M44DBS<OXDX+(L;D7'\X,SQ5.O
M[%LZ*V5"GUK7M+KWY=AYOI/W&P*'"!34CSUN^7,J\R>F?#E6FZ+RT-JV[2$<
M;F:DJ&>!"P"WR5L*I5L1HB1LO*H!HLD!+$DDSM-/TF^&XJ5,+./T:3T[U!3'
M)0'@A+ S(9N:=CWB)>HTY>'1 Q@(\$L&WCB O@)H]E1$/)3#B % .7#' S>/
M4;;298Q@1B=%=2!5R_U^])1SST32C-15, T8K'TN<.IX$$GT*%=P8%<0BT5E
M#-1[,P3V=64!L55FVPH /SB_#% 8#S8?_O.U-N\AG$F5SZEVYGW!8<<O[1TH
MWO=<F[<O+O_">&K9OU0XA:]IYH+WA^EU%%9HW@H=QIQD<; ;(8%_/O'SF[JL
M]A@6\(C38)0--L>U,_^ 7P.4P^8:7)_5Y^.I*'B"6*HO57,]D$ D"2;?.D)'
MDE\(SQ*R8LHLZ1XU)A%5T"9,@6M8DQ%K.,;@'@G<62,IFCG-5:R*1(J9;Q *
M4.SZK'!SQY\VC\+/^R'W*@]MQ[-4.!F<-A0"TVZ[>/K>D5RG:[RKWW!;=T.%
M%\SE98JNB;'#>=650935UMCCWW(@@,5#6-0.HZ]M5][2@+3.K%ZN7B%ZKS9T
MD3[FJNA.T69&^,HXP*1(8:R4WSO\*$+GPJO?.NJ1;0U2..U_-+^.W5'HUSKG
M4\92BD[]P#7-G</SV2F&M%8!#I_JKK85.#^V&4+TPRHJ8I#R)6Y]^KNC 4>9
MIU4<(G!>##[Y6[!BOV^LV)\6K-B"%?NT6+$O,BHJ ;#2TYPO^#\JHE7^/LCG
MRS03M6H($5$SJ<&I4"G$KE*$D#*D3+D:<#"XY'[@,F"J)V\;81PCPT0,,#+@
M (?A8, 9; RP\JVJJ@&4$U*]]"J48W_/MMQ/SV(EV20,6(9'E@%B'JK6N1!J
ME$E[V$3Z(4T$MA=H!^L<K2PN%KZXPPLA0Y$4W(KIZRCL^!H.#_O'"7?Y( T=
M^1\>PBO"65!8A:AW'!J0"/(1P$MX-0D./M0,S\MS()NVI1VL2Q. &UBO(%R7
M%:I;C.E0 9MQ9:DUAOI9+G .&#BD%J!8F<?B]$-<Q?RG9%E?6/H\YV%>8=)D
M!G]R8]S!4&L?@%*UU+](L(E].?@-VW\Q6>IGKS[\,K^IL);:=EI0GEGJ@L +
MLDLG5SMKQ/&+>2&?A'0FRV"1:W>MW1EM/-.FL^S3!<M<Z\1Q<^5]4.!+T>)"
M5'*(TMV"<^5"R<@*4QT$[&:W?>O< 3_J,ZVVHRL:Q</>VXL_BZ"AMGE;7A%-
M#CB]H>JEEN$ON&\I]5)TL#TY$>3DSZ7U*&D\HW)>55=M!YFN?T?A */GBL'J
MS(E$[%QF(7,V+;,_>Y_-T!N(YSBAR!$*FF;^F9J(>3S@VL'?>9R.(%[^1E*&
MJ #16[WV[['?E59:MW=YTCMNH3&2NX_8GE8Z#%:$V<F4^,EOUH8"M<%Q8:>W
M<!HE+VR.*4@_/\G*1[7P0:!=8T$$UG6X[G#\6#M_V5?'3HAR],E+Z@T2*,!B
MU^X*@@&6\@3$W+WIW?QB:&:48B:P$3"DG2RWAJ;=1>]7G(#SU4T[9 C$&C1(
M^O[,:S!S<MR L\6NP(.7*W@1O0/:J.T!\WL/+UJ1/:>9'VV3&Z$O )/TNP^/
M(>I3X(_T9C\G)<O@%M*EX$J8#O%"![VG[7[T[K0OF"@!S&X\<%T-HN2"?^*=
M)#2-W^LU@6=F9C]A5:""M*5<2E!D_NG)S5 '!UT,=I==!VE6C_,W"/IU+"T+
M"*6XC8ZQJ?\ICN5Q8A1&6 MI0&VIRHG^*3H61'L6'KL:XF"=%YH)"@%&H1/:
MR&($]<-D3D=!B5C><PT_B']KPJ(DT$T*L[GF1P6\+9V-X$@->4<$5@GA> 9K
MCR0_@>)#(=?(.&"ZXP;"=;*$RU03V\#0"B.F[58.JG@E<T=2Y,L!%7MOW-83
M6N.[8&"<->W*JK8<>7,<3K@Q*?.+C $;D#AN[O_K/^=+HW=+;_!BPL)!B>Y?
M_OP;:7'\$Y4X'CU^].B/C[[^X^.O__BGK__]\=>_=V&.Z9XGN(G A"<YD3F
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M"$2H,+1D[13!*<SVV#MNDN2PVQPYT8\5W&AW8>F&2NB&X"Z8R$V[][;;0?.
M2+4?ZUM(;^J:16\"H!T+]33+7ZY>/7OQFN2US+ K/04NX.HGV*NP2V@*55$&
MTGG"T7$8QA+RIZCKW<;W*,L4XP8ZX:BS+!SPY")K<_*21,8A1!SX3N@L)0$.
MEOR6#KN1[##T*H12IG!S 87_OD'A_[: PA=0^$(@^M6WVA+HKF >E9F:4%;6
MIP=XZA?!GP8]IE@LU!^9#N231/:WW+D+<.?>]V) 8# >>ADKR0?XN:9KZYH"
MN X  4-W%-=OSUBZDG7]DU@P4*)8C2T^U(41E71#X:RE\.0,99)[T_C_A8D$
M /]APIYF]'DA(/HRT7ET.A/R@^"$&9@C4400FX2*R1GUU%,#E1S!_*.,((F3
MB>[H;1)LYQ125I!2J(O7\TT;1@RX?"!OX3 #:2/$NFA@U!_3[:9"V\9L&W%!
M\B-;%@/;@C(!A,M!-(F_/5 \I'IL. \9(PU1]3E*IXAG<(IJO%R]\']ND6)_
M. /,Q55DD!D36!=JT$R^8!_J]P]V?V^TMN J,>ED8M'V#K59G_FN13; ,+,J
M$4K,V$0CS0RK-*RT:$7W!:W]25?;,#&$R2?-0B82U:W]#QQ\-1RX0@UAAHK.
MNK%;5/<-^*E\]WR=L-U%VM8S9H0Z2PRQ4GL2]=YY1'MP:Q;G^,$U&QD4OVG?
MFB*1"&"R=NI(5?KID]PQH@5CSQ,T?'R.X&0T,KE5?3_J#7F/WT?BK]/52I+J
M"LD$_1;L*V(K0D&6]$NVW'J&-J:^1KHK@$?WK@:"IQV>,BA)3W0?; :=@P$:
MGK294S5GQ8QT2!^67";M< #*YX#AA>K*AX<Y@?[C?R&6)*%&<E0MVK<J.FM"
M,+Q_^  .G\>(7^7]N4_!5@#;$CK8?3IWQB\U]6!HM)'T*<H$Y^<=1!')[OZS
M]SVBB1%AG$BM29$->AH8!F6'%>9\ 4XTCLV\CR:ZWA9_U:B/+\I=SS^^_,[+
M*CTLPS+!#=?$O?=N&M! 6727<=JF^R1L4W=Z\MB'6Q\,_,HM!$N#V5QWG"_G
M[+N3 Z_VZ?%>S8B26OU1MJE)(LZ,$R3>R#"/TN.;Q)4)1Z7K<G< ,W\$G^V3
M8K8C^D T!/WW$4::!CE84M0]C37F*37/?T%D8$)'2!SON:.MI.]?5VM4E"@F
MY#AQ3U3NQ8'*YR#]#^+3*JM.R<VBQLA=L\1%;I"XB)#'!]>9"LA5U]XBVW@+
M%9L/H\'['>=AN.I!S+MD!=1&B"PIXN4/X"P.5Z[R&._55=VN,2@)JG5V[(><
MFSA-R)A1B7X(E-D$-#$ +!+HYH)'U8@<""A,3,B95(5D[:A5%XR, CMINR%=
M0[>/3.L>Y8.?[ZU#_8BQ0C!<&>*AD[11C,@ ?-W1O/KT9\(="^TF^>H*>UP'
MAF_'$ZO3GJ0\B[J/7D@I).["^X=U&>#,P:0&[ T5)J&=JC>H$VSI-!1VAADL
M#FU0UU$9"PM5;8UJA%6?!(^6:3;F$X7UP\@PE-9L6,&M5!E!DK8A_08D0WR;
M>.-E#<?IV&!* 9J'6./%?^F<G1;CQ!8G@PV %XP%_Q98@TG=G$41\6#E>4-8
M+>^.01& ""ETH0)-&$EHXACV58-Y.BOO(/D%S%6/70_'(#;"V]8,VLHOKQ[\
MU].?']I:'RLF5I5]/C8%P\CO%[NB B2DC9KK$>FG7T:_TS *(MOR#V_C^W!L
MPNN1J_;"1ZC?H7*!#OJ&-PJL+[S0>".B38 W*^/%^?O0S61I8_:NG/2U 2_
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M8[Y3'_]S_!NOD<+SBE1\R/_[+_I'+6E2IB['9G,=]J0>$4_]:5/U/1]F/_F
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M(KI<&#&'Q[TOW<(G>0K?7HO\-.A";^#$&8RO0.AP<4)N7$O^@CG!06*:F6@
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MA*]KR](5&H5RJQF*OG[T.Z^1&"CZV<0C"*8GJ59D]NGI2>K(M)'6F?<#DK/
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MF,_*"HST<5#H\XT.G?NJ&9&!*$KM?/#F-M>X-C$G+7 )M4 NA,L6VO>7/E,
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M!CC'?*2_BU@8Q)9T)"+,1R8ZD??J!#W1+VXJB,OW-H:!KZ.>T_YM\:A\S-,
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M*H!*='-B*!5>-9.)Z&.JR0!GDC^IO32WJ_R[(FZ.8-0$6X(LIMVO251>5#3
MZMV *+.? 0F_ R#AZ1F0< 8DG $)'K@;!6\%ZVIM:D^=[WJH;?2":3R0^41.
M[*WZ<+GXOEG\YR%XVJ<?*00A<^ 'AI;])SDGA!/!58)D?2V7O4#)0IMHK\*Q
M'6*]KQ2I0.?$KJ+XO^YW<D0*[T%RGY:"Z7,0LB$_??%+1J(DFO94_=AN+BCB
MK"%J'W/+N9N2SB&>C5N'% FMN;2-7GLMD+E7$FUBS^G4RHMM>: #Z-&K%R_Z
MQP7:E^B6RID<J9!L('/'X=2"OB%'.-;Q,BZUFY,T7&6"8*!,C^+\WJ0!N/F(
MJ3,.A5 S,/VC))/(P@CDDA0G-FX46G7T?/=5?VN='K9]/&%?V5R"UN?QE)%M
M.SVES1JDZH\$UQ5XPU_#RX#LTT/)"</R?;\:6D$V/*-9"JG\+#ZG_P>  CJQ
M2L-&52I%T%IDG6S(1([8;4>O,D0#]Y7*8"%=T%&R^:W->X>DD)OPQLP/6"FK
M%0478@C AE@=782H GPG;Y*"L"]";*E0CV>684T&EO1S<A?C7VS5OSV!?WN?
M;W_\.:;*1T[-)IU6ZIR+.>;K,_,00#,0JW)#T3T6&5M^;CO$8EO<8Y,1;?C)
MK]O;"A/A:#Y:RKR^"<EL^!]777O8]VDKL#]<A2TU:,(1+G6,73?9<IJUGGXR
ME+C8'\6]*D5P@)Q",E3P#^B :MND^B]W&>GR((Y9*PI1A_ZFSL1CM""0#!:N
MQ$7?[838()**A8Y=D7H:"BN*Y8^%.MYVXY[1(%"S$*#&J73@!A^*+Q.\UJZE
M@^#VG2L9_ H5 KUIMKSG-L$K<,9>!B#P2P:_JKJZ76NW/HZ;Q%]"Z,1E..#1
M2K!,,+.1=)OKQKJ2 I_4,M(=]2ZZH0T9.O59K\4MI=C5I](ED9Q:A<% +7$;
M]S%?X'+QG%(X0S#61/ ^>IQ2[8!'^*7\F,X F0$<FJUV4F8/B7[Z4!+U,.'*
M.+$,_NU:@>>MJCKBLEQQQ[^@<W'G=RWNQ'<8"[@T><OP"#HZ:6NNN0Z>0J]'
M=I$E+KY //J%0M,-_:L["S_OZO65N[71GVSF24_>.TI6[^PY\SG@1K&+)IGS
M_-B5 HE*"H]0H/=RC]J.'\]<<]D;T/EMVT*3D^5RI(%#@=VN79.H,T<:0A[$
M'?R87/'TYV9+T_.8&55T6()&82:12:TYY:NY!TH%4Z/T.9,3&JAC*#Q9X4F@
M(GD ;>^VFD2:N!%# YPL7@%1HZ@9!AQJ3,10-'N^=,R [CCD*PWBU:3A '03
MLA'N%,:^HX]*@:+:,X!-;D-[BC8AE_4=VS7%ZAXP(].SF(+KH\P[QY;98N-F
MA%2*C"$V5VX-2%$D[4Z7PCI*0@8'A8O+W*-[OLB?(>\;Y"/5E2.(5D9("WA)
MS9N O&&QP\U13&$8J;S)IJ"M9-P.?#0Z,*\K6#=3Y#)HP$%_Y@%EXGG;V[@8
MTI!^<HH^Y\S0%^*MDBHN=*!0>!S^/[,U^/U0<Q-?<QD R03QD5FH\"T(1G4"
MCD-_>%R(/$]$J18S[D48//S\24+W(5)NG%]1A"KSHS.T6%@Y_':2"TTM% >E
M+$]AU."C.&>*"2"U^(0FB/>@KJLP7%2T0BK -!Y;?^1E%E4?C1GR:;LH79"A
M-!X7AJ#<UOI;PH,'9 ;348#] Z0VTK*.;#>%V[H-2'MN,M%G:6_#HS)R V!;
M YA&=KC4UT?(#M>.;Z]#_'3+-$[D$RV5)6<6/M)QS5!DX^8@U<.UT:]U4AFA
M@2A)EATJ%C9 9$PBF*>9^7;&W[YT4*AD]*53Q1D^7!-F_4P?>$)I@'XEY<$9
MP6)E;!F7OZUI%HT1-[&8D/S(F")C]OJ7*IRCYP8.3!EU6GM<G$")+'IA^%6!
MO643_[:UIKP/]CD#C*IUXD(.*0*^P-DOW%/TZJ@^PT"E+;A5'!S*CEP^CX(/
MO6"(KFS6=;6IFO7DZ3/: ;P("F0*>R'!29]%;>T((JI!DT@'VQCF^"O V/B5
MMB22B3>Q):(Y_(=%:\E^AH-J2._5>T3\X<4/W_>%$E(+%OF&Z3:Q(4+D112=
MQ'5=]Q9[*C:4F,_ ]S =@*;P0M&#B/K-AN&)8V+3% #O*D>/\$>QE*_-MX#^
MP@C__HV,0'BNX+_XG]9O81CAD(H?9*Y1\@Q"R9B>MA)-]+G/^^J+Y\7BRV^?
M+W1VM&.20L5:CTE&CXN$Y5B'A4L2*><XQ\UP\/J__8_ [/U]CIFWO)K-_0B9
M]18Q>@)^]HCDS,Y&QK+98"45LN76_H?Z14XFAJ@11S#<*#*+.=\BFSZ8IM>4
M>H-_+J-<S:#P* /V)UCEI$HXM/\^LPQGD,]O ?)Y=@;YG$$^OR[(YT]Y\.\Q
MIC#P25"X$[0PC=Z^X';SVL0.M8=)AP9/<$J1)IW7;<92Y;%XT!D!^HC#+T0'
M*]9;I+LY-*PWG!X%X<N[EI,FYOM?6?6_,&%V.L4IJ[R)Q2UW]Y.GR7UB R%(
MBQ)G%F-(@2XY%)' QK(X4<WSI[):J$(AQF3=,4XM57.-AZQXAGXZDP=;%[<-
M!)!0@FH\81I'W0$1E8OB..)#LP''-/D8U(E,:Z8JF3(AUU4;0,;AXD3JFW/W
MDK(Z=IZ.=KK5T46ICU.[R@=Q^?K[T:MJ51YX+6X9.,0)(.6@8B!LV*@$2. 1
M 0#+*FVVXO%#C$KF=6A(MA3AS*$)>P?1)87"R/!#5-,+^7EC22]]:T11/"KZ
MQ*!4"SPM5^</1#/2#]4.B2PN4YZF=U=.ZISGFFKI/!*EAH)H*-P#46ZO3<GU
MT%NQ07/N"):@)^-46B9,P_:_X6>F>5GFD69Z/"X+,$1??S(9#O*,*W-S0:G@
M+\HKM9;])QE;_%=^&7=V2@6=TF=''FJ\$8Y30]*BTW2_#AEU)-2.1-SL.96Q
M.RF6W(^MFAX,2W#-3)K0PT"W@2G80Y#=6.417NDW9[5^E\LC4]PH8^I!Z^BJ
M5,^+MNL.^V'QTGH<H +Z"O1<\/#*JDX:.,NN7E9"IH-_6/'7K=Y/KRF%TTXQ
M8B?E4VLGF*JGW!H5 KI!W6*/<=QU%0\@@:WL\*EIUOV)B3UR7-45*I@C=8K)
M*JQ(>RS<G7$8(">@+"[W,IQ^<L(:&7YX]U#J.&]GC5\I]\FDH;7=I)V-9!MX
MKOQ^UB=$L_2[4>E" \'>@1S%,?EP0OXM:BVAE0/I-/P<O'1+[6W$BQ0AUD(@
M5=](TU:+$;7J"<-RKKBD?(2VL.G'%<HVPRGU]LB'OOY7P:2LQ/*-;>2.@W 3
MM51''"RVV82+TG:P/Y=&=Q6K_=+P@!/&_XJM%5LZWU[N5;HE0=^C74SK]::J
M]HMEV[[1';H"]1J'>+&N@[.AK#N4>#;;2G"1P)!8L+*1 )9YQY3I V'736T#
MMT(58- F J ?*;CAR!C=MZTR^RJBFYP,J]J8]=9@MKFI(^&)<#\!7 %6'XG!
M4UXW_$3I>BZR/KKJ*7V&_J,*4V2O<B3JS%*+Q]S6BR@8R ,3MXW<K1B^B3][
M 7@$O2T'W3$OT2LYR[_5#HCC@E2'&!\A0M#(2BX7/P R!4NET8$O7^!'OJAH
M]R@80.<H$*[%%CUO/1A;WI@T[J\T]E_6[1!%K!&!4R02'%P(TU?E-MJGDMT@
M*UA$G"O;)*/2LGHS$:8Q;".I-@..UG(VA9,C+,46FM7%A'P.'7FQ639=ZDS8
MR<DM2&TQ!!&,F]4YERT-&V<B,9>+?R8S^L-\+IPG>1*.6A3K,CT7L2,*H]<-
M.&"7KU(:S$:#2M-&.G;7Y'TTC3/R2#CA6C3">:M+,3VE@./..^):1TJ0ULWS
MR^7-_0TPJQX,0TZOX=)^"^(<@T!9.\_)NG/L.^I>XS8[\%:"&2=I]OO64'8_
MY0"KD@6" TO/G31C"3<-PZ<+3?;#)Z@.'@QF)>.H<:]X'(58 'K?P//NN//O
MT^),)O#&WV4 5]N9<>M-%KJQ7/XM9[)CJUV/KZ.A1:1V2B][>UTUS@$5BZSW
MG-HJ]5#:'14/5E+@XL067>P4D2%$(^.(VWD[5T1*8N^4DG9Z11@RP61XZVI+
M)1RI9=7TDN@S$VQ0#/GRCZ21>\ODJ1X!%(LULS=!1+7X1O0+VZ&] @K>6%D9
MY<]C>8DA15NIE-$GFI05(C&^<5WO]7#4K"@![)DJ*/(3._]=S" .%;BG\+&P
M1RL) '!G]L/*S4*6EI=YU*BBM?OC@Y.?X'_'3U,XTI:<1\9'/L9^3\B[==74
M3 FACRR_3P"0FG!5";*'-@(X37_2/6#W&)$I!3[BZ<Z(IO6ZW@PB[-:U! XQ
M8_)Q!GU2>8S"0=N+?W4'-=??I*"J[T"6O)#JLAB.6W^L67*=_"!>5QH"'6)<
M8==:'O67Z9_C9]U)HFN2VFX1'Z--P$Y2J99X*O,!L>""$_?TO;4RE21K/3IR
MX\OJ*?M/OGLK*?@;N)8I)_-PD#%SQ]H/J  [!E -$"@L(;9G:E$TY9461PG5
M+9(U'(9U^07\NOYIZA._2T%-:M'( <//4;QG>).Q94OP1J*P4EZ5$$Z^V[^I
M,=_@9E4UB,:)H('>0RD2_5BI*N?V:'7Z'>5'0U7NO"B3\4AR>P8"0'HX\C=V
M[38L:H@PWH2(ER;"&QRE+?C^6WZ1=/ 0JI%FS[O@PPZUO*M"7I3L'*D@M -#
M6/_[0$S#-$&OG;(BG JU<%V&R)#23:267'B@*_#@&HZ!AB8@I,<!"&6BN(G"
M8FVA&B$+PQG2D"2W??UR\5+_9R0=LP 05M4;XQA_VT+<5=FM#*<D'2<!S].
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M-A7]G53'AJ@I-@^[O"/SDHTPBX.Y*]MRNV@V\4)R2%UO3/U3!*W/+7)U=X$
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M_.LIK2R<=,@1(GPYHI?O%<*,C\T[]A !)L@S3$0RA7),XJ['FS17L^,V;9O
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M<B<L(N9:NHD9T#S@>+!@%);6FZQ&Q':CZ^ET[W1ICY$$3-D[*IO,JWZB))1
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MN2NU*I9&G$I=,\V:ZR\/-:>*%]R1?S^:<_V;XLU7T=@;[^78B75<K5<U$+T
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MZK-57(<IMU"2]?/W"#"94D7HC'L\7H#F"BXAP-:T%-P(DC%J9FI+&;GO8M7
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M+T '\]%R>+!(2ZF"SLL6K9O,.OP5BH^BRKRF2$M"9( W%%$DD-3(L6N0?]]
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MPC(3HH*R-U9-Z1Q[+[$^A_LMF:7S]U.(UM3N?O"%"&A/#O5XDV<&SY/;*^S
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MER CQGE*W _24F]N=1&)+($+>DU( &F"[00;[LBG/,=YNH;7=A#IF95/;LV
MB):EG12*]SP%Q MYCO8Y2* U0Y8$N!U7 ODY!Y="K#R7[Y6KCQU/NEN@&OVQ
M&%*O!TE#K$E;M-+=%=J'J!W%CI+UIBU]8&ML?Y7ZQT,M.A0>YB)0!%:%9(T_
MSL-WR<9@.Y66SK(]\9NM8R\.FJ)4_K2*^>X10\%41F23C3,@*O M5")+0<3B
M^H/C^SCXNX?:B L)6^HI.U"'Q1*%*#>$X<:+:>W,2Q\/@]CJ;&,R1&,0$>[
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MRS-K-ZCGD9VCU^.#6"_"WR0(#57(ZGXEN:Z7AB(_J.OK=3 <[)B''8<>E6F
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MP60OH>E!%DP!\4-H*ET1/2P[E;E\$_2DD]E[N2[)@Q&13RSF@#K*FAKG72T
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M0T)QG(; WXPGBWHHBA2POI&62>=(Z,P9%DV5"=F7D%Y<?Y=]EUB8'>5)H3U
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MEU=0^^D@EPNN>H$"6 R5^;@EK'-1=)[<X)0,1N4D4N^V3D]!1ML=K-XOQYN
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MY%P8+Z3)##-[KEOHS"S38C&Q/^??\X\@,5V+LH2WP' A? XU4@N4&_E ^J$
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M^*\6^%/%(-O3S**8H3H'L2G>]W^^"J!/' +<B6*'#3#J4\:755_["YS"GR!
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MN<X!FRJA.11B00.<#@89<>/1'-QFO#[!1P,<\R Y(KY1>JKM.2R' #.HK1\
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M):>^]A10RWV2G9O1*8%'3_!\P)A&V3:\0O,537CI@YXH\R\$ZU(B_]2+'\@
M%MPS306#?<4LC9NLL>CUZ'N0X?-; AZ35R%C6UDN6;^W\QE422+Z=3X4R!1O
M8#3, WSO9 ,Z^8@&3=WCDZ%B9U@%T1/+S.YGR+O9.*/9Q'4)#_LE/Y6F<C16
M:G! ?,2UDN9L'!L76B5QN8QWR*MZ8?0,F0"@M$CB8:'!=AFK8\GPD+G(& B@
M)4\C?R*O0F:Q3[ <W27;;K&J3H4= 'T*'\%A0Q@KKS,PJD$K+ \.O=)1H\AL
MQT6F$AS'_G/MA^CC0.%Q[ \'8&)Q-C+H>@:<V= V<0$\D42-&<+'QD_<?V4D
M9;9_$P;_&YZN$M*+]#7V,Z'I$HQT&-Q$?"'CV46^L,^=#[PQ<3G9"KSQBH\A
M,(6'BVXS*2 ;2) "S!1P)/K86>\,?EAXI9K=F='\??WF+RD[:0H)JHXLJB.T
M5>)'B*'!PE><^L#@;\N5UL8-CS&'O*2P2IB98T+TE-4773EIIKABUG(6\^_1
M*!.PF]/,.R/KZDV01:&K<]3A-3P/X_@A180*]%2#SR/\<2;4FA6JS/:[M-A!
M!U,$_?O,$6OJBJ5TS=P&(^)<.@9M<!]MMP]4&H\JE0<N@L='IUHJ87RX*/@,
M\E*;)TRU_2))59#L1'H)E3Q0@5[+(KT0IQ>DQ$THO5PS],IC%A81EN1(@C9(
M]^MCWN[<W?J8$R64N:]6-<,78N*G/&<<O02%-&^]W>EG-U?G)W+?$C&W7J8O
M -\MDE=/F(2IW-N6D3$8CH+'1KIJ@#_UU5F*_D_(C..GP+^?#2=_G$TA?W2<
MOU+^,(<$5 L^)Y) 0I)<$ID 1%]ND:./1M?<H:08<0[_Q,E&$(Q^II[/L7 M
M+B.'3R0,\+=D6E"BBG*9]C[SP$TCS'?$\(;.=!*9@:Q5 YE<Q"=.8ZHP]70-
M;(.9TOHR&"Y%7QV.$KOUQY7KV&!?W'"W<I<ID3"9JW]?V3YS,Z%!*"X5ZM>0
M3I>F84W6"*6.1U.C.-%]X#^XU#/5#\$?$M,@7<?1[F$-V:%82SBT_  # [$1
M9_[6(0H\?(;Q:0W0,B7C+5F<-Q0F9/< _"R$?3MO/#S#)S]=^R'Q#MQC'AF2
M\+&?H'D8Q1LW<"+,-+O$0K[<+_$<_)431)BWB;\?5PTQY$+)S+ %.AX,)J5;
MH "3Q\N,KK>ER?T6[C,;\ R%:.7WNJE9OD ,DV/AO&%@3;FF#8154(_0@6!2
M#.<@Z*08'6(I24847<""M8A=T/W<[3?W4=!5N4AA.!2(D?0[!4MBKQ"A$T4:
M4?O1*-?(NZ0:3):+_%#F+Q:W.\OJUQT,$M64Y;)X/,,I_,FKY08]TP:4]U<Y
MJ[_#ACEQS.Z\$9$5-Z,:7>/;=!2, SV:!XF3C/_DW+B!A&"\ZB>Y5KZ%?IK<
MWGWKI?#*83)[#8'JO,%P#:9['A2SHO>\#+V#0J<4AX[7971MY!I4WID?'TG+
MA.5:?QN@_*<LJQ)-JC3SHFW:.1<C'1&\%PMI\=F@)^*O29;-:4<&QA_IT,YO
M*3Z.SLH-$C3ZAAVM#E ?]F# ZDH\OL:(O&8-,8.1Z'@T!"S>5=_".(-4- M!
MYMPL;P"6B J)1WF0-^C+=IS0<7Z1&]%B6T-2\37K1]#199WE&GF[ ,U7C8@W
M"P)6WFJ^*M=!(\G(1TZ^?L+5.1[+S48LJ.*Q=7Y;$)'=8))V:VA8"L+-BW\F
M-:;>\?UK2:6W^6I.U=EX8W?UHZ4EXS!..2BC&?G[8R)>#CDZ9[O$#]'X*4.$
MFO0DV0-$=_9(V2F6N"?P2#)24R7OA-+*=VZ P,";^T4)17)(%@^XB.E= 5+F
M&5I%,6AI^UBVQ6B_;#*G&/ I3.?$$>OTD#DX^20<F,6)<T_F 9KJET4M:2T1
M*0W&OWV^)7 W)ZF_P7/INM._T83J&9@I:Z#U0ZC G5"L$(<U99K\W'<"BIUD
MOA#Y'AW.,:,2C!\UKRGQHDC$V:[ZN@I% @J#"[>@"4/N.?[@+]U@%M(":]K\
M@3U3-W%MX9*->?CXR72A'#O"4I/X:)#<S&=.-$* 2;Q&,@IS?KL!J;.V+]_+
M9-P5#XJ[_5S<[32FOBX%ZOA,N22% ^4JALU(,1W',AR&D^6H$&L$7#XOB?;[
MJ[OIG*^:@7(X+ > C9Z9@I_TGJ<I@V/LC/2>>=4HGU][IO0@JI*PN4CT:Q2
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M-QXDA]Q%U;8\+ML[#!9L46#V%!HI3@3PS"3Y&P8+\>61+(0QX9H6%NN94H7
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MB-*9[>/[#S]]^$&;2K&^HQ4H?HE"M*?,[*==Z&EJ&,E;6H%$R7!03)\NO&?
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MW46UL%2ET["O'8A6:J7ICH^ZM17(U&EYQ>STPU6CKH=J!W%:ID^V,AT55_#
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MS]TXWN-KL) KOASTWZCO:[*-@TJVT672]95>2Y/7=)CN$&N3@95/L;RQ#2N
M3Z10$B>A2>F:KX>^^X3)?UJB9",2Q:38NJM5UG+ZQ$NR7%&*1M-/]G"S1&53
MFJ]8;EPWN(FH'VCMKF_0=3+$9)GU]/>LKH<-;_0T69$Z/F_R^NKJ%T[1WH9'
MKOX=FWI[U%[QE6:335A;EZPT:WG;*5_4K>N3>@A88H?DL_G\]/N[24\;=KH>
M"YN.9X/"/Y(CH.HQW44I+YHI'%?5C5G?<6(-A58E,?7D:IXC.PXF?A5WFUT
M&D%R7X!F/49K?(7XCR@ON?D5809LX3ZKW]964&RXAZ1R84=Q<CJ$;C$SZ8?(
MNW3C$-\UB; 2%VCE+WW5_FO0T2+9N+%,;%ML945%74C"7M()O^@@]T:ZY?I2
MEQ5-[E$0S:[$"3;8_)JK:NO+'AS))FJK4Q4)IR/S41"O';FDBM$CH9-,M_J:
M_Z:U(E1*LJ+7PHNED]Q87F6=CO4J:L)<-K_M7W02F-9LIU:G?Q2DLBN=D$WW
M4FMF4V6A&(-0CRB^C^S:20-QG".=NRAU YNHU8X^5:O,45Q.+?A+X7E\Z1=3
M/<.DL(D=Q9YI_/8WLKZ-D=/+.I*U>^DT3]RP9++MRN[SP&G-BT>QR5XS$ [,
M$S0Q]1[%SFJJ0#B2:ZKQ RA_Z@:-@;6..'WN\ 9JE6&)9]M!:WD_M?4V. H:
M#B0E*QP:QL@@:MT9;D>T)DX3HY#-MIW7][(;)_VJ?'?9'4%Y0VB]1JF_=+/Z
M1*_AE"9\DC'IYS&9FT<483<H)L'/]6[*RIZO(7XO/L3O-0;H-09HZ)N(YER8
M[=(U?@G_@;SZ&ZC2PX9#?#@Q0!5*7B7)KCG=66M[IJ\NS]6HBR5QH"T?Y(:=
M+4&NX1FOZ605,MI#H^E@%1+U1Z>NERTB61/GGD;L[U$X0[UZ1K]Z8KYZ8MIS
M'57?QZ-P,7CUF7MUV#%PKCBK=A1&W%?W@+&VD2PMY,NVL34C5%,Y]DB,0^U)
MIGS]AS40O1Q2E2[T05,AOR RR2ZL01,BRVEEG<TQ^XJ?NOD6T2IBU'U0\*0
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M@K[@[*1L-K";^+^Y&Y3<1'&:9^ NS$/1:-I#44?#3+TEP6Z<,AJC;_^F*0-
M$QI$R2Y&7T%;C>:KLUV"KXQDP@/1Q7%P'C^X(=/QYDD/8&N%WHTP]?F*\2QN
MD.=#J F=&@;V=#ZT;&$9#QR%2E_9:D,['K-!%[? UDI(8\YU:M+C?N8F?C)?
MB>3#U+S;;39NO)^O[OR'T%_Y2S=,F385TN)APB\%7^O#N!JJ\Z\+?U5WF.P0
M*Y9+MTH+3/FS0!TMV0ND'1=#_=**I[T?#5_TO: +DS^,4R[#H.:<:[M,&+ $
M)@'R=%V%8*S&>S2?*<LYE\\W],Y1##6JN$Q#W&;R>[[N%AAM.#MNB";;HJB2
M'8OZ+_K^^.3Z,<FC^06Y@/?$(G67<Y>AD*]>W06B[3+9!2*;5=TMH.]CQU%N
MLD#B4:ZAPXL^C\R.Q,*2#NPD5HU@Y[L8=D<]WU[3;[HT$$6/%/QN5"?;_,WN
M"LV.<]QX>4N5E+L1\$4?<^+TH$QM=!BG/5\U$H0@Y.TF.>2)*T>>V9L[?-1<
M!3V!3G9/-)[WF3CONONB+U0[[HUA-DJA-%]?:K_HRT4P#2 25GJ#8D*-P[I?
M>.5F/ON:FT/9?+([H3RCNM.N;F_'.:Y;$/&$:G!_T6</HO'\- L8B8A2$H6'
MIWS7()+?+S5'LAV,Z7*7-)EFW>%M"<2.$]UID<N5J]N0[D6?_6%L=*^VNLDN
M@F\)YB<OD]3?8"Y296PO-9K:L%BBXY[^;T,3XO_?WK<U-XY;Z_Z55-XGD^[L
M,\FD=DZ5Y$O'^[AM']N=J3DO4S0)64PHT@%)MY5??P"0$F^X4@ !D'I(QBT"
M)-8'8&'=(>JL.08)\8<0K6%8^_POT Z/B\<X_Q<NO]/>%22\+4;[FD^-II?:
M-_BVC.\JLRC?WQJ)-#=.-3@%WU[=P1E!7FYV1+TLUN;[WMKX$)U@)=I"Y!!7
M67W*KW%#YE$+/>@?"8NHSS0J.D-X$"TB55L..EVGX2+R.-56H\*9:B3?Q6_T
M>,>UB:06S^$2"@8FTE8\QTQ=^O RC65:HP$I:G<V&4Q/Q%.X!5&9("%QA486
MQ4E9Q.\MYGGU@3.M083+"F%/57D(>%=U#ACXD(_<PP3>LS9*TDYT'[G%;,*$
MJ1,BV/S\/BY$/%\D09ZCXPFGF&,W ,:X#)*ZDMK^$FG/9-4I1#6KO](-AJ8:
MN2Q8$(NP.)P0[3UBY4UGB7 EHMM'CC^_N.XJR0 )]:W8QWJ6HOOT$:]\B',1
MTN@N2^'AGT0OD&*>!C[D"FB4T5?#58-$_!HW^.'HD'F-2VP1!\^)0$LLRUD?
M-KUT!1^/F1DF+;24Y,$@I0X2A1>XL8U'I2:HP#1K&P$]&\''S7S.2:"R@:O=
M6Y+M 5*NX'L< OIM'*N$#(-8RW!1[]<T_@\BAQ3)(C3*<PW=WW, 0CH-9.?<
MD_V?UZ7T]HH<=O2+G06E*>1&J/B6QF@W? ]@I!4AU:^X<5#ISX4QN,L7<IN,
MR3D9SS86$2XS/?3*S&FZ&!N74L5\%/Z\3Q@[.Y.G3%$[NY*UE9Q<15%<$7>3
M;C*X(Y^[!$40)WZQD',U2G;4>(GKJAY++J:O3^"U4RVH'Q[.;&_S4OKFABIF
M5'N[C;6A/N+-DX+HP&M685CN2B(478)-',:L52;1T0U6;:XV*'NASOTZ5W.8
M=G?.0FX',P:GS.Z>\@X<;^->=<AP?DDH=#KO@AVXS'9H4;&\5:)N%D^Z"( =
M5C?1%GL'L(C1GP^'94V4=&K!>O7^]HJ(G:9?K/?T%ZP^8I848_*+SJ1A+EB_
M;]]A;TRW)Q_Q==/<]J]/T;M#FM?["M!JA\]2,^C4[]9</N ;"?H$[8N"LMVN
MMJ:S+S61Z6:/IQU\-HU'@'O:L=N[(3++BB==:5A: EA$3-H$XD*G0J=PRN:N
M-MNQ&G=N.)XMMKJ/<?'*53X!%\%4S,B>&F>#S[:6N4WHYZ:\,+2(& +G5W:+
MAYF8$%^7L80(O)#8BU,LH&Z[7G-8M+0@]*]& T+_^.T1W^))U7?Z3_4J:()A
M?8W3>%?NF /K/K=7MQ1G/J+E@?<-U_A+:6BUV&J6DA&MN)HNI:&U03^C=Z/C
M)<K$"CJUJ>WK*[ 3M C2*(!1_NTM"@KP^8^??OKT)RXE<GTGW9B$(U#,WMUG
M]M"._EG66<G7&>04NN%9[I7>X<#"\KAX"P?=>WBQQ0OJ)FVWB-,P?DNXYO?3
MWND=%"(S^^GOU6Q$KBH-D!1.FK&X_=C<E\E)_'>01.O]'9+U-ILXB2DEAZ6[
MV?-H'<(=VB(&A[NQVSM5C^4+$I$X,6+<+O8D*_9N8A[E1$X!$4L$.^&-_L&
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M0U*Y!_'P]9YT)Q56Y):/[L_9\T)E*=A7LL5UF4;\W =&8_NS3T#."8_ZQ*6
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MMX@<=5%0])II#R*D1G,/HL[SR82.,9*&[<.2+&%!'G>WC3UN1C=008A/'<S
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M+$'4NMM:9</WN[JVYRDB^,F&+>>(I$BM)XN]GO(#$]O[7/G G8Q6G8X=9>N
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M[) @LH_H_8:]L&D-9/#L+_K>;Q^B];ZU*:XA^'>)'3>\*'.)GBZ0=?SS[S&
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MCJ@L",*JF3^YZ$]3(EI8P876U_J=VQQ&125+W$^S.VHD1QEZI<:]R PU#%[
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M#51/IO=W*UA<5ZI^.X'@"K2G2\HW]'EB^H@UH,]Q .9M@%/[KZIR_)WE-'I
M!*.442=):0C'<_G9,K69M@YOT%LM5&83U/1W:'NS[;O&I$A)C"X+XI7M"2+.
M-R^IKYF74\N>![N&W$[368I+GL(@?,#V+JF"Z80I>06JZF0NR#>^W$N/QML?
M@Z2?UV<Y^*[[+/Z-D:A9W9B%"(I8\[R:10LBQ@.2V%N5W<P\CN6=T\9.$T?_
M >K,,ND<P*<B<JPQ-R4!(=%"KV4;Z8>HMA1@\3=5F?6N 7^7,KSF8FF9)[[O
M^7S34'GJD+<.#96>PKH%W2N1.=2.H\9>(@%Q7B5]T\;&&/@597&ACO%YG*_
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MZ_.$PUWZVOJ;GPYW_1?>_P]02P,$%     @ S#4(6;@0N!T."0   #\   \
M  !N=79L+65X,S%?,BYH=&WM6VU3&SD2_KZ_0D?J=J'* [:!0&R6*@><7:JV
M(,M+5>ZC9J2Q=6BD64ECX_OUURW-V,:88%X2<&*J$AA/J]7J>1[UR\@'?9?)
MPU_(09]3!K_)@1-.\L/NEVB[L=D\V J7(+!52AS$FHV(=2/)?U_+J.D)U2*T
M</I?(LNU<52Y=DX9$ZK7(OOY37O-JV5B4 TJ[T9.YZWZYJY0[4RHJ,]%K^_*
M#V)]$UGQ/]01:\.XB> 3T'205TI2K1R*\%:CGKMV,"2H;/M[*<V$'+4N1<8M
M.>5#<JXSJBK!6#NG,Y!U_,9%5(J>:DF>.IP#AU?3#/O"\<CF-.&MW/!H:&C>
MGIG[J]/!7$/!7+^5"A<E(,D53O+KN\;[>OM@"\<>'FSE\ \\Y#WU+9=HT,>S
M:TRTU*;UKNY_VO>O>!B>4*PE>PD7=&_Z(A:.!)R-';&@"QK-AZ:]WPL)&,#-
M&W'#4??\\N33R5'G\N3LE'R^.K^XZIQ>DLNSQ_ODR;!X4PXYO_JK>T$:VS1J
M[*S3#=(Y/2:-759>79T>=\_)Y9]=<M$]NCH_N3P!X>Z7HS\[IW]T2>?HDIQ]
M(HT/VSNUG]5_G0O2.3[[?-D]GD83NLLC;+O>1!=Y#W;./W9.NQ?1V9>_NO^I
MG->LUY_"QP?-?=S&NZCSGN>KDQKI2'Y#%3.4?*0RT5F-)-PXD8Z(ZU/7FO$$
MAK%$4FM_7P.+LD@*ZR(N><;Q08)5.3=KU1J8L+FDHU8*4TS[ZCU8^]_"XB25
M+5XFLHX:U_9.B5"];<74<BD4O^.^R8IV-G>W]_[]6OXL9Z^6*A1:&_D5?V6)
M:X>-S<JS4YE!4-FHUV<5OA(Z2)\..#%\(/B0,P"$L.3O A; C1R1<X[Y#M&*
M?-(F(XUZ]#?1*3DM!E2"@AHY4<GF),9C?)]$^1607@A(S24 TD=P/D.@9"-R
MK?10<M;CM8 G$U#$-&A2VA$<184B5(U(H9PI.-A*G0<&PHN2#*Z,H)*D-(&/
M#-$9I%%.![D[ HHGW%IJ1BB2T6L.\T[IM/ 9 V-@2HEQ".= @428I,A 3,%P
ML 22< +^2?K$%OC?9/R0&UXJP05DPDHH%2!W)T/A^K! F_/$&XAZ ==",UCF
M (8Q$H^FW;!BRS=FR_8RLX635"C (T)[@K\:4 7$X;:9NB]4"ILR=0+T")7(
M@H%.P/@4V&K #X$;.1AOD5W(.BDG]"F1:V>F!DN90,4UE"@D" !G-$#03V>]
M/0FU?9)*/;05H0SO 6H-U,>$XH?!;K"R-L4+6QESQ]H5-;XQ-7:6@!J7MW#T
MZ[N;9KWQH6U+])>)*^Z\.DT%7*[;#8^R$T(-]W@&?(I8<L0=X;#T&/#2QQ$H
MED'@P>"#U[#<1&I;P#B<WV@9@)T;G7 &'UNR#CAF'(@1P-J]2?I4]3CIP&Y_
M7DB0\%7<[CH/5O@J#J_"I<"B205"H7Z"(6&*9P'W:,O"$Z6W)DIA(ESG+/M
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M              "  0    !I;6<R-# U-38R-S5?,"YJ<&=02P$"% ,4
M" #,-0A9M!P_,HG/ @#S%1\ $0              @ %:%@( ;G5V;"TR,#(T
M,#8S,"YH=&U02P$"% ,4    " #,-0A98-U"J8.X  !K80L $0
M    @ $2Y@0 ;G5V;"TR,#(T,#8S,"YX<V102P$"% ,4    " #,-0A97*B&
M70D)  #W/@  #P              @ '$G@4 ;G5V;"UE>#,Q7S$N:'1M4$L!
M A0#%     @ S#4(6;@0N!T."0   #\   \              ( !^J<% &YU
M=FPM97@S,5\R+FAT;5!+ 0(4 Q0    ( ,PU"%E_\;>H\P0  )XD   /
M          "  36Q!0!N=79L+65X,S)?,2YH=&U02P$"% ,4    " #,-0A9
M<D;J+LT$  #0'P  #P              @ %5M@4 ;G5V;"UE>#,R7S(N:'1M
64$L%!@     '  < L@$  $^[!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>nuvl-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nuvl="http://www.nuvalent.com/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nuvl-20240630.xsd" xlink:type="simple"/>
    <context id="C_8082afd8-a4a7-4bb4-9a00-4af3037f710e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_81afe59a-ee6d-4907-9d22-6941e276a052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_84650898-1d7b-4a6d-9d23-20e46d3497a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_883bcdb9-2dfc-4e4d-8f72-50e4cd4d7ade">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_88495ead-dcd3-431a-99e7-37e3f2e1e634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_89bca620-1c60-420a-b2d6-3dff6795f400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_8b8d5f06-27af-40b6-b289-326a2478818b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_8d29fec8-02e5-44cb-889a-504ab81f9925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_92daaa6c-720c-4d58-8355-66e550d7df66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_988aec88-7f73-46c4-ac21-a91b3287ea03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_99559338-f498-4e29-bfdd-3b309f0eca12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_9a17bbbd-552a-4726-853e-2c935be60a16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9af9cb99-b002-4432-a278-828a6d780b37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d832d33-eda0-4982-a7a1-aa5692816a09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9f503e5f-2ff7-4088-814e-386b1247b152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a06a450e-d5b5-4bc2-993a-a482facfadc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a09fdef8-930b-40df-ac06-fe78e76477a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a4fd7116-d861-4be0-8726-91a1dd9e189f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a8d3411e-0ed4-454f-b70f-25a209c05079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_ac50ef0f-861a-4b28-a19c-6dd7b8e6e453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_ae08e807-c123-4741-9dfa-0c6b0be22746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b3935287-1f96-4f1d-9282-abc8a9aee1bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b405fb65-a7d6-40f5-8618-a2c821d37b18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_b52acea3-f3de-4d64-9ead-cf62a5c5a4f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_b64064b0-6d46-4f49-a54e-2ab50179487d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b727372e-2cfc-48db-824a-3abd0cf7dba1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_b8e8c5a4-91d7-4f1f-a636-6c63980a1c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_ba328089-ed54-41d2-ad71-894cccb07734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c11a9bc4-489e-4596-a690-f7a824830151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c71bc11f-7d4d-4e19-871d-ec730c358b89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c8785a1c-3f0b-4321-ac33-780c77788865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_c957d1b2-202c-4ada-b960-079ff36c0f99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c9924db4-0921-4c31-8fa1-a6b333ccd48c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_ca48becd-bf94-4320-8c36-a47233fe5233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_cd5fd91a-db75-43c1-9258-0ae8a9ebe099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_ceab70a5-e653-4ed2-a8bc-07d80f617df3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_cf25f6e9-997e-4fd3-8973-255b191f2346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_cf5818a4-e379-4f42-9868-d47198e49382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_d471e413-6554-4db6-8acf-61536b52edf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_d6836ade-3210-4068-9569-ee8d4b8489da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_dd5d8f9a-c02d-4126-aac2-509d06b9f750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nuvl:DebtSecuritiesAvailableForSalesSecuritiesDueAxis">nuvl:DueFromOneToThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_ddea1eeb-c815-4ae5-84ce-bc1859802e66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_dfe98025-5701-4a70-a255-fc81b13f1c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_e0b36d05-241e-4e01-9ba5-c205ade76ca0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_e15c1c22-7704-4697-a74e-3af37fe7c701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_e4332e9d-ecab-43c2-822a-5e2730476c0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e62e5e75-78d6-4cd9-95e2-9ba468b61771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_eb05446e-36b7-480d-9b8b-648cbb9b5d4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eb2dcb47-6bc3-4f5f-be73-df5f5439ce74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_ec26b0b0-5880-46be-8408-4d24973b61cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ecc9c26f-8f32-4e51-b3cd-fa8909aa654c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_f012d3bf-2d42-4757-97d5-7b4e06a3e34a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_f030d09a-bfcb-4f49-badb-80572c40436d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_f2ca2358-9edb-42a6-8d65-b04cc7207234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_f3e3d576-37a0-46cc-af33-ff50831dba6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f3ffb2d3-ee13-43a5-833d-7b195b6800b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f4058c19-abfa-40e6-be1a-4383ef698fe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f5a98332-a84d-4afb-92e2-c6864487eb2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f5bf5cdb-82a5-406c-8a83-540c8950da4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f6b5edb1-3582-4b9c-9677-0bc6546856c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_fc7521c0-d419-42f5-853e-f7e1a4596019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ffe8f47d-8106-4757-8e21-7ecfce183967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_01be8690-824b-416d-ad53-8ff91637a9af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_01ff6aaf-04b9-4c59-ba37-c7595a4c3d72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_03372593-ccd8-4694-bdcc-288af8b99337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_039ec984-4f30-4245-a719-3f78dc15fcec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_03f2a1f5-5552-4bb3-8054-73c7ba425664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_056481b1-615a-4a0b-be83-d7a61b440963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_05b26b2f-9751-4114-9b4d-1f27c7a082b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_073660e5-5cdc-4aa5-bdd8-945aa122a95e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_08022210-395d-4e18-8e81-25fb26ecc016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0c7272ae-5a35-4fd0-a989-3743ca61d47b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0ce95f97-e4b0-418a-afde-0fda932a5a74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_12550a26-38e1-43d4-ba71-fd211389e27b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_12f49acb-8742-41d4-9923-a2216a6f6c00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_1401fdb7-db69-4752-84b0-33a1bf08327e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_1b003891-9df8-4c3e-897c-1fb1aa2df080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1d08c9ae-2659-46a9-849d-76a9049ae98c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_1f7ddecb-f392-44f4-ad1e-e78403f10615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_21251a65-514d-4821-8601-a38593377a16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_26d88cb1-917a-47b7-bc4a-dda7edff6d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2772c92d-b1b2-4583-a232-57c12aa8bd76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_2bf2a1e3-cad2-4e60-8ad4-1deb2537ad3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2dee6185-6fe7-4fe7-9224-3070f221841e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2e43a4a8-0858-4032-9cd8-7e0c716a772a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_2f79acac-e627-48d5-9564-fc705c1b6bf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_312fe5af-47eb-44f8-b640-5fa199c3922a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nuvl:GovernmentAndAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_314e26da-7245-417b-9c1d-86a1223c91d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_36c20446-d6e8-4fbb-a272-98587f51dafb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_38bd045b-6b7c-45d4-b4db-ce9530ca306e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_39debf85-4fa8-4c07-b208-ccb5e963b79b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_39f6ee0b-635b-48d3-989f-20a78ce49678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_3a3bd4d5-6d69-48ff-b7ae-649b9726debb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_4087cba0-104d-4360-b9e5-71ace8a7d6ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4187e27a-41a0-40cd-9657-51ee99cb77a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_420d9d73-2ff1-4e4b-8061-261d7464f0ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_42889623-0040-458a-920e-d65790deccca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_43df5cb4-c8c5-4468-ad39-664e7ed58b84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4eea3c58-e991-4fc6-8757-166b21081709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_4f95f078-a582-42d7-8906-772ef768b12a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_51dedf03-534d-456b-bc8d-dbddd1b00ea3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_528c05d8-ffba-4060-b718-ab6ab294db2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_587b9996-792c-406a-9097-ea9d86361e65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_589e1185-37d3-427a-b335-fd22cdf25399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5af88fcb-7693-4986-8b59-4188cdbae19f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5b59d05e-c3b1-45c8-9ceb-30f281d1b071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_61343ea4-cef1-4e5a-bac8-86e012cbec65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nuvl:TwoThousandTwentyOneStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_6340f08b-92f6-445a-beaa-8a9f14410270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_64aecf04-4116-445d-a4a6-95702c1e60de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6ae41927-1c72-4a1d-ac10-40808ca06555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7397308e-56a8-4bd6-af70-4190269950ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7579b5b9-3b9e-41bc-94ba-1f9cf6e0adf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_7660fae2-d3c3-4c79-8e9e-2e0a0f620221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_76d6bf22-8e23-4100-ac8e-909ff6f3b8b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_7af8fcae-e898-443a-a9f6-0e043da02452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nuvl:DebtSecuritiesAvailableForSalesSecuritiesDueAxis">nuvl:DueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_7b51e495-8c14-4e56-ae9d-be367b379e30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_7bdeab21-6994-454d-9909-26915b05e48b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7c716e1a-4265-4608-b04f-9b2f56f2081f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_7fed8a7e-5f09-4c6a-ad30-c11b950611c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>nuvl:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_58fb946a-d3d5-4e31-9710-f5a6a16b59d3">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_7e821d15-2e20-483b-a052-6ab928643366">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_d4bee9f9-b1fa-48ec-9ef1-62d25451ea5c">0001861560</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_1618a2c7-bd1b-47dd-ac0a-f82d55af4c7c">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      id="F_c8b76d45-ca24-479d-bfc0-33cd63ec8f6f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      id="F_5a4c6053-1bda-44a6-bb38-708e59ad7023"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      id="F_a657f8ec-8294-4130-9623-1489cad84d2f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      id="F_03e6a0da-df8a-46ea-9b2f-331e1a872a11"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_8b8d5f06-27af-40b6-b289-326a2478818b"
      id="F_eeee3d3c-e24c-41bc-bc07-f38b69f1afef">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_8cdf292c-c2cb-42cb-87e5-32a992a51040">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_c3a6c3e2-63bd-4c1a-98f4-66360f23f7b3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_11daf5f1-42c5-4052-bbe6-adf2f2361fff">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_90b18be9-29f9-4d9f-ace4-002f9c9698a4">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_a29d074f-f714-49e3-acf8-587bc85f0a3c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_be51ae37-013d-467b-90eb-ee84f31aac28">001-40671</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_d5da89b9-5c19-43e0-892e-3b2a684796d2">NUVALENT, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_1dfb917f-42ee-4ea3-81b9-e13be1efd3e2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_3f4125af-eded-4fc2-b239-cda35c0ab535">81-5112298</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_2e1add9e-ed8a-46b6-a394-09358f0b4540">One Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_5897d42d-9b0c-4e0e-8ba7-0b80fa81254a">14th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_bac6abac-30e3-4f9d-ad8f-9cc82695ffa4">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_8227cf35-9d97-4a97-9714-2b8dcd0a5654">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_7dc4d630-b17a-4cb6-a7f6-54d3b1b6fecf">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_40086cad-f478-4a4e-88ad-745ecdbeb9c1">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_25b91616-0119-4b47-ab53-8aea6f877c60">357-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_52a15e38-22b5-4c86-a701-345c21161c97">Class A Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_4ae82631-ae5b-41c8-8bad-1368c62466fa">NUVL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_934e4eae-5309-4825-a697-f1b4946f782a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_6bba6315-79a7-45f3-bf9f-232444f35818">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_e7b932c8-f5f1-4b64-bfe2-360d3003d64f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_d3bce95a-b7a7-4ddb-a393-635a37250ded">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_6a9c6509-d078-4c9a-a9bb-a0af53f25666">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_d6b25ead-7691-4780-a9ad-7d25b5925403">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_4a65fad6-03e0-4c6a-bb20-1819a33c099a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_7660fae2-d3c3-4c79-8e9e-2e0a0f620221"
      decimals="INF"
      id="F_c0e2cc6e-dbbc-405e-a880-3193f3e011fe"
      unitRef="U_shares">59362349</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_7b51e495-8c14-4e56-ae9d-be367b379e30"
      decimals="INF"
      id="F_d6249cb2-b606-4313-9e25-b42942a67d41"
      unitRef="U_shares">5435254</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_fc565cf9-2b77-40f4-bc94-295fc17cd23f"
      unitRef="U_USD">77700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_4c5e8c2a-57ba-46c0-b0c0-4b97c4e848bf"
      unitRef="U_USD">335387000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_18c2b36c-edda-4e19-a186-d076ba5ef2d2"
      unitRef="U_USD">580294000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_d84d4a57-0c84-4300-b577-fda3e601b3f0"
      unitRef="U_USD">384518000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_92ea86a2-14e9-462b-980d-654d7284de15"
      unitRef="U_USD">8264000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_4b18d07f-e4dd-424d-8fe7-62abd91c5f84"
      unitRef="U_USD">6583000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_f8c7e1df-1586-4d7c-b012-2154aafe427f"
      unitRef="U_USD">666258000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_5e793e49-7cda-41f2-bf2b-e51468577ea8"
      unitRef="U_USD">726488000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_52558552-755c-4545-9ec4-508340aebdfc"
      unitRef="U_USD">8972000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_c9c95474-a283-4334-9c36-c97d5c9bf298"
      unitRef="U_USD">5896000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_713b254f-0be9-4c10-b5c2-fa23b71fc581"
      unitRef="U_USD">675230000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_6e319662-e6a5-4b50-96a2-0369386203ec"
      unitRef="U_USD">732384000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_2f0b67cf-01dc-481a-8910-da3937af307d"
      unitRef="U_USD">7403000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_69b0c469-3cf7-48f9-8c12-837967260187"
      unitRef="U_USD">9274000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_d4cdf029-1b5e-4dc6-99e1-63e8515df640"
      unitRef="U_USD">30789000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_d6cd5d0e-f4be-4028-bd8c-6ccc84d86011"
      unitRef="U_USD">22549000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_32320162-0c39-4c73-b43b-564c394dab15"
      unitRef="U_USD">38192000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_0129d1f4-bab5-413b-907e-1b2b6cb1d64e"
      unitRef="U_USD">31823000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_7059f1e3-ca7a-4b60-a781-6e83ad362284"
      unitRef="U_USD">38192000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_6477cbfc-281b-493c-a42e-3aa7cfba78e6"
      unitRef="U_USD">31823000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="INF"
      id="F_fcf083ee-e04f-421c-8866-2c7d0e1c7d8a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="INF"
      id="F_63b0851e-ed67-4e3f-81ae-43c93ab59c8e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="INF"
      id="F_c50fc542-b697-439d-9c59-b5503b2e5ead"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="INF"
      id="F_00b940c5-e4bd-4d71-9b44-7b623e93b89f"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="INF"
      id="F_5f602377-f4f1-43bb-bd0e-44137a9eb861"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="INF"
      id="F_d27a5750-5d13-4c8e-83f7-57303444915e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="INF"
      id="F_9f896590-55f1-4130-8b08-795b72a41ee0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="INF"
      id="F_4ba5efa7-44cb-4529-84fb-095f60959a7d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb"
      decimals="INF"
      id="F_67e501ac-da44-47ea-bdfb-4a29dfdd5780"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3"
      decimals="INF"
      id="F_a7fe9d3f-2fc1-41ba-b80a-b38a9b4ff409"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb"
      decimals="INF"
      id="F_3c816708-f7f2-4d1d-80b5-89281b5f43f8"
      unitRef="U_shares">140000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3"
      decimals="INF"
      id="F_c8d973bb-7fd4-4243-9e2e-bfe16b85e085"
      unitRef="U_shares">140000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb"
      decimals="INF"
      id="F_2e05c9c0-7234-48c5-a7e3-e3ecff3a9228"
      unitRef="U_shares">59284728</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb"
      decimals="0"
      id="F_3bd3dbe1-2bd8-425f-931b-35c092c187d2"
      unitRef="U_shares">59284728</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3"
      decimals="INF"
      id="F_abfeeb17-82f2-41ce-995f-d81f5873f067"
      unitRef="U_shares">58629896</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3"
      decimals="INF"
      id="F_adac4a6b-1c3f-45bc-a43f-c1ac15345eb6"
      unitRef="U_shares">58629896</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_36c20446-d6e8-4fbb-a272-98587f51dafb"
      decimals="-3"
      id="F_960b1f9b-8c35-43dd-a9ec-3d1c4978536f"
      unitRef="U_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_5a5cc9c4-d30b-45ef-8fb7-e08ac3c7b6b3"
      decimals="-3"
      id="F_692d9df4-31d0-4b89-8f39-671f639a773c"
      unitRef="U_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76"
      decimals="INF"
      id="F_2920a23e-aadc-4def-8de3-5f65c38490e4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7"
      decimals="INF"
      id="F_28274551-4469-473c-a2cc-87c133ee969a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76"
      decimals="INF"
      id="F_96fa5b9a-4255-49a9-828a-df29862f5bd6"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7"
      decimals="INF"
      id="F_ce989341-87b6-4670-a47a-af185ebe5efc"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76"
      decimals="INF"
      id="F_493780d7-e590-4eb5-998a-72e7c7da3f97"
      unitRef="U_shares">5435254</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7"
      decimals="INF"
      id="F_f5eb8ee6-230e-4664-a3ef-19789b580f4c"
      unitRef="U_shares">5435254</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76"
      decimals="INF"
      id="F_a8f22227-c662-4523-bb4e-b2ffdcac16a5"
      unitRef="U_shares">5435254</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7"
      decimals="INF"
      id="F_eb955bf0-0b46-45b9-aff7-9ee0c39b78be"
      unitRef="U_shares">5435254</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_2772c92d-b1b2-4583-a232-57c12aa8bd76"
      decimals="-3"
      id="F_ecdfb124-a2f7-4307-a852-8bcf4a259ac4"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_f4058c19-abfa-40e6-be1a-4383ef698fe7"
      decimals="-3"
      id="F_bdf338d4-6b5d-4dc7-bbd0-e0e8b6c6a0d3"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_78d085ef-f943-45cb-a269-65f3f6991b57"
      unitRef="U_USD">1026546000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_463917f9-860a-4fd5-b2dd-62b94ed5f444"
      unitRef="U_USD">986819000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_0fba43ce-3f47-4eb8-8878-63b403b54251"
      unitRef="U_USD">-1571000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_e0115430-d8c8-42ab-99d0-decf46ba7d52"
      unitRef="U_USD">31000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_2e250c4b-6da7-455c-b45a-0191d7e7d982"
      unitRef="U_USD">-387944000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_1bcd52bb-1298-49bd-9a54-def865474cac"
      unitRef="U_USD">-286296000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_b2b4092b-b0d0-4631-95b7-5240bbcb9012"
      unitRef="U_USD">637038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_ed1e4f8e-3cf8-4074-ad1e-f20224225208"
      unitRef="U_USD">700561000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_d0e314af-4865-4a2c-9b5b-54666d06106a"
      unitRef="U_USD">675230000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_ac68c8ff-c56b-4aa2-abaa-3d65cb1717b7"
      unitRef="U_USD">732384000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_f876768f-a168-4c2b-9ad2-fb494286eb95"
      unitRef="U_USD">49166000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_4e112934-ca0b-4a6a-8638-d10488c22197"
      unitRef="U_USD">25922000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_41c59717-3aaf-4a29-816b-4b8ba3ad81fc"
      unitRef="U_USD">87800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_eb73608c-ff0f-4714-8950-7b2c594ec64d"
      unitRef="U_USD">48047000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_ca8e8a7d-7ec8-432d-b6c3-cfcbb9c2391c"
      unitRef="U_USD">15984000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_9d173d60-4713-4e86-a8ef-ea2c0ae33022"
      unitRef="U_USD">8140000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_7f2d7ab8-e0ab-4811-93e4-d5f78f34aaf1"
      unitRef="U_USD">29938000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_6deab832-980f-4a70-a1f8-e35fad61668e"
      unitRef="U_USD">16225000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_7660161d-3865-4108-8ac5-d5e63d75fa82"
      unitRef="U_USD">65150000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_81b2bd26-29a3-44c8-a103-733890605557"
      unitRef="U_USD">34062000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_e89a7742-aa58-4fc3-85a8-2ad70d948c6b"
      unitRef="U_USD">117738000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_70953af2-4824-4df4-af8f-6109540f7112"
      unitRef="U_USD">64272000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_a17bbd8f-84cd-463b-81fa-dfb8248567b2"
      unitRef="U_USD">-65150000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_f3189760-bf6a-43b7-b339-2786dafe75f1"
      unitRef="U_USD">-34062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_e0bb061b-6873-4be5-9b04-e2e82051962c"
      unitRef="U_USD">-117738000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_13019e78-ca24-4d76-a018-ef696e5135fd"
      unitRef="U_USD">-64272000</us-gaap:OperatingIncomeLoss>
    <nuvl:InterestAndOtherIncomeExpenseNet
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_b9818e7c-d054-47dc-9c48-2367267db7f6"
      unitRef="U_USD">8154000</nuvl:InterestAndOtherIncomeExpenseNet>
    <nuvl:InterestAndOtherIncomeExpenseNet
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_e3c8ca2e-1e12-4c0b-91ff-2f2cab0f505f"
      unitRef="U_USD">4972000</nuvl:InterestAndOtherIncomeExpenseNet>
    <nuvl:InterestAndOtherIncomeExpenseNet
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_8655f50b-dd5a-429d-a52f-18f6e2ca2e2e"
      unitRef="U_USD">16643000</nuvl:InterestAndOtherIncomeExpenseNet>
    <nuvl:InterestAndOtherIncomeExpenseNet
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_d45edfa8-0138-44dc-b813-2603eb8d9787"
      unitRef="U_USD">9990000</nuvl:InterestAndOtherIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_0443fb05-c8ed-49af-acba-ea1747507a8b"
      unitRef="U_USD">8154000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_a0b30960-d061-416e-a735-366ca5ac3bb1"
      unitRef="U_USD">4972000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_bdbc338b-49b9-4dae-861d-c04fe253da84"
      unitRef="U_USD">16643000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_f3ea4eda-fb4b-44df-b907-d8879c709290"
      unitRef="U_USD">9990000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_af263d7e-c60a-40df-bb29-e343909888be"
      unitRef="U_USD">-56996000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_1b1d7840-6a90-4d7a-acf8-403ca1431ebb"
      unitRef="U_USD">-29090000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_74d9cfe6-d808-478f-a7d9-62b037ae91b5"
      unitRef="U_USD">-101095000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_fd42bdd4-a305-44ca-8801-3d03acd04d15"
      unitRef="U_USD">-54282000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_7bce75cb-feec-4073-845c-e75c700e12ab"
      unitRef="U_USD">170000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_0128d02b-2a24-43b7-8d6d-3fe8fa304293"
      unitRef="U_USD">553000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_42f9bf64-a2e7-48ef-945d-c1b4254fc249"
      unitRef="U_USD">-57166000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_ff6936f7-084e-4b52-b0ad-a58fc2bb6f79"
      unitRef="U_USD">-29090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_73ca6360-1811-464d-8a6f-000bff7e9047"
      unitRef="U_USD">-101648000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_2fa0da7a-e1b8-43e3-a92b-66f342e942e6"
      unitRef="U_USD">-54282000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="2"
      id="F_84dd5a17-0ceb-4450-911d-845b844f48fa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="2"
      id="F_6a63ba15-666d-4843-9461-267a5adc2238"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="2"
      id="F_38e2d560-6de3-4047-be5f-d00140fd3663"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="2"
      id="F_36d47359-8eb6-473b-8b8b-cb1e24e89e8a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="2"
      id="F_660a7cb2-4c97-4442-afdb-de5d8f789127"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="2"
      id="F_587bda6f-65a9-4335-bdf5-a34b99bf14b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="2"
      id="F_dba5232c-f382-4131-b8c9-ba1513cfef3b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="2"
      id="F_4a53bfa6-1a0d-4979-b6b9-d0e43c0169bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="0"
      id="F_57b72863-ac75-42c0-9f11-5f988d24bf68"
      unitRef="U_shares">64605308</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="0"
      id="F_f368eead-a5f0-4093-936f-1459d3d87a67"
      unitRef="U_shares">64605308</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="0"
      id="F_e61580bb-9e04-4885-9802-96fb64073c8c"
      unitRef="U_shares">56866991</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="0"
      id="F_2f930796-cb91-450d-a161-8c06a702ac94"
      unitRef="U_shares">56866991</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="0"
      id="F_213e320e-0e23-4bcf-a3fe-57587adfeaf8"
      unitRef="U_shares">64377948</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="0"
      id="F_88cb88df-7486-4ff3-90ff-87864953e05d"
      unitRef="U_shares">64377948</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="0"
      id="F_c7f4a722-5e39-4fa5-8008-c46a652d5973"
      unitRef="U_shares">56785883</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="0"
      id="F_780e7397-8ef7-4261-b34c-832a5aafeec8"
      unitRef="U_shares">56785883</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_8b744b7a-65b5-41f5-870f-69cf88270ded"
      unitRef="U_USD">-57166000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_e40d2376-bd77-46eb-b256-541512531061"
      unitRef="U_USD">-29090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_d4b66385-61b9-4715-92e8-bd6527cdbd24"
      unitRef="U_USD">-101648000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_07792f0b-ddfa-4245-91dc-784edae70bbd"
      unitRef="U_USD">-54282000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_47b2db93-2659-463b-9b51-27a776f1efc1"
      unitRef="U_USD">-253000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_255a53d2-af2f-48e2-a1aa-3a138005e321"
      unitRef="U_USD">-1235000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_81c04652-49da-4f3a-beb1-63f66a90b7d0"
      unitRef="U_USD">-1602000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_2734a4a9-db98-4c44-a9ea-b5ddc9c98a48"
      unitRef="U_USD">-1043000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_c5df27f6-2217-4f13-944f-41728e803cf0"
      unitRef="U_USD">-57419000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_ff6ea92c-7c05-4bda-957a-f68b5d910b6a"
      unitRef="U_USD">-30325000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_094dd18e-4099-466e-b23e-13b96fc68918"
      unitRef="U_USD">-103250000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_c5330ed6-73b1-45a1-8e00-014abf02228b"
      unitRef="U_USD">-55325000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_5af88fcb-7693-4986-8b59-4188cdbae19f"
      decimals="INF"
      id="F_9b9d76fb-48e9-4c1b-9406-bbb4ac7dcd7b"
      unitRef="U_shares">58629896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5af88fcb-7693-4986-8b59-4188cdbae19f"
      decimals="-3"
      id="F_438e0bce-10d8-48d0-b91c-e2a65df7b30a"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_528c05d8-ffba-4060-b718-ab6ab294db2f"
      decimals="INF"
      id="F_dabe91cd-f00a-495a-aa0a-e90f22b30396"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_528c05d8-ffba-4060-b718-ab6ab294db2f"
      decimals="-3"
      id="F_ba46e279-cfd3-4019-b11c-4e172c0f2f50"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6ae41927-1c72-4a1d-ac10-40808ca06555"
      decimals="-3"
      id="F_680349a8-5671-4553-92a6-6e24d48df2ad"
      unitRef="U_USD">986819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4087cba0-104d-4360-b9e5-71ace8a7d6ee"
      decimals="-3"
      id="F_1c3755b2-df12-4209-91e0-01b8a2e3bd9b"
      unitRef="U_USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c11a9bc4-489e-4596-a690-f7a824830151"
      decimals="-3"
      id="F_51b9a544-2684-4335-95fa-3836718eb7c9"
      unitRef="U_USD">-286296000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_2d120311-5154-45ff-b31b-e45e578afd74"
      unitRef="U_USD">700561000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ba328089-ed54-41d2-ad71-894cccb07734"
      decimals="INF"
      id="F_c697424b-6db2-4c35-b09c-6c1ededa653c"
      unitRef="U_shares">425737</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_21251a65-514d-4821-8601-a38593377a16"
      decimals="-3"
      id="F_aed87d07-3254-49d3-bfaf-316814bb7cc9"
      unitRef="U_USD">6452000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8"
      decimals="-3"
      id="F_f357cd5d-18a8-43c1-97ac-2e60ef7c9c4e"
      unitRef="U_USD">6452000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_e62e5e75-78d6-4cd9-95e2-9ba468b61771"
      decimals="-3"
      id="F_8370037c-f9c6-43c3-9707-8590f62cb517"
      unitRef="U_USD">-1349000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8"
      decimals="-3"
      id="F_20b95031-24ca-403a-989f-12007fb80455"
      unitRef="U_USD">-1349000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_21251a65-514d-4821-8601-a38593377a16"
      decimals="-3"
      id="F_91798bbd-9a54-4226-a146-ad74a6fecef8"
      unitRef="U_USD">13857000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8"
      decimals="-3"
      id="F_40d90ffa-657d-4844-bbee-eef9707b80a7"
      unitRef="U_USD">13857000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_314e26da-7245-417b-9c1d-86a1223c91d5"
      decimals="-3"
      id="F_4d0eb5ad-a6f6-4075-b957-5d7cdcab1876"
      unitRef="U_USD">-44482000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8e8c15c0-45f0-4e0d-94ee-401c7a3b8cf8"
      decimals="-3"
      id="F_08b77ba9-aac2-485f-bf93-4e813db173ba"
      unitRef="U_USD">-44482000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5b59d05e-c3b1-45c8-9ceb-30f281d1b071"
      decimals="INF"
      id="F_a08bb06b-8994-4470-94dc-dfa9a088405c"
      unitRef="U_shares">59055633</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5b59d05e-c3b1-45c8-9ceb-30f281d1b071"
      decimals="-3"
      id="F_49b11910-1e29-48f5-bb36-3dfc803a8705"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_f5bf5cdb-82a5-406c-8a83-540c8950da4f"
      decimals="INF"
      id="F_6411c369-ace0-4880-a909-5139beedbbf2"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f5bf5cdb-82a5-406c-8a83-540c8950da4f"
      decimals="-3"
      id="F_fed76f71-c0da-4a1d-b424-4ef92503cffb"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_01be8690-824b-416d-ad53-8ff91637a9af"
      decimals="-3"
      id="F_95aa8e28-45ba-46fb-93f4-20ec63e5511f"
      unitRef="U_USD">1007128000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f3ffb2d3-ee13-43a5-833d-7b195b6800b9"
      decimals="-3"
      id="F_1673f6d9-5a37-471b-8725-5c6927fadb8e"
      unitRef="U_USD">-1318000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b8e8c5a4-91d7-4f1f-a636-6c63980a1c7b"
      decimals="-3"
      id="F_837b039d-eb39-4535-aa1e-093065cb64a7"
      unitRef="U_USD">-330778000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_056481b1-615a-4a0b-be83-d7a61b440963"
      decimals="-3"
      id="F_9b242126-9a7e-4912-8985-0dc488c6a3de"
      unitRef="U_USD">675039000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2dee6185-6fe7-4fe7-9224-3070f221841e"
      decimals="INF"
      id="F_b44c6b9a-5aa9-4fef-947d-50987603cd40"
      unitRef="U_shares">223858</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6340f08b-92f6-445a-beaa-8a9f14410270"
      decimals="-3"
      id="F_7355db5f-8d0b-40f5-bbc2-317d1fb74f10"
      unitRef="U_USD">4001000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_086d5708-9672-41a0-ae6d-5ba7db713edd"
      unitRef="U_USD">4001000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_2dee6185-6fe7-4fe7-9224-3070f221841e"
      decimals="INF"
      id="F_c22dbf6d-31d6-4c68-8e06-bc62373a0393"
      unitRef="U_shares">5237</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_6340f08b-92f6-445a-beaa-8a9f14410270"
      decimals="-3"
      id="F_9975b75b-003a-4561-9758-d538b634b22c"
      unitRef="U_USD">292000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_c0c7994c-9eec-4f4c-a13b-aa39b71b5624"
      unitRef="U_USD">292000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_9a17bbbd-552a-4726-853e-2c935be60a16"
      decimals="-3"
      id="F_5799d41a-0bf8-4109-86f0-6daf167a8945"
      unitRef="U_USD">-253000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_c8c5bdf9-e948-4541-973a-83a565fd380e"
      unitRef="U_USD">-253000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6340f08b-92f6-445a-beaa-8a9f14410270"
      decimals="-3"
      id="F_133f08d3-2671-4784-a920-c9209de9efc3"
      unitRef="U_USD">15125000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_8edc59f2-a536-4f23-9abe-8d7fc0bdeb74"
      unitRef="U_USD">15125000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_c957d1b2-202c-4ada-b960-079ff36c0f99"
      decimals="-3"
      id="F_6bedf583-4637-4197-8b4c-90acd5620b1a"
      unitRef="U_USD">-57166000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_027a85d6-d6be-41e6-8228-d7b72b8d2f06"
      unitRef="U_USD">-57166000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_2f79acac-e627-48d5-9564-fc705c1b6bf5"
      decimals="INF"
      id="F_aa329878-b897-4582-a438-033e5cf1216d"
      unitRef="U_shares">59284728</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2f79acac-e627-48d5-9564-fc705c1b6bf5"
      decimals="-3"
      id="F_55f24ab0-4d7b-44ed-9b8e-d4733f699217"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_84650898-1d7b-4a6d-9d23-20e46d3497a3"
      decimals="INF"
      id="F_2fd1976f-5914-48c4-8d07-e06f6b40f57e"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_84650898-1d7b-4a6d-9d23-20e46d3497a3"
      decimals="-3"
      id="F_0f0864f9-0413-41c3-a1c2-b28821a01c05"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_81afe59a-ee6d-4907-9d22-6941e276a052"
      decimals="-3"
      id="F_a4e19094-004e-4f71-8f8e-f34697503568"
      unitRef="U_USD">1026546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7579b5b9-3b9e-41bc-94ba-1f9cf6e0adf5"
      decimals="-3"
      id="F_2029dbf4-0fa3-4aed-be6c-60ec09c9acec"
      unitRef="U_USD">-1571000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ecc9c26f-8f32-4e51-b3cd-fa8909aa654c"
      decimals="-3"
      id="F_f2fe8e05-338f-4a2a-9533-096c06477997"
      unitRef="U_USD">-387944000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_6d5ac3a9-565b-4060-b3c2-a44482059a14"
      unitRef="U_USD">637038000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_88495ead-dcd3-431a-99e7-37e3f2e1e634"
      decimals="INF"
      id="F_fe1ec0d1-1b78-4b96-8783-4da69c80d0b9"
      unitRef="U_shares">51233701</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_88495ead-dcd3-431a-99e7-37e3f2e1e634"
      decimals="-3"
      id="F_74ce2fa8-3cb9-4590-b445-3923a5627a18"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_420d9d73-2ff1-4e4b-8061-261d7464f0ac"
      decimals="INF"
      id="F_cd4b00b6-b543-434a-a947-053bce47efc0"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_420d9d73-2ff1-4e4b-8061-261d7464f0ac"
      decimals="-3"
      id="F_d87b84ae-745f-42a0-8a28-759d016d1105"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a4fd7116-d861-4be0-8726-91a1dd9e189f"
      decimals="-3"
      id="F_3748d225-b1f3-4b92-a512-751cac1ac2ba"
      unitRef="U_USD">623543000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9af9cb99-b002-4432-a278-828a6d780b37"
      decimals="-3"
      id="F_7c23f521-7790-431b-a7c8-5d69b502ecfa"
      unitRef="U_USD">-494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_988aec88-7f73-46c4-ac21-a91b3287ea03"
      decimals="-3"
      id="F_1594b370-3425-4215-bfbe-8ee95282606f"
      unitRef="U_USD">-160077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4187e27a-41a0-40cd-9657-51ee99cb77a5"
      decimals="-3"
      id="F_7f9bbf0f-bb7c-464f-9eb6-212d33d47129"
      unitRef="U_USD">462978000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_03f2a1f5-5552-4bb3-8054-73c7ba425664"
      decimals="INF"
      id="F_81915108-4469-4d15-bc71-2bf8ac530166"
      unitRef="U_shares">82989</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_76d6bf22-8e23-4100-ac8e-909ff6f3b8b0"
      decimals="-3"
      id="F_7b66bef7-3f39-469e-8189-2014f90caa6e"
      unitRef="U_USD">619000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_039ec984-4f30-4245-a719-3f78dc15fcec"
      decimals="-3"
      id="F_39d2798b-cde9-4e19-9bfc-b6b474eff6ae"
      unitRef="U_USD">619000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_cf5818a4-e379-4f42-9868-d47198e49382"
      decimals="-3"
      id="F_b773e99a-cf26-498e-9e30-488f37ff2a71"
      unitRef="U_USD">192000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_039ec984-4f30-4245-a719-3f78dc15fcec"
      decimals="-3"
      id="F_3f9a36bc-f7ce-41f1-b00c-7fb1e9a4e5bb"
      unitRef="U_USD">192000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_76d6bf22-8e23-4100-ac8e-909ff6f3b8b0"
      decimals="-3"
      id="F_845328ce-7247-4c9f-9461-d809f117f334"
      unitRef="U_USD">5371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_039ec984-4f30-4245-a719-3f78dc15fcec"
      decimals="-3"
      id="F_4b4ae049-96c9-493f-b2fa-b692ccc266b4"
      unitRef="U_USD">5371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_dfe98025-5701-4a70-a255-fc81b13f1c68"
      decimals="-3"
      id="F_64f93b3e-a616-4668-9bfd-b2fc234c8404"
      unitRef="U_USD">-25192000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_039ec984-4f30-4245-a719-3f78dc15fcec"
      decimals="-3"
      id="F_5893b0bd-909d-4826-84a2-9699d9cc6565"
      unitRef="U_USD">-25192000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_eb2dcb47-6bc3-4f5f-be73-df5f5439ce74"
      decimals="INF"
      id="F_fac325ed-e8f5-4b4d-8878-455f2a42b08a"
      unitRef="U_shares">51316690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_eb2dcb47-6bc3-4f5f-be73-df5f5439ce74"
      decimals="-3"
      id="F_fbede22a-106e-4ff2-98d3-cdd08dd8b188"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_92daaa6c-720c-4d58-8355-66e550d7df66"
      decimals="INF"
      id="F_039982db-950a-40df-9be9-bcd3ca572c6c"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_92daaa6c-720c-4d58-8355-66e550d7df66"
      decimals="-3"
      id="F_09368350-fae7-4cf5-9e66-2d5f1eb4cd7a"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_03372593-ccd8-4694-bdcc-288af8b99337"
      decimals="-3"
      id="F_9b381368-578c-4aba-8992-2ce89505b82b"
      unitRef="U_USD">629533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d6836ade-3210-4068-9569-ee8d4b8489da"
      decimals="-3"
      id="F_c9581a92-b80c-4267-9985-3539827498ab"
      unitRef="U_USD">-302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_89bca620-1c60-420a-b2d6-3dff6795f400"
      decimals="-3"
      id="F_6102081e-9bcb-4632-aaee-3d6484b782ba"
      unitRef="U_USD">-185269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_38bd045b-6b7c-45d4-b4db-ce9530ca306e"
      decimals="-3"
      id="F_aeaa0c38-b334-4af6-86dd-ea722f8b39f2"
      unitRef="U_USD">443968000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1401fdb7-db69-4752-84b0-33a1bf08327e"
      decimals="INF"
      id="F_cf439f77-6f6c-4f9b-823f-35a052e600f1"
      unitRef="U_shares">202210</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f012d3bf-2d42-4757-97d5-7b4e06a3e34a"
      decimals="-3"
      id="F_11ba6487-5221-4ed8-bc5e-f6a0b844b8ae"
      unitRef="U_USD">1469000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_7b348634-e942-4026-9677-05bed080dc39"
      unitRef="U_USD">1469000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_1401fdb7-db69-4752-84b0-33a1bf08327e"
      decimals="INF"
      id="F_921da313-d58b-4793-aa74-5749e08cf15f"
      unitRef="U_shares">6575</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f012d3bf-2d42-4757-97d5-7b4e06a3e34a"
      decimals="-3"
      id="F_5e425508-d891-4ec5-8152-cad6ae36b70e"
      unitRef="U_USD">193000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_0b072f96-045d-41bb-86aa-8640a58d34f8"
      unitRef="U_USD">193000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_2e43a4a8-0858-4032-9cd8-7e0c716a772a"
      decimals="-3"
      id="F_7ba8b1b2-2af5-400b-84c6-22c8e82ee5a9"
      unitRef="U_USD">-1235000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_321db90e-df50-4bbf-9d27-2e2e8e83172e"
      unitRef="U_USD">-1235000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f012d3bf-2d42-4757-97d5-7b4e06a3e34a"
      decimals="-3"
      id="F_42cdf691-2eb7-4974-8a19-91c8a2452ebc"
      unitRef="U_USD">5848000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_9abd964a-cd3a-40bb-8a60-8e59d310c245"
      unitRef="U_USD">5848000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_fc7521c0-d419-42f5-853e-f7e1a4596019"
      decimals="-3"
      id="F_43aa1b8c-8611-4932-8625-a6bca10ece6a"
      unitRef="U_USD">-29090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_aaccab83-0348-412b-be7d-527dcb2a39c0"
      unitRef="U_USD">-29090000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_a8d3411e-0ed4-454f-b70f-25a209c05079"
      decimals="INF"
      id="F_82739b6a-ee4a-475c-9956-15749f8cfccc"
      unitRef="U_shares">51525475</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a8d3411e-0ed4-454f-b70f-25a209c05079"
      decimals="-3"
      id="F_6d2ab028-a647-4da5-9e36-c8626f76733e"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_883bcdb9-2dfc-4e4d-8f72-50e4cd4d7ade"
      decimals="INF"
      id="F_10ba5d56-6421-458e-af79-2771e7ff278d"
      unitRef="U_shares">5435254</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_883bcdb9-2dfc-4e4d-8f72-50e4cd4d7ade"
      decimals="-3"
      id="F_c24dd821-7539-4a45-8a33-be84dbf4b761"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1f7ddecb-f392-44f4-ad1e-e78403f10615"
      decimals="-3"
      id="F_601c1405-3fa7-470f-9c4d-9ba4f60ac3f8"
      unitRef="U_USD">637043000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_39f6ee0b-635b-48d3-989f-20a78ce49678"
      decimals="-3"
      id="F_e3b60d60-5f33-4d1c-be5d-e16b9c5f087e"
      unitRef="U_USD">-1537000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cd5fd91a-db75-43c1-9258-0ae8a9ebe099"
      decimals="-3"
      id="F_6236ef17-ba33-47ff-bfdc-33f2996bd001"
      unitRef="U_USD">-214359000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ffe8f47d-8106-4757-8e21-7ecfce183967"
      decimals="-3"
      id="F_1a073118-398f-4b13-a233-6ad29642a743"
      unitRef="U_USD">421153000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_ff072c03-3d36-4528-a533-afc8afa1453c"
      unitRef="U_USD">-101648000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_81099827-94d7-45fa-b59d-120fe4ddd8ef"
      unitRef="U_USD">-54282000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_826e3b11-d69d-4132-a955-c5b98b51234b"
      unitRef="U_USD">28982000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_6b53503c-5cb3-4ffe-b431-593865a69519"
      unitRef="U_USD">11219000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_163ad27c-da5d-4752-a798-dc00c21fa90f"
      unitRef="U_USD">-6815000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_3bbce9fe-70a5-4059-97ca-9e3a016ce3be"
      unitRef="U_USD">-5387000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_cf128fd7-47b5-4933-998d-014f7e6c4cb1"
      unitRef="U_USD">1681000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_4852226d-8eea-46e1-8252-0e0fc7b7b842"
      unitRef="U_USD">-75000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_8598f898-a66a-4fb4-8f5c-6c4a629de929"
      unitRef="U_USD">3076000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_ba117d8b-964d-4335-a3ce-1d2709e3ae29"
      unitRef="U_USD">488000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_b6e3482c-8f22-489f-acb7-ee4e79c69ccd"
      unitRef="U_USD">-1871000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_bd5eaeff-afd1-4a88-8f48-45110c090eda"
      unitRef="U_USD">1012000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_031f516d-a4c2-4e91-97ed-0f48c16c9e21"
      unitRef="U_USD">8862000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_0326a3d1-f37f-4ff9-b61e-2308f5581a05"
      unitRef="U_USD">1302000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_dc34e24c-8998-483f-bef9-662120ab639a"
      unitRef="U_USD">-77247000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_cf4c19db-0edd-454a-bbda-63af5d427016"
      unitRef="U_USD">-46549000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_be615a6b-fb6e-4bb0-ae0f-097b23eaef58"
      unitRef="U_USD">371849000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_7f925127-d1a4-484c-9fc5-5e729be2304c"
      unitRef="U_USD">269559000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_3788560f-64c0-449c-917f-51402e87e165"
      unitRef="U_USD">181286000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_5e6e38a1-8dde-47d9-abd1-489137de5062"
      unitRef="U_USD">143893000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_c0aec934-b3ee-472b-bf47-ccf76cfd8d4a"
      unitRef="U_USD">-190563000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_209762f2-8bd7-44fb-a441-f1105380e1ad"
      unitRef="U_USD">-125666000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_9f3f7672-000b-48d8-ab83-fd2d881bd0d1"
      unitRef="U_USD">10745000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_9cf2514e-a3ba-4698-ae38-81c42e31bdb4"
      unitRef="U_USD">2281000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_22fd05d6-d656-4f5e-80ed-e2f796ce678a"
      unitRef="U_USD">622000</nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty>
    <nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_96953237-5232-40c6-a189-9f0d42444d63"
      unitRef="U_USD">910000</nuvl:RepaymentsOfInsuranceCostsFinancedByThirdParty>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_a93b4952-10ba-4846-8703-999ae2f77e14"
      unitRef="U_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_de439d71-5a82-46a1-92f5-b2a217f3cf8d"
      unitRef="U_USD">90000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_d1a96656-3a1c-4f8e-9c57-f192fe1fed2b"
      unitRef="U_USD">10123000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_d090fe52-5ca0-42b7-acf7-0a0bd4b3735a"
      unitRef="U_USD">1281000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_31023f9c-bc3e-4079-9319-cdb639b88b39"
      unitRef="U_USD">-257687000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_8b76609d-6e3d-4d69-a0b5-bfcbe1cbb6b0"
      unitRef="U_USD">-170934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_faa9ae53-7094-4e4c-8ce7-e5dd75e174b4"
      unitRef="U_USD">335387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4187e27a-41a0-40cd-9657-51ee99cb77a5"
      decimals="-3"
      id="F_f0d0c330-3f99-4fa4-b987-74aebe41e544"
      unitRef="U_USD">241806000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_d77e729f-80b3-4186-8e3e-8cab0cd40a1a"
      unitRef="U_USD">77700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ffe8f47d-8106-4757-8e21-7ecfce183967"
      decimals="-3"
      id="F_17c2fe33-f1a6-4584-b306-762cdae8626b"
      unitRef="U_USD">70872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_1fd910f7-5dcc-42cf-96dd-4c9df48bc791">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Nature of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nuvalent, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company was founded in January 2017 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts, and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment. All of the Company&#x2019;s operations are in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks similar to those of other pre-commercial stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of which are larger and better capitalized, the need to obtain adequate additional financing to fund the development of its product candidates, the need to obtain and maintain adequate protection for the Company&#x2019;s intellectual property, and the impact of public health emergencies, natural disasters and geopolitical events on the Company&#x2019;s business. There can be no assurance that the Company&#x2019;s research and development will be successful, that adequate protection for the Company&#x2019;s intellectual property will be obtained and maintained, that any product candidates will receive required regulatory approval or that approved products, if any, will be commercially viable. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has incurred recurring losses since inception, including net losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;101.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023. As of June 30, 2024, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;387.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these condensed consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will need to obtain additional funding through public or private equity offerings, debt financings or strategic alliances. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company may be required to delay, reduce or eliminate some or all of its research and development programs or the Company may be unable to continue operations. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="INF"
      id="F_41fbd0ad-3f05-4dfb-818f-b39af9fa2e56"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NetIncomeLoss
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-5"
      id="F_35e89615-26d3-41f0-b45e-b9b3dcea7fea"
      unitRef="U_USD">-101600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_eb05446e-36b7-480d-9b8b-648cbb9b5d4a"
      decimals="-5"
      id="F_95b15860-08f9-45bf-b9b1-288e2ed4fec0"
      unitRef="U_USD">-126200000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-5"
      id="F_b89894e5-f057-4b72-ab0d-5db1f618632e"
      unitRef="U_USD">-387900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_00402dff-297a-4c55-863f-2d7fee41762d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and under the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial statements. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto for the year ended December 31, 2023, included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023 (the &#x201c;Annual Report&#x201d;), on file with the SEC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company&#x2019;s financial position, results of operations, and cash flows. The results for the period are not necessarily indicative of the results that may occur for future interim periods or the full fiscal year. Certain prior period amounts have been reclassified to conform with current period presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting policies the Company used in preparing these condensed consolidated financial statements are substantially consistent with those applied in the Company&#x2019;s Annual Report.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in Accounting Standards Codification 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which requires public entities, on an annual basis, to provide disclosure of specific categories in their tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_20e44edc-98ed-4e58-b84b-9f60eee4a7a5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in Accounting Standards Codification 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which requires public entities, on an annual basis, to provide disclosure of specific categories in their tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the impact of the adoption of this guidance to be material to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_c9132130-3e84-47e9-bd97-f01ca89bf745">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables provide the amortized cost and fair value of the Company&#x2019;s available-for-sale securities by security type (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.629%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.013%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.013%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.013%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.013%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.834999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;321,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;581,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;580,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.475%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.120999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;384,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;384,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the amortized cost and fair value of the Company&#x2019;s available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due after one year through three years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;581,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;580,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s available-for-sale securities are classified as current assets as they are readily available to be converted to cash and for use in the Company&#x2019;s current operations. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; credit losses recorded during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and six months ended June 30, 2024 and 2023. Interest income for the three months ended June 30, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Interest income for the six months ended June 30, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_662e8e41-1fad-489e-be84-e9669500a007">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables provide the amortized cost and fair value of the Company&#x2019;s available-for-sale securities by security type (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.629%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.013%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.013%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.013%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.013%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.834999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;321,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;581,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;580,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.475%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.120999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;384,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;384,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b727372e-2cfc-48db-824a-3abd0cf7dba1"
      decimals="-3"
      id="F_8be2acd1-54c0-4a4b-9388-488630a87d51"
      unitRef="U_USD">105591000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b727372e-2cfc-48db-824a-3abd0cf7dba1"
      decimals="-3"
      id="F_53e5fd4b-089d-4e95-9a6b-4f2bfb5156e7"
      unitRef="U_USD">146000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b727372e-2cfc-48db-824a-3abd0cf7dba1"
      decimals="-3"
      id="F_20b0f1fb-15ac-4bc9-8acd-7c0872f28080"
      unitRef="U_USD">105445000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f030d09a-bfcb-4f49-badb-80572c40436d"
      decimals="-3"
      id="F_008242b7-d9eb-40c9-8599-a99c6d38cae9"
      unitRef="U_USD">321594000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f030d09a-bfcb-4f49-badb-80572c40436d"
      decimals="-3"
      id="F_9957e3e5-1e32-4e78-b90a-50e7109ce2b0"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f030d09a-bfcb-4f49-badb-80572c40436d"
      decimals="-3"
      id="F_b6024b93-8a7c-48fe-ba14-36ee0bce3b7b"
      unitRef="U_USD">1235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f030d09a-bfcb-4f49-badb-80572c40436d"
      decimals="-3"
      id="F_13ce140e-d20d-4c22-9b23-25dea24a0b61"
      unitRef="U_USD">320383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_08022210-395d-4e18-8e81-25fb26ecc016"
      decimals="-3"
      id="F_64547350-8831-468f-886e-3e77d0bbf3e1"
      unitRef="U_USD">124967000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_08022210-395d-4e18-8e81-25fb26ecc016"
      decimals="-3"
      id="F_05b54129-6c7d-4df0-ac3e-0fd99551a4ef"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_08022210-395d-4e18-8e81-25fb26ecc016"
      decimals="-3"
      id="F_05c80478-3b2d-4610-9bc0-a72ac5839f11"
      unitRef="U_USD">212000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_08022210-395d-4e18-8e81-25fb26ecc016"
      decimals="-3"
      id="F_e1aa5417-fb0c-4ff4-bd18-4b995af3d472"
      unitRef="U_USD">124763000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_42889623-0040-458a-920e-d65790deccca"
      decimals="-3"
      id="F_e6c4efe0-0a9f-4f2d-9615-56cc030056b7"
      unitRef="U_USD">29713000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_42889623-0040-458a-920e-d65790deccca"
      decimals="-3"
      id="F_90280f27-5174-4966-8911-95edd5908291"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_42889623-0040-458a-920e-d65790deccca"
      decimals="-3"
      id="F_f0b94151-c03c-4b91-9ed1-69ca8f99369c"
      unitRef="U_USD">29703000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_b1b1f1fc-7ca6-4563-ac9e-dd59a6eebeef"
      unitRef="U_USD">581865000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_32cf77b3-946b-46a9-8c7c-683fea578b70"
      unitRef="U_USD">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_d10d5341-0a76-4e39-95d8-a89843f8f60a"
      unitRef="U_USD">1603000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_c7859cf9-7d25-4207-aa3d-5eadabd60347"
      unitRef="U_USD">580294000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ae08e807-c123-4741-9dfa-0c6b0be22746"
      decimals="-3"
      id="F_78ba332d-9104-4d61-bd27-a3ac639c5f71"
      unitRef="U_USD">67098000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ae08e807-c123-4741-9dfa-0c6b0be22746"
      decimals="-3"
      id="F_791a625d-235a-4651-b80c-0ab013a56dff"
      unitRef="U_USD">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ae08e807-c123-4741-9dfa-0c6b0be22746"
      decimals="-3"
      id="F_c68d7ccd-1592-49bf-a8a0-951b4cf8d4ac"
      unitRef="U_USD">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ae08e807-c123-4741-9dfa-0c6b0be22746"
      decimals="-3"
      id="F_4df83a36-43f2-4c09-9575-d916fe900c29"
      unitRef="U_USD">67080000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f5a98332-a84d-4afb-92e2-c6864487eb2f"
      decimals="-3"
      id="F_10b16c5d-038c-446e-8601-4ab6fb8d7937"
      unitRef="U_USD">193876000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f5a98332-a84d-4afb-92e2-c6864487eb2f"
      decimals="-3"
      id="F_70a686ee-1491-418e-847f-f61a7910b15f"
      unitRef="U_USD">328000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f5a98332-a84d-4afb-92e2-c6864487eb2f"
      decimals="-3"
      id="F_b16258e7-5f4b-448c-bf41-d48139c03ee2"
      unitRef="U_USD">255000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f5a98332-a84d-4afb-92e2-c6864487eb2f"
      decimals="-3"
      id="F_62a420f8-993f-4818-9054-4582d61dc9d0"
      unitRef="U_USD">193949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56"
      decimals="-3"
      id="F_2ea79a6d-019e-43b3-850b-32e7520c710d"
      unitRef="U_USD">89044000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56"
      decimals="-3"
      id="F_a0b14bb6-ed5c-49e1-9e74-0562eb24ab9c"
      unitRef="U_USD">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56"
      decimals="-3"
      id="F_384cb85f-3614-4cb2-a6a6-c61ce273d3b4"
      unitRef="U_USD">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fd2bea08-bc22-4dbe-9b55-af4cf65d1d56"
      decimals="-3"
      id="F_849b1fb4-4b3d-45e0-8961-06dd28d216c4"
      unitRef="U_USD">89027000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ec26b0b0-5880-46be-8408-4d24973b61cb"
      decimals="-3"
      id="F_bb03b855-244b-4a38-80ab-54f595700e4c"
      unitRef="U_USD">34469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ec26b0b0-5880-46be-8408-4d24973b61cb"
      decimals="-3"
      id="F_3277a3d3-afed-434f-8c3b-58dd5c52f9c1"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ec26b0b0-5880-46be-8408-4d24973b61cb"
      decimals="-3"
      id="F_421bae12-3d1b-450a-a3cb-b02b016e1a19"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ec26b0b0-5880-46be-8408-4d24973b61cb"
      decimals="-3"
      id="F_28f2a6a2-7bba-4c7f-9c4d-d9f5dc6ec186"
      unitRef="U_USD">34462000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_5fa72cba-1309-4fca-aa34-ace90481a41b"
      unitRef="U_USD">384487000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_deb9d29d-102b-4ca8-9b82-f5dbfcec1006"
      unitRef="U_USD">419000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_d3e25523-547d-4a95-9bd9-8684ee35a14e"
      unitRef="U_USD">388000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_f230a04a-94df-42ac-b7c4-309131c9c689"
      unitRef="U_USD">384518000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_1536dad2-b8c3-4022-8407-d92a65509de8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the amortized cost and fair value of the Company&#x2019;s available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due after one year through three years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;581,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;580,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7af8fcae-e898-443a-a9f6-0e043da02452"
      decimals="-3"
      id="F_ef6b438c-c012-4c07-a7cc-c40bb14b4ecb"
      unitRef="U_USD">423126000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7af8fcae-e898-443a-a9f6-0e043da02452"
      decimals="-3"
      id="F_f1cda0f3-4031-4f67-9ff3-6dbccdb7e373"
      unitRef="U_USD">422244000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_dd5d8f9a-c02d-4126-aac2-509d06b9f750"
      decimals="-3"
      id="F_763c34cd-ea17-4c59-b503-6849e637cc68"
      unitRef="U_USD">158739000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_dd5d8f9a-c02d-4126-aac2-509d06b9f750"
      decimals="-3"
      id="F_49845b69-22d7-4142-9bf4-17da4121dc46"
      unitRef="U_USD">158050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_04abf05f-553c-4497-a7eb-f56ac7631f87"
      unitRef="U_USD">581865000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_5197f8f0-906f-4dac-9bb3-5a1fc572fae7"
      unitRef="U_USD">580294000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="INF"
      id="F_6fa40e54-4e51-4de4-b32f-e1d699b77a23"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="INF"
      id="F_0b534aa6-1eee-4a3b-9a76-c29ff8895037"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="INF"
      id="F_e9711b40-2cc8-44fb-bcbc-cce89c13f864"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="INF"
      id="F_d4076341-0c86-46da-b1e1-2971ad445951"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-5"
      id="F_3a7bbe5f-c54b-4507-aa48-60aac3eb16c8"
      unitRef="U_USD">8100000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-5"
      id="F_f0b85bb5-7ac3-437e-8f59-f4fe47af7229"
      unitRef="U_USD">5100000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-5"
      id="F_c8960557-e488-415d-844e-b4f44ef822e0"
      unitRef="U_USD">16600000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-5"
      id="F_d67d1296-8089-4993-a371-71595559e648"
      unitRef="U_USD">10100000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_10015dc9-d8b5-4861-b607-dfc544998b32">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present the Company&#x2019;s fair value hierarchy for its assets, which are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.475%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;580,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;637,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.417%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.046%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.107%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.107%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.288%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;327,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;327,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;327,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;384,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Commercial paper,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;corporate bonds, government and agency securities and U.S. treasury bills were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the three and six months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; transfers in or out of Level 3. The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_0241df43-9683-4f55-a391-d962af54ac17">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present the Company&#x2019;s fair value hierarchy for its assets, which are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.475%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;580,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;637,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.417%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.046%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.107%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.107%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.288%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;327,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;327,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;327,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;384,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d471e413-6554-4db6-8acf-61536b52edf5"
      decimals="-3"
      id="F_d25b0f49-c9f5-47a1-be42-677635c55568"
      unitRef="U_USD">57001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f6b5edb1-3582-4b9c-9677-0bc6546856c2"
      decimals="-3"
      id="F_b3bb4a32-39fe-4070-9482-d533e059fec7"
      unitRef="U_USD">57001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e0b36d05-241e-4e01-9ba5-c205ade76ca0"
      decimals="-3"
      id="F_c9c54faf-9521-40de-85aa-4ca85048977d"
      unitRef="U_USD">105445000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f2ca2358-9edb-42a6-8d65-b04cc7207234"
      decimals="-3"
      id="F_51a216ce-d4ed-4c96-9302-e918d73ba93a"
      unitRef="U_USD">105445000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_cf25f6e9-997e-4fd3-8973-255b191f2346"
      decimals="-3"
      id="F_b8516ffd-d846-4251-9bfa-eeb8c71b748c"
      unitRef="U_USD">320383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e15c1c22-7704-4697-a74e-3af37fe7c701"
      decimals="-3"
      id="F_a64abd59-e994-453a-813b-43b0b98d67a4"
      unitRef="U_USD">320383000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0c7272ae-5a35-4fd0-a989-3743ca61d47b"
      decimals="-3"
      id="F_8eab3bec-dcdc-4b3a-930e-62612cf40fc4"
      unitRef="U_USD">124763000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8082afd8-a4a7-4bb4-9a00-4af3037f710e"
      decimals="-3"
      id="F_5d294a17-4975-4f3e-8d07-e1a972b6e5d7"
      unitRef="U_USD">124763000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3a3bd4d5-6d69-48ff-b7ae-649b9726debb"
      decimals="-3"
      id="F_7a824828-f897-4007-8571-df5e6331a51a"
      unitRef="U_USD">29703000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_99559338-f498-4e29-bfdd-3b309f0eca12"
      decimals="-3"
      id="F_81aab72b-6e27-4d3b-a5ef-a23a9082852d"
      unitRef="U_USD">29703000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ddea1eeb-c815-4ae5-84ce-bc1859802e66"
      decimals="-3"
      id="F_550f7ca2-753e-4e0d-9d6f-efcd5e7a8a74"
      unitRef="U_USD">57001000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7c716e1a-4265-4608-b04f-9b2f56f2081f"
      decimals="-3"
      id="F_33d07e5f-5f71-4bce-80dc-25fd6eef6ff2"
      unitRef="U_USD">580294000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4eea3c58-e991-4fc6-8757-166b21081709"
      decimals="-3"
      id="F_c5525aff-e6b1-4ed0-b329-a40edf8b51af"
      unitRef="U_USD">637295000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_01ff6aaf-04b9-4c59-ba37-c7595a4c3d72"
      decimals="-3"
      id="F_c9c873b9-f715-4171-b4d1-48ff91087870"
      unitRef="U_USD">327055000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a09fdef8-930b-40df-ac06-fe78e76477a8"
      decimals="-3"
      id="F_2186c33a-176d-4365-8b50-db49adea6d30"
      unitRef="U_USD">327055000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_05b26b2f-9751-4114-9b4d-1f27c7a082b0"
      decimals="-3"
      id="F_b66113c0-18a4-471e-a0b4-eaa94d3cc1d9"
      unitRef="U_USD">67080000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_39debf85-4fa8-4c07-b208-ccb5e963b79b"
      decimals="-3"
      id="F_720d6f7a-4406-42b4-9bf9-db8f902a1a44"
      unitRef="U_USD">67080000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1b003891-9df8-4c3e-897c-1fb1aa2df080"
      decimals="-3"
      id="F_42767ac3-1f6b-4878-9106-1a4caba17f6f"
      unitRef="U_USD">193949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b3935287-1f96-4f1d-9282-abc8a9aee1bf"
      decimals="-3"
      id="F_1293a7e7-0e06-4c19-9266-e15fd81da85d"
      unitRef="U_USD">193949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_312fe5af-47eb-44f8-b640-5fa199c3922a"
      decimals="-3"
      id="F_e17998fd-af17-4b75-84f6-10f2677c9bd3"
      unitRef="U_USD">89027000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f3e3d576-37a0-46cc-af33-ff50831dba6c"
      decimals="-3"
      id="F_058ef4a0-8eb1-4afa-8b14-bd2fc68b4cac"
      unitRef="U_USD">89027000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7397308e-56a8-4bd6-af70-4190269950ff"
      decimals="-3"
      id="F_b3c0d709-faf3-42a6-897d-3284f7ae6a83"
      unitRef="U_USD">34462000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9f503e5f-2ff7-4088-814e-386b1247b152"
      decimals="-3"
      id="F_ed43f038-12f3-4c0d-a62c-5a835173e1b5"
      unitRef="U_USD">34462000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_43df5cb4-c8c5-4468-ad39-664e7ed58b84"
      decimals="-3"
      id="F_404c9e7e-c72e-4eb1-b40a-47a3cd6bb6cd"
      unitRef="U_USD">327055000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7bdeab21-6994-454d-9909-26915b05e48b"
      decimals="-3"
      id="F_ed838b65-ad6b-49de-8a53-f2cc4476a820"
      unitRef="U_USD">384518000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e4332e9d-ecab-43c2-822a-5e2730476c0b"
      decimals="-3"
      id="F_6e7d76c8-217f-4a14-a236-5619497480de"
      unitRef="U_USD">711573000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_213d9169-45c9-41ba-9df4-2f959d7b7254"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_0a31aaa6-fc1c-4e08-b34f-e8a801ab8b92"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_e5a5ca1f-a36c-42e4-9438-bf94d225e8c4"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_f201afb4-99db-44dd-bdd8-702cf5c5c9ca"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_bd88d8fb-09fb-4559-a295-ba598fa8558d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Accrued Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical and other research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_997ebb5e-3a7f-4190-85c4-bbb74fefd098">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical and other research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_c93b1a2d-d49d-4454-aaa9-d2a119ff65f5"
      unitRef="U_USD">13977000</nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses>
    <nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_74d8eb99-5bc0-49e2-b342-65161d5c1c8a"
      unitRef="U_USD">6769000</nuvl:AccruedClinicalAndOtherResearchAndDevelopmentExpenses>
    <nuvl:AccruedManufacturingExpenses
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_0e74a510-a144-4480-baff-9729afc25241"
      unitRef="U_USD">10548000</nuvl:AccruedManufacturingExpenses>
    <nuvl:AccruedManufacturingExpenses
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_cf1e2872-8a54-427b-b195-644257dd34ef"
      unitRef="U_USD">6830000</nuvl:AccruedManufacturingExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_2c39434a-9576-4e32-bf55-df0ccc9bac96"
      unitRef="U_USD">4914000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_c9845437-270d-4872-b612-53f48975171c"
      unitRef="U_USD">7326000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_c9aafb30-50e0-490f-8588-8fd34737beff"
      unitRef="U_USD">1350000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_2c4a58ff-a3ba-4a4f-ab52-094f8011c553"
      unitRef="U_USD">1624000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_6d8ed96d-1b15-4806-b381-4fc85aa194fc"
      unitRef="U_USD">30789000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_eb3f73fb-a82c-4a8a-899b-dc64bf9daac9"
      unitRef="U_USD">22549000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_e7e700f6-bf71-46fc-9fb8-9963c98c0c64">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recorded stock-based compensation expense within its condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.475%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024, total unrecognized compensation cost related to equity-based awards was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 equity incentive plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2021, the Company adopted the 2021 Stock Option and Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units (&#x201c;RSUs&#x201d;), unrestricted stock awards, cash-based awards and dividend equivalent rights. Stock awards granted under the 2021 Plan with service-based vesting conditions generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_eeee3d3c-e24c-41bc-bc07-f38b69f1afef;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;- or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; service periods, and stock options expire after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,068,809&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock remained available for future issuance under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2021, the Company adopted the 2021 Employee Stock Purchase Plan, as amended and restated (the &#x201c;ESPP&#x201d;). The ESPP permits eligible employees to purchase shares of Class A common stock at a discount in accordance with the terms of the offering and consists of consecutive, overlapping 12-month offering periods, each consisting of two six-month purchase periods beginning in December and June of each year. During the three and six months ended June 30, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;5,237&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were sold under the ESPP. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,873,832&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock remained available for issuance under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s option activity since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,034,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;449,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,198,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;649,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,561,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,113,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;256,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options exercised during the three months ended June 30, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock on the date of exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average grant-date fair value of stock options granted during the three months ended June 30, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. The weighted average grant-date fair value of stock options granted during the six months ended June 30, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s RSU activity since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;652,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_b6d3d4ea-aec1-4591-ade3-00bb46813855">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recorded stock-based compensation expense within its condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.475%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4f95f078-a582-42d7-8906-772ef768b12a"
      decimals="-3"
      id="F_0619e668-d00e-444a-ab86-a5b324de7813"
      unitRef="U_USD">7322000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_12550a26-38e1-43d4-ba71-fd211389e27b"
      decimals="-3"
      id="F_2d2d6acd-b0af-48be-a647-dc1c74ee0e8c"
      unitRef="U_USD">2693000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_073660e5-5cdc-4aa5-bdd8-945aa122a95e"
      decimals="-3"
      id="F_79e858f4-3c2c-44f4-b58c-b223289591d3"
      unitRef="U_USD">13985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_587b9996-792c-406a-9097-ea9d86361e65"
      decimals="-3"
      id="F_3cb75b27-bea1-49e7-ac58-123221db8d4b"
      unitRef="U_USD">5206000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c71bc11f-7d4d-4e19-871d-ec730c358b89"
      decimals="-3"
      id="F_cb7c6e96-47bf-4885-ac0a-1d4756cc9749"
      unitRef="U_USD">7803000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b405fb65-a7d6-40f5-8618-a2c821d37b18"
      decimals="-3"
      id="F_41a31ecc-03db-4d18-8e64-2de69be5b82e"
      unitRef="U_USD">3155000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_589e1185-37d3-427a-b335-fd22cdf25399"
      decimals="-3"
      id="F_884e1cad-5288-4752-8cbd-ec825a2cc9d2"
      unitRef="U_USD">14997000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b52acea3-f3de-4d64-9ead-cf62a5c5a4f2"
      decimals="-3"
      id="F_b880bdd3-a453-44e3-a0db-90bb158d83ad"
      unitRef="U_USD">6013000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-3"
      id="F_79314ae3-88b5-4675-b452-df59904fa4f6"
      unitRef="U_USD">15125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-3"
      id="F_2871b463-7582-42f3-ba37-d8b3cc157c90"
      unitRef="U_USD">5848000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-3"
      id="F_41c0f9eb-b431-4c91-9cbf-f32d9ecacc1c"
      unitRef="U_USD">28982000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-3"
      id="F_ff005323-705a-42e3-8f68-76876042a698"
      unitRef="U_USD">11219000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-5"
      id="F_b5adc72c-5ee6-4157-b40a-f6f8883d7776"
      unitRef="U_USD">150900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_15bb8ac9-23e7-447b-ae1d-ada77db4a43f">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_c9924db4-0921-4c31-8fa1-a6b333ccd48c"
      id="F_d5b8076c-d2af-4dba-be54-12444d03ae12">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_51dedf03-534d-456b-bc8d-dbddd1b00ea3"
      id="F_90a0dc5e-7031-4c4c-88cf-30e326ff63b7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_61343ea4-cef1-4e5a-bac8-86e012cbec65"
      decimals="INF"
      id="F_78681455-be4d-4146-9ac6-93c2ab6308d9"
      unitRef="U_shares">7068809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_26d88cb1-917a-47b7-bc4a-dda7edff6d61"
      decimals="INF"
      id="F_c24f72cc-5c2d-4a50-a4b7-da131e80253f"
      unitRef="U_shares">5237</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a06a450e-d5b5-4bc2-993a-a482facfadc4"
      decimals="INF"
      id="F_a00aff39-ee75-4240-bcbb-90991db47ec8"
      unitRef="U_shares">5237</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_12f49acb-8742-41d4-9923-a2216a6f6c00"
      decimals="INF"
      id="F_22e79810-7494-43b3-94c8-458d936fa2d0"
      unitRef="U_shares">1873832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_688180a3-0258-4175-9a3a-1047d391dd71">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s option activity since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,034,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;449,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,198,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;649,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,561,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,113,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;256,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="INF"
      id="F_47cbe160-0e49-4526-97d3-36f5a29434a5"
      unitRef="U_shares">8034755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="2"
      id="F_938a1f8f-9eae-45ca-96f1-d75a8d1d3997"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_eb05446e-36b7-480d-9b8b-648cbb9b5d4a"
      id="F_021d1d4b-cfd6-408f-8ebd-743ee3d69721">P8Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="-3"
      id="F_e9eeeaae-f61a-430f-8490-59d37921925a"
      unitRef="U_USD">449403000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="INF"
      id="F_596a1c13-1a35-41de-b2e0-fdcd34100e77"
      unitRef="U_shares">1198801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="2"
      id="F_27b9b825-b48f-484c-81f6-809420b0dde3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">75.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="0"
      id="F_89afb13a-8f76-4a0c-83ae-145ab775e13c"
      unitRef="U_shares">649595</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="2"
      id="F_45ed9db7-c272-4720-9382-79cb814c59e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="INF"
      id="F_1cdc734b-8e07-4dc0-94c2-66ab5f197d27"
      unitRef="U_shares">22717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="2"
      id="F_24213ff0-a754-435e-8565-d0fbef840d7f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="INF"
      id="F_4165118c-b33f-4f47-98f3-430b31e60d9f"
      unitRef="U_shares">8561244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="2"
      id="F_4d99f24f-3427-4d57-806a-de667ac5ba05"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_af608ffa-173d-4033-b6fb-b7155ea55a8c">P7Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_f465f2ea-e58a-47d3-8d32-6b63edcf62d5"
      unitRef="U_USD">430979000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="INF"
      id="F_86db961a-5cdc-40cf-8da6-90ffbe541a0e"
      unitRef="U_shares">4113020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="2"
      id="F_7b10d035-8d1a-4592-b699-306db617f190"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_8726e2b2-2f63-456d-92c1-cabee4237502">P7Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="-3"
      id="F_782abb8d-54f5-4bbd-96e0-b7754f0202ca"
      unitRef="U_USD">256837000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="-5"
      id="F_8b4273a6-7f69-418d-9695-88b00df751d4"
      unitRef="U_USD">12200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="-5"
      id="F_7ba3fd67-7d53-403e-a31f-92059e8648ff"
      unitRef="U_USD">6300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="-5"
      id="F_c8069dfb-1a9f-4ecb-a6de-c5706d5630de"
      unitRef="U_USD">40200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="-5"
      id="F_93996564-82f1-4c2a-9841-deaa62c6e76a"
      unitRef="U_USD">8100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      decimals="2"
      id="F_39ceb954-8250-48de-a264-1c0291077010"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">50.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0ce95f97-e4b0-418a-afde-0fda932a5a74"
      decimals="2"
      id="F_d8c78598-1644-490a-84a0-84b54ffd540e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="2"
      id="F_890f62fb-fb41-41d0-9f7d-608f2744d6f4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">51.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="2"
      id="F_d5b1dd56-d071-4656-8d88-90006c797721"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_af661204-0339-40d8-9fea-410adbaa7020">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s RSU activity since &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;652,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_9d832d33-eda0-4982-a7a1-aa5692816a09"
      decimals="INF"
      id="F_a4bfd5dd-eae7-438a-960c-ff26f42ade38"
      unitRef="U_shares">652281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9d832d33-eda0-4982-a7a1-aa5692816a09"
      decimals="2"
      id="F_d388a5c3-ed8f-4f77-b322-15842b074b29"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">73.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_9d832d33-eda0-4982-a7a1-aa5692816a09"
      decimals="INF"
      id="F_dd568673-e192-4b06-8c6e-c361ecfb7fe0"
      unitRef="U_shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_9d832d33-eda0-4982-a7a1-aa5692816a09"
      decimals="2"
      id="F_6fe9d4ba-ce0f-4c0a-909e-c0314455d74c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">72.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ceab70a5-e653-4ed2-a8bc-07d80f617df3"
      decimals="INF"
      id="F_e8459efa-94b8-4dd5-a50d-478b9bc73318"
      unitRef="U_shares">650281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_ceab70a5-e653-4ed2-a8bc-07d80f617df3"
      decimals="2"
      id="F_b0b53d9f-3fa5-42ce-9ee2-51a2a05eeefa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">73.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_01219a17-7b18-4df0-938e-33128c09403d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has two classes of common stock outstanding: Class A common stock and Class B common stock. The rights of the holders of Class A and Class B common stock are substantially identical, except with respect to voting and conversion. Class B common stock is nonvoting, and each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company&#x2019;s amended and restated certificate of incorporation. The Company allocates undistributed earnings attributable to common stock between the common stock classes on a one-to-one basis when computing net loss per share. As a result, basic and diluted net loss per share of Class A common stock and share of Class B common stock are equivalent.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,561,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,514,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,211,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,514,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_12c3892f-e9a2-4ff3-9ebb-cc344205aecf">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,561,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,514,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,211,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,514,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2bf2a1e3-cad2-4e60-8ad4-1deb2537ad3d"
      decimals="0"
      id="F_553a51f5-9d4c-477f-877b-8de1c5811a84"
      unitRef="U_shares">8561244</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ac50ef0f-861a-4b28-a19c-6dd7b8e6e453"
      decimals="0"
      id="F_d40271a7-65a8-4db4-8275-71d12664cdae"
      unitRef="U_shares">8514372</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7fed8a7e-5f09-4c6a-ad30-c11b950611c2"
      decimals="0"
      id="F_30f8d6c2-64fa-4cc9-949d-6eb90c991b49"
      unitRef="U_shares">650281</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8d29fec8-02e5-44cb-889a-504ab81f9925"
      decimals="0"
      id="F_b0778c2b-924c-4b61-af81-a560b91422e0"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      decimals="0"
      id="F_1f36f55f-3f57-4676-b804-fd7793a630a5"
      unitRef="U_shares">9211525</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1d08c9ae-2659-46a9-849d-76a9049ae98c"
      decimals="0"
      id="F_ad2cf8ca-974c-4c05-a81c-205619bbd01a"
      unitRef="U_shares">8514372</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_64aecf04-4116-445d-a4a6-95702c1e60de"
      id="F_9e1b9fbb-8d51-4c4d-a9eb-e728dcc0e58f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has revenue sharing agreements with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund, IV, L.P. (collectively, &#x201c;Deerfield&#x201d;), each an investor in the Company, and the Company&#x2019;s scientific founder to pay each of Deerfield and the scientific founder a low single digit percentage rate of net sales of certain commercial products. The payment obligation expires on the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country for both Deerfield and the Company&#x2019;s scientific founder. The Company accounts for the liability with Deerfield at fair value with changes recognized in the consolidated statements of operations and comprehensive loss. The Company accounts for the obligation to the scientific founder as a contingent liability. Given the inherent risks associated with obtaining regulatory approval and achieving commercialization, the Company ascribed no value to the revenue sharing agreement with Deerfield at inception or at June 30, 2024 or December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company currently does not have any net sales and, as a result, has not paid any amounts under these agreements and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t accrued any liability as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 under these agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnification agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="INF"
      id="F_325049ae-5f6c-4b00-8677-b8775c46c740"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_b64064b0-6d46-4f49-a54e-2ab50179487d"
      decimals="INF"
      id="F_d74bc77d-7849-4e5d-b97e-60301ce5df39"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      id="F_02728285-7fd0-41a0-aace-8e51f42def34">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table describes for the quarterly period ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, each trading arrangement for the sale or purchase of Company securities &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a Rule 10b5-1 trading arrangement) or (2) a &#x201c;non-Rule 10b5-1 trading arrangement&#x201d; (as defined in Item 408(c) of Regulation S-K):&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:14.94%;"&gt;&lt;/td&gt;
      &lt;td style="width:12.4%;"&gt;&lt;/td&gt;
      &lt;td style="width:25%;"&gt;&lt;/td&gt;
      &lt;td style="width:10%;"&gt;&lt;/td&gt;
      &lt;td style="width:26.38%;"&gt;&lt;/td&gt;
      &lt;td style="width:11.28%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;background-color:#f2f2f2;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Name (Title)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Action Taken &lt;br/&gt;(Date of Action)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Type of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nature of Trading &lt;br/&gt;Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Duration of Trading &lt;br/&gt;Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Number &lt;br/&gt;of Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;James Porter &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;April 2, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-style:italic;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rule 10b5-1 trading arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;Until &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;October 20, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;, or such earlier date upon which all transactions are completed or expire without execution&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;351,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;shares of Class A common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      id="F_56a44532-722d-4dad-9128-1e8db40ca93e">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      id="F_f7771458-a53c-4206-982b-a23bf7199352">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      id="F_ab979a02-7e09-427e-9926-69d8968db931">James Porter </ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      id="F_53a66eea-66c6-4f06-b771-5cea644466bf">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      id="F_b64b0eb2-37a0-4444-befa-30791de1abb8">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      id="F_5aec9579-86bf-439e-9e6b-a89784f25973">April 2, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate
      contextRef="C_ca48becd-bf94-4320-8c36-a47233fe5233"
      id="F_eb53e007-807d-4106-a578-840e1121fac5">October 20, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_c8785a1c-3f0b-4321-ac33-780c77788865"
      decimals="0"
      id="F_b48d7541-2db6-4ba7-b910-6e8b825bf319"
      unitRef="U_shares">351000</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
